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ABSTRACT 
 
Uganda has experienced 1.6 million deaths due to HIV/AIDS related illnesses. Introduction 
of free-ART in rural hospitals that bear the burden of AIDS reduces adult morbidity and 
mortality. The study design was a quantitative, retrospective and descriptive design through 
data mining of medical records.  
 
In the six years, hospital admissions decreased by 16.7% and the median age at death 
increased by seven years. Hospital mortality increased from three to seven deaths per 100 
admissions per month. Male to female mortality was 1:1.6 and females in the 15-34 age 
group had a 37% higher likeliness of dying in hospital compared to males. Deaths from sub-
counties with an ART site reduced by 4% to 8.6%. The data revealed that despite ART 
coverage of 60%, mortality rates showed a rising trend.  Free access to ART's over three 
years did not make any observable changes to overall mortality. 
 
 
Therefore, ART access contributed to a decline in overall hospital admissions, an increase in 
median age at time of death and a reduction in deaths from sub-counties with an ART site. 
There was no reduction in overall hospital mortality rate.  
 
Key terms: Adult, Antiretroviral treatment (ART), HIV/AIDS, hospital, Mawokota South 
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CHAPTER 1 
 
Orientation to the Study 
 
 
1.1 INTRODUCTION 
 
One of the key objectives of any well-functioning health care delivery system is to 
maximise the prevention of disease and to reduce or contain the incidence of disease 
and the rates of mortality. A careful monitoring of the prevalence of morbidity and rates 
of mortality is, therefore, a vital function of any effective health service delivery system. 
In this study, the researcher has undertaken an audit and analysis of adult mortality 
trends both before and after the introduction of free anti-retroviral therapy (ARV) in a 
rural hospital setting in Uganda. 
 
The researcher deliberately chose a rural setting in Uganda as the focus of this study 
because, in a previous study undertaken in Masaka, a rural district in Uganda, where 
the number of HIV-infected people was calculated to be 8% of the total number of 
people in the district, 41% of all adult deaths were attributed to HIV infection and its 
subsequent complications and progression towards full-blown AIDS (Lopman, 
Barnabas, Hallet, Nyamukapa, Mundandi, Mushati, Garnett & Gregson 2006:189; Nunn, 
Mulder, Kamali, Samarti, Chiesi, Geraci, Andreoni & Vella 1997:[1]). Increases in the 
overall morbidity and mortality rates in Uganda during the past three decades have 
therefore been associated with the very large number of people in the general 
population who have been infected by the human immunodeficiency virus (HIV) and 
who died from opportunistic infections and other complications that are associated with 
the acquired immunodeficiency syndrome (AIDS).  
 
While Ugandans have had free access to antiretroviral treatment (ART) for the past four 
years, the monitoring of mortality trends in rural hospitals has either been inadequately 
undertaken or non-existent.  
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The researcher undertook this study in order to answer important questions such as: 
 
• What was the incidence of adult hospital mortality before free ART became 
available to the general population in Uganda? 
• What was the incidence of adult hospital mortality after free ART had become 
available to the general HIV-infected population? 
• Was there any statistically significant correlation between factors such as gender 
and the age of patients among those groups who experienced the highest 
mortality rates? 
 
Other important questions that the researcher took into consideration before arriving at 
his conclusions were the following: 
 
• Were there any other significant factors that needed to be taken into 
consideration because they correlated significantly with the hospital mortality 
rates in this rural setting in Uganda? 
• What conclusions should one reach about the overall effect of free ART on 
hospital mortality rates in the selected rural hospital in Uganda? 
 
There are two main reasons why the answers to these questions were chosen by the 
researcher as the focus of this study. Firstly, such questions are the key questions that 
every district management team, hospital manager and health unit management team in 
high HIV-prevalence settings should be asking themselves on a quarterly and annual 
basis. Secondly, the findings and recommendations of this study became the basis for 
implementing targeted interventions that were designed to reduce mortality rates. These 
answers serve as benchmarks for comparison and future research in comparable 
situations and contexts. 
 
The researcher sought the answers to these questions by reviewing the history and 
trends that have been evident in the global HIV/AIDS epidemic, and by focusing his 
attention on sub-Saharan Africa and Uganda in particular because it is one of the 
countries that has been most affected by this virus.  
 
In the first part of the study, the researcher retrospectively reviewed all adult admissions 
and deaths in a rural hospital between July 2002 and June 2008 in order to determine 
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mortality trends and those related demographic aspects of mortality that were 
identifiable from the hospital’s records. The data thus accumulated for the specified 
period (between July 2002 and June 2008) was arranged in two sets that reflected the 
age of patients at the time of death, the gender of deceased patients, and the reported 
causes of death (where these had been indicated in the hospital’s record). These two 
sets of data (one from the era before free ART had been available and one from the 
period in which free ART was available to patients), were then compared and analysed.  
 
1.1.1 The human immunodeficiency virus epidemic in perspective  
 
The Human Immunodeficiency Virus is largely spread by means of unprotected sexual 
intercourse (sexual intercourse without the use of condoms) between an infected 
person and an uninfected person. Once an individual is infected with the HIV, he or she, 
if left untreated, eventually begins to manifest the syndrome called AIDS (the Acquired 
Immunodeficiency Syndrome). The HIV was first identified in 1981 in the United States 
of America (USA) among men who had been engaging in anal sexual intercourse with 
other men (Centres for Disease Control and Prevention (CDC) 1998:[1]; Hall, Geduld, 
Boulos, Rhodes, An, Mastro, Janssen & Archibald 2009:S13). Ever since the 
identification of the HIV, an increasing number of men and women throughout the world 
have become infected with the virus and have eventually succumbed to one or another 
of the opportunistic infections and conditions that accompany AIDS and that invariably 
result in the death of the patient (Hall et al. 2009:S13). What was thus originally called 
“the gay plague” because it seemed to affect only sexually active homosexual men, is 
now known to be a virus that is affects all men and women who engage in unprotected 
sex – regardless sexual orientation or preferences.  
 
In over 75% of cases that have been positively identified throughout the world, the virus 
has been transmitted by means of heterosexual contact in which either blood or other 
bodily fluids have been exchanged between partners. These infections have resulted in 
a spectacular increase in various kinds of morbidity and mortality in all affected 
countries throughout the world – but especially in the countries of sub-Saharan Africa. 
This overwhelming predominance of HIV infections is indicated in figure 1.1 below (Joint 
United Nations Programme on HIV/AIDS [UNAIDS] & WHO 2007:3). The factors that 
have made the countries of sub-Saharan Africa especially vulnerable to the impact of 
the HIV and AIDS, are discussed in the following chapter (chapter 2). 
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1.1.2 The global human immunodeficiency virus disease situation  
 
Figure 1.1 (below) shows that sub-Saharan Africa is the region globally that is most 
severely affected by the HIV/AIDS epidemic. The number of people who are infected in 
this region is far out of proportion to the total number of people who live in it.  Sub-
Saharan Africa accounts for 22.5 million people who are living with HIV/AIDS (PLWHA 
is often used as a working acronym for “people living with HIV AIDS”). This 
extraordinary number should be compared with a number of infections in the North 
America (estimated at  1.3 million), Eastern Europe and Central Asia (1.6 million), South 
and South-East Asia (800 000), the Middle East and North Africa (380 000), and 
Western and Central Europe (with 760 000 HIV-infected people in this region) (UNAIDS 
& WHO 2007:39). Sub-Saharan Africa is therefore the most affected region of the world 
with more than two thirds of the HIV burden in the world.  
 
 
Figure 1.1:  The estimated number people living with HIV worldwide (2007) 
(Source: UNAIDS & WHO 2007:39) 
 
Although HIV was regarded in 2007 as the most serious infectious disease in the world 
(UNAIDS & WHO 2007:4), a review of global prevalence trends shows that there were 
localized reductions in the prevalence of HIV infection in some countries. This reduction 
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in prevalence was associated with a reduction in HIV-related deaths. This reduction can 
be partly attributed to the increasing number of people who have free access to ART 
and partly to a 53% decrease in the number of new HIV infections (Fang, Hsu, Twu, 
Chen, Chang, Hwang, Wang, Chuang & The Division of AIDS and STD 2004:883; 
UNAIDS & WHO 2007:4). 
 
In East Africa, the prevalence of HIV reduced from 12·9% (7·0–16·9%) in 1997/98 to 
8·5% (5·3–14·0%) in 2002. Uganda (the country that is the focus of this study), reported 
a “rapid decline in prevalence during the mid and late 1990s” (Asamoah-Odei, Garcia-
Calleja & Boerma 2004:38); likewise, in Kenya, HIV infections fell from 13·6% (12·2–
27·1%) in 1997/98 to 9·4% (6·6–14·3%) in 2002 (Asamoah-Odei et al. 2004:38) 
 
A closer examination of global and regional trends showed that HIV infections were 
distributed in two different patterns: (1) a generalized epidemic pattern of distribution in 
sub-Saharan Africa, and (2) a concentrated epidemic pattern of distribution in the rest of 
the world (Halperin & Epstein 2004:4; UNAIDS & WHO 2007:4).  
 
Figure 1.2:  Number of people living with HIV throughout the world (1990 – 2007) 
(Source: UNAIDS & WHO 2007:4) 
 
As figure 1.2 indicates, the number of PLWHA has progressively increased between 
1990 and 2007. By the end of 2007, an estimated 33 million (between 30 and 36 million) 
PLWHA were living with the disease throughout the world (WHO, UNAIDS & United 
6 
Nations International Children's Education Fund [UNICEF] 2009:7). It was also 
estimated that 29.5 million new HIV infections occurred in 2007 alone, which showed 
that the HIV infection rate is still on the increase throughout the world (UNAIDS & WHO 
2007:3). 
A recent report released in September 2009 showed that more than four million people 
throughout the world were receiving ART by the end of 2008; this represented a 36% 
increase in the number of ART users over the previous year in that year alone, and a 
ten-fold increase in the number of ART users over a period of five years (WHO, 
UNAIDS & UNICEF 2009:54). In spite of such progress, the report also indicates that an 
estimated five million people who were living with HIV still did not have ready access to 
life-prolonging treatment and care (WHO, UNAIDS & UNICEF 2009:113).  
 
1.1.3 The human immunodeficiency virus disease in sub-Saharan Africa 
 
Sub-Saharan Africa is the region that is most seriously affected by HIV infections, with 
AIDS as the leading cause of death in this region (UNAIDS & WHO 2007:15). It was 
estimated that, in 2007 alone, 2.1 million people (namely, 1.7 million adults and 330 000 
children under the age of 15 years) died from AIDS-related causes (UNAIDS & WHO 
2007:1). 
 
 
Figure 1.3:  A comparison of the HIV prevalence trends globally and in sub-
Saharan Africa (1990-2007) 
(Source: UNAIDS & WHO 2007:17) 
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Figure 1.3 shows that the global prevalence of HIV stabilised in 2000 and then 
embarked on a downward (reducing) trend in 2006. By contrast, there was a steep 
increase in the prevalence of HIV-infected people in sub-Saharan Africa from 1990. 
After this upward trend reached a peak in sub-Saharan Africa in 2000, it began to show 
a gradual decline between 2000 and 2007 (Ellman & Simms 2008:1071). 
 
For the purposes of this research, it is sufficient to note that the number of people who 
are infected with HIV in sub-Saharan Africa steadily but slowly began to decline after 
the year 2000. 
 
1.1.4 The human immunodeficiency virus epidemic in Uganda 
 
Uganda is one of the sub-Saharan Africa countries that has been most severely 
affected by the HIV/AIDS epidemic because “more than three quarters of all AIDS 
deaths [throughout the world] in 2007 occurred in sub-Saharan Africa” (UNAIDS & WHO 
2008:7). In recent years, a number of interventions have been implemented in Uganda 
to contain the HIV epidemic, and these efforts have been rewarded with some degree of 
success (The United States President's Emergency Plan for AIDS Relief [PEPFAR] 
2008:[1]). Uganda was the first sub-Saharan country to register a drop in the number of 
HIV-infected patients (Asamoah-Odei et al. 2004:38; UNAIDS & WHO 2008:11). While 
the HIV-infection rate peaked in 1992 in Uganda, it thereafter displayed a downward 
trend that stabilised in 2000 and that persisted through to 2005 (Kirungi, Musinguzi, 
Madraa, Mulumba, Callejja, Ghys & Bessinger 2006:i38). Similar reductions in the 
prevalence of HIV-infections have since been reported in Zimbabwe, Rwanda, Malawi 
and Ethiopia (Shelton, Halperin & Wilson 2006:1121).  
 
In addition to this, there was a levelling of the HIV-infection rate among both men and 
women in rural Uganda since 2000 (UNAIDS & WHO 2008:12). Since Ugandan women 
demonstrate a high average fertility rate of 6.7 pregnancies per woman during the 
reproductive phase of their lives, Uganda's population rate is growing very rapidly. 
Therefore, though the rate of HIV infections remained stable among the population at 
large, amidst a high population growth rate, this implies that an increasing number of 
people are becoming infected with HIV each year (UNAIDS & WHO 2008:13). 
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Since there are approximately 1.1 million PLWHA in Uganda, the HIV epidemic in that 
country remains a cause for serious concern with infections highest among urban 
residents (10% compared to 5.7% among rural residents) and females (7.5% compared 
to 5.0% among males) (Ministry of Health – Government of Uganda 2009:42; UNAIDS 
& WHO 2008:11).  
 
The prevalence of HIV infections in 2004 in Uganda among inpatients in medical and 
surgical wards was 35% and 12% respectively, while the overall HIV burden was 38% 
among all inpatients (Wanyenze, Nawavvu, Namale, Mayanja, Bunnel, Abang, 
Amanyire, Sewankambo & Kamya 2008:302).  
 
The cause of 70% of all deaths in the age group of patients between 25 and 44 years 
old has been attributed to HIV (Lopman et al. 2006:189; Nunn et al. 1997:[1]). It has 
been estimated that, by 2010, the crude death rate in Uganda will increase by 5.6 per 1 
000 of the population because of the effects of HIV/AIDS (Stanecki & Walker 2002: 
293). This implies that the crude mortality rate in the whole population will increase from 
9.5 per 1 000 without AIDS to 15.1 per 1 000 with AIDS in the population at large 
(Stanecki & Walker 2002: 293).  
 
In 2005, the HIV infection rate among adults between the ages of 15 and 49 in Uganda 
fell by a margin of 6.7% from the national average of 18% that was established in the 
1990s (Ministry of Health – Government of Uganda 2006: 97,101; Uganda AIDS 
Commission – Government of Uganda 2008:3). 
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Figure 1.4:  The prevalence of HIV infections in urban and rural areas 
disaggregated in by gender 
(Source: Uganda AIDS Commission – Government of Uganda 2006a:6) 
 
Figure 1.4 shows that the prevalence of HIV infections in the urban areas of Uganda 
was 10.2% in comparison to 5.7% in the rural areas. It is noticeable that the number of 
HIV infections is also greater among females (12.8% and 6.5% in urban and rural areas 
respectively) when compared to the number of infections among males (6.7% and 4.8% 
in urban and rural areas respectively) (Uganda AIDS Commission – Government of 
Uganda 2006a:6; Ministry of Health – Government of Uganda 2006:97,103). 
 
The World Health Organisation (WHO) country profile for Uganda on HIV/AIDS 
treatment scale-up indicated that the sectors of the population who were most 
vulnerable to HIV infection in Uganda included young women, people who practised 
prostitution and military personnel (PEPFAR 2008:[1]). According to the UNAIDS Report 
on the Global AIDS Epidemic, HIV/AIDS was responsible for 91 000 deaths by the end 
2005 and for 61 306 deaths by December 2008 (Ministry of Health – Government of 
Uganda 2009:42; PEPFAR 2008:[1]).  
 
Since HIV/AIDS is therefore by far the most significant cause of death among 
Ugandans, it is a condition that requires careful monitoring and investigation. It was for 
this reason that Bennett, Boerma and Brugha (2006:72) recommended that evaluations 
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and assessments about the effect of HIV/AIDS interventions on AIDS morbidity and 
mortality rates should include a thorough understanding of the factors that drive these 
changes. 
 
1.1.5 The impact of the human immunodeficiency virus on other diseases 
 
While HIV has exerted a significant impact on the prevalence and incidence rates of 
other infections and non-infectious diseases, the contrary is also true. Thus, for 
example, the high prevalence of untreated sexually transmitted infections (STIs) has 
contributed significantly to the spread of HIV. It is also known that patients who are HIV-
positive are characterised by an increased susceptibility to tuberculosis and clinical 
malaria (in terms of the frequency and severity of the episodes) (Corbett, Steketee, ter 
Kuile, Latif, Kamali & Hayes 2002:2177.)  
 
The interaction between HIV and other infectious diseases (and vice versa) in sub-
Saharan Africa is an increasingly important public health issue throughout the world. 
The net effect of this interaction between HIV and other infectious diseases is increased 
rates of transmission, morbidity and mortality. “HIV-1 has become a major endemic 
infection in Africa, with an unusually high potential to interact with other disorders, both 
through the generation of many immunosuppressed individuals and because its own 
infectivity and clinical course is altered by other infections” (Corbett et al. 2002:2177). 
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Figure 1.5:  Potential interactions between HIV-1 and other infectious diseases 
(Source: Corbett et al. 2002:2177) 
 
The interactions set out in figure 1.5 (above) between HIV and other infectious diseases 
affect the effective control of HIV in a number of ways. The effects of these interactions 
between HIV and associated infectious diseases vary from one disease to another. The 
most notable interaction occurs between HIV and tuberculosis. This particular 
interaction is directly associated with an increased burden of disease that results in 
increased rates of mortality and morbidity (see effect one [1] and two [2] in figure 1.5 
above). 
 
But there are also other conditions and diseases that are associated with increases in 
transmission and morbidity. Diseases that are associated with the presence of HIV in 
the human body are numerous and various. HIV-infected patients have become, for 
example, the locus for a recent resurgence in once-rare diseases such as 
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cryptococcosis, enteric pathogens, bacterial pneumonia and malaria, all of which have 
now become common causes of morbidity and mortality in HIV-infected patients. 
 
It has been observed, for example, that patients who are infected with HIV are far more 
vulnerable to various kinds of morbidity, and that their mortality rate is higher than 
comparable mortality rates among HIV-negative individuals infected with the same 
pathogens (see effect three [3] and four [4] in figure 1.5 above). Increased rates of 
transmission of these infectious diseases and increased HIV replication (see effect 
three [3] and four [4] in figure 1.5) result in an acceleration of the effect of HIV that 
ultimately culminates in full-blown AIDS. It is also known that HIV infectivity (see effect 
four [4] in figure 1.5) can be increased by the involvement of other infections, especially 
the kind of sexually transmitted infections that are often responsible for high HIV 
transmission rates in the first place. 
 
The direct or indirect compounded effect of this increased incidence and prevalence of 
infectious diseases on HIV-infected and non-infected individuals poses a serious threat 
to the already-overextended public health systems in the countries of Africa, and it will 
undoubtedly exert a significant effect on future survival trends (Corbett et al. 
2002:2177). 
 
1.2 BACKGROUND TO THE RESEARCH PROBLEM 
 
The greatest impact of HIV/AIDS over the past two decades on rural communities in 
Uganda is that it has increased mortality rates. HIV/AIDS-related mortality and morbidity 
have significantly contributed to the overall burden of disease and death with which 
Ugandan health services have had to cope. It has been estimated that of the 2.6 million 
people who were infected by HIV, approximately 1.6 million have already died of HIV-
related illnesses and conditions. Most of these people were in the most productive age 
groups that range between 15 and 49 years old. The loss of so many people from the 
country’s most economically and educationally active population sector has obviously 
affected the productivity of Uganda, and bodes ill for a future in which the accumulated 
talents and ability of such people would have been decisive for the progress and welfare 
of their country (Uganda AIDS Commission – Government of Uganda 2008:12). It has 
also been estimated that 130 000 new HIV infections continued to occur annually in 
Uganda (Uganda AIDS Commission – Government of Uganda 2008:12). HIV is 
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therefore currently responsible for the enormous burden of disease in Uganda. A 
proportionately huge number of people have already died from the HIV virus, and, of 
those who are still alive, a large number continue to succumb to the effects of HIV/AIDS 
every year.  
 
Mermin, Were, Ekwaru, Moore, Downing, Behumbiize, Lule, Coutinho, Tappero and 
Burnell (2008:752) state unequivocally that “antiretroviral therapy [ART] is the most 
effective clinical intervention for reduction of mortality in people with HIV-1 infection”. 
The key objective in encouraging HIV-infected people to participate in freely available 
ART treatment programmes in high-prevalence, low-resource settings is therefore, 
firstly, to reduce as far as possible the extremely high levels of morbidity and mortality 
that are associated with the prevalence of HIV/AIDS among patients. Secondly, to 
reduce the devastating and destructive effects that such levels of morbidity and 
mortality have on urban and rural communities and on the limited resources of the 
health care system. By 2003, 100 000 people living with HIV/AIDS in sub-Saharan 
Africa were participating in free ART programmes. This figure rose to 810 000 by the 
end of 2005 – only two years later (WHO 2006a:7). By the end 2008, three million 
people who were living with HIV/AIDS in sub-Saharan Africa were actively participating 
in ARV treatment programmes (WHO, UNAIDS & UNICEF 2009:54). 
 
While the monitoring of HIV trends is still dependent upon sentinel surveillance at 
selected antenatal clinics, there is little or no monitoring of the overall impact that ART 
programmes make on the mortality rates that prevail in all facilities that provide free 
access to ART (Asamoah-Odei et al. 2004:40). By 2008, freely available ART in the 
health care facilities of Uganda had been available for more than four years (i.e. since 
2003) (Uganda AIDS Commission – Government of Uganda 2008:25). In Uganda, there 
are 286 ART sites including hospitals and health centres (Uganda AIDS Commission – 
Government of Uganda 2008:26). 
 
This annual increase in the access that HIV-infected people have to free ART in the 
rural communities of Uganda is therefore expected to diminish and ultimately reverse 
the mortality rates that are attributed to the effects of HIV/AIDS. “Knowledge is lacking 
with respect to which combination of prevention and treatment strategies work best, and 
under what circumstances” (Bennett et al. 2006:79). There is therefore an urgent need 
to identify, analyse and assess the numerous ways in which HIV/AIDS increases the 
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mortality rate in countries such as Uganda, and to determine the impact of ART on 
mortality rates because some aspects of the HIV/AIDS mortality equation are not yet 
fully understood and because, as Bennett et al (2006:79) point out: “The global 
commitment to scale up HIV/AIDS services is a huge experiment.” These researchers 
have also pointed out that “there is need for data to demonstrate the effect and [to] 
secure future funding” (Bennett et al. 2006:79).  
 
The introduction to this chapter and the explanation of the background to the HIV/AIDS 
epidemic in Uganda that the researcher presented in this section indicate that it is likely 
important for both those responsible for the programmes and the public at large need to 
appreciate the beneficial effects of free access to ART for those who are HIV-positive or 
suffering from the effect of AIDS. It is therefore vitally important to understand the 
factors that influence the mortality and morbidity trends in the rural settings of Uganda. 
After four years of access to free ART in the rural areas of Uganda, a study of this kind 
should be able to provide some useful answers to the questions raised by the genuine 
concerns of the people of Uganda about the devastating effects of the HIV epidemic. 
The researcher feels that that carefully planned research and the correct 
implementation of properly designed interventions should be able to achieve the 
ultimate goal of making ART freely available to HIV-infected people: that goal is, of 
course, a significant and meaningful reduction in current morbidity and mortality rates.  
 
The purpose of this study was therefore to investigate the mortality trends before and 
after the introduction of free antiretroviral treatments in a selected rural setting in Mpigi 
district of Uganda in order to obtain a more comprehensive view of the successes and 
challenges that result from the implementation of the ART programme in Uganda. The 
results of this study have provided a useful practical and theoretical basis for the 
ongoing monitoring of mortality trends and the implementation of targeted interventions. 
The study has also emphasised the critical importance of the role that health managers 
should play in the refinement, maintenance and extension of the scope of hospital 
records systems. It is only when hospital records are meticulously designed and 
maintained by the nursing, medical and administrative personnel of a hospital that they 
are capable of indicating which patients are most at risk of future HIV infection.   When 
such predictions can be made on the basis of reliable and comprehensive hospital and 
clinic record-keeping, it will be possible for health care personnel to arrange and 
manage access for HIV-infected patients to ART. This factor alone will exert a profound 
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and significant impact on the mortality rates that result from HIV infection and the 
progression of AIDS in affected patients.  
 
The results and recommendations of this study will benefit the health status of the 
citizens of Uganda and other countries because it provides a rational explanation of 
those factors that contribute and cause the high mortality rates that are associated with 
HIV/AIDS. Many of these factors have not yet been adequately investigated and 
described. This research also indicates how important it is for health systems to monitor 
mortality trends because they are a key indicator to the quality and efficacy of health 
service delivery in any country. Although this research focuses on the situation in 
Uganda, the findings of this study should be equally applicable to all countries in which 
HIV is the most common current precursor to morbidity and death. 
 
1.2.1 Country profile: Uganda 
 
This short introductory section will orientate the reader with regard to the position of 
Uganda in Africa and the world. It therefore offers a brief profile of the Uganda and the 
countries that surround it.  
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Figure 1.6:  Map of Africa indicating the location of Uganda 
(Source: Department of Peacekeeping Operations – Cartographic Section – United 
Nations 2004:[1]) 
 
While figure 1.6 sets Uganda in the context of the other countries of Africa, figure 1.7 
contains a much closer review of the countries that border Uganda, and indicates the 
situation of the Mpigi district where this study was conducted. The Republic of Uganda 
is a land-locked African country that is situated in East Africa. Uganda shares common 
borders with Kenya in the east, Tanzania in the south, Rwanda in the south-west, the 
Democratic Republic of Congo in the west, and Sudan in the north (see figure 1.7: Map 
of Uganda).  
Uganda 
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Figure 1.7:  Map of Uganda indicating the location of Mpigi district 
(Source: Department of Peacekeeping Operations – Cartographic Section – United 
Nations 2004:[2]) 
 
Figure 1.7 shows where the Mpigi district is located in Uganda. This district is 
surrounded by the Masaka and Kalangala districts in the south, the Wakiso district in 
the east, the Sembabule district in the west, and the Mubende and Luweero districts in 
the north.  
 
Although Uganda is land-locked, it covers a total area of 241 038 square kilometres with 
Lakes Victoria in the southern border, Albert and Lake Edward on the western border. 
From an administrative point of view, it is divided into 79 districts, and it operates on the 
basis of a decentralised local governance system (Uganda AIDS Commission – 
Mpigi District 
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Government of Uganda 2008:1; Uganda Bureau of Statistics – Government of Uganda 
2006a:1). The total population of Uganda in July 2008 was estimated to be 31 367 972 
(Central Intelligence Agency 2008:[1]). It was also estimated that about 86.9 of the 
population lived in rural areas and that 61.2 % of the whole population could be 
classified in the age groups of between 10 and 59 years old (Uganda AIDS Commission 
– Government of Uganda 2008:1). At the annual population growth rate of 3.2% per 
annum (United Nations Development Program [UNDP] 2007:21; Uganda Bureau of 
Statistics – Government of Uganda2006c:viii), Uganda is reported to have one of the 
highest population growth rates globally. This population growth rate can be compared 
to the average of all the other sub-Saharan Africa countries, which have a population 
growth of 2.4% (Uganda AIDS Commission – Government of Uganda 2008:1). 
 
The age distribution of Ugandans is as follows: 50% of the population are between zero 
and 14 years of age; 47.8% of Ugandans are between 15 and 64 years old, and 2.2% 
are 65 years old or older (CIA 2008:[1]). One may therefore regard Uganda as a 
predominantly “young” society because nearly half of its population is within the sexually 
active and reproductive phases of human development. 
 
The mortality rate of adults in Uganda is 9.3 and 8.2 per 1000 of the population for 
males and females respectively (Uganda Bureau of Statistics – Government of Uganda 
2006a:278). The life expectancy at birth is 52.3 years (CIA 2008: [1]). AIDS has exerted 
a considerable effect on the average Ugandan’s life expectancy, on the infant mortality, 
and on exceptionally high mortality rates. It has also created a number of anomalous 
and unusual effects in population distribution when these factors are examined in terms 
of age and gender (CIA 2008:[1]). The burden of disease throughout the country is 
abnormally high if one compares it to that which the country experienced in the years 
before 1980. This is a direct result of the excessive mortality that results from HIV- and 
AIDS-related illnesses. 
 
1.2.2  Profile of the Mpigi district  
 
Mpigi is a rural district situated in central Uganda (see figure 1.7). Mpigi town is the 
main town of the district, and is located approximately 35 km south of the capital city of 
Uganda, Kampala. The district occupies a total area of 3 714.9 km2 (Mpigi District 
Information 2008:[1]). 
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The 2002 national census revealed that the Mpigi population was 414 757 in that year 
(Ministry of Health – Government of Uganda 2003a:14).. The population growth rate in 
the Mpigi district is 1.3% (Uganda Bureau of Statistics, Government of Uganda 
2006a:47), therefore, the projected population of Mpigi district in June 2008 was 446 
930. Only 7% of the people who live in the Mpigi district actually live in urban areas, and 
the rural communities are often remote and widely dispersed (Uganda Bureau of 
Statistics – Government of Uganda 2006c:46). 
 
 
Figure 1.8:  A map of the Mpigi district that indicates the sub-counties 
(Source: Mpigi District Local Government 2008:11) 
 
The Mpigi district consists of 17 sub-counties (see figure 1.8 above) and four counties. 
The hospital in which the researcher conducted his investigations for this study is 
situated in the Nkozi sub-county of the Mawokota South county, which consists of the 
Nkozi, Kituntu and Buwama sub-counties. The main language spoken by the people 
who live in the Mpigi district is Luganda. The major economic activity in the district is 
agriculture, and food crops such as sweet potatoes, beans, cassava, maize, bananas, 
groundnuts and coffee are all actively cultivated by the local population (Mpigi District 
Information 2008:[1]). 
 
1.2.3  Health services in the Mpigi district 
 
The health services in the Mpigi district are organised in terms of the National Health 
Policy set out by the Ugandan government which has decentralised health services to 
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the level of health sub-districts. A health sub-district in this context is defined as the 
operational unit at county level that is mandated with the responsibility of delivering the 
minimum health care package that the government makes available to the people of 
Uganda (Ministry of Health – Government of Uganda 2005:20).  
 
The health system is divided and organised into levels II, III and IV. The Mpigi district 
has 27 health units at level II, which is the first level of care in the community and which 
offers out-patient services. Level III offers basic preventive, promotive and curative 
services and also supports level II facilities. Mpigi has 23 level III facilities. The highest 
level in the district is level IV which consists of two hospitals and two health centres. 
The facilities that provide level IV care are also referred to as health sub-district 
headquarters and they are responsible for providing leadership, preventive, curative and 
surgical services, and together they constitute the physical base of the health sub-
district management team (Ministry of Health – Government of Uganda 2005:20.)  
 
While a level II health centre serves a catchment population of approximately 5 000, 
level III facilities offer services to an average population of up to 20 000. Level IV 
facilities are staffed by resident medical officers and cover a population of up to 100 
000. A general hospital covers a population of between 100 000 and 1 000 000 people 
(Ministry of Health Uganda 2000:11, 12, 71.) 
 
This study focused on only one of the four health sub-district headquarters in Mpigi, 
which is responsible for one of the two hospitals in the district. 
 
1.3 PROBLEM STATEMENT 
 
In the 1990s, the rural communities of Uganda and other developing countries (but 
especially those in sub-Saharan Africa) experienced very high levels of HIV infections 
(WHO & UNAIDS 2004a:25). This high HIV infection rate was directly associated with 
the significant increase in mortality rates that were generated by the opportunistic 
infections that are characteristic of the advanced stages of HIV/AIDS. In Mwanza in the 
United Republic of Tanzania and in Rakai in Uganda, HIV was a causative factor in 
between 50% and 66% respectively of all the deaths during this period (Lopman et al. 
2006:189).  
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It was in the early 2000s that access to free ART for all members of the HIV-infected 
population was first “rolled out” (initiated) in Uganda. This programme was subsequently 
extended in scope and intensity in Uganda and in 14 other developing countries, and 
was supported financially and in other ways by the PEPFAR, the Global Fund, and the 
WHO (Mermin et al. 2008:758). While the “roll out” of free access to ART in Uganda 
began in 2003, it has since been expanded to offer ART to 106 000 PLWHA in 2007 
and to 153 718 PLWHA by December 2008 (Ministry of Health – Government of 
Uganda 2009:42; Mermin et al. 2008:758).  
 
Ever since the roll out of free access to ART, observers in Uganda have noted the 
impact of the efforts that have been made since 2002 to minimise the impact of 
HIV/AIDS on the population of Uganda. The success of the programme to make ART 
freely available to those who needed it is evident from the following reported 
observations: 
 
• Uganda was able to report a reduction in the prevalence of HIV infection from 
13.0% (in the early 1990s) to 4.1% (by the end of 2003) (WHO & UNAIDS 
2004a:25).  
• Free antiretrovirals (ARVs) have also been freely available to the public through 
public and private-not-for-profit [PNFP]) hospitals for more than four years 
(Uganda AIDS Commisison – Government of Uganda 2008:25).  
• Health care workers such as medical doctors, clinical officers, pharmacists, 
nurses and other categories of health care providers (such as laboratory staff 
who offer health-related services) have been trained in large numbers in the 
counselling, diagnosis and management of HIV and HIV-related illnesses 
(Uganda AIDS Commission – Government of Uganda 2008:24).  
• Mermin et al (2008:757) reported a 90% reduction in the mortality rate among 
HIV patients who adhered strictly to their ART regimen in Uganda. 
 
1.3.1 The impact of antiretroviral therapy on morbidity and mortality rates 
 
A large number of researchers and experts have asserted that ART has contributed to 
the decline in HIV-related illness and death in HIV-positive individuals in developed 
countries (Beck, Mandalia, Williams, Power, Newson, Molesworth, Barlow, Easterbrook, 
Fisher, Innes, Kinghorn, Mandel, Pozniak, Tang & Tomlinson 1999:2160; Mocroft, 
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Ledergerber, Katlama, Kirk, Reiss, d'Arminio Monforte, Knysz, Dietrich, Phillips & 
Lundgren of The European Union Research Strategy to Infections Diseases [EuroSIDA] 
Study Group 2003:22-29; WHO & UNAIDS 2002:3). In addition, Carter (2005:[1]) is of 
the opinion that “consistent with the introduction of potent anti-HIV treatment, 
admissions fell from 129,000 in 1996 by 25% to 97,000 in 1998 and by a further 6% to 
92,000 in 2000”. 
 
The four years from June 2004 to June 2008 when free ART access was available in 
Uganda have resulted in major health gains that have unfortunately been inadequately 
documented. An insufficient amount of research has been undertaken to address key 
issues about the effect and long-term impact of ART on morbidity and mortality trends in 
poorly resourced countries. The National HIV/AIDS programmes in sub-Saharan Africa 
confined themselves only to monitoring the number of patients who are using ART in a 
systematic way and the prevalence and incidence of HIV as indicators of the success or 
otherwise of their HIV interventions. But they have neglected to keep careful track of the 
mortality trends and patterns that are the focus of this study, and which need to be 
monitored if researchers and administrators wish to know just how effective (or 
otherwise) these ART programmes have been.  
 
Knowledge about the extent of ART access on the part of those who need it remains a 
crucial limitation to the successful implementation of ART programmes. We know, for 
example, that in 2008, ART in sub-Saharan Africa was being accessed by 44% (41%-
48%) of those who needed it. This means that more than five million people who 
needed ART were not accessing treatment. It is information such as those that makes 
“it absolutely critical to accelerate programme delivery to reach universal access goals” 
(WHO, UNAIDS & UNICEF 2009:5). Such limitations in ART coverage contribute to late 
start of treatment (or a further discussion of this point, see 1.3.2 below) and to the 
discontinuation of treatment at one stage or another during the course of treatment. It 
has also been determined that inadequate coverage contributes to a higher degree of 
erratic or “intermittent” use of ARVs on the part of who have commenced treatment. The 
intermittent use of ARV medications results in poor adherence rates to ARV dosage 
requirements, and this ultimately negates the potential beneficial effects of ART for the 
patients themselves and can make the drugs become increasingly resistant to HIV in 
the long term. But the concept of the free universal access to ART for those in need of it 
is, therefore, of the utmost importance for ensuring that the ultimate objective of 
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reducing morbidity and mortality in the general population is achieved. Limitations of 
access that include interruptions in the supply of ARVs is one of the main reasons why 
the high HIV/AIDS mortality rates in developing countries continues to persist (Wood 
Montanera, Bangsberg Tyndalla, Strathdeed, O’Shaughnessya & Hogga 2003:2424). 
 
Late access to treatment also affects mortality trends among patients who are being 
treated by ART. Before 2003, the high cost of ART was the main reason why many 
patients who needed ART medications were unable to access them. But since ART has 
become freely available in most sub-Saharan African countries that have functioning 
health care systems, other factors such as socio-economic status, race, gender, the 
perceived stigma of being HIV-positive, geographical factors, cultural barriers and the 
hesitation of some physicians who should be actively encouraging their patients to 
participate in ART, are increasingly playing a significant role in limiting access to these 
free medications (Wood et al. 2003:2421, 2422).  
 
The commencement of ART before the manifestation of advanced forms of HIV disease 
that tend to occur concurrently with very low CD4 T cell counts, are reported to be 
associated with more favourable long-term prognoses and better patient survival rates 
(Rosen, Fox & Gill 2007:1698; Wood et al. 2003:2421. The contrary is also true 
because very low CD4 count levels (and especially counts of less than 200 cells/µl) 
usually indicate a poor prognosis. In an a review of mortality trends among patients on 
ART in sub-Saharan Africa, the median baseline CD4 T cell count ranged from between 
43 and 147 cells/µl. This was also associated with a short median duration of follow-up 
ranging from between 3 and 46 (Lawn, Harries, Anglarete, Myer & Wood 2008:1898.) It 
is important to note that late initiations of treatment have been widely reported in sub-
Saharan Africa even though such late commencements continue to be a critical factor in 
the success or otherwise of ART services – especially in settings with inadequately 
financed, staffed and managed facilities. 
 
Poor or intermittent adherence to ARV dosage regimens and low patient retention rates 
also exert a highly negative effect on the mortality trends in ART programmes. Rosen et 
al (2007:1696) reported an average attrition rate of 22% in sub-Saharan Africa. The 
death of the patients concerned and the failure to pursue follow-up (for whatever 
reason) were responsible for 40% and 56% respectively of the incidence of attrition. 
WHO has reported an attrition rate of 25% at 12 months and 33% at 24 months (WHO, 
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UNAIDS & UNICEF 2009:5). While attrition rates continue to be so high in high 
prevalence settings, it is unlikely that ART programmes will significantly improve the 
morbidity and mortality trends in hospital settings.  
 
1.3.2 Limitations on the optimisation of antiretroviral treatment  
 
There are four major factors reported by researchers that may limit the optimisation of 
the benefits of ART. 
 
Firstly, Carter (2008:[2]) reports a significantly higher risk of deaths in South Africa 
among HIV/AIDS patients because patients are given ART when the AIDS-related 
diseases and conditions that are associated with HIV have reached an advanced stage 
of manifestation. It therefore seems probable that late diagnoses in combination with the 
commencement of ART treatment when the health status of patients has already been 
significantly undermined (especially in low resource settings such as Uganda) will be 
unlikely to result in significant long-term reduction in morbidity and mortality.  
 
Secondly, Uganda is deficient in the infrastructural and program monitoring systems 
that enable physicians adequately to monitor the viral loads and CD4 counts of all 
patients whenever they report for diagnosis and follow-up. This places physicians in a 
very difficult position because they are unable to track the success or otherwise of the 
ART that has been offered to the patient. This absence of monitoring systems 
contributes to the inability of the health care system to reduce mortality rates among 
HIV-positive patients (Jahn, Floyd, Crampin, Mwaungulu, Mvula, Muntali, McGrath, 
Mwafilaso, Mwinuka, Mangongo, Fine, Zaba & Glynn 2008:1607).  
 
Thirdly, Mermin et al (2008:758) reports how the effects of rampant poverty have 
prevented HIV/AIDS patients from successfully accessing and utilising ART. Poverty 
also prevents patients (and especially patients from rural areas) from producing the 
necessary transport fees that will enable them to keep follow-up appointments at their 
health care facilities. Poverty thus contributes to poor attendance rates at clinics and 
prevents patients from renewing their prescriptions by obtaining refills of their 
medications. This also interrupts the regularity with which these medications should be 
taken (a factor that is especially important with ARV) medications and it prevents 
patients from being examined for the secondary infections or any other AIDS-associated 
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symptoms. Poverty also obviously contributes to poor nutrition and this in itself results in 
a progressive deterioration in the health condition of HIV/AIDS patients on ART. All 
these factors that result from the poverty of the patients concerned are endemic among 
ART patients in developing countries.  
 
Fourthly, the poverty of many patients in developing countries and the limited resources 
they have to pursue follow-up and surveillance, negatively affect ART patient retention 
rates and thus limit the benefits that properly administered ART can have on prospects 
for patient survival (Mermin et al. 2008:758; Rosen et al. 2007:1696). Since poverty 
contributes to below-optimal adherence levels, it also increases the probability of poor 
treatment outcomes and the development of resistance in ARV medications (WHO 
2005a:[1]).  
 
Increased access to ART is beset by a number of barriers and challenges that are 
discussed in detail in section 2.10. But as more and more people make use of ART but 
fail to use it as rigorously as it should be used, HIV drug resistance increases and this 
creates a whole range of problems for future and current ART users (Bartlett & Shao 
2009:644). Other notable challenges faced by ART programmes in resource-limited 
settings include insufficient funding, inadequate diagnostic facilities, a lack of properly 
qualified staff and serious defects in (or the simple absence of) adequate data 
management systems (Miti 2008:[1]). 
 
Although the significance of these factors varies from place to place and depends on 
the magnitude of these problems experienced, the impact that they make on mortality 
rates should not be underestimated. Such challenges may negate most or all of the 
advantages that patients may gain by having free access to ART in the first place. 
Another negative outcome may be that mortality rates merely remain more or less static 
or (worse) may even increase over time – even for patients who are being treated with 
ART. When it becomes evident that the mortality rate of patients on ART is not 
decreasing, one may expect that mortality rates in general will either stagnate or 
increase.  
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1.3.3 Goal and purpose of antiretroviral treatment 
 
The reduction of morbidity caused by HIV- and AIDS-related illnesses and conditions, 
and the subsequent reduction in the general mortality rate of the affected population, 
remains the ultimate goal of any ART programme. This is especially true for 
programmes that have been designed for populations in which the rate of HIV infections 
is far above the national population average. The current goal of antiretroviral 
treatments is to reduce the HIV viral load in each individual patient to the lowest 
possible level until the virus becomes undetectable by means of normal tests, and then 
to maintain patients in that state of equilibrium for as long as possible (Amoroso, Davis 
& Redfield 2002:323). In order to achieve this, it is essential to enroll as many HIV-
infected people in need of ART as possible in an ART programme. 
 
But this kind of programme can only be effective if the mortality and morbidity rates of 
patients who are enrolled in the programme are continuously monitored so that the 
health care personnel who administer the programme will be able to judge the 
effectiveness or otherwise of the programme that they administer. Unless this is done, 
there is no way of knowing (apart from unreliable anecdotal observations) just how 
effective an ART programme might be. Continuous monitoring is therefore an essential 
component of any serious ART programme. The obvious and logical assumption is that 
after four years of increased access to free ART in rural hospitals, in combination with 
other factors, one should be able to observe a notable reduction in the prevalence of 
HIV in a country such as Uganda where, as indicated above, the overall mortality rates 
are expected to exhibit a downward trend. The key objective of this particular study was, 
therefore, to determine the trend of adult mortality over a six-year period.  
 
The accurate determination of mortality trends will provide a “reality check” or 
benchmark for programme managers in Uganda, and it will enable them to review 
mortality trends and identify deficiencies, problems and challenges in the provision of 
ART access. This, in turn, will enable managers to administer ART programmes in such 
a way that they will be able to radically to reduce rates of patient mortality. It was 
because there was an urgent need to obtain reliable data about mortality trends in 
Uganda after free access to ART had been introduced, that the researcher undertook 
this study in a particular rural community that, he believed, could serve as a microcosm 
of the wider trends in Uganda as a whole.  
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Even three years after free ART had first been made available in hospital settings 
across Uganda, there was no reliable data in terms of which adult mortality trends were 
occurring could be evaluated. It was therefore essential to obtain the kind of data that 
would enable researchers to review the effect of free ART delivery on the overall adult 
mortality trends – especially in rural settings where one encounters the highest rates of 
HIV/AIDS mortality. It was obviously essential for researchers and administrators to be 
able to evaluate the effect of making ART freely available to HIV-infected people so that 
the effects of the programme in Uganda could be measured and compared to similar 
programmes in other settings in the developed world. 
 
Not only was it important to be able to track the impact of the ART roll-out on the 
mortality rates of HIV/AIDS patients; there was also an urgent need to be able to track 
the mortality trends that were being caused by other significant diseases. Corbett et al 
(2002:2177) have explicitly recommended that any increased access to HIV prevention 
and care should be accompanied by an intensified routine programme of public health 
surveillance so that all who are concerned with the problems of health care in Africa will 
be able to acquire an accurate understanding of the current realities of infectious 
disease control in Africa. Statistics and information from those countries where mortality 
and morbidity rates have been monitored over the past two decades have revealed that 
there has been an enormous resurgence in other serious and potentially fatal infectious 
diseases such as treatment-resistant tuberculosis and malaria (McMichael, McGhee, 
Shkolniko & Valkonen 2004:1155). 
 
From the introduction above and the information that the researcher has provided, the 
following question suggested itself as the basis for detailed research: 
 
What was the overall trend of mortality in a rural hospital setting since the 
introduction of free ART in Uganda? 
 
This study therefore undertook to determine the mortality rates, mortality trends and 
causes of adult mortality in a particular rural hospital in Uganda. The study period was a 
six year period, three years before introduction of free ART (pre-free ART era) and three 
years after  introduction of free ART (post-free ART era) from the time this research was 
undertaken. 
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1.3.4 Research questions 
 
The high prevalence of HIV/AIDS in Uganda increased the overall morbidity and 
mortality rates of those who were infected by the virus. At the time when this study was 
undertaken, it was more than three years since free antiretroviral medications (ARVs) 
had been made available to the HIV-infected population of Uganda. In spite of the 
inadequate monitoring of mortality and morbidity trends in rural hospitals in Uganda, the 
following questions required urgent answers:  
 
• What trends did adult mortality and morbidity rates reveal when one compared 
the period before ART became freely available to the period after ART became 
freely available in the rural hospital in the Mpigi district of Uganda?  
 
• What overall effect did the availability of free ART access have on the rates of 
morbidity and mortality in the rural hospital in Mpigi district of Uganda? 
 
• What recommendations could one make that will ensure that the provision of free 
ARVs is more effective so that they would reduce the high mortality rates that 
were being experienced in Mpigi district and in similar settings in Uganda?  
 
1.4 PURPOSE AND OBJECTIVES OF THE STUDY 
 
The overall purpose of this study was to identify and analyse the mortality trends and 
demographic characteristics of the patients who died in the rural hospital in the Mpigi 
district of Uganda over a period of six years. The researcher therefore undertook to 
investigate the mortality trends in terms of causes and the percentage of deaths that 
were known to be associated with HIV- and AIDS-related illness both before and after 
free ART became available to the people lived in the rural setting in the Mpigi district.  
 
1.4.1 Study objectives  
 
The researcher defined the specific objectives of the study in the following way:  
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• To investigate the trends exhibited by adult hospital mortality rates and to 
compare the trends of the pre-free ART period to the trends of the post-free ART 
periods in the rural hospital in the Mpigi district of Uganda. 
 
• To determine the overall effect of free ART access on hospital mortality rates in 
the rural hospital in the Mpigi district of Uganda.  
 
• To make recommendations about ways in which the provision of free ARVs could 
be administered so that the exceptionally high mortality rates in the Mpigi district 
and in similar settings in Uganda could be radically reduced. 
 
1.4.2 Assumptions of the study  
 
An assumption is an opinion that is believed to be true for the matter in hand although 
there may be no immediate evidence that proves its veracity (Polit & Beck 2006:495). 
The researcher made the following assumptions other purposes of this research:  
 
• All hospital-based deaths were recorded and certified, and this contributed to the 
available data about the practice of hospital-based medicine and nursing science 
in the hospital concerned.  
• All hospital-based deaths have been investigated and recorded in terms of 
primary and associated causes of death by qualified health care personnel.  
• ART was freely and uninterruptedly available to all HIV-infected patients in the 
hospital in which this study was conducted ever since it was first introduced to 
the catchment population who used the hospital concerned as their primary 
source of health care.  
 
1.5 DEFINITION OF KEY TERMS 
 
For the purpose of this study, the researcher defined the terms that were used in this 
study below in the following way: 
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1.5.1 Acquired immunodeficiency syndrome 
 
Acquired immunodeficiency syndrome - AIDS is an acronym that is made up of the 
following letters, each of which has a different meaning:  
 
A – Acquired: AIDS is called an acquired disease because it is a disease that one must 
“acquire” or obtained from another infected person or medium such as an infected 
needle or blood. It is not therefore a condition that can be inherited or transmitted 
genetically.  
 
I – Immune: This component of the acronym refers to the fact that the disease works to 
undermine and eventually destroy the human body's immune system. The immune 
system represents that physiological function of the human body that is programmed to 
resist and destroy invasive hostile entities such as bacteria, viruses and other disease-
causing agents.  
 
D – Deficiency: The word “deficiency” in the acronym AIDS refers to the fact that the 
disease undermines the human immune system so extensively that it becomes unable 
to function properly – and is therefore “deficient” or disabled.  
 
S – Syndrome: The word “syndrome” is used to describe AIDS because an HIV-
infected person will gradually deteriorate and become susceptible to a wide range of 
different diseases, morbid conditions and opportunistic infections, one or another of 
which will eventually prove fatal to the human host. Since the immediate cause or 
causes of death in each AIDS suffering varies from person to person, the ultimate 
effects of the HIV virus are characterised as a “syndrome” (San Francisco AIDS 
Foundation 2008:[3]). 
 
HIV is transmitted by means of infected human bodily fluids for example semen and 
blood, through unprotected sexual intercourse (sexual intercourse without condoms), 
the use of HIV-contaminated hypodermic syringes, and by means of a placental transfer 
from an infected mother to her foetus. Although no cure or vaccine has been developed 
for the prevention of infection in a person who has been positively exposed to HIV, a 
number of antiviral drugs are available that can decrease the viral load in the body of 
patients and the potentially lethal infections to which patients with AIDS can become 
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exposed. AIDS is defined in an adult when at least two major signs and one minor sign 
appear in a patient in the absence of other known causes of immunosuppression such 
as cancer or severe malnutrition. The major signs of HIV/AIDS include a weight loss of 
more than or equal to (≥) 10% of body weight, chronic diarrhoea for more than (>) 1 
month, and prolonged fever >1 month. Minor signs of HIV/AIDS disease include a 
persistent cough for >1 month, generalized pruritic dermatitis, recurrent episodes of 
herpes zoster, oro-pharyngeal candidiasis, and generalized lymphadenopathy. The 
presence of either generalized Karposi’s sarcoma or cryptococcal meningitis is also 
regarded as sufficient evidence for a positive diagnosis of AIDS (Grant & De Cock 
2001:1475; WHO 1986:72.) 
 
AIDS can also be diagnosed in an HIV positive person who has a CD4 (T-cell) count of 
less than 200 cells/µl or one or more of the opportunistic infections mentioned above 
(San Francisco AIDS Foundation 2008:[4]). A diagnosis of AIDS is not revealed by 
means of laboratory tests but is based on the clinical presentation of a patient. AIDS is 
also defined as a “disease of the human immune system that is characterized 
cytologically especially by a reduction in the numbers of CD4-bearing helper T cells to 
20 percent or less of normal – thereby rendering the subject highly vulnerable to life-
threatening conditions” (Merriam Webster’s Dictionary 2009a:[1]). 
 
In this study, the term “AIDS” is used to describe a clinical condition that is caused by 
HIV and that is responsible for most of the widespread adult morbidity and mortality that 
one encounters in Uganda.  
 
1.5.2 Antiretroviral treatment  
 
Antiretroviral treatment or therapy or “ART” is defined as the use of a combination of at 
least three drugs that will typically include either a protease inhibitor or non-nucleoside 
reverse transcriptase inhibitors (NRTI) and two NRTIs for the management of HIV 
infection (Sterne, Heman, Ledergerber, Tilling, Weber, Sendi, Rickenbach, Robins & 
Egger 2005:378). ART is also sometimes regarded as a synonym for the term “HAART”, 
which is an acronym for the words “highly active antiretroviral treatment” (Webster's 
Online Dictionary 2009a:[1]).  
 
Antiretroviral drugs (ARVs) are medications that are used in the treatment of retrovirus 
infections such as HIV. ARVs target viral enzymes, including reverse transcriptase and 
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protease, which are pivotal in the lifecycle of the HIV virus and which have been proven 
to be effective in reducing the extremely high levels of morbidity and mortality that are 
caused by HIV/AIDS (Morris & Cilliers 2008:79). The objective of this kind of 
antiretroviral treatment is to reduce the HIV viral load in a patient’s body to (if possible) 
undetectable levels, and thus to assist the person who is living with HIV/AIDS to regain 
health and to live a productive and healthy life (Amoroso et al. 2002:323). 
 
For the purpose of this study, ARVs refer to the medications that are prescribed for HIV 
positive patients in terms of the protocols issued by the Ministry of Health in Uganda, 
which were based on the guidelines and recommendations of the WHO (WHO 
2006b:11,17-64). In this study, the phrase pre-free ART period/era refers to the three-
year period between July 2002 and June 2005 before the hospital in the study offered 
free antiretroviral treatment to HIV-infected members of the public in the Mpigi district. 
The phrase post-free ART period/era in this study refers to the three-year period 
between July 2005 to June 2008 after free access to ART was offered to the patients of 
the hospital under review with the support of the Ministry of Health of the Ugandan 
government and its development partners. 
 
1.5.3 Cause of death  
 
“Cause of death” is defined in Webster’s Dictionary (2009b:[1]) as “the causal agent 
resulting in death or factors which produce cessation of all vital bodily functions”. 
 
In this study, the death refers to the clinical death of a patient that is characterised by 
the cessation of breathing and a detectable pulse rate or heartbeat and various other 
physiological signs of life. The cause of death may be attributed to the effects of disease 
or physical injury. These effects are documented in writing in the hospital records of the 
patient by the attending medical personnel as the primary or associated cause(s) of 
death. The leading causes of death in developing countries are infectious diseases. 
 
1.5.4 The cluster differential 4 receptor  
 
“The cluster differential 4” (CD4) is a glycoprotein that appears “on the surface of T 
helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells” (Morris & 
Cilliers 2008:79). CD4 is the primary receptor that is used by HIV-1 viruses to gain entry 
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into host T cells. HIV as a retrovirus infects and replicates primarily in the cluster 
differential 4 plus (CD4+) T-cells and macrophages. The virus gains entry into the cell 
by attaching itself to the CD4 receptor. It then encodes the enzyme reverse 
transcriptase in such a way that this allows a DNA copy to be made from the viral RNA 
(Morris & Cilliers 2008:79.)  
 
The CD4 cells are involved in coordinating and helping the immune response to 
proceed smoothly in protecting the body from infections (Gray 2008:123). Any disease 
such as an HIV infection that impedes or destroys CD4 cells causes the body's immune 
system to lose its ability to function, to become disorganised and to degenerate until it 
can no longer protect the body from alien invasive entities (Gray 2008:124).  
 
1.5.5 Human immunodeficiency virus  
 
“HIV” (also colloquially known as “the AIDS virus”) is a group of retroviruses that infect 
and destroy the helper T cells of the human immune system thus causing a significant 
reduction in their numbers – a deviation from their normal average number in the human 
body that is a diagnostic indicator of the disease AIDS (Webster's Online Dictionary with 
Multilingual Thesaurus Translation 2009:[1]). HIV is also defined as the agent that is 
responsible for the acute infectious manifestations, neurological disorders, and 
immunological abnormalities that are typical manifestations of the acquired 
immunodeficiency syndrome. HIV is a member of a group of viruses that belong to the 
primate-infecting lentiviruses of the family Retroviridae – which is why they are called 
“retroviruses” (Williamson & Martin 2008:109).  
 
In this study, HIV is used as an acronym for the human immunodeficiency virus – the 
highly infective retrovirus that causes the most common form of acquired 
immunodeficiency.  
 
1.5.6 Mortality  
 
“Mortality” is defined in this study as “the ratio of deaths in an area [proportionate] to the 
population of that area; [it is] expressed per 1000 [members of a population] per year” 
(Webster's Online Dictionary 2009c:[1]). Mortality in this study refers to the “number, 
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magnitude or frequency of deaths over a period of time among the total sick and well 
population of an area” (Webster's Online Dictionary 2009c:[2]). 
 
An “adult” in Uganda is defined in this study and by the Uganda Bureau of Statistics as 
an individual who is aged 15 years or older. “An adult death” therefore refers to the 
death of any person or individual who is 15 years or older (Uganda Bureau of Statistics, 
Government of Uganda 2006b:42).  
 
This study focuses on the phenomenon of adult mortality in rural settings in Uganda, 
and is particular concerned with the incidence of hospital mortality or the death of 
individuals who are 15 years or older who died in a hospital setting during the study 
period. 
 
1.5.7 Trend  
 
A “trend” is defined as “long term movement in an ordered series” (Webster's Online 
Dictionary 2009d:[2]). In terms of this definition, a trend may therefore remain 
unchanged, or show an upwards or downwards movement. The word “trend” is used in 
this study to describe the monthly and annual frequency of adult deaths in a particular 
rural hospital in Uganda. This study identified and analysed the significance of trends in 
the hospital’s mortality rates during the pre-ART and post-ART era in order to determine 
the impact of ART on the overall mortality trends of the hospital.  
 
1.5.8 Voluntary counselling and testing  
 
“Voluntary” is defined as “proceeding from the will or from one's own choice or consent” 
(Merriam-Webster's Medical Dictionary 2009b:[1]). “Counselling” is defined the ability “to 
advise especially seriously and formally after consultation” (Merriam-Webster's Medical 
Dictionary 2009c:[1]). “Testing” can be defined as a diagnostic process and a 
“procedure for determining the presence or nature of a condition or disease”(Merriam-
Webster Medical Dictionary 2009d:[1]).  
 
Voluntary counselling and testing are the processes to which individuals or couples 
subject themselves when they undergo pre-test (“before the test”) counselling, the 
assessment of risks, the HIV test itself, and post-test (“after the test”) HIV prevention 
counselling. 
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For the purpose of this study, voluntary counselling and testing are the processes that 
are used when individuals or a couple agree to subject themselves (under the guidance 
of health care professionals) to a pre-test counselling session, to the collection of a 
sample of their body fluid (blood) for the purpose of HIV testing, and to participation in a 
post-counselling session after the results of the test(s) have been made known to them.  
 
1.6 SIGNIFICANCE OF THE STUDY 
 
The significance of this study is that it has, by following widely standardised procedures 
for scientific research, produced a new understanding of mortality trends in settings 
where HIV/AIDS are widely prevalent. It also sets out to demonstrate how these trends 
were affected by the provision of free access to ARV treatment. The results of the study 
will enable programme managers to design evidence-based interventions to reduce the 
magnitude of HIV-related mortality and thus overall mortality rates in general in hospital 
settings such as the one in which this study was undertaken.  
 
Since the results of this study are not generalisable to the mortality trends in all rural 
hospitals across Uganda, this might be regarded as one of the limitations of this study. 
In spite of this, the study describes the dynamics of infection, treatment and mortality in 
Mpigi district and Mawokota South health sub-district – districts that are similar in many 
ways to other rural areas of Uganda.  
 
1.7 DEMARCATION OF THE FIELD OF STUDY 
 
The demarcation of the study field provided a framework within which the research took 
place, and the objectives of the study demarcated the problems and issues that needed 
to be included in the study and those that needed to be excluded from the research 
(Struwig & Stead 2001:44).  
 
The study took place in a private not- for-profit hospital that is situated in Mpigi district of 
Uganda. It was selected by the researcher because he was able to determine from the 
hospital's records that the hospital had admitted a significant number of people who 
were HIV-positive, and that it had consequently been compelled to deal with a very 
large number of AIDS-related deaths over the years. Another factor that made the 
hospital ideal for this research was that it had been providing free ART to HIV-positive 
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patients for more than three years prior to the commencement of the study. This 
coincidental factor provided the researcher with an ideal opportunity to compare the 
mortality trends in the three years preceding the provision of free ART with the mortality 
trends in the three years after free ART had become available to patients.  
 
The hospital in which this research was undertaken was a 100-bed private (not-for-
profit) hospital that charged a fee for all patients who were admitted for treatment. The 
hospital served as the health sub-district headquarters for Mawokota South, an area 
that is located in the Mpigi district and that had a projected catchment population of 99 
607 – 50 401 of whom were adults (i.e. who were 15 years or older in terms of the 
Ugandan government’s official definition of “adult”) (Lumala 2008:5,10). The hospital is 
supported by means of (1) grants from the government of Uganda (these are called 
“delegated funds”), (2) other funds obtained from bilateral donor arrangements, (3) 
privately allocated funds, and (3) other revenues (such as user charges) generated by 
the hospital (Lumala 2008:5). This hospital was also selected by the researcher 
because it was accessible, because the costs involved in the process of data collection 
were affordable, and because the process of data collection could be accomplished by 
the researcher in a shorter time than would have been possible in other hospitals.  
 
The study focused on hospital mortality trends among all admitted individuals who were 
15 years and older at the time of admission, over a period of six years. All pregnancy-
related deaths and any other deaths that occurred before admission to the hospital were 
excluded from the study. The researcher reviewed all the case notes that described the 
circumstances of the patients’ deaths that occurred during the study period. All in all, the 
researcher reviewed a total of 561 case files for the purposes of this study. 
 
Since the Ugandan government had been providing free ART to health care facilities, 
there was a prevalent assumption that the affected patients were following the 
recommendations of the medical staff by accessing free ART early after they had been 
diagnosed as HIV-positive. (“Early” here refers to the period before the onset of 
advanced AIDS and the appearance of any of the large number of illnesses or 
conditions that are associated with full-blown AIDS.) If patients were, in fact, doing this, 
they would have been able to avoid the severely compromising health conditions that 
eventually result in death for those who are infected with HIV. For the past two decades, 
HIV had been the leading cause of morbidity and mortality in Uganda, and the provision 
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of free ART and public education about HIV/AIDS is expected to have been able to 
reduce the incidence of the long-standing effects of untreated HIV infection and the 
inevitability of the mortality rates that follow from such a condition.  
 
This study therefore focused on the impact that free access to ART in the hospital 
setting made on mortality trends in the rural setting in which the hospital operated.  
 
1.8 RESEARCH METHODOLOGY 
 
Bowling (2002:143) defines research methodology as the practices and techniques that 
are used to collect, process and analyse data. Struwig and Stead (2001:44) also define 
research methodology as the collection and analysis of information in a way that will 
solve a problem, assist in the interpretation of a problem, or that will confirm or refute a 
specific hypothesis. The research methodology presents in specific terms the scientific 
method and procedures that the researcher will use to gather and analyse information. 
Included in the ambit of research methodology is the determination of sample size, the 
methods that the researcher uses to obtain a suitable sample, the way in which the 
researcher collects the data (such methods may include, for example, structured 
questionnaires, interviews and the examination and analysis of documents and 
historical records), the choice of measuring instruments, and clear explanations of how 
the researcher proposes to process and analyse the data (Bowling 2002:143).  
 
The definition in the previous paragraph indicates that research methodology includes 
the research design, the study population, the sample variables (which referred to the 
characteristics of the individuals in the chosen population), their status (in so far as this 
is important), their relationships with one another, the instruments that are used for data 
collection, and the procedures that the researcher uses for data analysis (WHO 
2001:11). Van Wyk (2005:728) notes that the term research methodology includes the 
essentials of research methodology, information about the questionnaires that are used, 
the size of the sample, the techniques of analysis, the types and sources of data, and 
the methods that are used in the analysis of the data. There is also importance in dating 
the various phases of the research such as the beginning and completion of all the 
major steps involved. This sets the research in a time framework that enables the 
reader to make sense of the methodology and the results (Van Wyk 2005:728). Since 
the research methodology thus frames all the activities that contribute to the success of 
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the research, the researcher has to make very careful decisions about the best ways to 
accomplish the research objectives.  
 
This chapter only provided a brief introduction to the question of research methodology. 
This topic will be discussed in much greater detail in chapter 3, which contains a 
comprehensive description of the research methodology the researcher applied in order 
to accomplish this study. 
 
1.8.1 Research design 
 
A “research design” has been defined as “the overall structure or plan of a research 
activity” (Bowling 2002:143). A research design is, in other words, “a summary or a 
master plan to be followed to realize the research objectives or hypothesis” (Van Wyk 
2005:82). The research design specifies the methods and procedures that were used 
for collecting and analysing the required information. A research design may be 
descriptive, exploratory or causal in nature (Van Wyk 2005:83).  
 
The researcher opted for a quantitative, retrospective, descriptive and cross-sectional 
research design approach for this study. By using this particular approach, the 
researcher was able to provide a detailed description of the significance of the adult 
mortality trends before and after the introduction of free antiretroviral therapy in the 
particular rural hospital in Uganda that he had selected for this research.  
 
1.8.1.1 Quantitative research 
 
The research method that is used in a descriptive design is structured and quantitative 
in nature (Van Wyk 2005:86). Quantitative research consists of a formal, objective and 
systematic process for generating information. In quantitative research, a researcher 
connects evidence according to a carefully predetermined plan under rigorous and 
controlled circumstances, and uses formal instruments to collect the required 
quantitative information (Somekh & Lewin 2006:215). Quantitative methodology focuses 
particularly on the collection of quantitative and numeric data. In this way, it is very 
different from a qualitative methodology, in which quantitative and numeric data play a 
minor (if any) role. 
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In other words, a quantitative methodology makes use of quantities and numbers in 
order to describe relationships between predetermined attributes, and it involves the 
collection and analysis of numerically or quantitatively structured data (Bowling 
2002:194). According to Van Wyk (2005:89), “quantitative research involves the 
collection of primary [numeric] data from large numbers of individuals with the intention 
of projecting the results to wider populations” in comparable circumstances. The aim of 
quantitative research is to be able to generalize about a specific population and to 
project its findings onto other populations that are similar in every respect to the 
experimental population that was involved in the original research. The data collected in 
quantitative research is then subjected to mathematical or statistical manipulation to 
produce conclusions that are broadly representative of the total population and 
forecasts of the probable course of future events under different but essentially similar 
conditions (Van Wyk 2005:89). Quantitative data consists of numerical data that is 
gathered by means of counting or measurement (Bland 1995:46).  
 
In this study, the researcher collected quantitative data by using structured data 
collection tools that are known as audit tools. After the data had been collected, he was 
able to analyse the relationships between various attributes and variables, and make a 
number of interpretations that he subsequently used to inform the discussion and 
recommendations. 
 
1.8.1.2 Retrospective aspect of the study  
 
The retrospective aspect of a study design refers to the collection of information that 
describes events that occurred in the past (Bowling 2002:195,197). In this study, the 
researcher transcribed data that he collected from the case files of patients who had 
died in the period between June 2002 and June 2008. The collection of information 
about events that have already occurred in the past thus refers to the retrospective 
aspect of the study. 
 
1.8.1.3 The descriptive aspect of the study  
 
Bowling (2002:195) referred to descriptive surveys as information that has been 
collected from a sample of the population. This kind of information can be analysed and 
interpreted to provide answers in terms of descriptive statements and measures. 
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Descriptive research is designed to answer “who, what, when, and how questions” (Van 
Wyk 2005:86). Beaglehole, Bonita and Kjellstrom (2000:30) note that descriptive studies 
often constitute the first step in an epidemiological investigation. Descriptive research 
identifies and analyses the significance of various human activities, events and attitudes 
in such a way that they are able to shed light on the meaning of certain phenomena that 
occur in the population of interest. It is therefore typical of descriptive research that it 
examines the prevalence and extent of certain prevalent conditions. In descriptive 
surveys, phenomena are observed rather than tested. Descriptive studies literally 
describe the phenomena of interest as thoroughly and meticulously as possible. It also 
brings together into a coherent whole the various associations between variables so 
that a researcher is able to estimate certain population parameters for testing and 
generating hypotheses (Beaglehole et al. 1993:30; Bowling 2002:196). 
 
In this study, the researcher collected information about mortality trends and other 
related data from all the death records of individuals who were 15 years or older in the 
selected rural hospital in the Mpigi district of Uganda at the time of their demise. He 
then analysed this information in order to arrive at an understanding of the effects of 
free access to ARV medications for the HIV-positive patients who were receiving 
therapy and treatment in the Mpigi rural setting.  
 
1.8.1.4 The cross-sectional nature of this study  
 
Cross-sectional studies entail the collection of data from a cross-section of a population. 
The cross-section may be taken from the whole population or from a proportion 
(sample) of it (WHO 2001:17). 
 
In this study, morbidity and mortality rates in a rural setting were the focus of 
investigation. Because the mortality records of deaths that have occurred in home 
settings are usually never reported in any statistical record systems and because such 
deaths constitute a significant proportion of all the deaths in rural settings in Uganda, a 
cross-section of the deaths that occurred in the hospital were considered to be a proxy 
measure of mortality trends that were more or less representative of a number of deaths 
in rural settings in Uganda.  
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1.8.2 Research methods 
 
The research method serves as the rationale for research, and it also articulates the 
criteria that are used for interpreting data (Burns & Grove 2001:223). In this section, the 
researcher describes the study population, the method of sampling, the sample itself, 
the method of data collection and the method that he used for data analysis. 
 
1.8.2.1 Population and sample 
 
The population in a study includes all the elements (which might be either objects or 
people) that meet the criteria that make them typical of a particular population (Burns & 
Grove 2001:47). Polit and Beck (2006:259) describe a population as “the entire 
aggregation of cases that meet the” requirements of specified criteria. The population 
represents the entire set of individuals (either human beings or objects) that have 
common characteristics. The accessible population comprises those individuals who 
conform to the eligibility criteria and who are available for participation in a particular 
study, whether directly or from the evidence of the records of their experiences in the 
hospital (Burns & Grove 2005:342). 
 
In this study, the population consisted of all the individuals who had died in a selected 
hospital in the Mpigi district of Uganda. 
 
A sample can be defined as a subset of a population that is selected to participate in a 
study (Polit & Beck 2006:260). A convenient sample consists of the most readily 
available or most convenient group from a particular sample (Cohen, Manion & 
Morrison 2000:102). The researcher chose this method because it enabled him to gain 
ready access to the hospital files of the deceased.  
 
The sample that was selected for this study included all those adult individuals who had 
been admitted to the medical and surgical wards in the hospital, and had subsequently 
died in the hospital. Because of the relatively low incidence of deaths in rural hospitals, 
the researcher included all adult hospital deaths of patients who had been admitted to 
hospital during the study period. The eligibility criteria were therefore fixed as follows:  
 
42 
(1) The cases that were used in the study included all adult hospital deaths (i.e. only 
those individuals who were 15 years or older when they died were included in the data). 
(2) All the patients were included for the collection of data had died in the medical and 
surgical wards of the hospital in the period between June 2002 and June 2008.  
 
The researcher fixed the exclusion criteria as follows: (1) All maternal- or obstetric-
related deaths, (2) All deaths that had occurred before admission, and all dead bodies 
that had been admitted to the hospital for post-mortems or autopsies were also 
excluded from the sample. The researcher identified the study population from by 
examining the hospital patient records (such records included death certificates, 
hospital inpatient case notes and registers).  
 
Sampling can be defined as the process of selecting a portion (component) of the 
population that is representative of the entire population. The elements that are selected 
are then referred to as the sample (Polit & Beck 2004:291.) According to Bryman 
(2004:87), a sample has to be representative of the population it purports to represent if 
one wants to be able to make generalizations about the findings from the sample to any 
wider and similar populations. 
 
Sample size refers to the number of elements that are included in the sample. Brink, 
Van der Walt and Van Rensburg (2006:135) and De Vos, Strydom, Fouche and Delport 
(2002) suggest that “a study with an over-large sample may be deemed overly 
sensitive”. A large sample is therefore no guarantee of an increased degree of accuracy 
in the findings (Brink et al. 2006:136). The sample size for this study consisted of 561 
patient records of deaths that occurred between June 2002 and June 2008.  
 
1.8.2.2 Data collection 
 
Burns and Grove (2001:49) defined data collection as “the precise systematic gathering 
of information relevant to specific research objectives or questions”.  In this study, the 
researcher collected data by using two (tools A and B), both of which were structured 
audit tools.  
 
In order to place himself in a situation in which he could compile a case-by-case 
summary, the researcher designed a data collection called tool A, which consisted of 
four sections:  
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• Section 1: This section reflected the individual’s demographic profile, and it 
included the hospital or in-patient number, the hospital ward, the sub-county of 
the patient’s home location, the patient’s date of birth, and the patient’s recorded 
age at the time of admission and death.  
• Section 2: This section consisted of the record of the patient’s last visit, including 
the date of admission, the date of death, the diagnosis upon admission, the 
recorded cause of death and the associated causes of death.  
• Section 3: This section consisted of recorded information from the patient’s 
record that related to his/her HIV infection status, and it included the following: 
the patient’s HIV status, his/her history of ART participation, the date when ART 
commenced, and the assumed causes and evidence for the causes of death as 
recorded in the records.  
• Section 4: The last section consisted of endorsements by the research assistant. 
 
After the data collections tools had been pre-tested, they were thereafter used for data 
collection. On the basis of diagnosis and the cause of death, all deaths were classified 
as being either HIV-related or non-HIV-related – or “undetermined”. All this data was 
compiled by making use of this structured audit tool (data collection instrument), and the 
data collection process entailed the scrutiny of all patient records during the audit or 
review of the patients’ records. Data collection tool A collected information about the 
following features: the age of the patient at time of death, the patient’s gender, the 
hospital ward, the date of admission, the date of death, the cause(s) of death, the 
primary cause of death, the associated cause(s) of death, the HIV status of the patient 
(if indicated in the records), and the patient’s history of participation in ART treatment.  
 
The researcher also designed data collection tool B specifically for this study so that he 
would be able to compile summaries of the statistics in the medical records department 
about overall mortality and morbidity parameters. This information was used to enhance 
the analysis of mortality trends. The second Audit tool (which was referred to as tool B) 
consisted of the following three sections that summarised the following information:  
 
• Section 1: Hospital name, district, date of data collection. 
• Section 2: A month-by-month summary of the number of adult admissions, the 
number of patients on ART, the number of new patients started onART, the total 
number of all deaths of individuals of less than 15 years old, and the total number 
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of deaths of all individuals of 15 years and older that were documented in the 
hospital records during the study period.  
• Section 3: Records of the medicines and drugs in the hospital on a monthly 
basis, the number of days when the hospital had no stock of the five ARV 
medicines in hand that are indispensable for the treatment of HIV patients in the 
hospital (these essential ARVs included Lamivudine, Stavudine, Efavirenz, 
Zidovudine, Nevirapine – and combinations of these medicines).  
 
The researcher used data collection tool B to collect data about all adult admissions to 
the hospital, the cumulative number of patients who were on ART at any given time, and 
the overall number of deaths that were certified by the hospital’s medical staff.  
 
For the purpose of this study, the data was collected over a period of four weeks in 
December 2008. 
 
1.8.2.3 Data analysis 
 
The data was carefully scrutinised for accuracy before it was entered into the Epi Info 
database. The researcher performed the data analysis with assistance from a colleague 
with extensive statistical skills by using the Epi Info (Version 3.5.1, August 2008) and 
the Statistical Package for the Social Sciences (SPSS version 12). Frequencies were 
determined for the responses to all the items in the audit, and this information was used 
in the results section as a basis for discussion and the reaching of conclusions. 
Bivariate analysis was carried out and categorical variables that were in three or more 
levels were re-categorised into two and analysed by use of two by two dummy tables. 
The results were presented in terms of prevalence proportion ratios (PPR). All factors 
with significant odds ratio (p < 0.05) in the bivariate analysis were included in the 
subsequent discussion. Chi-square statistics were also conducted on those variables 
that demonstrated a high statistical significance of association with hospital mortality 
rates. 
 
This study also made use of the technique of trend analysis. Statistical trend analysis 
provide “an indication of the underlying movement of a statistical series. Trends can be 
used to get a general impression of the underlying behaviour of a variety of series” 
(Office of National Statistics 2008:[1,2]). The trend analysis enabled the researcher to 
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understand the significance of the course of events that characterised the delivery of 
ART in the hospital under study. 
 
The remainder of the trend data was compiled and presented as trends that occurred 
over time in line graphs. Trend studies are appropriate for assessing change over 
periods of time because variables are measured on more than one occasion (Office of 
National Statistics 2008:[1,2]). 
 
1.9 VALIDITY AND RELIABILITY OF THIS STUDY 
 
1.9.1 Validity  
 
“Validity refers to whether or not the measurement collects the data required to answer 
research questions” (Somekh & Lewin 2005:216). Content-related validity is defined by 
Burns and Grove (2001:400) as “the extent to which the method of measurement 
includes all the major elements relevant to the concept being measured”. These authors 
add that it is useful for a researcher to cite sources from the literature in order to create 
a synthesis that will enable a more accurate understanding of the phenomenon under 
study.  
 
In this study, two consultants reviewed the research tool for clarity and content, after 
which certain identified items that had been omitted or unclear were added for purposes 
of clarification. 
 
The internal validity was also enhanced by the structured nature of the data collection 
method, by the careful training of the data collection assistants, by triangulating data 
from a wide variety of hospital records that included ward registers, patients’ case files, 
death certificates, and by cross-checking information with health workers. Internal 
validity was also enhanced by random verification of the completed data collection tools 
by the researcher on a sample of records that had been completed by the research 
assistants so that he would be in a position to determine the completeness and 
accuracy of the information that had been collected.  
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1.9.2 Reliability 
 
Reliability also refers “to the stability or consistency of measurements; that is whether or 
not the same results would be achieved if the test or measure was applied repeatedly” 
(Somekh & Lewin 2005:216). In this study, reliability was enhanced by a structured data 
collection tool that the researcher had developed on the basis of the research objectives 
and had pre-tested to ensure that the tools were able to measure the key variables of 
the study accurately and as comprehensively as possible. The data collection method 
therefore consisted essentially of a process whereby the researcher and his research 
assistants retrieved the required information about the frequency distribution of hospital 
deaths from the hospital’s records by using a custom-made structured audit tool. 
 
1.10 ETHICAL CONSIDERATIONS 
 
The most important ethical requirement for the research included carrying out the 
research competently, managing the resources honestly, acknowledging the role of 
those who contributed guidance and assistance, the accurate and unbiased 
communication of results, and a careful consideration of the impact that the research 
would make on society in general (Brink et al. 2006:30).  
 
Since this study focussed on the medical records of deceased patients, an attitude and 
principle of respect was maintained  through unconditional participation in the study by 
the district authorities and the hospital management (Brink et al. 2006:32). Participation 
in this study entailed no risks, penalties or prejudicial treatment, and the members of the 
hospital’s management were informed that they had an unequivocal right to withdraw 
from the study at any time without incurring any prejudice or penalty, and that they also 
had the right to ask for whatever clarification they needed about the purpose of the 
study (Brink et al. 2006:32). 
 
The information that was collected was treated as entirely confidential, and it was never 
made available to any unauthorised individuals who were not directly involved in the 
study. Throughout the course of this study, the researcher adhered to the principles of 
voluntary participation, confidentiality, informed consent, the minimisation of harm, and 
the anonymity of the deceased patients whose records supplied the necessary data.  
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The researcher trained the data collection assistants to maintain the confidentiality of 
the patient records with the utmost strictness, and they only used the data collection tool 
to extract the required information from the hospital’s patient records. The data 
collection assistants worked under the supervision of the records section staff of the 
hospital. No patient file was ever removed from the hospital’s records department, and 
all files were returned to the shelves from which they had been collected when the 
required information had been recorded.  
 
1.11 LIMITATIONS OF THE STUDY 
 
Despite the extensive efforts that the researcher made to eliminate and minimise errors 
by using a structured audit tool and by carefully training the research assistants, the 
information obtained from a number of the medical records was incomplete. The 
incompleteness of the records made the process of data collection to some extent 
vulnerable to researcher biases – especially in those cases where diagnoses had not 
been not well written or in cases where the information contained in the records was 
incomplete or absent.  
 
Where inconsistencies and inadequacies in data were identified, the records were 
verified (wherever possible) with the responsible health care workers. An agreement 
about how to treat missing information was reached through the triangulation of records. 
This enhanced the possibility that missing information could still be accurately compiled 
by the data collection tool. In cases where all these measures were not able to produce 
a plausible rendition of missing all fragmentary information, the cases concerned were 
identified as incomplete and the data that had been obtained from them was not 
included in the analysis.  
 
1.12 LAYOUT OF THE STUDY 
 
This dissertation consists of the following six chapters: 
 
Chapter 1:  This chapter introduces the study area, the research problem, the purpose 
of the study, the objectives and research design, the methodology that the 
researcher utilised in the study, and the definition of key terms. 
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Chapter 2: This chapter contains the literature review. 
 
Chapter 3:  This chapter discusses the research design and method. 
 
Chapter 4:  This chapter presents the findings, analysis and the interpretation of the 
results. 
 
Chapter 5:  This chapter discusses the conclusions and limitations of the study, and 
makes various recommendations for practice and further research. 
 
1.13 CONCLUSION 
 
This chapter described the background in context of the study, the profile of the country 
in which the research took place, a brief description of the Mpigi district of Uganda, the 
research problem, and the research questions. Chapter 1 also discussed the purpose of 
the study, its objectives and assumptions, the demarcation of the field of study, the 
research design and method, and the general layout of the study.  
 
Chapter 2 will present the literature review that informs the research.  
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CHAPTER 2 
 
Literature review 
 
 
2.1 INTRODUCTION  
 
In order to provide an authoritative understanding of HIV/AIDS situation globally and 
specifically in sub-Saharan Africa, the researcher undertook a comprehensive review of 
the literature on the subject. This chapter therefore contains a detailed review of the 
existing literature about the key concepts and issues that constitute the basis of this 
study. Because such an enormous amount of literature and research already exists on 
this subject, the researcher approached the literature study in a systematic and 
selective manner that illuminated his specific research interests. By doing this, he 
excluded all references to topics in the literature that were irrelevant or marginal to his 
central thesis. 
 
It is the purpose of a literature review to critically examine and discuss the research that 
has already been undertaken and documented on a particular topic. The researcher 
therefore located, analyzed, synthesised and interpreted all the previous research and 
documents (such as periodicals, books and abstracts) that related to the topic of his 
study. According to Roberts (2004:73), a literature review serves the following 
purposes: 
 
• It helps to bring a study into proper focus by relating it to what is already known 
about the topic. 
• It identifies key variables for research and suggests the relationships that might 
obtain among them. It also provides suggestions about how previous research on 
the topic could be usefully extended by means of further research and study. 
• It identifies the exact way in which the study topic relates to present and past 
studies and findings. 
• It also provides a basis for determining the significance of the study. 
• It helps a researcher to make strong logical and contextual links between the 
findings and procedures of the present study and all previous studies in the field. 
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The literature review of the study also enabled the researcher to achieve a more refined 
and in-depth understanding of the intricacies of HIV disease, and it revealed a wealth of 
additional information about morbidity and mortality trends in the Western (developed) 
world and in the context and settings of developing countries such as those of sub-
Saharan Africa. The researcher also reviewed and assessed the methodology, 
instruments, findings, conclusions and limitations of different studies. By carrying out a 
literature review of this kind, the researcher familiarized himself with current trends, 
developments and achievements in reducing morbidity and mortality in high and low 
HIV prevalence settings. This gave him the information that he needed to make clear, 
authoritative and meaningful comparisons between the two settings mentioned above.  
 
The researcher also made use of the literature review the document the socio-
demographic impact of HIV/AIDS. It also placed him in a position to describe the 
significance of the present study to HIV/AIDS programme managers, district health and 
hospital managers. After he had identified and examined a variety of approaches and all 
available data about trends, he then reviewed information that he had acquired and 
formed the basis for selecting the study population and the site in which the study would 
take place. He also summarised whatever critical information was relevant to this study 
so that his understanding of the research question would be refined and enhanced. As a 
result of this approach, the researcher was able to define three scenarios to describe 
expected trends in this field and to identify the most important lacunae in current 
HIV/AIDS research (especially as it applies to the countries of sub-Saharan Africa). 
These scenarios provided a researcher with a basis for reaching conclusions about the 
central research questions of the study.  
 
This literature review captured documented comparative experiences in both developed 
and developing (resource-constrained) settings are not concerned with the details of 
protocols of HIV morbidity and treatment but in the overall effect of interventions. The 
review took into account the enormous impact that ART has made to different aspects 
of HIV/AIDS morbidity and mortality. It has also increased the prevalent understanding 
of the morbidity and mortality rates in the pre-ART and post-ART eras.  
 
The researcher carried out a comprehensive online search of medical bibliographical 
databases and journals by making use of the following subject headings: HIV/AIDS, 
ART, hospital mortality, hospital morbidity, sub-Saharan Africa, Mpigi district and 
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Uganda. While the literature review mainly covered the ten-year period between 1998 
and 2009, it also incorporated a few references to the period before 1998 because of 
their specific relevance to the topic of this research. 
 
The references that were identified are contained in journal articles, books, reports and 
websites. This enabled the researcher to compile a comprehensive and relevant 
literature review. Because this section offers the reader an in-depth understanding 
many of the intricacies of the current state of knowledge about HIV/AIDS, it also 
provides a basis for the discussions that follow and the conclusions of the study. 
 
2.2 HUMAN IMMUNODEFICIENCY VIRUS DISEASE  
 
This section provides a brief overview of the HIV that includes information about the 
origins of the virus, the historical background of the epidemic, and the distinctive 
characteristics of the HIV virus. It also includes the ways in which it operates in the 
human body, and the means by which it is transferred from one human being to 
another. 
 
2.2.1 Origins of the human immunodeficiency virus  
 
The origins of HIV have been the subject of numerous theories and a great deal of 
speculation. Although any detailed discussion about the origin of HIV is beyond the 
scope of this study, one theory is discussed here because it provides a feasible 
hypothesis about the origins of HIV. Some researchers have discussed the probability 
and likelihood that HIV originated from an ancestral HIV-1 M virus that was transmitted 
(by means that as yet unknown) from chimpanzees to human beings in equatorial West 
Africa as long ago as during the 1930s (Williamson & Martin 2008:109).  
 
The first documented case of HIV-1 was positively identified in the human being from a 
blood sample that was taken in 1959 from a man in Kinshasa in the Democratic 
Republic of the Congo. While the particular way in which this first documented case of 
HIV infection became infected is unfortunately unknown, a genetic evaluation of this 
blood sample dates the origin of this form of HIV-1 to the late 1940s or even the early 
1950s (CDC 2009:[1].)  
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Because of host selection presssure, the HIV virus has proliferated its genetic diversity 
by subdividing into a number of closely related subtypes (Essex & Mboup 2002:4). It is 
this capacity of HIV to mutate into forms of “extreme genetic diversity that is a 
consequence of the error-prone and recombinogenic nature of HIV replication [which] 
seriously threatens our chances of containing the [HIV] AIDS epidemic”
 
 (Williamson & 
Martin 2008:109). 
2.2.2 Historical overview of the epidemic  
 
HIV/AIDS was first positively identified in the United States of America in 1981 as a new 
and apparently highly lethal disease that was initially thought to infect only homosexual 
men (Essex & Mboup 2002:1). Subsequent to this discovery, the term “AIDS” was first 
coined in 1982 to describe the syndrome of opportunistic infections that caused rapid 
sequences of deterioration in the health status of previously healthy people. It was in 
the same year (1982) that the health authorities in the United States began their formal 
tracking (surveillance and monitoring) of HIV and AIDS wherever and whenever it 
appeared. It was in 1983 that the virus that causes AIDS was first positively identified 
and described (CDC 2009:[1].) Soon after this discovery and description of AIDS and 
HIV, the disease began to be reported in other parts of the United States of America 
and also in different parts of the world, including Europe and Africa (Essex & Mboup 
2002:1).  
 
Ever since the discovery of HIV in the early 1980s, the number of people who have 
been infected and who are currently living with HIV increased exponentially from a mere 
handful to more than 40 million cases. More than 20 million of these people have 
already died from the effects of AIDS-related illnesses and conditions (Abdool Karim 
2008:31). In sub-Saharan Africa, the spread and course of the HIV/AIDS epidemic has 
varied from country to country and from region to region, and has displayed a variety of 
patterns of diffusion in rural and urban settings and made an enormous impact on the 
lives of those who are infected and the societies in which these infections occur.  
 
In Uganda, for example, the prevalence of HIV has been reduced from 23.2% in 1989 to 
11.8% in 1995, to 5.2% in 2000, and to 7.1% in 2007 (Ministry of Health – Government 
of Uganda 2009:14). But in South Africa, in contrast, the HIV/AIDS epidemic has been 
characterised by an “‘explosive' spread with no sign of a ‘saturation' plateau and 
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predominance in women at [a] younger age”
 
 (Abdool Karim & Abdool Karim 2002:38). 
The spread of the virus in South Africa has been characterised by a rapid rise in HIV 
prevalence from 0.8% in 1990 to 10.4% in 1995 and 22.4% in 2000, and a 
concomitantly high mortality rate. In South Africa, 40% or more of all adult deaths are 
attributed to the effects of AIDS (Abdool Karim & Abdool Karim 2002:39). 
These two patterns of diffusion and infection in Uganda and South Africa describe the 
variability of the impact of HIV/AIDS in two countries in the same sub-region of the world 
called sub-Saharan Africa. 
 
2.2.3 Characteristics of the human immunodeficiency virus  
 
HIV is the infective agent that compromises the immune system of the human body to 
certain extent that it becomes defenceless against the various opportunistic diseases 
that ultimately collectively culminate in a syndrome colloquially known as AIDS. This 
disease is called acquired 
 
because it is not genetically inherited but is caused by a viral 
infection. A deficiency is a shortcoming which, in this context, refers to the way in which 
the HIV weakens the immune system and so makes the body unable to defend itself 
against infections and diseases (Van Dyk 2005:3). Some of these opportunistic 
infections (such as tuberculosis) to which the infected person becomes vulnerable tend 
to occur in the combination with a variety of other health defects in the patient in such a 
way that an untreated patient is soon overwhelmed by the burden of morbidity and 
succumbs to death.  
Van Dyk (2005:4) therefore describes AIDS as a “collection of many different conditions 
that manifest in the body (or specific parts of the body) because the HIV has so 
weakened the body’s immune system that it can no longer fight [the] disease-causing 
agents that are constantly attacking it”. Van Dyk (2005:4) further describes AIDS as “a 
syndrome of opportunistic diseases, infections and certain cancers – each or all of 
which has the ability to kill the infected person in the final stages of the disease”. This is 
the ultimate fate for HIV-infected human beings who do not enjoy the privilege of 
treatment or whose health status has so deteriorated that there are no longer amenable 
to the benefits of modern antiviral therapeutic medications.   
54 
2.2.3.1 The nature of the human immunodeficiency virus 
 
The HIV virus is a member of the group of viruses referred to as the primate infecting 
lentiviruses of the family Retroviridae (thus called retroviruses) (Williamson & Martin 
2008:109). A virus is an extremely small parasitic organism that hijacks the naturally 
occurring biochemical facilities of living cells (such as human cells) to reproduce itself in 
a manner that allows it to spread rapidly until it pervades the whole human body (Van 
Dyk 2005:9). Viruses contain all the genes that are necessary for their replication in 
form of deoxyribonucleic acid (DNA) in their cores (Van Dyk 2005:9). But some viruses 
have cores that contain ribonucleic acid (RNA) rather than DNA, and this class of 
viruses are therefore called retroviruses (Van Dyk 2005:9).  
 
RNA is characterised by the fact that it is single-stranded while DNA is characterised by 
the fact that it is double-stranded. The RNA nucleotides (like the ones of the HIV) 
contain ribose while DNA contains deoxyribose, and RNA contains uracil compared to 
DNA that contains thymine (Essex & Mboup 2002:1-3). HIV is therefore classified 
among the retroviruses because its genomes contain RNA and their ability to mutate is 
dependent upon the use of an RNA template that utilises the enzyme reverse 
transcriptase (Essex & Mboup 2002:1-3; Morris & Cilliers 2008:80). A more detailed 
description of DNA and RNA is beyond the scope of this study. What is relevant to this 
discussion is the HIV-1 genome that is depicted in figure 2.1.  
 
2.2.3.2 The human immunodeficiency virus genome  
 
The HIV genome consists of HIV-specific proteins, which are indicated by the colours 
pink and purple in figure 2.1, and all the other elements that are common to 
retroviruses.  
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Figure 2.1:  The Human Immunodeficiency Virus genome 
(Source: HIV Laboratory – Yale University 1998:[1]) 
 
Key to the abbreviations used in descriptions of the HIV-1 virus: 
  LTR – long terminal repeats; repetitive sequence of bases 
gag – group specific antigen gene, p24, a nucleoid shell protein 
pol – polymerase gene; encodes the viral enzyme, protease (p10), reverse 
transcriptase (p66/55); and integrase (p32) 
env – envelope gene; encodes the viral envelope glyocproteins gp120 
(extracellular glycoprotein, and gp41 (transmembrane glycoprotein) 
tat – encodes transactivator protein 
rev – encodes a regulator of expression of viral protein 
vif – associated with viral infectivity 
vpu – encodes viral protein U 
vpr – encode viral protein R 
nef – encodes a “so-called” negative regulator protein 
 
Of special interest are the gag, pol and the env sections (see Figure 2.1), which encode 
the nucleocapsid, polymerase, and envelope proteins respectively. These sections of 
the virus are all critical for the replication of the HIV and are crucial for the diagnosis and 
management of the infection. The polymerase section of the genome consists of the 
protease enzyme (p10), reverse transcriptase enzyme (p66/55) and the intergrase 
enzyme (p32). These three enzymes are indispensable for the ability of the HIV to 
replicate itself (see figure 2.2). These three enzymes are therefore specifically targeted 
by ARVs because they have the ability to prevent the HIV from replicating itself (see 
section 2.3.1 for further information about this process).  
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HIV is categorised into to types, namely HIV-1 and HIV-2. (AIDS Information 
Switzerland 2009:[3]; Essex, Mboup, Kanki, Marlink & Tlou 2002:4). HIV-1 is far more 
virulent and aggressive (pathogenic) virus than the HIV-2 virus (Van Dyk 2005:20). HIV-
1 exists in three lineages that had been labelled as the M, N and O groups respectively, 
and they are widely prevalent in East and Southern Africa. The HIV-2 is found in the 
lineages that have been labelled as the A, B and G groups, and these are most 
prevalent in West Africa (Essex & Mboup 2002:4; Williamson & Martin 2008:109). The 
viruses from the HIV-1 M group are primarily responsible for virulence of the global 
AIDS epidemic (Williamson & Martin 2008:109). The HIV-1 M lineage has been further 
subdivided into the subtypes A, B, C, D, F, G, H, J and K (Montano & Williamson 
2002:11; Williamson & Martin 2008:110).  
 
2.2.3.3 The human immunodeficiency virus replication cycle  
 
Like other viruses, the HIV survives and replicates specifically in human body cells that 
are referred to as “host cells” (AIDS Information Switzerland 2009:[3]; Van Dyk 
2005:10). HIV invades and replicates itself primarily in the CD4+ and T helper cells (Van 
Dyk 2005:9). When a HIV invades the host cells, it transforms the viral genetic material 
(RNA) into human genetic material (AIDS Information Switzerland 2009:[3]). In figure 
2.2, step 2 shows how the HIV attaches itself to the CD4 receptor before it gains entry 
into a human cell (step 3). Once the virus has invaded a human cell, it then encodes the 
reverse transcriptase enzyme (step 4). The encoding of the reverse transcriptase 
enzyme enables the virus to make a DNA copy from its viral RNA (Morris & Cilliers 
2008:79).  
  
57 
 
 
Figure 2.2:   Graphic portrayal of the HIV replication cycle 
(Source: Indian River State College 2008:[1]) 
 
In step 5 of the process of replication, the HIV DNA that has been formed combines with 
the DNA of human cells by making use of the enzyme intergrase. Once the HIV has 
succeeded in inserting its genetic material into that of the host cell, it then proceeds to 
utilise the human cells that it has hijacked to replicate itself and form new virus 
components (AIDS Information Switzerland 2009:[3]). Step 6 shows how transcription 
occurs and how long chains of proteins are created that join together (step 7) to form an 
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immature virus that buds to the cell membrane (step 8) and eventually breaks through 
the wall of the host cell (step 9). By making use of the enzyme protease, the newly 
formed immature virus (now mature, as is illustrated in step 10), it attaches itself to new 
host cells and proceeds to infect those new cells, thereby initiating the whole cycle all 
over again (AIDS Information Switzerland 2009:[3]). 
 
The CD4 cells are indispensable for coordinating the body’s immune response against 
invasive infections and intrusive toxins (AIDS Information Switzerland 2009:[4]; Gray 
2008:123; Van Dyk 2005:9). During the cycle of HIV replication, the CD4 cells of the 
body are systematically destroyed and this causes the human immune system to 
become progressively compromised, disorganised and degenerate until it can no longer 
perform the function for which it exists (Gray 2008:124). This cycle of destruction 
initiated by the HIV results in a progressive reduction of the body’s average number of 
CD4 cells, and this in turn undermines the body’s immune system until it is no longer 
capable of defending the body in a way in which it was designed to do (Zijenah & 
Katzenstein 2002:34). The ever-expanding number of human immunodeficiency viruses 
eventually makes the body’s immune system so weak in the terminal phase of the 
disease that it becomes vulnerable to a great number of disease-causing agents that 
the immune system would normally be able to resist in its normal healthy state. This 
final concatenation of diseases and pathological conditions that ultimately cause the 
death of the patient is what is called “AIDS” (Van Dyk 2005:4). This progressive 
depletion of the normal number of CD4 cells and the eventual inability of the body to 
meet the demand of any kind of immune responses ultimately results in clinical disease 
and death (Zijenah & Katzenstein 2002:34). The HIV therefore acts as a catalyst, so to 
speak, of the acquired immune deficiency syndrome. It is therefore correct, but 
somewhat misleading without further amplification, to refer to HIV as a cause of 
mortality in patients whom it has infected. 
 
It is important to realise that the virus has perfected a strategy to integrate itself into 
each individual healthy human cell and so transform those human cells into “factories” 
that become extremely efficient producers of large numbers of further viruses. In the 
process of making new virus particles, the cells of the human body and the receptors 
sites that are critical for the protection of the body are destroyed one by one, thus 
leaving the body vulnerable to a variety of disease-causing agents.  
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2.2.4 The transmission of the human immunodeficiency virus 
 
HIV is transmitted from one HIV-infected person to people who are free of the virus by 
means that have now been well understood and described (AIDS Information 
Switzerland 2009:[6]). HIV transmission and infection occur when body fluids that 
contain the virus come into contact through microscopic cracks in the mucous 
membranes or the broken skin of the recipient. The virus can also directly enter the 
circulatory system by means of, for example, the use of HIV-infected needles that are 
shared between HIV-positive people and HIV-negative people (Morris & Cilliers 
2008:85). While the virus is present in high concentrations in bodily fluids such as blood, 
semen and vaginal secretions, other human body fluids such as saliva, breast milk, 
tears and urine contain much lower concentrations of the virus and are therefore less 
infectious (AIDS Information Switzerland 2009:[6]). Most cases of transmission occur 
when those body fluids that contain very high concentrations of the virus such as sperm 
and vaginal secretions some way or the other enter the bloodstream of an HIV-negative 
person (Van Dyk 2005:23). 
 
HIV is transmitted primarily through sexual intercourse because this enables HIV-
infected body fluids to pass from the body of an infected person to another person or 
from a mother to her baby during pregnancy or childbirth. A baby can also become HIV-
positive as a result of breast feeding from a mother who is HIV-positive (AIDS 
Information Switzerland 2009:[6]; Morris & Cilliers 2008:80; Van Dyk 2005:23;). Of the 
3.7 million new HIV infections that currently exist throughout the world, an estimated 
75% to 87% were acquired by means of heterosexual intercourse (Abdool Karim 
2005:243; Kristensen, Sinkala & Vermund 2002:217).  
 
HIV infection is therefore primarily a sexually transmitted infection and the main mode of 
HIV transmission is through unprotected sexual intercourse (intercourse that takes 
place without a condom), and through penetrative vaginal or anal sexual intercourse 
(AIDS Information Switzerland 2009:[6]; Van Dyk 2005:23). HIV is also transmitted 
when drug addicts who are accustomed to injecting themselves share HIV-
contaminated syringes and needles (AIDS Information Switzerland 2009:[6]) and in low-
resource settings where unsterilized needles have to be reused because sterile ones 
are unavailable.  
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HIV can also be transmitted through blood transfusions or the constituents of other 
blood products that contain HIV and through needle-stick injuries and bite wounds. HIV 
transmission also occurs in other incidences of skin-penetrative injuries such as those 
that are inflicted by traditional healers in some African societies to make traditional 
therapeutic skin markings on the skin of their clients (Kristensen et al. 2002:225; Van 
Dyk 2005:29.) There has been no documented and verified incidences of HIV 
transmission from everyday life activities such as contacts between the skin of the 
human buttocks and the seats of public toilets, casual (i.e. non-penetrative) skin 
contacts, kissing, hugging or the sharing of swimming bath water with people who are 
the HIV-infected (AIDS Information Switzerland 2009:[7]). There is also no evidence at 
all to suggest that HIV can be transmitted through airborne droplets as is the case with 
influenza. It is indeed fortunate for the human race that there is thus far no evidence 
that HIV can be transmitted by means of the microscopic droplets that are produced by 
coughing, and that it can only be transmitted from one person to another when the virus 
enters a non-infected person’s blood stream from infectious body fluids into a healthy 
human body through the numerous but almost invisible cracks in the mucous 
membranes during the act of vaginal or anal sexual intercourse (Van Dyk 2005:24).   
 
But there are several other factors that are thought to increase the risk of contracting 
HIV infection from infected people. These include being a person who has habitual 
contacts with multiple sex partners, the presence of sexually transmitted infections, high 
concentrations of the virus in the semen or vaginal fluids of an infected sex partner, and 
the occurrence of trauma during sex
 
 (Kristensen et al. 2002:219; Van Dyk 2005:27). 
In sub-Saharan Africa (including Uganda), the main modes of HIV transmission is 
unprotected heterosexual intercourse. A much smaller number of injections is caused 
by the use of blood products not screened for HIV in blood transfusions and the use of 
HIV-contaminated needles (Benatar, Doherty, Heunis, McIntyre, Ngwena, Pelser, 
Pretorius, Redelinghuys & Summerton 2004:277). Sub-Saharan Africa remains the 
region of the world in which the greatest number of infections occurred. In fact, an 
estimated 70% of all new HIV infections in the global AIDS epidemic occur in sub-
Saharan Africa (Kristensen et al. 2002:217). In 2007, it was estimated that 1.7 million 
(i.e. between 1.4 million and 2.4 million) people had been newly infected with HIV, and 
that 68% of all these new HIV infections as well as 76% of all AIDS-related deaths had 
occurred in sub-Saharan Africa (UNAIDS & WHO 2007:15). 
61 
2.2.4.1 The prevention of HIV infection 
 
Since there is no vaccine that will prevent a healthy person from contracting AIDS or 
any kind of curative treatment, the only way to prevent infection is to minimise the risk of 
being infected by means of sexual transmission. The best methods of preventing 
infection to date are abstinence, faithfulness to one uninfected sexual partner, and the 
use of condoms during sexual intercourse. If people who are sexually active, they 
should strive to be completely be faithful to one sexual partner and or always use 
condoms whenever they engage in casual sexual intercourse with anybody whose HIV 
sero-status is unknown to them (AIDS Information Switzerland 2009:[7].) 
 
2.2.5 The progression of the human immunodeficiency virus disease  
 
When an HIV-negative person is infected with the HIV, the viruses invade host cells and 
immediately begin to replicate themselves in human cells (see figure 2.2). This process 
leads to the rapid multiplication of the HIV which attacks and destroys its host cells by 
taking them over and making them into instruments for the replication of new versions of 
themselves. It is this process of viral multiplication and its consequent destruction of 
human cells that is the cause of HIV disease.  
 
2.2.5.1 The weakening and destruction of the immune system 
 
The human immune system performs two critical functions in the body. Firstly, it 
combats the infections caused by bacteria, viruses, funguses and parasitical agents. 
Secondly, the immune system prevents cancer by destroying the body's own damaged 
or deteriorated cells (AIDS Information Switzerland 2009:[3]; Van Dyk 2005:12-13).  
 
During the acute infection phase, thousands of new viruses are formed, and the 
immune system responds to this by destroying as many viruses as it can (AIDS 
Information Switzerland 2009:[3]; Morris & Cilliers 2008:85). Thereafter, during the 
symptom-free latency phase (which is also known as stage I of the disease), HIV 
replicates millions of copies of itself. In the meantime, the body’s immune system 
continues to destroy as many viruses as it can in order to maintain a balance between 
new and destroyed invading viruses. In the last stage of the infection (which is known as 
AIDS), the capacity of the human immune system has become exhausted and 
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uncoordinated, and it is unable to cope any longer with the overwhelming HIV load (or 
number of viruses present) within the body. With the progressive weakening of the 
immune system, the overall number of HIV steadily increase until the body becomes 
vulnerable to all kinds of infectious diseases and various forms of cancer (AIDS 
Information Switzerland 2009:[3].)  
 
The kind of infections that occur when the body’s immune systems is compromised are 
called “opportunistic infections”, and they contribute significantly to the mortality and 
morbidity experienced by people who are living with HIV/AIDS. It is reported that the 
development of opportunistic infections such as pulmonary tuberculosis, oropharyngeal 
candidiasis and Pneumocystis Carinii pneumonia, is associated with radically 
decreased rates of survival in patients (Kumarasamy, Solomon, Flanigan, Hemelatha, 
Thyagarajan & Mayer 2003:83). 
 
2.2.5.2 The course of the disease 
 
The whole HIV infection cycle begins with an acute phase that is called the acute 
primary infection stage or an acute sero-conversion illness (Onen 2002:297; Van Dyk 
2005:40). Sero-conversion can be defined as the the point at which an HIV-negative 
“person’s HIV status converts or changes from HIV-negative to HIV positive” (Van Dyk 
2005:40). The sero-conversion phase usually occurs within six weeks after the initial 
infection of a person with HIV, and about 30-60% of all patients at this stage develop 
symptoms of an illness that is characterised by fever, headaches, fatigue, the swelling 
of lymph nodes, a rash and flu-like symptoms that last for only about a week or two 
(Onen 2002:297; Van Dyk 2005:40). During this sero-conversion stage, the viral load is 
very high indeed with each micro-litre of plasma containing more than ten million HIV 
particles. This is also stage at which the infected person is at their most infectious stage 
of the disease (Morris & Cilliers 2008:85; Van Dyk 2005:40).  
 
But because of the emergency of cytotoxic T lymphocytes (CTL) and the neutralising 
antibody response, the viral levels in the human body in the subsequent stage actually 
decline until they reach a steady state at about 16-24 weeks. It is at this point after the 
initial infection that the infection slowly enters what is called the latency phase (AIDS 
Information Switzerland 2009:[1]; Morris & Cilliers 2008:85). After the latency  phase, 
the increase in HIV virus particles  and the rate at which new diseases and HIV-related 
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opportunistic infections appear begin to follow a well-known pattern and the dieases 
progresses steadily. The clinical progression of HIV infection can be described in terms 
of following four stages: (1) the initial infection stage during which they are no obvious 
symptoms, (2) the acute syndrome phase, (3) the asymptomatic (latent) period, and (4) 
the advanced disease period (Onen 2002:298).  
 
The progression of HIV infection from the initial asymptomatic disease stage to the 
advanced illness stage known as AIDS, ranges in Africa are from between 34.2 months 
and 44.6 months (Onen 2002:298). Another study by Jaffar, Grant, Whitworth, Smith 
and Whittle (2004:463) calculated a median survival time for HIV-1-infected patients at 
9.8 years. But other studies have reported wide variations in the amount of time that 
elapses between the HIV primary infection stage and the terminal AIDS stage and have 
produced cases that range from between one year to 20 years with an average interval 
of 12 years (AIDS Information Switzerland 2009:[1]; Zijenah & Katzenstein 2002:35). 
But all HIV-infected people will sooner or later begin to present with the full-blown AIDS 
syndrome unless the progress of the disease is somehow checked by means of, for 
example, the use of antiretroviral drugs (AIDS Information Switzerland 2009:[1]; Van 
Sighem, Danner, Ghani, Gras, Anderson & De Wolf 2005:212). 
 
The definition of AIDS as a disease condition is fraught with inherent limitations if one 
relies largely on the clinical criteria that have been drawn up by the WHO (Onen 
2002:300). To ensure consistency between the adult and paediatric classification of 
HIV/AIDS, the WHO later endorsed a new definition of HIV infection and AIDS in terms 
of which any diagnosis of HIV-related disease should rather be made in terms of clinical 
symptoms and signs (WHO 2006b:13). The 2006 classification (WHO 2006b:13) divides 
HIV disease into the following four distinct clinical stages: the asymptomatic stage 
(stage 1); the mild stage (stage 2); the advanced stage (stage 3); the severe disease 
stage (stage 4).  
 
2.2.6 Signs and symptoms of human immunodeficiency virus disease 
 
Each clinical stage of the progression of HIV disease is characterised by a set of 
symptoms and signs that determine the degree of severity that the patient is suffering.   
In addition to this, the signs and symptoms suggest ways and means of managing each 
particular stage of HIV disease. Table 2.1 sets out the stages of the HIV disease in 
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terms of their characteristic symptoms and signs (WHO 2007:16). Each of these clinical 
stages is characterised by a definite set of clinical conditions and clinical presentations. 
Although a patient may present with any of the conditions listed below, the HIV status of 
a patient (whether HIV positive or negative) must be confirmed because the disease 
staging and management needs to be supported by a positive HIV diagnosis (WHO 
2004a:13).   
 
Table 2.1: Clinical staging of HIV/AIDS for adults and adolescents 
 
Clinical stage 1 
Asymptomatic disease, persistent generalized lymphadenopathy  
Clinical stage 2 
Moderate unexplained weight loss (<10% of presumed or measured body 
weight), 
recurrent respiratory tract infections, Herpes zoster, angular cheilitis, recurrent 
oral ulceration, papular pruritic eruptions, seborrhoeic dermatitis, fungal nail 
infections 
Clinical stage 3 
Unexplained severe weight loss (>10% of presumed or measured body weight),  
unexplained chronic diarrhoea that lasts for longer than one month,  
an unexplained persistent fever (above 37.6°C) that is either intermittent or 
constant for longer than one month), persistent oral candidiasis, oral hairy 
leukoplakia,  
pulmonary tuberculosis (current), severe bacterial infections (such as 
pneumonia, empyema, pyomyositis, bone or joint infection, meningitis or 
bacteraemia), 
acute necrotizing ulcerative stomatitis, gingivitis or periodontitis, 
unexplained anaemia (<8 g/dl), neutropaenia (<0.5 × 109 per litre) or chronic 
thrombocytopaenia (<50 × 109 per litre) 
Clinical stage 4 
HIV-wasting syndrome, pneumocystis pneumonia, recurrent severe bacterial 
pneumonia,  
chronic herpes simplex infection (orolabial, genital or anorectal, of more than one 
month’s duration or visceral at any site), oesophageal candidiasis (or candidiasis 
of trachea, bronchi or lungs), extrapulmonary tuberculosis, disseminated non-
65 
tuberculous mycobacterial infection, 
Kaposi’s sarcoma, cytomegalovirus infection (retinitis or infection of other 
organs), 
central nervous system toxoplasmosis, HIV encephalopathy, extrapulmonary 
cryptococcosis including meningitis, progressive multifocal leukoencephalopathy, 
chronic cryptosporidiosis (with diarrhoea), chronic isosporiasis, disseminated 
mycosis (coccidiomycosis or histoplasmosis), recurrent non-typhoidal salmonella 
bacteraemia, lymphoma (cerebral or B-cell non-Hodgkin) or other solid HIV-
associated tumours, 
invasive cervical carcinoma, atypical disseminated leishmaniasis, symptomatic 
HIV-associated nephropathy or symptomatic HIV-associated, cardiomyopathy 
 (Source: Onen 2002:303; WHO 2007:16) 
 
Table 2.1 (above) shows that the stages of HIV/AIDS, according to the WHO 
classification of 2006, can be divided into the following four stages. Clinical stage 1 is 
characterised by acute infection but a symptom-free (asymptomatic) presentation – a 
stage that can last up to 12 years (AIDS Information Switzerland 2009:[1]). Even though 
the virus is replicating in the human body during this stage, the infected person shows 
no outward symptoms or signs of the disease.  
 
During the so-called latent stage of the disease, infected people (unless they were 
tested for HIV) would not be aware that they infected with HIV and could therefore 
unknowingly and unwittingly infect their sexual partners. Despite the lack of symptoms 
and physiscal manaifestations of the disease during stage one of the disease, the HIV is 
active in damaging and continuously undermining the integrity of the body’s immune 
system During this assymptomatic stage or phase, the CD4 cell count decreases by 40-
80 cells/mm3
 
 per year (Van Dyk 2005:41). 
During clinical stages 2 and 3, a set of symptoms and signs that are caused by the 
advanced weakness and deterioration of the immune system, begin to manifest 
themselves. These symptoms include persistent fevers, nocturnal sweating, loss of 
weight, intermittent bouts of diarrhoea and a general deterioration in the patient's health 
status. The patient may also begin to experience frequent fungal infections of the mouth 
and oesophagus that are caused by candida or by viral illnesses such as shingles 
(Herpes Zoster) (AIDS Information Switzerland 2009:[5].) 
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During clinical stage 4, the immune system has more or less completely collapsed and 
the patient begins to present with the well-known symptoms and signs of AIDS. During 
this stage, a wide variety of infectious diseases and forms of cancer may appear. The 
patient will experience fungal diseases of the oesophagus, pulmonary inflammation, 
tuberculosis, viral diseases, parasitic diseases, rare tumours, as well as neurological 
diseases and a drastic loss of weight (the “wasting syndrome”). It is during clinical stage 
4 (the AIDS stage) that the risk of patient mortality is highest. 
 
Because immunosuppression can also be caused by a number of conditions including 
various kinds of cancers and other infections, this HIV/AIDS staging is positively 
confirmed after HIV antibody testing from a sample of the patient's blood (WHO 
2004a:13).  
 
2.2.7 Human immunodeficiency virus infection and testing  
 
HIV counseling can be defined as a confidential dialogue that takes place between a 
client (patient) and a care provider. The purpose of counselling is to enable the client 
(the patient) to cope with anxiety and stress that is generated by their awareness of 
their potential HIV status (whether positive or negative), and to enable them to make 
important personal decisions on the basis of a confirmation of their HIV status (Ministry 
of Health, Government of Uganda 2003b:2.) Although HIV is a chronic disease, in many 
settings it is a terminal disease that requires proper pre-test counselling before an HIV 
test is undertaken and before the results are communicated to a patient. The most 
common approach to HIV counselling and testing throughout the world is called 
voluntary counselling and testing (VCT). In the sessions that are based on this model, 
the physician or health care provider informs the patient (in terms that they can 
understand) of all the salient facts that relate to HIV disease, and the meaning and 
implications of an HIV-positive or HIV-negative result.  
 
This widely used approach is described as voluntary because a patient voluntarily 
agrees to undertake the test and receive the results. Voluntary counselling and testing 
is an indispensable foundation for both prevention and treatment (Abdool Karim & 
Abdool Karim 2003:1499). Other counselling and testing approaches include HIV 
Counselling and Testing (HCT) and Provider-Initiated Counselling and Testing (PICT). 
These alternative methods of counselling have been implemented by researchers and 
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health care providers in various settings in which they are more appropriate to the 
conditions that prevail in such settings. These alternative approaches will not be 
described in this study because they were not used in the setting in which the research 
took place.  
 
The CDC recommends that patients must receive information about HIV testing, HIV 
infection and the possible outcomes and meaning of test results (CDC 2007:[1]). Since 
HIV screening is voluntary, it should always the performed in an a setting of optimum 
confidentiality (Marum, Campbell, Msowoya, Barnaba & Dillon 2002:527).  
 
The information that is given to patients includes an explanation of what HIV infection 
and disease are, and the possible meanings and implications of either a positive or 
negative test result (CDC 2006:[10]). The patient should then be offered an ample 
opportunity to ask questions, explain concerns and to accept or decline testing (CDC 
2006:[10]). VCT is divided into pre- (“before”) and post- (“after”) test counselling, and it 
includes the provision of information, counseling about various methods of prevention 
and the services that are locally available to HIV-positive patients (CDC 2007:[1]). The 
information that is imparted also includes facts about the HIV test itself, its benefits and 
its possible consequences. After pre-test counselling has taken place and the client has 
freely given his or her consent to be tested, an HIV test is performed.  VCT is critically 
important because it encourages people who may be HIV positive to be tested so that 
they can be aware of their HIV status and access the care and support that they require 
at the earliest possible stage of the disease (Marum et al. 2002:527). VCT is also 
important for those who are HIV-negative so that they can take whatever steps 
necessary to ensure that they will maintain their HIV-negative status in the future. 
 
2.2.7.1 Negative test results  
 
When a test result is negative, the health care provider will inform the client that unless 
he or she has engaged or participated in any act or event during the previous three 
months in which he/she might have been exposed to HIV infection, they can regard 
themselves as being uninfected by HIV (CDC 2007:[1]). But retesting is strongly 
recommended for the clients with history of possible exposure to HIV because at least 
six weeks to three months elapse before HIV antibodies can be detected by the most 
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common antibody tests (AIDS Information Switzerland 2009:[4]; CDC 2007:[2]; Puren 
2008:97). 
 
2.2.7.2 Positive (reactive) test results 
 
For all clients who test positive for HIV, an additional confirmatory test is required. If the 
second test confirms that the client is indeed HIV-positive, they are informed of the 
meaning of the positive results in simple terms (CDC 2007:[2]; Puren 2008:97). A 
positive HIV test result means, of course, that the patient is infected with HIV, and that 
the client’s body will become progressively weaker and more susceptible to 
opportunistic infections if the client’s infection is not properly managed by the health 
care provider in terms of the best available treatments and precautions.  
 
The results of a positive HIV test are personally communicated to the client in a post-
test counselling session in order to ensure that the patient has a clear understanding of 
the implications of disease and of the available methods for managing the disease. 
 
Careful and well-informed counselling and testing are a critical success factor in the 
delivery of ART because they constitute a point at which the client enters the treatment 
and management phase of the disease. They also help the health care provider to 
understand the extent to which the patient understands the possible implications of the 
disease and the services that are available to minimise its associated risks of 
progressive illness and death. 
 
2.2.8 Tests that are used for the detection and management of infection 
 
In order to determine whether or not an individual is actually infected with HIV, it is 
essential for an individual to be tested for HIV. One of the subsidiary purposes of testing 
for HIV is to screen apparently healthy individuals who wish to donate blood so that their 
blood products can be screened for HIV  before they are used for transfusion into 
patients (Puren 2008:89-91). And HIV testing is also carried out (as has already been 
stated above) in order to confirm a diagnosis of HIV disease after certain clinical 
symptoms that are typical of HIV infection have already appeared in the patient. Thirdly, 
HIV testing is also performed in order to determine the degree of severity that the 
disease has reached prior to testing (Puren 2008:89-91).  
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HIV infection can be established by the identification of certain markers and can also be 
indirectly but accurately determined by the measurement of a number of antibodies 
generated by the presence of HIV in the human body. The presence of HIV infection 
can also be directly established by observing the presence of viral particles and 
circulating antigens or viral nucleic acids (Gueye-Ndiaye 2002:121). The positive 
presence of HIV infection can thus be determined in a number of different ways.  
 
2.2.8.1 Detection of human immunodeficiency virus antibodies  
 
Once an individual has been infected by HIV, the immune system of that person's body 
begins to develop antibodies to counteract the activities of the virus. Since these 
antibodies are produced by the body in an attempt to destroy the virus, they can be 
detected by certain laboratory tests, the results of which provide an indication of 
whether or not a person is infected with HIV (AIDS Information Switzerland 2009:[4]; 
Puren 2008:94-95). But in most clinical settings, HIV testing is currently accomplished 
by making use of rapid HIV tests. While HIV antibodies can be detected from between 
two and six weeks after infection, they can only be detected in most patients within a 
period of three months (AIDS Information Switzerland 2009:[4]). Serologic antibody 
testing is the testing method that is most widely used, and it consists of a screening test 
and a subsequent supplementary or confirmatory test (Gueye-Ndiaye 2002:122).The 
Enzyme-Linked Immunosorbent Assay (ELISA) test is the best known immunological 
test for detecting HIV antibodies (Puren 2008:93).  
 
The outcome of these tests indicates whether a patient is HIV-positive or HIV-negative, 
and thus confirms the positive or negative HIV status of the patient.  
 
2.2.8.2 Detection of the human immunodeficiency virus  
 
The second category of tests actually detect the presence of the virus itself rather than 
the antibodies that are produced by the human body’s reaction to the presence of the 
virus in the body. This test is designed to detect the HIV antigen that is one of the 
components of the virus's genetic material and is called the polymerase chain reaction 
(PCR) test (AIDS Information Switzerland 2009:[4]). The PCR test is used to measure 
the number of these virus particles in the blood (colloquially called “the viral load”). It 
has been reported that a two-fold reduction in plasma HIV RNA reduces the risk of 
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disease progression and progression to death by approximately 30% (Puren 2008:102). 
By extension, a four-fold and ten-fold reduction in the viral load would reduce the risk of 
progression of HIV disease progression by 55% and 65% respectively (Puren 
2008:102).  
 
The size of the viral load in the human body is therefore a factor of the greatest 
importance in the monitoring the treatment and management of an HIV infection (AIDS 
Information Switzerland 2009:[4]; Puren 2008:102). 
 
2.2.8.3 Determination of human immunodeficiency disease severity  
 
The health of an HIV-infected person depends on the condition of their immune system 
at any particular time (Van Dyk 2005:38). Since HIV/AIDS patients experience a variety 
of clinical conditions throughout the course of their infection, the severity and frequency 
of these conditions (which include opportunistic infections and malignancies) increase in 
proportion to a decline in the CD4 T-cell count (Mocroft, Barry, Sabin, Lepri, Kinloch, 
Drinkwater, Lipman, Youle, Johnson & Phillips 1999:1255). A third category of tests are 
therefore used to determine the severity of the HIV disease. These are tests that 
actually determine the CD4 count. Since the virus primarily attacks and destroys the 
CD4 cells, the ability to measure the number of CD4 cells in the blood is an accurate 
indicator of the status of any individual’s immune system (Van Dyk 2005:38).  
 
The measurement of the CD4 count is an important indicator of the health status of an 
HIV-infected person and is undertaken to determine the amount of damange that has 
already been inflicted on the patient’s immune system. Once a patient ‘s treatment 
commences, the CD4 count is used in conjuction with the viral load test to measure the 
response of the body to treatment (Puren 2008:102). The “CD4 lymphocyte count at 
[the time of] AIDS diagnosis remains a strong predictor of [the patient’s potential for] 
survival in the era of HAART”
 
 (Dore, Li, McDonald, Ree & Kaldo 2002:394).  
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2.3 TREATMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS  
 
A number of medications have been developed to disrupt or interfere with the action of 
HIV. These medications are called antiretrovirals (ARVs) (UNAIDS ca 2003:[1]). While 
they cannot actually completely cure “a person [who] has been infected with HIV, [they 
have the ability] (in a variety of their formulations) to act on different stages of the life-
cycle of HIV” (UNAIDS ca 2003:[1]). HIV disease is thus currently managed by the 
administration of the combinations of appropriate antiretrovirals to infected patients.   It 
is for this reason that the management of HIV disease is called “antiretroviral therapy” or 
“antiretroviral treatment” (ART). Since this form of managing treatment depends on 
administering a combination or regimen of antiretroviral medications over a period of 
time, this approach to treatment is also referred to as “highly active antiretroviral 
treatment” (HAART) (WHO 2006b:13). “The current goal of antiretroviral chemotherapy 
is to reduce viral load to the lowest level possible (undetectable) for as long as possible” 
 
(Amoroso et al. 2002:323).  
The key objectives of managing HIV disease by means of antiretroviral treatments are 
as follows:  
 
• Firstly, the treatment is designed to contain the unchecked expansion of the 
HIV virus in the body (this is called “virus suppression”). If the expansion of 
the virus is suppressed or prevented, the progression of HIV disease can be 
halted and the consequence is that the health status of the patient will 
improve (Van Sighem et al. 2005:212; WHO 2006b:13).   
• Secondly, treatments are designed to manage and treat the presenting 
diseases and conditions that are typical of HIV infection and AIDS (WHO 
2006b:13).   
 
The key principles of HIV treatment are to:  
 
• preserve and maintain the capacity of the immune function 
• reduce the incidence of HIV-related morbidity and mortality  
• encourage the maximum suppression of the viral load over a long period of 
time 
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• preserve the health status of the patient until more effective future treatment 
options become available  
• minimise the impact and effects of toxicity  
• reduce the possibility that the patient will transmit HIV to other people 
(Amoroso et al. 2002:323). 
 
After the HIV status and clinical staging of the patient has been confirmed, ART is the 
principal treatment that is used to manage HIV disease. ART invariably effects 
improvements in the clinical status of an HIV-infected patient and effectively reverses 
the progress of the clinical stages in patients who present with symptomatic diseases 
and conditions (WHO 2006b:13).  
 
2.3.1 Antiretroviral therapy for the human immunodeficiency virus  
 
The HIV has three critical enzymes that it requires for its replication and propagation. 
These enzymes include reverse transcriptase (p66/55), protease (p10) and integrase 
(p32) (see figures 2.1 and 2.2 for stages 4, 10 and 5 respectively). The commonest 
antiretroviral medicines that are used in the treatment of HIV include nucleoside reverse 
transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), 
and protease inhibitors (PI) (Wood 2008:504). The reverse transcriptase inhibitors 
(including NRTI and NNRTI drugs) indirectly prevent the HIV viral genome from being 
incorporated into a human host cell by blocking the enzyme reverse transcriptase that is 
used by the virus for viral DNA synthesis. The protease inhibitors block the enzyme 
protease that is responsible for the formation of new viruses (AIDS Information 
Switzerland 2009:[5]; Wood 2008:509).  
 
2.3.1.1 Antiretroviral medicines and regimens  
 
The NRTI drugs and their accompanying acronyms include zidovudine (AZT), stavudine 
(d4T), lamivudine (3TC), emitricitabine (FTC), tenofovir (TDF), abacavir (ABC) and 
didanosine (ddi). The NNRTIs include efavirenz (EFV) and nevirapine (NVP) 
(Gilks,Crowley, Ekpini, Gove, Perriens, Souteyrand, Sutherland, Vitoria, Guerma & 
DeCock 2006:506.) To optimise the success of any HIV treatment regimen, these HIV 
ARVs are used in combinations that are referred to as “HAART” (Wood 2008:505). 
HAART is therefore the name that is being given to the treatment regimens that are 
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recommended by the world's leading HIV experts because they function aggressively to 
suppress viral replication and the progress of HIV disease (Amoroso et al. 2002:323). 
HAART consists of “two nucleoside reverse transcriptase inhibitors (NRTIs) and [one] 
non-nucleoside reverse transcriptase inhibitor (NNRTIs) or a protease inhibitor (PI)” 
(Amoroso et al. 2002:323; WHO 2006b:18-19). HAART suppresses the level of the virus 
in the blood and lymph nodes and thus slows down the progression of the disease 
(AIDS Information Switzerland 2009:[5]; Van Sighem et al. 2005:212). 
 
2.3.1.2 Regimens used in the treatment of the infection  
 
The combination of three or more ARV medicines are referred to as “regimens” (WHO 
2006b:18-19). For all patients who are commencing treatment (i.e. patients who have 
never been treated with antiretroviral medicines before), the recommendation is that 
their treatment should begin with a first-line regimen. It is only after a first-line regimen 
has been observed to fail or be ineffectual (because the virus does not respond to the 
treatment) that a second-line regimen (and other regimens thereafter) are 
recommended (WHO 2004a:11; WHO 2006b:18-19.) The WHO public health approach 
to ART recommends that patient management should focus on the “four Ss of simplified 
clinical decision making: when to start, when to substitute for toxicity, when to switch 
treatment after failure, and when to stop” 
 
(Gilks et al. 2006:506).  
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Figure 2.3: 
(Gilks et al. 2006:506) 
Recommended antiretroviral treatment regimens for HIV 
management 
 
Figure 2.3 (above) indicates that the recommended first line regimens include: [AZT + 
3TC + EFV] or [AZT + 3TC + NVP] or  [D4T + 3TC + EFV] or [D4T + 3TC + NVP] or 
[TDF + 3TC + NVP] and the other combinations listed above. The recommended 
second-line regimens include: [ddi + 3TC + PI] or [TDF + 3TC + PI] or [ddi + PI + EFV] 
(Gilks et al. 2006: 506; WHO 2004a:16). 
 
2.3.1.3 Guidelines for starting antiretroviral treatment  
 
Since there is no cure for HIV disease, HIV infection is a lifetime condition that can only 
be contained by means of ARVs. In the early nineties, antiviral therapy was used only 
for the treatment of advanced cases of HIV infection. ART is currently recommended for 
all stage three and stage four manifestations of HIV disease (AIDS Information 
Switzerland 2009:[5]). When the health-care provider initiates treatment in stage three 
of the disease, he or she does it in the hope of “firstly, stopping further proliferation of 
the HIV virus and destruction of the immune system, thus halting the progress of the 
disease; secondly, of suppressing the formation of resistant HIV variants; and, thirdly, of 
reducing proneness to infection” (AIDS Information Switzerland 2009:[5]). The 
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commencement of an ART regimen should therefore result in an improvement in the 
clinical health status of the patient and bring about an effective reversal of the clinical 
stage in patients with symptomatic diseases or conditions (WHO 2006b:13). In Uganda, 
ART is recommended for “WHO stage IV disease – irrespective of [the] CD4 count or 
advanced WHO stage III disease, for any patient at any stage of HIV disease [with] a 
CD4 count of 200 cells/µl (and below) or any patient with tuberculosis and a CD4 cell 
count of between 200 and 350/µl” (Ministry of Health, Government of Uganda 
2003b:11).  
 
These guidelines were applicable in the early 2000s and were designed for patients 
whose somatic immunity had already been severely compromised. In some patients, 
the damage to their overall health status may already be so extensive before the 
commencement of treatment, that the treatment itself may be relatively ineffectual. This 
study analyses and discusses the key indicators of when access to ART will be most 
effective. Indicators of the severity of the patient’s illness on presentation at the hospital 
included the average length of the patient’s stay in the hospital before death intervened, 
the median length of hospital admission, and out-of-pocket payments. This study 
analyses and discusses the mortality trends of a number of HIV-related and non-HIV 
related conditions.  
 
2.3.1.4 Antiretroviral treatment failures  
 
Treatment failure in this context can be defined as the clinical and CD4-related 
manifestation of treatment failure. It is realistic to assume that clinical treatment may be 
failing when new opportunistic infections or malignancies that signify the progression of 
clinical disease or the recurrence of previously treated opportunistic infection appear in 
the patient. Treatment failure can also be suspected if there is an onset or recurrence of 
WHO Stage III conditions (such as, for example, HIV wasting, chronic diarrhoea, and 
prolonged fevers of unknown aetiology, recurrent invasive bacterial infections, or 
persistently recurrent mucosal candidiasis). The failure of a CD4-related treatment is 
almost certain when the CD4 cell count returns to its to pre-therapy baseline (or when it 
sinks below that level) in the absence of any other concomitant infections that might 
account for a transient CD4 cell decrease or a >50% reduction in the CD4 cell count in 
the absence of any other concomitant infection that would explain a transient CD4 cell 
decrease (WHO 2004a:23). 
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It is worth noting that HIV is unlike any other chronic disease known to human beings 
because “effective control of HIV using vaccines and drug therapy...is compromised by 
the massive evolutionary potential of this virus” (Williamson & Martin 2008:109). This 
potential for evolution in the virus itself combined with the “error-prone nature of the 
HIV” reverse transcriptase enzyme, ensures that multiple mutations of the virus can 
occur quite rapidly (Wood 2008:521). In those cases where such changes in the 
structure of the virus are a result of treatment failure, they are greatly enhanced when 
HIV is exposed to a low-potency drug regimen or inadequate drug levels (as is the case 
when patients fail to participate in an optimal ART adherence regimen) (Wood 
2008:520).  
 
2.4 FACTORS THAT FUEL THE SPREAD OF HIV IN AFRICA 
 
As earlier highlighted, The greatest burden of HIV/AIDS globally is concentrated in sub-
Saharan Africa (UNAIDS & WHO 2007:7). “Infection rates in adults in South Africa, 
Botswana, Zimbabwe, and western Kenya range from 20% to 40%, which is higher than 
anywhere else in the world” (Halperin & Epstein 2004:4). The most obvious question 
that is raised by this extraordinary phenomenon is: “What accounts for this high 
prevalence and burden of disease in sub-Saharan Africa?”  
 
The association between the absence of male circumcision among many males in this 
region and the high prevalence HIV partly explains the four- to five-fold difference in the 
HIV rates between southern and Western Africa (Halperin & Epstein 2004:4; Quinn, 
Wawer, Sewankambo, Serwadda, Li, Wabwire-Mangeni, Meehan, Lutalo & Gray For 
the Rakai Project Study Group 2000:928). But there are also other factors that have 
fuelled the high incidence and prevalence of HIV infection and the consequent spread of 
HIV disease in sub-Saharan Africa that are clearly visible from a comparison of the 
statistics of HIV-related mortality and morbidity from this region and those that describe 
the incidence of HIV infection in other regions of the world. These additional factors are 
discussed below.  
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2.4.1 Factors influencing the spread of the virus 
 
An increased susceptibility to HIV infection is associated with numerous environmental, 
cultural, socio-economic, behavioural and racial factors (Benatar et al. 2004:277). 
Studies have shown that African men do not have more sexual partners in number over 
a specified period than men in all the other regions of the world, and that a very small 
percentage of women report contact with five or more sexual partners a year. Studies 
have shown that the promotion of condoms as a prophylactic (barrier) against the 
disease and recommendations that men should use condoms during sexual intercourse 
have been the cornerstone of HIV prevention efforts in Africa for many years. But a 
recent review of the relevant factors states that “no clear examples have emerged yet of 
a country that has turned back a generalized epidemic primarily by means of condom 
promotion” 
 
(Halperin & Epstein 2004:5.)  
It is now widely recognised that the factors that have fueled the HIV/AIDS epidemic in 
Africa (and especially in sub-Saharan Africa) are both multidimensional and complex 
(Benatar et al. 2004:277). Of notable interest in this regard is the observation that, in 
Africa, men and women have been reported to have more than one concurrent 
(ongoing) sexual partnerships that overlap for many months or years (Halperin & 
Epstein 2004:4). “This pattern of sexual behaviour differs from that of the serial 
monogamy more common in the west, or the one-off casual and commercial sexual 
encounters that occur everywhere else [in the world]” (Halperin & Epstein 2004:4). By 
making use of mathematical modelling, Morris, Serwadda, Kretzschmar, Sewankambo 
and Wawer (ca 1997:[1]) established the impact of concurrency on HIV transmission by 
comparing the spread of HIV in populations where serial monogamy was the norm and 
in settings where long-term concurrency was the norm (Halperin & Epstein 2004:5). It 
was noted that “although the total number of sexual relationships was similar in both 
populations, HIV transmission was much more rapid with long-term concurrency – and 
the resulting epidemic was ten times greater”
 
 (Halperin & Epstein 2004:5).  
One is therefore lead to conclude that, in sub-Saharan Africa, unlike in Asia and 
Europe, it is the practice of concurrent sexual relationships that has fuelled the spread 
of HIV (Halperin & Epstein 2004:5). This concurrency of sexual partnerships accounts 
for the significant difference in HIV prevalence between sub-Saharan Africa and the rest 
of the world.  
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One may sum up these factors by saying that the high incidence of multiple concurrent 
sexual partners, the low rates of condom usage and the low male circumcision 
coverage in various parts of Africa, have significantly fuelled the spread of HIV in sub-
Saharan Africa (Benatar et al. 2004:277). 
 
2.4.2 Myths and misconceptions  
 
Among the factors that are fuelling the spread of HIV in sub-Saharan Africa are the 
many myths and misconceptions that relate to HIV infection and disease. These myths 
and misconceptions have contiributed significantly to the spread of the virus and have 
grossly undermined and nullified the utility of the interventions that are being used to 
halt or slow down the spread of HIV in sub-Saharan Africa. It is this an astonishing fact 
that during the quarter of a centrury in which this disease and its treatments had been 
better and better understood, none of the interventions that have been so successful in 
other regions of the world have resulted in a sustained reduction in the incidence of 
HIV/AIDS in in sub-Saharan Africa (Shelton 2007:1809). It is because of this that these 
life-threatening myths and misconceptions need to be properly understood and 
debunked (not only by health care professionals but by the public at large) if the 
interventions that had been successful in other parts of the world can also make a 
profound difference to the HIV infection rate in sub-Saharan Africa.  
 
There are a number of misconceptions that impede the successful prevention and 
treatment of HIV. One of these is that HIV spreads like wildfire. But this is simply untrue. 
On average, in typical cases, HIV does not spread like wildfire. Although an HIV-
infected person may be very infectious in the first weeks after infection (Cassell & Surdo 
2007:492; Shelton 1809), they are not as infectious 
 
in the subsequent latent phase of 
the disease. There is also a myth that it is sex workers who contribute significantly to 
the spread of HIV. This theory also does not hold water because, in sub-Saharan Africa, 
formal sex work as a profession is uncommon, and cannot therefore be a significant 
contributor to the prevalence of HIV in this region (Shelton 2007:1809).  
Other myths encourage the belief that certain behavioural patterns on the part of men 
are responsible for the unusual prevalence of HIV in this region. But it is important to 
emphasise the fact that in a heterosexual epidemic (such as the AIDS epidemic in sub-
Saharan Africa), a significant number of women must also have multiple partners if this 
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factor is to be regarded as responsible for the rapid spread of a generalised epidemic in 
this part of the world (Cassell & Surdo 2007:492; 
 
Shelton 2007:1809).  
There is also a widespread misconception that poverty and discrimination contribute 
significantly to the high prevalence of HIV-infected people in sub-Saharan Africa. 
Paradoxically, however, the prevalence of HIV has been shown to be much higher 
among the wealthier sectors of society than among poorer people, perhaps because 
there is a correlation between wealth and mobility and a high incidence of concurrent 
sexual partnerships (Shelton, Cassell & Adetunji 2005:1057-8; Shelton 1809).
 
 Many 
researchers have also regarded condoms as the most effective intervention for 
containing the HIV epidemic (Shelton:1809). But condoms (when used alone as an 
intervention) have been shown to have a limited effect on the reduction of HIV infection 
in the context of an epidemic (Shelton 1809). Since many people (mostly men) are 
strongly averse to using condoms (especially in the context of a regular and ongoing 
relationship), they tend to use them intermittently or not at all (Shelton 2006:1947; 
Shelton 2007:1809).  
Another myth that has contributed to the spread of HIV/AIDS in Africa are those that are 
based on ignorance and a lack of recognition of the fact that the risk of HIV infection is 
equally likely for all sexually active individuals (Benatar et al. 2004:293). There are 
others in Africa that still blame the epidemic on the effects of witchcraft while others 
attribute AIDS to the anger of the spirits of ancestors who have not been adequately 
appeased and propitiated. There are also some black South Africans who believe that 
white people introduced HIV as a means of punishing blacks after the demise of 
apartheid in South Africa (McGeary 2001:[4] Benatar et al. 2004:277). But since the 
appearance and diffusion of the virus preceded the democratic revolution of 1994 in 
South Africa, this belief is yet another rationalisation of a disease whose dynamics are 
still imperfectly understood. Anecdotal evidence suggests that these myths and 
misconceptions are important factors that impede the effectiveness of HIV prevention 
programmes in rural clinics (Benatar et al. 2004:294). The most abhorrent of all these 
myths and misconceptions is the belief “that having sex with a virgin will cure HIV/AIDS” 
(Benatar et al. 2004:2794). 
 
This brief description of the myths and misconceptions that surround the phenomenon 
of HIV/AIDS and the behavioural factors that are associated with the spread of 
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HIV/AIDS in the sub-continent, indicates why the HIV virus continues to spread so 
prolifically in sub-Saharan Africa. Despite the numerous efforts that have been made to 
mitigate the spread of the virus, a great number of new infections still occur on a daily 
basis in this region (UNAIDS 2008b:5). Shelton (2007:1811) points out that, in the 
context of these myths and misconceptions, “our priority must be on the key driver of 
generalised epidemics – concurrent partnerships”. 
 
  
An examination of all available data indicates that the main factor that is contributing to 
the high prevalence and burden of HIV disease in sub-Saharan Africa is the fact that 
sexually active human beings engage in concurrent or overlapping sexual relationships.  
 
2.5 THE IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS DISEASE  
 
HIV/AIDS has exerted a significant and destructive socio-economic impact on 
communities, on the resources of health systems, and on the overall development of all 
the countries of the subcontinent – especially those countries in which the incidence 
and prevalence of HIV infection are high.  
 
“HIV/AIDS has brought about a global epidemic far more extensive that what was 
predicted even a decade ago. Still rapidly growing, the epidemic is reversing 
development gains, obliterating millions of lives, widening the gap between rich and 
poor, and undermining social and economic security. It has become a major cause of 
disease burden in South Africa, and arguably the single most [significant] phenomenon 
that will shape future demographic, health and development trends in the country” 
(
 
Benatar et al. 2004:276).  
2.5.1 Mortality trends in sub-Saharan Africa 
 
As highlighted earlier, in 2008, an estimated 75% of all AIDS-related deaths throughout 
the world occurred in sub-Saharan Africa (Sani, Mohammed, Adamu, Yusuf, Samaila & 
Borodo 2006:862; UNAIDS 2008:5). In the 1990s, HIV-related mortality contributed to 
40% - 69% of the overall mortality rate in high-prevalence settings (Lopman et al. 
2006:189; Nunn et al. 1997:[4]). Another study indicates that the hospital mortality rate 
that was attributed to AIDS-related illnesses was 43% among females and 37% among 
males (Sani et al. 2006:864). In other studies carried out in rural settings in Tanzania, 
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65% and 60% of male and female deaths (respectively), and 74% of all deaths people 
aged between 35 and 44 years old, were attributed to HIV (Senkoro, Boerma, Klokke, 
Ng’weshemi, Muro, Gabone & Borgdorff 2000:194,198).  
 
A study undertaken Ethiopia concluded that the mortality rate was five times higher in 
2001 than the mortality rate in 1984 mortality. This demonstrates the severe impact of 
HIV on the causes of mortality among populations of the subcontinent (Sanders, Araya, 
Kebede, Schaap, Nagelkerke & Coutinho 2003:1212.) An HIV prevalence between 25 
and 30% was detected in Lusaka, Zambia, and the likelihood of dying between the ages 
of 15 and 60 was very high because the death rate of 778 per 1 000 of the Zambian 
population was demonstrated as being due to the effects of HIV/AIDS (Kelly, Feldman, 
Ndubani, Baboo, Timaeus, Farthing & Wallman 1998:883).  
 
2.5.1.1 Causes of death in sub-Saharan Africa  
 
In Zambia, the most frequently reported causes of death had been reported as being 
due to diarrhoea (20%), tuberculosis (7%) and HIV/AIDS (3%) (Kelly et al. 1998:883). 
 
In general, the adult mortality rates have risen substantially in East and Central Africa. 
In the absence of other factors, the high prevalence of HIV among local populations 
suggests that these excessive mortality trends are being driven by the patterns of HIV 
prevalence in the populations as a whole (McMichael et al. 2004:1156).  
 
2.5.1.2 Mortality trends and the risk of death  
 
In Abidjan, Ivory Coast, with an estimated HIV sero-prevalence of between 11% and 
15% between 1985 and 1992, mortality doubled in the urban population (Garenne, 
Madison, Tarantola, Zanou, Aka & Dogoré 1996:1282). In Uganda and Zambia, the 
rates of premature mortality doubled or tripled, and the possibility of adult death doubled 
(McMichael et al. 2004:1156; Nunn 1997:[5]).  
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This kind of mortality trend is further exemplified in Zimbabwe, where the highest 
increase in mortality was noted among males aged between 15 and 55 years old. The 
probability of death has therefore “increased from 0·15 in the mid-1980s to 0·5 in the 
late 1990s” because of the ravages of HIV-related illnesses (McMichael et al. 
2004:1156). In another study, the overall mortality rate among adults was fixed at 12.5 
per 1000 people per year with HIV/AIDS in comparison to 7.0 per 1000 people per year 
without AIDS (Le Coeur, Halembokaka, Khlat, Brouard, Purhuence, M’Pele´, Baty, Barin 
& Lallemant 2005:1685).  
 
In Uganda, fully one third of all adult deaths in 2005 were ascribed to HIV-related 
causes. HIV/AIDS therefore “continues to be the leading cause death” in this country 
(Hladika, Musinguzi, Kirungi, Opio, Stoverc, Kaharuza, Bunnella, Kafuko, & Mermin 
2008:509). It has been projected that global HIV/AIDS deaths will rise from the figure of 
2.8 million annually in 2002 to a pessimistic worst-case scenario of 6.5 million deaths 
per year in 2030 – even if one makes the assumption that ART access will reach an 
80% coverage by the year 2012 (Mathers & Loncar 2006:8). 
 
HIV/AIDS has therefore increased the overall mortality rates in all the populations of the 
world – especially for males, and has increased the risk or probability of death, 
especially in the countries of sub-Saharan Africa where most of these AIDS-related 
fatalities occur.  
 
2.5.1.3 Demographic impact of the human immunodificiency disease  
 
In addition to the overall inpact of HIV prevalence on mortality, Stanecki and Walker 
(2002:289) noted that all demographic indicators are affected by a high HIV prevalence.  
Demographicaly, 58% of all those living with HIV/AIDS are women, and about a third of 
all PLWHA are between the ages of 15 and 24 years old. In addition to this, women are 
affected at an earlier age when compared to men (Benatar et al. 2004:276, 283.)  
 
Demographicaly, in settings with a high prevalence of HIV, women experience a higher 
rate of HIV infection than do males, and they are also affected at an earlier age than are 
men in all settings where there is a high prevalence of HIV-infected people.   
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2.5.2 The impact of human immunodeficiency disease on life expectancy  
 
The average life expectancy of the population is reduced by between 15 and 20 years in 
countries where there is a high rate of HIV-infected people when one compares such 
countries to those with a low prevalence of HIV infection reported (Mathers, Sadana, 
Salomon, Murray & Lopez 2000:1687). Another study by Mathers et al. confirms these 
figures. It reports an average reduction of between five and ten years of life expectancy 
due to the HIV factor alone in sub-Saharan African countries (Mathers et al. 2000:1687; 
McMichael et al. 2004:1156). In addition to this, the average life expectancy of black 
South Africans is expected to drop by nine years by the year 2011as a result of the 
increasing rates of HIV/AIDS that have been reported in that country. By 2011, AIDS-
related deaths will account for half of all the causes of death in South Africa alone 
(Benatar et al. 2004:279). 
 
The epidemic has also increased the burden on the already drastically under-financed 
and resourced health services of the countries of sub-Saharan Africa, not only for the 
general population at large but also for the health care workers who have to cope with 
the burdens imposed by the increased rates of illness and death because of the 
HIV/AIDS epidemic (Benatar et al. 2004:298; Abdool Karim, Abdool Karim & Baxter 
2005:43). Since the prevalence of HIV/AIDS has reduced the quantity and quality of 
health services available in developing countries in sub-Saharan Africa, the quality of 
public health services in these systems that are already dangerously overextended, has 
been undermined to the extent that the systems themselves have become a factor that 
contributes to the already-high mortality rates in developing countries in sub-Saharan 
Africa (Abdool Karim et al. 2005:43). In a study carried out in the Masaka district of 
Uganda, the average life expectancy was determined to be 42.5 years in 1997 (Nunn et 
al. 1997:[5]). HIV/AIDS has also contributed to similar reductions in the average life 
expectancy in all sub-Saharan African countries. 
 
2.5.2.1 Age at the time of death in sub-Saharan Africa  
 
In a study carried out in India, Teja, Sudha and Lakshmi (2007:558) have noted that the 
burden of HIV/AIDS mortality has shifted from the older generation to the younger 
generation. This trend in mortality rates is exactly the opposite of what epidemiologists 
expect in epidemics of this severity and magnitude. But it does mean that more and 
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more young people are dying prematurely in developing countries. In South Africa, the 
prevalence of HIV among adults rose from 12.9% in 1997 to 19.9% in 2004 – largely 
due to the increase in HIV infections among young women (Benatar et al. 2004:279). 
 
In a study carried out in the Republic of the Congo, AIDS was determined to be the 
cause of death in 45.1% of patients fatalities, and “in the 25–44 years age group, AIDS 
was the cause of two-thirds of the deaths” 
 
(Le Coeur et al. 2005:1684). In the same 
setting in which this research took place; the effect of HIV/AIDS tripled the mortality rate 
among young adults (Le Coeur et al. 2005:1685). Significant increases in the mortality 
rates of young adults leads to a reduction in the mean and median age at death and a 
downward trend as more and more young people die at a younger and younger age and 
are exposed to higher risks of disease and death during their lifetimes. The 
unprecedented increase in the incidence of HIV/AIDS has shifted mortality trends more 
and more towards younger people – causing them to die prematurely and at younger 
ages. 
These facts are indication of the impact of a high prevalence of HIV infections on 
mortality and life expectancy trends. In such settings, high rates of HIV infections have 
contributed to an increase in premature mortality, a reduced life expectancy and 
reductions in population growth. This brief review of the facts indicates that the high 
prevalence of HIV infections in sub-Saharan Africa is closely associated with high 
overall mortality rates in the population of all these countries. The introduction of ART 
into such settings has been reported (as was expected by health care administrators 
and epidemiologists) to increase the average life expectancy and median age of the 
population at the time of death. These changes in mortality trends are also closely 
associated with certain demographic changes.  
 
2.5.3 Out-of-pocket payments and the average lengths of stay in hospitals 
 
Since the government of Uganda has sponsored the availability of free ART to private-
not-for-profit hospitals by means of dedicated (delegated) funds, one cannot use the 
amounts that patients pay to calculate the exact cost of the health services that are 
delivered to patients in such hospitals. The costs of service delivery can be partly 
calculated by taking user charges into account. Part of the cost that can be calculated 
from user charges must take into account the cost of the professional labour that have 
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to be paid out in salaries and allowances as well as the cost of utilities. The exclusion of 
these costs from the overall calculation of the cost of health services ensures that most 
members of the public should be able to afford the fees. Such a calculation also enables 
one to determine a break-even point that will ensure that these hospitals will continue to 
provide services to the public. These excluded costs are funded by means of delegated 
funds from the Ugandan government itself and from donor support funds. In this study, 
user charges were fees that were payable for theatre costs, pharmaceuticals and 
laboratory services. 
 
Through an analysis of out-of-pocket payments, the researcher was able to determine 
the estimated direct cost of health services delivery to the patient in the hospital in 
which he conducted his research. (This calculation excluded the cost of food and the 
cost of ARVs, both of which are provided free to the all patients.) 
 
By bearing in mind the fact that there are a variety of cost categories that a patient has 
to finance in a local setting during the process of accessing health care (and that such 
costs include what has to be paid for food, transport and communication), the 
researcher who undertook this study used user charges to estimate the direct cost of 
health service delivery for the patients who were admitted to the hospital. The focus of 
this calculation was the amount (user charge) represented the direct out-of-pocket cost 
of health services at the point of care to the patient. The researcher focused on the 
financial liability to the patient because the cost of health services is a key factor in 
determining the timely availability of and access to essential health services in a 
hospital of this kind. Late access to essential services (especially in cases of HIV 
infection), has been demonstrated to be strongly correlated with high rates of morbidity 
and mortality (Yisa, Akinola & Awolade 2004:53). When the direct cost of service cannot 
be afforded by an average member of the population, patients only consider accessing 
the hospital for treatment as the last resort. Patients will exhaust all other options for 
treatment and health care, including the use of traditional medicines from traditional 
healers, the services of private clinics and of herbalists before finally presenting 
themselves to the hospital (Yisa et al. 2004:53).  
 
Therefore, in circumstances of above average cost of services, patients tend access 
health services late in the course of disease and at the time of accessing hospital 
services, the presenting condition is advanced and severe and with complications of the 
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disease.  This study analysed the direct cost of services in relation to overall income of 
the population and variables that are indicative of late access to health services that 
may determine the possibility of death as an outcome of a hospital admission.    
 
2.5.3.1 Average length of stay in the hospital 
 
The average length of stay (ALOS) in a hospital can be defined and calculated as the 
total number of in-patient days (or “hospital days”) from the date of admission divided by 
total number of admissions or discharges (including the number of deaths) in a 
predetermined period (European Union Public Health Information System – EUPHIX 
2009:[1]; Pennsylvania Department of Health 2001:[1]). The total number of in-patient 
days is represented by the sum of each daily in-patient hospital census for the time 
period under examination, while the total number of admissions can be represented by 
the total number of individuals who are admitted into the in-patient wards of the hospital 
during the period that is being considered. The ALOS is a vector that is used for 
monitoring trends and the efficiency of health care, and for the purposes of planning 
future forms of health care (Pennsylvania Department of Health 2001:[1]).  
 
While the average length of a hospital stay (ALOS) is a key indicator of the degree of 
efficiency with which hospitals handle patients, it is also an indicator of the degree of 
severity of the conditions with which patients are presenting. ALOS is therefore 
determined by the age of the patient, the severity of the illness and the capacity of the 
hospital’s systems to manage the treatments and care that patients need, and by the 
efficiency with which hospitals discharge patients at the right time (Black & Pearson 
2002:611). When one combines ALOS with the bed occupancy rate, ALOS is also a 
good indicator of the efficiency with which a hospital is able to deliver its services (Effe 
2006:76). Hospital stays that are extended beyond the point at which patients can 
derive any further benefits, represent an unnecessary increase in the expenditure to 
which both the hospital and its patients incur. Black and Pearson (2002:611) have both 
observed how even the low percentage increase of 2.5% in ALOS expenditures 
ultimately result in “huge potential costs”.  
 
In Northern Uganda, the average length of a hospital stay during the years 2004 and 
2005 in four private-not-for-profit hospitals was 9.2 days (Effe 2006:76). In another 
study conducted in Northern Uganda, patients with AIDS-related illnesses stayed in the 
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hospital for an average time of 17 days and contributed 11.5% to the overall mortality 
rates recorded in the hospital (Fabiani, Accorsi, Aleni, Rizzardini, Nattabi, Gabrielli, 
Opira & Declich 2003:64-64). The impact of HIV-related illnesses on the length of time 
which patients remained in hospital should not therefore be underestimated.  
 
In Britain, the average length of a hospital stay has been reduced from 11.7 days in 
1980 to 6.95 days in 2002. This indicates an increase in the efficiency with which 
inpatients were managed during this period (Black & Pearson 2002:611). In other 
settings in developed countries, the average length of a hospital stay ranged from 
between 4.6 days (Staff 2009:[1]) and 10·0 (±9·8)days (Cabre, Bolivar, Pera, Pallares & 
The Pneumonia Study Collaborative Group 2004:[2]).  
 
In Northern Uganda, the prevalence of HIV among in-patients was 42%, and 37.2% of 
the available bed-days were taken up by HIV-positive patients (Fabiani et al. 2003:64-
64). 
 
The focus of this study in this population of hospital deaths was to determine the ALOS 
before death. This analysis is a key indicator of the trends in the severity of illness 
patients present with and a determinant of the capacity of the hospital to manage 
severe or critical illnesses that often result in death.    
 
2.5.3.2 Out-of-pocket payments for hospital services  
 
An out-of-pocket payment can also be defined as an expenditure in cash that is 
personally paid by the recipient in exchange for a service (Dictionary.com n.d.:[1]). The 
daily costs of maintaining patients in a hospital vary from country to country. In Uganda, 
out-of-pocket payments are an indicator of the direct cost of health service incurred by 
patients and/or their relatives. The researcher used an average out-of-pocket payment 
amount in this study to define the amount of money a patient or his/her relatives was 
required to pay for the services they received from the hospital (out-of-pocket payments 
are also referred to as “user charges” in Uganda).  
 
Hospitals calculate user charges for the services rendered to patients on the basis of an 
established tariff, and expect patients or their relatives to pay out-of-pocket payments 
for services rendered. In the mission hospital setting in Kenya (similar to the hospital in 
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which the research undertook the present study), the hospital treatment costs per child 
were calculated at US$ 88.2 for malaria, US$ 142.2 for pneumonia, and US$ 201.6 for 
meningitis (Ayieko, Akumu, Griffiths & English 2009:27). The literature indicates that 
there are wide variations in the average hospital costs per day among different kinds of 
hospitals in Africa. The ways in which hospital costs are calculated also vary, and 
depend on what is included and what is excluded from the cost calculation. In Mali, 
Mozambique and Algeria, for example, the cost per bed day in public facilities for a 
hospital with an 80% occupancy rate excluded drug costs but included food costs and 
ranged between  US$ 7.4 and US$ 26.3 (Adam, Evans & Murray 2003:[8]). In South 
Africa, the cost of a day in hospital per patient (for services that included laboratory 
costs, length of hospital stay, therapy, blood products and imaging studies) was US$ 
225.7 for an average stay of 6.5 days for a patient who was being treated for firearm 
injuries (Allard & Burch 2005:592).  
 
In Uganda and in the setting in which this study was performed, user charges are 
regarded as a method of recovering a certain amount of the costs from patients and as 
a payment for the use of health services and the administration of treatments. User 
charges are also regarded as a way of generating the shortfall in funds from the 
government and other funding agencies (Yisa 2004:49). In Uganda as well as in a 
number of other African settings, user charges in fact make a minor contribution to the 
actual operating costs of hospitals concerned (Yisa et al. 2004:50). In a study performed 
in Tanzania, it was calculated that patient fees for inpatient services only contributed 
25% of the costs of service delivery (Flessa 1998:404). 
  
The task of this study was to determine the ALOS and the out-of-pocket payments in 
the pre-free and post-free ART eras, and to find out whether there were any variations 
in the ALOS and out-of-pocket payments received from patients who had died from 
HIV/AIDS-related causes and those who died from non-HIV/AIDS-related causes. The 
researcher therefore investigated trends in user out-of-pocket payments for each 
recorded death in an effort to determine possible explanations for the impact of hospital 
deaths on user charges and in order to be able to compare similar factors in the pre-free 
and post-free ART eras.  
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2.5.4 The need to monitor morbidity and mortality trends 
 
The impact of HIV/AIDS on mortality and morbidity trends makes it imperative to 
monitor vital mortality statistics. 
 
“Reliable information on global and regional deaths by cause are an essential input to 
planning, managing and evaluating the performance of the health sector in developing 
countries. The numbers of deaths by cause influence the manner in which resources 
are allocated to different service programmes and research activities. An accurate 
assessment of current death rates by cause in different regions also forms the baseline 
against which new health programmes must be evaluated. Without a reasonable 
baseline, we shall not, in 5 or 10 years from now, be able to assess what has worked 
and what has failed. In addition, reliable information on deaths by cause is an essential 
input to the assessment of cost effectiveness of new technologies for disease control 
and health promotion”
 
 (Murray & Lopez 1994:447). 
Few sub-Saharan Africa countries have implemented death-registration record systems 
in which up to 50% of the recorded information is complete. (The recording and 
coverage of vital statistics is about 50% in Kenya and Zimbabwe, and about 90% in 
South Africa.) This incomplete coverage of the vitally important statistics (including 
mortality data) implies that the health systems of sub-Saharan Africa do not possess 
accurate information about who is dying, when they are dying, and what they are dying 
from.  
 
This lack of accurate information about mortality trends prevents researchers and 
health-care administrators from effectively monitoring the impact of interventions that 
had been targeted at reducing the burdens of disease and unwanted and unnecessary 
deaths.  
 
2.6 HUMAN IMMUNODEFICIENCY VIRUS DISEASE IN UGANDA 
 
“The HIV/AIDS epidemic in Uganda remains a serious public health challenge 
contributing a disproportionate burden of morbidity and mortality. The epidemic has had 
serious social and development impacts and has affected quality of life indices including 
child survival and life expectancy. It has also imposed a heavy burden on the health 
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care delivery system in the country in the last quarter of a century.” 
 
(Ministry of Health – 
Government of Uganda 2009:ii). 
Uganda has been heavily hit by the effects of HIV/AIDS disease. The HIV/AIDS 
epidemic has significantly influenced morbidity and mortality trends and continues to be 
a critical factor in the delivery of health services in Uganda. The WHO estimated the 
adult (15-49) HIV prevalence in Uganda at between 3% and 7%, and at 7% in 2003 and 
2005 respectively (WHO 2005b:1). Uganda is therefore considered to be a high 
prevalence setting with significant morbidity and mortality trends that are a direct result 
of the HIV/AIDS epidemic. 
 
The impact of HIV/AIDS in terms of age, gender, race and ethnicity in Uganda has been 
largely summarised by the Uganda HIV/AIDS sero-prevalence behavioural survey that 
was undertaken in 2004/2005. HIV prevalence was higher among women than among 
men (8% and 5% respectively), and the prevalence of HIV infection for both women and 
men increased with age and peaked between the ages of 30 and 34 for women and 
between the ages of 35 and 44 for men. This represented 12% for women and 9% for 
men (Ministry of Health – Government of Uganda 2006:101). This higher prevalence of 
HIV infection among females correlates with the high mortality due to AIDS that has 
been observed among females in Uganda when their mortality rate is compared with 
that of men (Le Coeur et al. 2005:1685; Sanders et al. 2003:1212). On the other hand, 
in the age group of people between 40 and 59 years of age, HIV was found to be more 
prevalent among men (Ministry of Health Uganda 2006:101). 
 
The prevalence of HIV infection in urban settings was 10% in comparison with an 
infection rate of 6% among rural residents (Ministry of Health – Government of Uganda 
2006:102). Uganda has also experienced a gradual increase in the prevalence of HIV 
among both sexes with wealth quintile from 4% among those in the lowest quintile to 
9% in the highest quintile (Ministry of Health Uganda 2006:104). 
 
Available records also show that malaria has been a leading cause of death in sub-
Saharan Africa for more than century. But in the period covered by the last two 
decades, HIV/AIDS has exceeded malaria as a leading cause of death in sub-Saharan 
Africa – and it is the cause of even more fatalities among Africans than the effects of 
war (Benatar et al. 2004:276).  
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Women are therefore affected much at a much younger age than men, and have an 
overall higher prevalence of HIV than males during their sexually reproductive age (i.e. 
between the ages of 15 and 49). It is therefore evident that HIV/AIDS has exerted a 
direct socio-economic impact on the quality of human life in Uganda, and that the 
categories of people who are affected correlate with age, gender, wealth and place of 
abode (whether urban or rural).  
 
In a background of high HIV/AIDS prevalence, to determine whether there was a 
notable change in mortality patterns, this study analysed the mortality patterns by age 
and gender and compared the pre and post-free ART eras.   
 
2.6.1 Adult mortality trends in Uganda  
 
In a hospital sero-survey conducted in 1999, more than 52.6% of the patients in the 
medical wards of a hospital in northern Uganda hospitals were HIV-positive. Because of 
this, HIV disease was said to be crowding out places that would have been taken by 
other patients in all the departments of the hospital (Fabiani et al. 2003:63-4). It was 
also noted that the mortality rates were higher among HIV-positive patients than they 
were among HIV-negative patients. HIV accounted for 38.0% of hospital bed-days and 
the average length of hospital stay (Fabiani et al. 2003:63-4).  
 
This pattern of morbidity and mortality in Uganda because of the high prevalence of HIV 
infections corresponds with other findings by the WHO (WHO 2004a:2). The WHO 
estimated in 2002 that HIV/AIDS was the cause of 25% of all mortality in all age groups. 
HIV had therefore become the number one cause of mortality in Uganda, followed by 
malaria and lower respiratory infections which contributed 11% each to the overall 
mortality rate (WHO 2004a:2). These three conditions (HIV, malaria and lower 
respiratory infections) are therefore the cause of 47% of mortalities during the period 
under consideration (WHO 2004a:2; WHO 2006a:2). By 2003, it was estimated that 78 
000 (or between 54 000 and 120 000) deaths in Uganda had been caused by AIDS 
(UNAIDS, UNICEF & WHO 2004:2). HIV/AIDS was the leading contributor (together 
with lower respiratory infections) to the global burden of disease that currently affects 
the human race (McMichael et al. 2004:1155). In Nairobi, Kenya, the hospital bed 
occupancy increased from 69% to 81% between 1985 and 1990 largely due to 
HIV/AIDS-related illnesses (Colvin 2005:337). 
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HIV/AIDS has therefore been (and continues to be) a major cause of mortality in 
Uganda because it causes more than a quarter of all deaths that are recorded in all 
health facilities. The introduction of freely available ART is therefore expected 
significantly to reduce the morbidity and mortality trends that have been attributed to 
HIV/AIDS in Uganda. Determination of morbidity and mortality trends in a rural setting 
was therefore the key focus of this study and through the analysis of mortality and 
morbidity data, the researcher demonstrated an overall trend of morbidity and mortality. 
Using a simple and straight forward approach to analysing trends, the researcher 
determined three year projections that can enable ART programme mangers and district 
authorities look into the future mortality patterns so that specific targeted interventions 
can be implemented to optimise the positive benefits of ART of reducing morbidity and 
mortality.  
 
2.6.2 Uganda’s response to the human immunodeficiency virus epidemic 
 
In response to the impact of HIV/AIDS, Uganda has implemented a national plan to 
increase the affected population’s access to treatment. In June 2004, the Minister of 
Health, Mr Jim Muhwezi, announced that all people living with HIV in Uganda would in 
due course be granted free access to ARVs (WHO 2004b:[1]). Charging fees for ART 
services inhibits HIV-prevention activities because they discourage testing, reduce the 
uptake of antiretroviral therapy and can negatively affect adherence to ART of patients 
who have already begun to participate in an ART programme regimen (WHO 
2005a:[1]). Uganda has accordingly been careful to adopt the WHO recommendation 
that all access to ART should be free at the point of service delivery since this is one of 
the key interventions that enhances access to ART and optimal medication adherence 
behaviour (WHO 2005a:[1]). 
 
The introduction of ART of the population at large has obviously raised expectations 
that HIV-infected individuals will now also live longer. Since ART was expected to 
reduce morbidity and mortality rates, it was also expected to reduce the overall mortality 
of the population and to ensure an opportunity for even HIV-infected patients to live 
healthy and productive lives (Mermin et al. 2008:752).  
 
Uganda is one of the 15 United States President Emergency Plan’s focus countries, 
which collectively represent approximately 50% of all HIV infections worldwide 
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(PEPFAR ca 2008:[1]). The response of Uganda to HIV/AIDS has been “a model for the 
rest of sub-Saharan Africa” (PEPFAR ca 2008:[1]). “Uganda’s strategy involves strong 
public commitment; mass mobilization and education efforts; political openness; an 
extraordinary range of community and faith-based partners; and the political vision that 
recognizes HIV/AIDS as a threat to development, as well as a health problem”
 
 
(PEPFAR ca 2008:[2]).  
Since HIV/AIDS was reported to have been the cause of 25% of the overall mortality 
rate of the population in 2002 (WHO 2004c:2), the introduction of free ART to Ugandans 
should exert a significant impact on mortality trends by reducing mortality rates by 
between 1% and 25% – thus significantly reducing all the causes of mortality. This study 
determined the reduction in overall mortality in a rural setting and made 
recommendations that can be considered by programme managers in designing long 
term ‘reduction in mortality’ focussed ART interventions.  
 
2.6.3 Achievements attributable to Uganda’s response to the epidemic  
 
Uganda has been described as a “pioneer
 
 among African governments in its response 
to the HIV/AIDS epidemic” (PEPFAR ca 2008:[1]). The programme goal of the Health 
Sector Strategic Plan of the Ministry of Health of Uganda is [are] to expand economic 
growth, to increase the rate of social development and to accelerate the rate at which 
poverty is being eradicated (Ministry of Health Uganda – Government of Uganda 
2000:5). In order to achieve this goal, the main objective of the Ugandan government 
has been to “reduce morbidity and mortality from all the major causes of ill health” 
(Ministry of Health – Government of Uganda 2000:5) and to reduce the various 
disparities in access to health care in Uganda (Ministry of Health – Government of 
Uganda 2000:5). It has therefore become imperative to carefully monitor the mortality 
trends in the country as a whole and to produce well-documented evidence-based 
mortality information if the health delivery system in Uganda is to achieve the goal and 
objectives that had been set by the Health Sector Strategic Plan.  
Free access to ART in Uganda has dramatically increased over a period of between 
four and six years – and is revealing a shorter and shorter doubling time. By the end of 
2004, 35 000 PLWHA were accessing ART. By August 2005, 67 369 people were doing 
the same, and, by June 2007, 106 000 PLWHA were receiving ART. By September 
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2008, 145 500 PLWHA were receiving ART (Mermin et al. 2008:758; PEPFAR ca 
2008:[1]; Uganda AIDS Commission – Government of Uganda 2008:26; WHO 2004c). 
This can only be described, by any standards, as a remarkable achievement in the 
delivery of ART and in the willingness of those members of the HIV-infected population 
to participate in these programmes. 
 
Uganda has achieved a reputation as being “one of the most successful countries in the 
fight against HIV/AIDS” after having been one of the countries that has been most 
ravaged by the effects of HIV/AIDS (McMichael et al. 2004:1156). In a study undertaken 
in rural Uganda, the mortality rate among HIV-positive adults was reduced by 90% 
among adults with HIV (Mermin et al. 2008:757). Similarly, the overall effect of ART on 
the overall mortality rate in Uganda has been found to be similar to or better than that 
which has been observed in facility-based studies in Europe, Haiti and other countries in 
Africa (Mermin et al. 2008:757). This is an indication that the introduction of ART into 
rural Uganda has effected a noteworthy reduction in the overall population mortality 
rates in these areas of the country.  
 
This study analysed and compared the mortality patterns with the perspective of 
increasing ART access and coverage in a rural setting to determine whether in this rural 
setting a positive impact of ART had been observed and if not possible reasons for the 
observed trends.  
 
2.6.4 The effect of tuberculosis in the Mpigi District of Uganda 
 
It has already been mentioned, the Mpigi district of Uganda was the area in which this 
study was undertaken. The prevalence of tuberculosis (TB) among the population of the 
Mpigi district is currently on the increase, with 1 300 cases being reported annually (Miti 
2008:[1]). The district tuberculosis and leprosy supervisor has expressed the opinion 
that the rise in the infection rate has been caused by the presence of the HIV among a 
large number of the district population. This is evident from a co-infection rate of 70% 
and 74% between the TB and HIV infection rates respectively (Miti 2008:[1]). The Mpigi 
district is therefore afflicted by a high burden of HIV/AIDS and TB, and the prevalence of 
TB is even now currently on the increase. This was one of the key justifications and 
motivations for the researcher to locate this study in the Mpigi district of Uganda.  
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The most recent HIV infection trends are a source of tremendous concern, with 
approximately 130 000 Ugandans contracting HIV annually (The New Vision 2009:[1]). 
Dr Kihumuro Apuuli, the Director General of the Uganda AIDS Commission, has “urged 
the Government to reinvent new strategies to fight HIV/AIDS”. He has also written: “To 
defeat HIV/AIDS, we need to start a new social movement to fight it [HIV].” 
 
(The New 
Vision 2009:[1].)  
This recent development has encouraged all HIV programme managers to re-think their 
strategies for monitoring HIV/AIDS. This study is the researcher’s contribution to the 
new perspective of HIV programming in low resource settings of focussing on the 
overall goal of reducing morbidity and mortality through evidence based targeted 
interventions and careful morbidity and mortality monitoring. 
 
2.6.5 Enhancing access to antiretroviral treatment in Uganda 
 
The Uganda Ministry of Health has suggested various strategies for reducing the impact 
of HIV disease. Uganda has made pragmatic and challenging responses to the 
HIV/AIDS epidemic. These responses have ensured an increased awareness of 
HIV/AIDS, an increase in advocacy for greater attention to be paid to PLWHA, a 
reduction in the incidence of stigma and discrimination, the development and 
implementation of policies to combat HIV infection (which include HIV counselling and 
testing, ART, the Orphans and Vulnerable Children Programme, and other policies) 
(Uganda AIDS Commission – Government of Uganda 2008:8). These policies have 
ensured the implementation of a properly integrated HIV/AIDS program arena.   
 
While it is therefore imperative to note that Uganda has made notable strides in the fight 
against HIV/AIDS, a great deal still needs to be done before access to ART for PLWHA 
becomes universal in that country. By the end of 2006, Uganda reported that 39% (91 
500) of adults and children with advanced HIV infections were receiving ART (Uganda 
AIDS Commission – Government of Uganda 2008:8). By September 2008, of the 322 
819 PLWHA who needed ART, 47.6% (153 719) were already receiving ART (Ministry 
of Health – Government of Uganda 2009:43). But this implies that 52.4% of PLWHA in 
2008 still had no access to ART.  
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New HIV infections are occurring at an alarming rate – with an estimated 110 694 new 
HIV infections and 61 306 AIDS-related deaths occurring in Uganda in 2008 (Ministry of 
Health – Government of Uganda 2009:43). But the Ugandan national response 
(strategy) to the AIDS epidemic for the period between 2007/08 and 2011/12 gives a 
strategic national direction to efforts to address the problem of HIV/AIDS (Uganda AIDS 
Commission – Government of Uganda 2008:16). The overall goal of their strategy is “to 
achieve universal access for HIV/AIDS prevention, care and treatment and social 
support by 2012” (Uganda AIDS Commission – Government of Uganda 2008:16). In 
order to achieve this objective, the strategy includes the objective of increasing access 
to ART through all health centres, of improving the effect of all the factors involved in 
health service delivery,  and the development of a National Communication Strategy 
(Uganda AIDS Commission – Government of Uganda 2008:17).  
 
Ever since the launch of free access to ART in 2003 in the Ugandan public sector, the 
World Bank, PEPFAR/United States Agency of International Development (USAID), the 
Global Fund against AIDS, the Global Fund against Tuberculosis and Malaria (GFATM) 
and the government of Uganda, have all contributed to ensuring free access to ARVs 
for affected Ugandans (Uganda AIDS Commission – Government of Uganda 2008:25).  
 
In spite of the extensive coverage that now ranges between 47.6% and  53% (Uganda 
AIDS Commission – Government of Uganda 2008:26), there is still a very high number 
of new infections and a high AIDS-related mortality in the country. Uganda needs to 
radically revise and rethink its current strategy on how to contain or halt this epidemic.  
 
2.7 THE EFFECT OF ANTIRETROVIRAL TREATMENT ON MORTALITY 
 
This section describes the impact of ARVs on morbidity and mortality trends. ARVs and 
ART are the most effective known form of clinical intervention for reducing HIV-1 
mortality. ARVs are becoming increasingly available in the developing countries where 
90% of HIV-infected people live (Mermin et al. 2008:752; WHO 2002:1). 
 
Figure 2.4 (below) indicates the global trend of the number of adult and child deaths that 
have been attributed to HIV/AIDS over the seventeen-year period between 1990 and 
2007. What is noticeable (and most encouraging) is that these figures reveal a 
downward trend that began in 2006.  
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Figure 2.4: The estimated number of adult and child deaths due to AIDS 
throughout the world (1990-2007) 
(Source: UNAIDS & WHO 2007:5) 
 
Figure 2.4 (above) shows a progressive increase in HIV/AIDS-related mortality from 
between 1990 and 2005 and a slower but progressive downward trend thereafter from 
between 2005 and 2007. This encouraging news of this fairly recent downward trend in 
mortality rates from between 2.2 million deaths attributable to AIDS per annum in 2005 
and the figure of 2 million deaths attributable to AIDS per annum in 2007, is largely a 
result of the increasing access that HIV-infected individuals have to ART (United 
Nations [UN] 2008:28).The burning question now is: “Are these changes in mortality 
rates also visible at the level of hospitals in the rural communities of Uganda?” 
 
Experience of health care providers in India shows that patients who received 
antiretroviral therapy revealed better survival rates – even when they presented with 
advanced symptoms of the disease if one compares their mortality rates with those who 
were never on ART (Kumarasamy et al. 2003:83). Patients who commenced with an 
ART regimen when they had a CD4 <200 cells/µL demonstrated a 45-month average 
survival rate compared to those who were not on HAART – who demonstrated a 33-
month survival rate (Kumarasamy et al. 2003:83). In another study, a 39% increase in 
ART utilisation caused death rates to fall from 7.0 (1996) to 1.3 deaths per 100 person 
years (2004), and AIDS-related deaths to decline from 3.8 (1996) to 0.3 deaths per 100 
person years (2004) (Palella, Baker, Moorman, Chmiel, Wood, Brooks, Holmberg & HIV 
Outpatients Study Investigators 2006:29).  
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“The increasing availability of antiretroviral therapy through resources from 
governments, the Global Fund against AIDS, Tuberculosis and Malaria and other donor 
agencies is a major step forward in the global effort against AIDS”
 
 (Abdool Karim & 
Abdool Karim 2003:1499).  
ART has therefore definitely made a significant impact on the increasing survival rate of 
PLWHA and in on the reduction of AIDS-related mortality rates and the overall death 
(mortality) rates throughout the world where free ART has been made available. 
 
The survival rate of patients on ART was beyond the scope of this study. However, the 
researcher examined trends in median age at time of death to determine whether 
patients were dying at an older age in free ART era. The death at time of death was 
therefore a key indicator of adult survival patterns that will need to be further analysed 
by other approaches to determine whether the rural population in Uganda is actually 
living longer in the era of free access to ART and factors associated with increased 
survival.  
 
2.7.1 Antiretroviral therapy and the risk of disease progression  
 
The progression of HIV infection from its earlier stages of the most advanced stage of 
the disease (AIDS) is a key determinant of mortality. Increases in the incidence of the 
most advanced stage of HIV disease (AIDS) has thus greatly influenced morbidity and 
mortality trends. One of the objectives of initiating ART programmes is to slow down the 
average rate of progression that characterises HIV disease (Flanigan, Wools-
Kaloustain, Harwell, Cu-Uvin, Kimaiyo & Cater 2007:1499). ARVs have in fact exerted a 
significant impact on the progression of AIDS, even among patients presenting with 
advanced symptoms (Van Sighem et al. 2005:212).  
 
“HAART has been extremely successful in suppressing HIV infection, restoring immune 
function and improving health” (Flanigan et al. 2007:1499). HIV/ AIDS as a cause of 
disease has been reduced since the introduction of ART (Mocroft Ledergerber, 
Katlama, Kirk, Reiss, D'Arminio Monforte, Knysz, Dietrich, Phillips & Lundgren 2003:28; 
Carter 2008:[1]). This reduction in the prevalence of all AIDS-defining illnesses due to 
the systematic utilisation of ART has been associated with a dramatic “decline in the 
number of AIDS-related deaths” (Cohen, French, Benning Kovacs, Anastos, Young, 
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Minkoff & Hessol 2002:96). When one compares figures from the early-ART (1996-97) 
and the late-ART (1998-2002) eras, one immediately notices that the overall incidence 
of AIDS is 50% lower in the late-ART period (Mocroft et al. 2003:27).  
 
In the Royal Free Hospital in London, the death rate among patients who are being 
treated with ART stands at one-sixth of pre-ART levels, while the incidence of new 
AIDS-defining illnesses and hospital admissions stand at one-seventh and one-fifth 
respectively of the rates that were prevalent in the pre-ART era (Mocroft et al. 
1999:1258).  
 
The cumulative effect of all the evidence assembled above leads one to the inevitable 
conclusion that increases in free access to ART has led to the reduction in the rate of 
progression of AIDS disease, and that this has significantly contributed to a reduction in 
the mortality rates due to HIV/AIDS. It is therefore of the greatest importance to monitor 
morbidity and mortality trends in all countries of the world where free access to ART has 
become available in order to determine the actual impact that is being made by free 
ART access. Since morbidity and mortality trends are used to guide decision-making 
and the adoption of the most effective interventions for minimising the risk of developing 
AIDS and its associated mortality rates, it is essential to implement accurate and 
comprehensive record-keeping in all the countries of the world and especially in the 
countries of sub-Saharan Africa.    
 
2.7.2 The impact of antiretroviral treatment on morbidity and mortality  
 
One of the key goals of ART “is to reduce HIV-related morbidity and mortality”, both at 
the level of patients and in the overall mortality rate of the population as a whole 
(Amoroso et al. 2002:323). It was therefore envisaged that the provision of free 
antiretroviral therapy would save lives and ameliorate the widespread suffering that is 
caused by HIV/AIDS (Abdool Karim & Abdool Karim 2003:1499). According to UNAIDS, 
“everywhere ART was introduced, spectacular improvements in the treatment of HIV 
patients ensured, dramatically reducing mortality among treated patients by about 70% 
and improving the quality of life” (WHO & UNAIDS 2002:3).  In addition to this, “HAART 
has lead to dramatic decreases in morbidity and mortality in those areas of the world 
where HIV infection is most prevalent”
 
 (Flanigan et al. 2007:1499). 
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In addition to reducing the rates of morbidity and mortality in those settings where ART 
has been introduced, the perceptions of the population at large with regard to HIV/AIDS 
has changed from “a death sentence to that of a manageable chronic illness” (WHO & 
UNAIDS 2002:3). As the use of ART in India, for example, has increased, and as death 
rates have declined from 25 deaths per 100 person-years in 1998 to 5 deaths per 100 
person-years in 2003 (Kumarasamy, Solomon, Chaguturu, Cecelia, Vallsbhaneni, 
Flanigan & Mayer 2005:1526), the stigma that has widely been associated with 
HIV/AIDS is correspondingly diminished. Because of the increasing availability of 
resources for the procurement and distribution of ARVs, there has been a notable 
downward trend in the prevalence of HIV (Corbett, Marston, Churchyard & De Cock 
2006:926).  
 
 
 
Figure 2.5: AIDS resources and prevalence between 1990 and 2007 
(Source: Ellman & Simms 2008:1071) 
 
Figure 2.5 shows that HIV prevalence among adults decreased in the years between 
2001 and 2007 as increases in the funding and availability of resources to counteract 
the effects of the epidemic, have occurred. “Countries that have received tens or even 
hundreds of millions of dollars [during] the past few years (particularly those countries in 
East Africa) have recorded large reductions in adult prevalence rates” (Ellman & Simms 
2008:1071). 
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The PEPFAR and the GFATM have significantly contributed to an increase in the 
number of people who are being treated. In high-prevalence settings, the increased 
availability of resources to fight the epidemics has been positively correlated with a 
reduction in HIV prevalence.  
 
2.7.2.1 The impact of antiretroviral therapy on hospital admission trends  
 
One of the key objectives of antiretroviral treatment has been to halt the multiplication of 
the HIV and thus reduce the risk of the progression of HIV disease among people who 
are living with HIV/AIDS (Van Sighem et al. 2005:212). Hospital admission trends have 
also shown that there is been a significant impact on the costs and workloads that have 
to be borne by public hospitals in particular. In northern Uganda, HIV positive patients 
have accounted for 37.2% of bed occupancy rates in medical wards (Fabiani et al. 
2003:65). In a study carried out in England, the increased uptake of antiretroviral 
therapy among PLWHA has coincided with a decreased use of inpatient hospital 
services (Beck et al. 1999:2160). Similarly, in a private hospital in Chicago (United 
States of America), after the introduction of ART, HIV-related admissions fell by 50% 
between 1995 and 1998 (Kumar, Wester, Ariga , Singh, Smith & Pulvirenti 2000:[1]). 
There was also a 29% reduction rate in hospital admissions and inpatient deaths in HIV-
positive patients between 1996 and 2000 following the introduction of free ART (Carter 
2005:[1]; Smart 2008:[1]).  
 
In 1996, each AIDS patient spent an average of 20 days in hospital per annum. But 
after the introduction of ART, the average amount of time that a patient spent in hospital 
fell to 11 days (Beck et al. 1999:2160.) 
 
Despite the notable reductions in admissions caused by an increased access to and 
use of ART, there has been evidence of a rebound effect in hospital admission rates 
among people with HIV in the USA (Bauer, Mathews & Barber (2001:[1]). Admission 
rates in San Diego fell from 10 per 100 in 1993 to 3 per 100 person months in 1997. 
However, since that time, admission rates once again rose to 9 per 100 person months 
in 1999 (Bauer et al. 2001:[1]). In addition to this, while mortality rates among HIV-
infected individuals since 1996 had fallen with the use of ART in developed nations, an 
increase in the number of deaths of HIV-infected hospitalised patients has been 
recorded (Teja et al. 2007:555).  
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The evidence cited above clearly shows that ART has made a far-reaching impact on 
the burdens that have been borne by hospitals, including a reduction in admission rates, 
in overall costs, in the amount of time that patients spend in hospitals and in mortality 
rates in general. These studies emphasise how extremely important it is to ensure that 
an effective monitoring of mortality trends in high HIV-prevalence settings will continue 
and be expanded in terms of both quality and comprehensiveness. 
 
2.7.2.2 The impact of antiretroviral therapy on causes of admission  
 
Ever since the introduction of ARVs, the reasons that had been recorded for patient 
admission have changed and that they are proportionately fewer in admissions for 
patients with the kind of opportunistic infections that are typical of HIV infection (Beck et 
al. 1999:2161). In another setting, there was a significant decline in the incidence of 
opportunistic infections and the risk of illness over time once free access to ART had 
become available (Carter 2005:[1]; Kumarasamy et al. 2005:1526; Mocroft et al. 
2003:25-26;). In India, for example, the incidence of opportunistic infections was 
reduced to <2 cases per 100 person years after the introduction of ART, compared to 
up to 10 cases per 100 person years in patients who had not been on HAART 
(Kumarasamy et al. 2005:1526).  
 
In spite of the documented reduction in opportunistic infections as a cause of admission 
and death in the ART era, Teja et al. (2007:559) have noted that 61% of deaths are still 
being caused by the opportunistic infections that are typical of HIV infection. 
Opportunistic infections have therefore remained the most common cause of death 
among hospitalized patients – even in the ART era (Teja et al. 2007:559).  
 
But the evidence unambiguously suggests that ART has reduced the incidence of 
opportunistic infections. It is also evident that, despite the availability of free ART, HIV-
related causes will continue to be important and will require careful monitoring. It is 
notable from the literature cited above that the impact of ART on opportunistic infections 
varies from hospital to hospital and should therefore be carefully monitored and 
meticulously recorded. This study focused on overall adults morbidity patterns by using 
hospital admission trends but did not delve into the analysis of the causes of admission 
but on the reported causes of death.  
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2.7.3 The impact of antiretroviral therapy on mortality trends  
 
With an increased access to ART, the reasons for hospitalisation and causes of death 
for HIV-positive individuals are changing and must therefore be carefully monitored. 
This section explores the causes of mortality and the overall (“all cause”) mortality 
trends since the introduction of ARVs.  
 
2.7.3.1 Impact of antiretroviral therapy on causes of mortality  
 
In 2005, Carter (2005:[1]) reported a significant increase in liver disease and ART side 
effects as a cause of death among patients. In addition to this, there was an increase in 
the proportion of non-HIV-related causes of death, from 14% to 15% in the pre-ART era 
to 39% to 52% in the ART era (Teja et al. 2007:559; Bonnet, Morlat, Chêne, Mercié, 
Neau, Chossat, Decoin, Djossou, Beylot & Dabis 2002:197).  
 
In a study that was undertaken over a 14-year period, the AIDS-related causes of death 
declined to 56% whereas the non-HIV-related causes of death increased to 32% (Crum, 
Riffenburgh, Wegner, Agan, Tasker, Spooner, Armstrong, Fraser and Wallace on behalf 
of The Triservice AIDS Clinical Consortium 2006:195) – with more deaths in the post-
ART being caused by cardiac disease, trauma and liver disease (when one compares 
the incidence of these causes to those that prevailed in the pre-ART era) (Crum et al. 
2006:198).  
 
Another study has demonstrated that ART has improved the survival rate for patients 
who present with Karposi’s Sarcoma (KS) and Non-Hodgkin’s Lymphoma (NHL), 
revealing an 81% and 84% reduction in the risk of death among patients with Karposi’s 
Sarcoma and Non-Hodgkin’s Lymphoma patients respectively (Tam, Zhang, Jacobson, 
Margolick, Chmiel, Rinaldo & Detels 2002:918,919). Crum et al. (2006:195) have noted 
that oopportunistic infections as a cause of death had been occurring less frequently 
and have declined from 59% in the pre-ART era to 24% during the ART era. In was also 
interesting and important to note that deaths in the post-ART era were less likely to be 
caused by an infection than in the pre-ART era (with 44% vs. 80%; P, 0.01) (Crum et al. 
2006:196). The use of HAART has therefore improved the overall survival among 
PLWHA and it was a key area of interest for this study to determine the pattern of 
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causes of death in the pre and post-free ART eras and compare this patterns with other 
trends in sub-Saharan Africa and throughout the world. 
 
2.7.3.2 The impact of ART on the overall mortality trends  
 
Because mortality trends are closely related to morbidity trends, changes in morbidity 
trends affect mortality trends. The key objective of ART is to reduce the burden of both 
morbidity and mortality (Mermin et al. 2008:758). All programs need the kind of 
documentation that is able to show the exact extent of this impact. 
 
Studies on responses to antiretroviral treatment in low-income countries, have indicated 
thedegree of success in immune recovery and reductions in mortality (Carter 2005:[2]). 
Evidence shows that an increased access to ART in resource-limited settings with a 
high prevalence of HIV leads to an overall (“all cause”) reduction in mortality (Gomez, 
Romero, Bernal, Gonzalez-Outon, Briceno, Ruiz &Garcia-Gil 2004:[1]). In the United 
States of America, the overall mortality rate fell from 9% in 1996 to 6% in 2000 (Carter 
2005:[2]). In another study in Malawi, the overall mortality decreased by 10% from 10 to 
9 deaths for each 1 000 person-years of observation (Jahn et al. 2008:1607). 
 
In KwaZulu, Natal, in the Republic of South Africa, there were declines in death rates 
from all causes of death between the first half of 2003 (before ART was introduced) and 
the second half of 2006 (Thaczuk & Differding 2008:[2]). The all-cause mortality rate in 
the 25 to 49 age group fell by 22%, and fell by 20% in men (Thaczuk & Differding 
2008:[2]).  
 
What is also a great interest is that the mortality rate after the introduction of ART varies 
by gender. Mortality was originally higher in men than in women (Braga, Cardoso & 
Segurado 2007:326; Nicastri, Angeletti, Palmisano, Samati, Chiesi, Geraci, Andreoni, 
Vella & The Italian Antiretroviral Treatment Group 2005:582). “The introduction of ARVs 
in 1996 significantly transformed the treatment of HIV and AIDS, improving the quality 
and greatly prolonging the lives of many infected people in places where the drugs are 
available” (UNAIDS ca 2003:[1]). Globally, the use of ART has improved therapeutic 
outcomes at the patient level and this has led to an overall reduction of morbidity and 
mortality rates among people living with HIV/AIDS (PLWHAs) (Kumarasamy et al. 
2005:1528). Increased access to ARVs has also contributed to a 80% decline in HIV-
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related deaths and an increased survival rate in India between 1997 and 2003 
(Kumarasamy et al. 2005:1527). In yet another study, HIV-related deaths declined from 
86% of all-cause deaths in the pre-ART era to 61% in the ART era (Teja et al. 
2007:559). Similarly, deaths due to HIV/AIDS and tuberculosis fell from 22 and 23 per 1 
000 person-years in women and men respectively in 2003/2004 (the pre-ART era), to 
16 in women and 18 in men in 2005/2006 respectively (the era after the introduction of 
ART) (Thaczuk & Differdin
 
g 2008:[2]). Another study found that women were 
significantly more likely to practice and achieve good adherence rates with 54% of 
females and 49% of males achieving more than 80% adherence (Nachega, Hislop, 
Dowdy, Lo, Omer, Regensberg, Chaisson & Maartens 2006:78). Women therefore 
reveal a better ART adherence than men in similar circumstances. 
In Europe, between 1994 and 2001, HIV/AIDS-related death rates declined from 16 to 3 
per 100 person-years of follow-up (Mocroft, Brettle, Kirk, Blaxhult, Parkin, Antunes, 
Francioli, D'Arminio Monforte, Fox, Lundgren & EuroSIDA1
 
 Study Group 2002:1666). 
Mortality due to AIDS therefore declined from 93% to 73% in a seven-year period 
(Mocroft et al. 2002:1666).  
Similarly, in lower income countries such as Malawi, Uganda, Cote d’Ivoire and India, 
more than 75% of patients on HAART demonstrated excellent rates of viral suppression 
(Flanigan et al. 2007:1499). There has therefore been a significant decline in overall 
adult mortality rates within two years of ART programme roll-outs in a high-prevalence 
communities, even where ART coverage rates of only 11% have been reported 
(Thaczuk & Differding 
 
2008:[2]). This shows that even with low ART coverage, ART has 
exerted a significant impact on mortality trends. 
In Malawi, mortality due to AIDS has been reduced by 19% in the 15 to 60 year old age 
group within eight months of the introduction of free ART in a rural community clinic 
(Jahn et al. 2008:1607). It was interesting to note that because of free access to ART in 
the Malawi study, there was a 35% reduction in the mortality rate among a community 
of adults who lived near the main road (Jahn et al. 2008:1607). In another study carried 
out by Smith, Gardner, Phelps, Hamburger, Carpenter, Klein, Rompalo, Schuman and 
                                               
1 The EuroSIDA study is a prospective observational cohort study of patients followed in hospitals in European countries 
in addition to hospitals in Israel and Argentina (Copenhagen HIV Programme 2009).  
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Holmberg (2003:680), a 42% increase in ART usage decreased incidence of AIDS as a 
cause of death from 58% of all deaths in 1996 to 19% in 1999. In Ethiopia, over a five-
year period of ART programmes administration, adult AIDS deaths were reduced by 
50% (Reniers, Araya, Davey, Nagelkerke, Berhane, Coutinho,& Sanders 2009:511). “In 
populations with access to these drugs [ARV medicines], death rates have plummeted”
Rabkin
 
( , El-Sadr, Katzenstein, Mukherjee, Masur, Mugyenyi, Munderi & Darbyshire 
2002:1503). These are extremely encouraging statistics in the difficult battle to contain 
the damage inflicted by the HIV virus throughout the world.  
 
In contrast to these encouraging reductions in mortality, not all ART programmes have 
been successful in reducing the rates of mortality that are attributable to HIV/AIDS. 
Smith et al. (2003:679) reported that the all-cause death rates among HIV-infected 
women remained unchanged between the pre-ART and ART eras.  
 
In another study of mortality rates, there were actually increases during the first year in 
which ART was made available. Mortality rates also increased in low-resource settings 
in comparison to those in developed countries where mortality rates were reduced by 
the availability of  ART  (Braitstein, Brinkhof, Dabis, Schechter, Boulle, Miotti, Wood, 
Laurent, Sprinz, Seyler, Bangsberg, Balestre, Sterne, May & Egger 2006:821). 
Similarly, in contrast to the reported reductions in mortality rates with an increased 
access to ART, another study reported that while the virological response after the 
commencement of ART has improved over calendar years, such improvements have 
not translated into a corresponding decrease in mortality (May, Sterne, Costagliola, 
Sabin, Phillips, Justice, Dabis, Gill, Lundgren, Hogg, de Wolf, Fätkenheuer, Staszewski, 
d'Arminio Monforte & Egger 2006:451). 
 
Another study revealed a notably higher death rate in the early HAART era compared to 
the later HAART era, and an 80% overall decrease in deaths from between 1990 and 
2003 (Crum et al. 2006:195). 
 
It is therefore clear that, in some settings at least, increased access to ART has 
significantly reduced mortality rates while, in other settings, mortality rates have not 
shown any significant change. It is also important to note that while some studies have 
reported a reduction in mortality rates over a short period of access to ART, other 
studies have reported that a reduction in mortality rates occur only after calendar years 
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and not after over a short period of time. In the present study, the researcher focused 
on a three-year period of access to ART and the three years before any free access to 
ART was available. He expected to find that specific mortality patterns would be 
observable during this period, and he devised three-year projections to enable health 
mangers drew design effective interventions.  
 
2.7.3.3 Survival trends and antiretroviral treatment  
 
Studies have reported an overall reduction of between five and 20 years in life 
expectancy rates in sub-Saharan African countries because of the effects of HIV/AIDS 
(Benatar et al. 2004:279; Mathers et al. 2000:1687; McMichael et al. 2004:1156). In 
South Africa, it was projected that, by 2011, AIDS would be the cause of half of all the 
national deaths that will occur in the country (Benatar et al. 2004:279). 
 
In India, the mean duration of survival from the date of HIV sero-diagnosis was 7.7 
years (92 months) (Kumarasamy et al. 2003:83). In another study, the median time of 
survival after HIV sero-conversion before HAART was 8 years compared with 10 years 
during the early ART era and 12 years during the late ART era (Crum et al. 195). These 
statistics are, however, not conclusive because the onset of advanced HIV disease 
depends on a multitude of factors. The challenge in determining the time that elapses 
between infection and advanced disease arises out of fact that acute HIV infection is 
rarely diagnosed in African settings (Onen 2002:297). The experience from Southern 
India, in a low-resource setting similar to those found in sub-Saharan Africa, has 
reported that HIV patients on ART had been surviving for at least six months and the 
these patients displayed a median survival of three years (36 months) compared with 
patients who were not on ART and who displayed a median survival of 1.7 years (20 
months) (Kumarasamy et al. 2005:1526). Crum et al. (2006:195) have also noted a 
decreasing trend in AIDS-related conditions as a cause of death from 80% in the pre-
ART era, to 65% in the early post-ART era, and 56% in the late post-ART.  
 
Although there is contradictory evidence about reductions in mortality after the 
introduction of ART to previous ART-free environments, there is mounting evidence that 
the introduction of ART into a high HIV-prevalence setting is associated with a reduction 
in the risk of the usual progression towards AIDS, and thus a corresponding reduction in 
the risk of mortality due to AIDS (Van Sighem et al. 2005:212). It is therefore worth 
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noting that “HAART has had a profound impact on the natural history of AIDS related 
opportunistic disease”
 
 (Dore et al. 2002:394). The advent of free ART has therefore 
basically transformed the whole complexion of the AIDS epidemic. But, because of this, 
changing trends in causes of mortality have to be very carefully monitored in view of 
increasing incidence of liver disease and the mortality rates that are attributable to the 
side effects of ARVs. 
The median age at death is defined as “the age at which exactly half the deaths 
registered (or occurring) in a given time period were deaths of people above that age 
and half were deaths below that age” (Australian Institute of Health and Welfare (AIHW) 
– Australian Government: ca 2005[257]). The median age at death is significantly 
influenced by the age structure of a population as a whole (AIHW - Australian 
Government: ca 2005[257]). The median age at death changes over time if the age 
structure or distribution of the population changes or because of changes in mortality 
patterns that influence mortality rates in specific age groups when these are compared 
to mortality rates in other groups (Jannerfeldt & Hörte 1988:679). The median age of 
death trends are an indication of the changes that take place over time in premature 
mortality. The median age of death is an easy indicator to calculate. It does not require 
standardisation and is useful for determining the impact of a disease on premature 
mortality. Premature mortality is defined as the potential years of life that are lost for 
whatever reason (Jannerfeldt & Hörte 1988:678.) Crum et al. (2006:195) have 
demonstrated that an increase in age at the time of death from 37 to 40 years has 
coincided with an increased access to ART. 
 
In summary, the introduction of ART has resulted in a profound overall decline in HIV-
associated morbidity and mortality (Kessler 2003:S101). The impact of increased 
access to ART in high HIV-prevalence settings even with low coverage has been an 
increase in patient survival rates and reduced overall mortality rates. It is therefore 
imperative that increased access to ART in high HIV-prevalence settings should be able 
to be directly related to increases in survival through the median age at the time of 
death and life expectancy if ART provision is to be considered a success. This is why 
the researcher in this study has focused on the overall impact how an increased access 
to ART has influenced morbidity and mortality rates in a rural setting in Uganda. 
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2.7.3.4 Demographic impact of antiretroviral treatment  
 
The review of mortality trends has demonstrated the demographic patterns inherent in 
mortality. Crum et al. (2006:195) have also reported that despite increased access to 
ART, the sex or race of patients who have died has not substantially changed among 
HIV-infected persons.  
 
2.8 GLOBAL FOCUS ON HUMAN IMMUNODEFICIENCY DISEASE  
 
The Millennium Development Goals (MDGs) have further emphasised the need to 
control the HIV epidemic and their overall goal is to reduce morbidity and mortality and 
thus foster the welfare and sustained development of their individual countries (UN 
2008:28). The sixth goal of the MDGs is to “combat HIV/AIDS, malaria and other 
diseases”,
 
 and the HIV-related target for this goal is to halt and begin to reverse the 
spread of HIV/AIDS by 2015 (UN 2008:28). The PEPFAR and GFATM are massive 
responses to the ravages of the HIV/AIDS plague (Abdool Karim & Abdool Karim 
2003:1499; The GFATM 2007:6). WHO, The European Commission and other bilateral 
funding agencies such as the the Japanese International Development Agency (JICA) 
have been rolled out to tackle the impact of HIV/AIDS in sub-Saharan Africa as a 
medical emergency and as a development issue with significant macro- and micro-level 
economic impacts (Whiteside 2005:408). 
Increased access to these funds has made a significant impact on HIV/AIDS and on the 
overall mortality caused by HIV/AIDS (McCarthy 2007:1155). These programmes have 
not only focused on HIV/AIDS but also on general and specific improvements to all the 
health delivery systems that operate in affected countries. Jaime Sepulveda has written: 
“PEPFAR has demonstrated what many doubted could be done, namely that HIV/AIDS 
services can be scaled up rapidly in countries with severe resource constraints and 
other daunting obstacles”
 
 (McCarthy 2007:1155).  
The five-year US$15 billion initiative was launched as an act of Congress in 2003. Most 
of PEPFAR resources go to the 15 so-called focus countries that have been hardest hit 
by the ravages of the epidemic. These include the 12 sub-Saharan African countries (of 
which Uganda is one), as well as Guyana, Haiti and Vietnam (McCarthy 1155.) Among 
PEPFAR's five-year performance targets are those that contemplate the provision of 
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antiretroviral therapy to two million people with HIV/AIDS, and consequent prevention of 
seven million HIV infections. According to the Office of the Global AIDS Coordinator 
(OGAC), PEPFAR had, by September 2006, provided antiretroviral therapy to 822 000 
adults (McCarthy 1155).  
 
UNAIDS has guided and co-ordinated the global response while governments and the 
variety of non-government organizations and initiatives funded by civil society have 
been funded to implement programmes that will mitigate the impact of HIV/AIDS. The 
provision of ART to two million people in the 15 most HIV/AIDS-affected countries has, 
because at the PEPFAR funding alone, already made a significant impact on morbidity 
and mortality trends, especially in sub-Saharan Africa. The GFATM estimates that two 
million lives have been saved through the programmes that it supports, and that an 
estimated 100 000 lived are saved every month (GFATM 2007:7) 
 
By June 2008, the GFATM had committed US$11 billion and disbursed US$6 billion to 
mitigate the impact of the three diseases that are especially associated with HIV/AIDS. 
By the end of 2007, The Global Fund delivered ART to 1.4 million patients (GFATM 
2007:7). 
 
The global response to HIV has therefore had – and will continue to make – a significant 
impact on HIV/AIDS mortality trends. The envisaged impact of ART iss reduced 
morbidity and mortality. This is the most important goal for all programme implementers 
and should be the focus for all future mitigation interventions. 
 
2.9 THE JUSTIFICATION FOR MONITORING MORTALITY TRENDS  
 
Over the years, a significant amount of attention has been invested in monitoring child 
morbidity and mortality in sub-Saharan Africa while minimal emphasis has been focused 
on adult mortality trends. There are, however, numerous indications that adult mortality 
rates are high and that they require the most meticulous and comprehensive attention 
and monitoring (Dgedge, Novoa, Macassa Sacarlal, Black, Michaud & Cliff 2001:546). 
There is, for example, a critical lack of accurate mortality data from the countries of sub-
Saharan Africa (Corbett et al. 2002:2185). The challenges in Uganda include severe 
limitations in the independent evaluation of the impact of health interventions on 
mortality. The WHO recommends sustained and regular tracking (monitoring) of the 
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causes of death and mortality (WHO 1999:17). This setting up of surveillance and 
monitoring standards is one of the most critical components of any national surveillance 
plan and needs to focus on a list of diseases that urgently need the most careful 
surveillance (WHO 1999:10). This list of diseases or conditions to be considered for 
careful monitoring and surveillance should be as short as possible and should be based 
on the following simple guidelines:  
 
• Does the disease create high impacts in terms of morbidity, disability, mortality? 
• Does it have significant epidemic potential?  
• Is it a specific target for a national, regional or international control programme? 
(WHO 1999:10). (Thus, for example, is the disease targeted for surveillance by a 
WHO Regional Plan or is it a notifiable disease in terms of WHO International 
Health regulations)? 
• Will the information that is being collected enable health care professionals, 
researchers and administrators to promote significant public health action? 
 
In the first place, if one considers the WHO criteria mentioned above, it is indubitable 
that HIV/AIDS results in high morbidity and mortality rates and is therefore a disease 
that should be considered for intensive routine mortality monitoring. Secondly, HIV/AIDS 
is currently a plague of pandemic proportions, and this alone justifies specific and 
concerted efforts to track its impact on communities and on efforts to assess the 
interventions that are designed to mitigate the effects of the disease. Thirdly, HIV/AIDS 
is a targeted disease, both at regional and global levels of the WHO. Fourthly, detailed 
and accurate data about trends in HIV/AIDS mortality and the impact of interventions 
such as free access to antiretroviral treatments need to be made because they 
constitute the necessary evidence on which health-related decision making has to be 
based. This kind of evidence is needed because it guides and determines the design 
and implementation of effective public health interventions that will further reduce the 
impact of HIV/AIDS. Lastly, since mortality trend data is routinely collected in all 
hospitals and clinics, it should be easily obtainable and analysed.  
 
With regard to HIV/AIDS, WHO recommends a routine monthly reporting of aggregated 
data from a peripheral to an intermediate level and a quarterly reporting of mortality 
reports and statistics (WHO 1999:28). This reporting requirement has been 
inadequately accomplished in low-resource settings. In sub-Saharan Africa, mortality 
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estimates are based on household surveys or information from replies to census 
questions (McMichael et al. 2004:1156).  
 
The regular monitoring of mortality trends guide programme managers as they attempt 
to determine the magnitude of the problem, to plan public health measures, to plan 
health care services and supplies, to assess the impact of the disease on clinical 
services and to validate the accuracy of HIV surveillance data (WHO 1999:28). The 
WHO Resolution AFR/RC48/R2 of the Regional Committee recommends that member 
states should make effective use of epidemiological data in decision-making, priority 
setting and resource allocation (WHO 1999:18.)  
 
In Uganda, as in other sub-Saharan Africa countries that monitor the epidemic from the 
health facilities that provide ART, the focus is on the number of patients enrolled in ART 
programmes, the number of patients who have been screened for ART, the number of 
patients who have attended follow-up clinics, and on the number of treatment 
defaulters. Other parameters that are recommended include descriptive information 
about adherence, the nature and frequency of side effects and other toxic effects, the 
extent of treatment failures, and the efficiency or otherwise of drug procurement and 
laboratory services (Ministry of Health – Government of Uganda 2003b:26.)  
 
Apart from this ongoing research activity, the Uganda HIV/AIDS programme is severely 
deficient in monitoring hospital morbidity and mortality trends as a measure of 
monitoring the progress that is being made towards meeting the MDGs (UN 2008:28). 
 
Since Uganda has experienced a dramatic increase in access to ART, this increased 
access to ART should result in a dramatic reduction in morbidity and mortality which 
should also be appreciated and carefully documented at the level of hospitals and 
clinics. It is also notable that the ART programmes in Uganda and sub-Saharan Africa 
falls generally short of the WHO recommendations for monitoring morbidity and 
mortality trends of serious epidemics such as HIV/AIDS so that mortality data can be 
used as a basis for critical programmatic decision making. Even though free ART may 
be become widely available, other significant factors that fuel the spread of HIV/AIDS 
and that act as obstacles to the reduction of morbidity and mortality, should be carefully 
evaluated if health-care administrators wish to sustain a permanent improvement in the 
treatment of people who are living with HIV/AIDS.  
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In order to optimize the benefits of ART, a much greater focus should be invested in the 
meticulous, comprehensive and ongoing monitoring of morbidity and mortality trends. 
That is why the researcher undertook this study in the first place. This study focused on 
the mortality trends in a rural setting in Uganda and the findings provided an insight on 
what is happening in and in similar settings as well as indications of what needs to be 
done.  
 
2.10 BARRIERS TO THE SUCCESS OF ANTIRETROVIRAL PROGRAMMES  
 
Since ART services are currently provided free of charge in many developing countries, 
the challenge is to ensure that HIV-positive patients who are in need of treatment will 
gain access to ART treatment before the HIV disease  reaches an advanced stage. By 
doing this, the health care services of sub-Saharan countries should be able to reduce 
the rates of morbidity and mortality. Delayed access to ART may be caused by an 
inadequate perception of the risks involved and an inadequate perception of the severity 
of AIDS as a lethal disease. Other barriers to ART access include a lack of ARVs in 
facilities, and certain demographic, social, psychological and structural barriers. But all 
these factors are beyond the scope of this dissertation.  
 
2.10.1 The cost of antiretroviral treatment as a barrier to access 
 
The single most important barrier that disrupts access to and adherence to ART is 
poverty. This implies that it is financial limitations that contribute most frequently to 
treatment interruptions (Wilson & Fairall 2008:485). In Botswana, for example, the 
impacts of various factors on adherence were modelled, and when cost restrictions 
were removed, adherence to ART was projected to increase from 54% to 71% (Wilson 
& Fairall 2008:485). It is therefore expected that by providing free access to ARVs at the 
point of service, more HIV individuals will be able to access ART at an early stage 
(before the disease advances to its terminal manifestations), and that sufferers will 
experience fewer interruptions in treatment because of a lack of medicines caused by 
their inability to afford the costs related to ARV access. Interruptions in the supply of 
ARVs are caused by an absence of medicines in a health facility or an inability of a 
patient to access ARVs in good time, resulting in periodic breaks in ARV regimen 
adherence, and result in poor treatment outcomes.  
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Wilson and Fairall (2008:487) have also reported stigma as a key barrier to access. The 
existence of a stigma surrounding HIV/AIDS and its implications, are creating significant 
challenges to the provision of antiretrovirals in the public sector. The provision of free 
antiretrovirals without a parallel effort to reduce the effects of social, religious and 
community stigma issues in public facilities will significantly hamper the achievement of 
universal access (Wilson & Fairall 2008:487).  
 
The cost of access to ART treatment and care consists of a number of required 
expenditures that include the cost of appropriate food for good and healthy nutrition, the 
cost of transport (especially in the case of rurally best patients), and the cost of paying 
for the treatment of treatment for other opportunistic infections. All these barriers are 
created by the effects of poverty and can effectively negate the achievement of the 
benefits of ART for HIV-infected patients. 
 
2.10.2 Poor adherence to antiretroviral treatment regimens as a barrier 
 
Adherence to the requirements of a treatment regimen is a critical determinant of the 
reductions in morbidity and mortality even after free access to ART. If a patient 
manages to access treatment but, for one reason or another, does not adhere 
meticulously to the requirements of the dosage regimens that are optimal for the 
success of the treatment, treatment outcomes will be poor and morbidity and mortality 
trends will thus either stagnate or increase. “Effective ART programmes require high 
adherence to medication” (; Lieb, Brooks, Hopkins, Thompson, Crockett, Liberti, Jani, 
Virkud, West & McLaughlin 2002:251; Mermin et al. 2008:752).  
 
2.10.3 Overextended health systems as a barrier  
 
The availability of free access to ART in conjunction with inadequate systems and 
resources to cater for the increased number of patients that desire to access it, has led 
to severe strains on the already profoundly overextended health care systems of many 
sub-Saharan African countries (Abdool Karim et al. 2005:43). The overloading of the 
health care system because of an increasing demand for HIV/AIDS care and support 
services has already compromised the quality of service delivery and of health service 
delivery in general in many other countries mentioned in this study (Uganda AIDS 
Commission – Government of Uganda 2008:40). Because of numerous problems 
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associated with the time the delivery of services to PLWHA, many overextended and 
under-resourced health care system are already in themselves a significant barrier to 
the successful delivery of ART to those who need it. Because of the very large number 
of patients and the lack of capacity of many health systems to cope with them (Abdool 
Karim et al. 2005:43), waiting times are frequently long, privacy is compromised, and a 
proper responsiveness to the demands of PLWHA is far from what it should be. McCoy, 
Chopra, Loewenson, Aitken, Ngulube, Thabale, Muula, Ray, Kureyi and Ijumba 
(2005:18–22) have reported 
 
a number of obstacles that already been encountered in 
the campaigns to rapidly expand access to antiretroviral therapy in sub-Saharan Africa. 
These obstacles include undesirable opportunity costs, the fragmentation of health 
systems, the disintegration of many health systems under the impact of pressures of 
which they cannot cope, the steady worsening of health care inequities, and poor and 
unsustained treatment outcomes.  
2.10.4 Human resource challenges as a barrier  
 
Human resource constraints also pose a significant barrier to ART access. The skills of 
the available doctors, nurses and other health workers that are required to administer 
successful programmes of free ART delivery fall far short of what is required to deliver 
an above-average health service in many countries of sub-Saharan Africa including 
Uganda (McCoy et al. 2005:18). In Malawi, there is only one physician for every 50 000 
to 100 000 people (Aitken & Kemp 2003:18; Mills, Schabas, Volmink, Walker, Ford, 
Katabira, Anema, Joffres, Cahn & Montaner 2008:685). In Uganda there is only one 
physician per 12 500 members of the population, one nurse for every 1 818 people, and 
one pharmacist per 33 300 members of the general population (Mills et al. 2008:686). 
As the burdens of HIV-related disease increase, the capacity of health care systems in 
sub-Saharan Africa to deliver quality care to PLWHA has been severely compromised 
(Fabiani et al. 2003:62). The increasing migration of health care workers to countries in 
which they can improve the prospects for their careers, is also projected to lead to 
numerous further reductions in the required number of health workers who are available 
to manage the HIV/AIDS pandemic and the projected number of patients with HIV 
infection who will be in need of care. Projections show that as this process of attrition 
continues, the number of patients for each available physician will increase from 9 000 
(in 2006) to 26 000 (in a 2012) (Mills et al. 2008:687).  
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2.10.5 Other barriers and obstacles 
 
Other challenges include an inadequate state of preparation and understanding on the 
part of communities and patients, an erratic and unsustainable supply of the necessary 
medications, and inadequate levels of training and support for health care providers 
(Stevens, Kaye & Corrah 2004:280). These barriers have resulted in a lack of 
monitoring of poor adherence to treatment, and an increased threat of the development 
of drug resistance (Stevens et al. 2004:280).  
 
While an uninterrupted supply of ART increases the prospects of patient survival and 
reduces morbidity and mortality among HIV/AIDS patients (Lieb et al. 2002:356), 
barriers that interrupt and compromise access to ARVs contribute to unchanged or the 
increasing morbidity and mortality rates that are associated with HIV disease – despite 
the availability of free access to ARVs. These are but a few of the many barriers that 
prevent timely access to ART before advanced HIV disease (AIDS) reaches its final 
outcome. All of these barriers significantly deter timely access to ART, proper 
adherence to treatment programmes and the necessity for strict adherence to HAART 
dosage regimens. The major barriers thus include the cost of ARVs and other related 
costs, the stigma that is still widely prevalent in many countries, and overloaded health 
care facilities that are unimaginably overextended and under-resourced. Therefore, 
despite free access to ART in many of the health facilities in sub-Saharan Africa, they 
are still other barriers that prevent access to these free ARVs that so important in their 
effects that they cannot be overlooked or ignored in the delivery of ART. All of these 
barriers to access can result in increasing or stagnant mortality trends. Aspects of these 
barriers were included in the analysis of the study results and formed a critical 
component of the discussion and conclusions. 
 
2.11 MORTALITY TRENDS IN THE ERA OF ANTIRETROVIRALS  
 
In the 1980s and 1990s, an HIV-positive status was considered to be a death sentence 
and was regarded as a deadly disease in Uganda (Teja et al. 2007:555; WHO & 
UNAIDS 2002:3). Since AIDS was a disease for which there was no known treatment, it 
was well known that any individual who had been infected with HIV would finally 
succumb to the effects of AIDS and death. It is therefore very clear to HIV-positive 
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patients in Uganda that AIDS is a very serious disease that may, if untreated, ultimately 
lead to death (Ministry of Health – Government of Uganda 2006:44).  
 
While ART delays the progression of AIDS and reduces the risk of death for HIV-
infected patients (Wood 2008:504), mortality and morbidity trends in high-prevalence 
settings even with free access to ARVs, are affected by a number of factors. These 
barriers and obstacles result in late access to ART or to no access to ART at all. While 
ART significantly reduces mortality among HIV-positive individuals, mortality has been 
noted to be high in the first six months of treatment (WHO 2006b:25)In addition to this, 
studies have also shown that ART does not completely prevent the development of the 
clinical symptoms of HIV-related illnesses, and that an increased  risk of death is 
especially evident among patients who have begun treatment when HIV disease has 
reached an advanced stage and their immune systems have already been severely 
depressed (WHO 2006b:25; Wood 2008:504).  
 
A review of HIV-related mortality trends of patients on ART in sub-Saharan African 
countries revealed that the mean or median time to death was 57-182 days after the 
commencement of treatment, and that 55-100% of deaths occurred within the first six 
months of treatment (Sutcliffe, Van Dijjk, Bolton, Persaund & Moss 2008:484-85). It is 
therefore valid to conclude that the mortality of patients on ART in developing countries 
is especially high during the first year of ART treatment. Therefore, since a significant 
proportion of HIV patients access ART too late (i.e. when HIV disease has already 
reached an advanced stage), mortality trends in hospitals may remain unchanged 
(stagnant) or may even increase. 
 
It is therefore imperative to ensure that HIV positive patients access treatment before 
the appearance of advanced forms of HIV-related illnesses if they are to receive the 
therapeutic benefits of ART. Once patients had commenced on treatment, they should 
faithfully adhere to all treatment requirements for the remainder of their lives in order to 
ensure that they receive the optimum benefits that ARVs are able to confer. In order to 
determine the impact of ART, there is therefore an urgent need to monitor morbidity and 
mortality trends as completely and thoroughly as possible in the prevailing 
circumstances.  
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2.12 SCENARIOS OF EXPECTED MORTALITY TRENDS  
 
The researcher has posited three mortality and morbidity trends that will occur in any 
rural setting in which patients have access to an antiretroviral treatment programme.  
These trends are all based on the factors mentioned above – all of which are factors 
that can either negatively or positively affect morbidity and mortality rates. The three 
scenarios are trends that display increasing, stagnant and reducing patterns of 
morbidity and mortality. 
 
The first scenario involves an increasing trend in admissions and mortality that may be 
caused by inadequate ART coverage for PLWHA or by late access to ART by people 
living with HIV/AIDS, or the effects of an inability to tolerate the toxicity that is 
associated with some ARVs (Mocroft et al. 1999:1260). Increasing mortality and 
morbidity trends are an indication that in the absence of other factors that significantly 
affect mortality patterns, the introduction of free access to ART in a rural setting has not 
significantly affected mortality and morbidity trends in a rural setting.  
 
The second scenario is a stagnant morbidity and mortality trend that may be caused by 
a number of factors that indicates the absence of any impact of ART on mortality rates. 
Stagnant mortality trends indicate a mortality rate which is equal to the population rate 
growth rate. Alternatively, stagnant trends may indicate that the programme did indeed 
successfully reach all PLWHA in need and thus stabilised mortality trends with a 
constant balance of new patients and mortality. 
 
The third scenario involves a reducing morbidity and mortality trend which a largely 
caused by a successful ART programme and patients who are able to enrol in good 
time with an efficient and well-functioning ART programme, with the availability of 
treatment to those in the community who need, and good adherence rates. The third 
scenario is the best-case scenario that programme managers can hope to expect. 
 
Apart from gross mortality trends, a review of mortality data also reveals a number of 
aspects of mortality that guide programme decision-making. In a study of “comparisons 
of causes of death and mortality rates among HIV-infected persons”, the annual death 
rate peaked at 10.3 per 100 patients (1995) and then steadily declined to 2 deaths per 
100 persons in 6 years during the ART-era (Crum et al. 2006:195). It is a recognized 
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fact that trends in hospital admissions and trends in mortality are likely to reflect the 
healthiness of the population in general (Mocroft et al. 1999:1260).  
 
The most important focus of this study was to determine the morbidity and mortality 
trends in the particular rural setting and has already been described. A clear 
understanding of these trends are needed to inform health care decisions and guide 
research activities that will provide answers to why these trends occur in the way that 
they do, and to ultimately reduce overall morbidity and mortality rates. It was thus the 
task of this study to determine which of the three scenarios was actually taking place in 
the rural hospital in which the study took place. 
 
2.13 RESEARCH GAPS  
 
It is by means of this literature review that the researcher has noted that without a 
reliable comparative morbidity and mortality trend analysis before and after free access 
to ARVs available in a hospital setting, HIV programmes are in many ways working in 
the dark. In such circumstances, health programme managers become lost in fairly 
short term results or process indicators such as the number of HIV patients who had 
commenced ARV treatment, and they unfortunately remain ignorant of the significance 
of many critical short- and long-term impact indicators.  
 
After more than four years of free access to antiretroviral treatment in public facilities in 
Uganda and in sub-Saharan Africa, the researcher undertook a critical review of the 
morbidity and mortality trends in the hope that these could be extrapolated to the larger 
picture in order to inform decisions about the arrangements that will be made for ART 
programming in the years to come. Such information will ensure that patients receive 
the optimal benefits that are available to them through the health care systems that 
have the responsibility of reducing the burden of disease and mortality among their 
clients. “Our ability to define and monitor the full effect of the HIV epidemic is seriously 
compromised by scarce research and routine surveillance data for most infectious 
diseases in Africa” (Corbett et al. 2002:2185). These researchers have recommended 
that “surveillance of disease trends and research into infectious disease control should 
be priorities in countries severely affected by HIV-1 and public health investment and 
standards should be enhanced to cope with the new realities of infectious disease 
control since the HIV-1 epidemic” (Corbett et al. 2002:185). 
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There is an inadequate amount of reliable and comprehensive information in sub-
Saharan African countries about morbidity and mortality trends that will enable health 
care administrators adequately to make sound evidence-based decisions about cost 
effective interventions that will be able to reduce the impact of HIV/AIDS. 
 
2.14 CONCLUSION  
 
This chapter reviewed the literature about HIV disease, the impact of HIV disease 
globally and in sub-Saharan Africa in particular, the numerous factors associated with 
the provision of ART, and the interventions that Uganda has implemented to contain the 
epidemic. It is, however, noteworthy that mortality trends in Uganda and a number of 
other low-resource settings have been inadequately monitored over the years. In this 
era of ART access, mortality and morbidity trends are vital indicators for determining 
policy and for ensuring the success of programmes.  
 
Chapter 3 deals with the methodology that the researcher used for prosecuting this 
research. 
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CHAPTER 3 
 
Research methodology 
 
 
3.1 INTRODUCTION 
 
Research can be defined as “the systematic and rigorous process of inquiry which aims 
to describe phenomena and to develop and test explanatory concepts and theories” 
(Bowling 2007:1). Research methods or techniques consist of various methods of data 
collection such as, individual face-to-face interviews, focus group interviews, structured 
questionnaires, the examination of historical records, and any other instrument or 
technique that the researcher deems appropriate for the collection of data (Bowling 
2007:436). This chapter describes the research design, the approaches and the 
methods that the researcher applied to achieve the aims of this study. His methods of 
investigation included a careful review of the whole study population, the determination 
of a sample by the application of a particular sampling method, the collection and 
analysis of data, the abdication of techniques to ensure validity and reliability, and the 
use of widely accepted ethical principles to guide all aspects of the research. His 
research methodology also comprised a research design, the identification and 
description of the study population, the use of various data collection instruments and 
techniques, the application of the ethical principles that are recommended by the 
university throughout the course of the research, an analysis of the raw data, and the 
use of various methods to the results obtained in to make extrapolations and projections 
from these results.  
 
The methodology of any particular research project guides the researcher and enables 
the reader to understand and appreciate why the research progresses or progressed in 
the way that it does or did. 
 
The most basic method that the researcher adopted in study was deductive reasoning 
or the deduction approach. Deduction in research refers to the process whereby one 
begins with the formulation of one or more general ideas or hypotheses, and that one 
uses these hypotheses to develop a more specific and exact theory , after which one 
proceeds to test the hypothesis in terms of the data that one has collected(Bowling 
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2007:118; Trochim 2006a:[1]). The deductive approach in research is sometimes 
referred to as a "top-down" approach (Trochim 2006a:[1]) (see figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: The Flow of deductive thinking approach in research 
(Source: Trochim 2006a:[1]) 
 
The researcher therefore approached his research topic by making use of a deductive 
method which is illustrated in figure 3.1 (above).  
 
Theory has been defined as “the analysis of a set of facts in their relation to one 
another or a belief, policy, or procedure proposed or followed as the basis of action or a 
plausible or scientifically acceptable general principle or body of principles offered to 
explain phenomena” (Merriam-Webster Online Dictionary 2009e:[2]). Theory was also 
defined by Hornby (2005:1532) as “a formal set of ideas that are intedended to explain 
why [something] happens or exists”. In this study, the initial overall theory that guided 
the progress of research was that a high rate of HIV infections in a particular population 
will always be associated with a high degree of adult morbidity and mortality, and that 
the widespread use of ARVs among HIV-infected people in such a population will 
significantly reduce the rates of adult mortality and morbidity. This theory has in fact 
been backed up reports in the literature on the topic (see section 2.7 for a detailed 
discussion of this evidence). When researchers utilise a deductive approach in research 
within the broader framework of a particular evidence-based theory, one will have 
opportunities to develop one or more hypotheses that will either confirm or disconfirm 
reports from earlier research. It is in this way that research develops and is refined by 
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the results of other research that confirms the original premises or modifies the terms 
and assumptions which frame the original theory and its findings. 
 
A hypothesis may be defined as ”an idea or explanation of [something] that is based 
on a few known facts but that has not yet been proven to be true or correct” (Hornby 
2005:736). A hypothesis may also be defined as a “proposition [that is] tentatively 
assumed in order to draw out its logical or empirical consequences and [to] test its 
consistency with facts that are known or may be determined” (Merriam-Webster Medical 
Dictionary 2009f:[1]). The main hypothesis of this study was that if free ARVs were 
introduced into a rural hospital in a high-HIV prevalence setting in Uganda, the 
prevailing morbidity and mortality rates would be reduced (and that this, if represented 
graphically, would be clearly visible in a downward trend). The hypothesis that was 
tested in this study was therefore framed by the researcher in the following words: “The 
introduction of free antiretroviral treatment in a rural hospital leads to a reduction in 
overall morbidity and mortality rates.”  
 
This study therefore commenced with a theory-specific hypothesis that the researcher 
tested by collecting a large amount of information about adult morbidity and mortality 
trends from the specific group of patients who attended a particular hospital in a rural 
setting in Uganda over a particular period of time. The research extended over a period 
of years which included three years in which free antiretroviral (ARV) treatments were 
not available, and three years in which free antiretroviral treatments were available. This 
fundamentally important variation in the conditions that the patients in the sample 
encountered in the rural hospital in which the study was performed, allowed the 
researcher to make significant conclusions from the influence of free ARV on a large 
sample of HIV-infected patients. The researcher compiled as much relevant information 
as he could obtain from all the mortality records in the hospital. These records included 
ward registers, death certificates and patient files, and the hospital authorities made 
them freely available to him for the purposes of his research. Through the information 
that he assembled and collated in this way, the researcher was able to construct further 
observations that helped him to refine his theories in such a way that would be more 
effective in either confirming or disconfirming his hypotheses. This process enabled the 
researcher to test his hypotheses by measuring them against the specific data and 
information that he was able to assemble, and this resulted in the confirmation or 
modification of his original theories (Trochim 2006a:[1]). “Deductive reasoning is more 
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narrow in nature and is concerned with testing or confirming hypotheses.” (Trochim 
2006a:[1]).  
 
3.1.1 Study variables 
 
A variable is defines as a characteristic of an individual, object or unit that can be 
measured or observed, and that has the capacity to vary in extent, quantity or quality 
among the individuals or units that are being studied or examined (Creswell 2003:93; 
Rudestam & Newton 2007:22).  
 
An independent variable can be defined as a variable that causes or influences or 
affects a specific outcome (Creswell 2003:94; Somekh & Lewin 2005:216). The 
independent variables in this study included the primary and associated causes of 
death, age, gender, the length (in a number of days) that patients remained admitted to 
the hospital before their death, and the out-of-pocket payments that patients or relatives  
made for health services in the hospital under study. A dependent variable can is a 
variable that an independent variable causes to change. Dependent variables are 
therefore the outcomes of the effects of independent variables (Creswell 2003:94). The 
dependent variables in this study include the number of admissions, the number of 
patients on ART, the extent of ART coverage among the population sample that the 
researcher was studying, and the number of deaths that occurred in the hospital (which, 
in this study, are represented as the number of deaths per 100 patient admissions).  
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Table 3.1:  Variables, research questions and data collection items 
 
Variable 
name  
Research question  Item on the data collection tool 
and the tool that was used to 
compile the data 
Dependent 
variables 
What is the overall adult hospital mortality 
trend in reference to the pre-free ART 
period and the post-free ART period? And 
what is the projected trend?   
• Accomplished by analysing mortality 
rate (number of deaths per 100 
admissions) and by comparing these 
mortality trends with the estimated ART 
coverage 
Data collection tool B:  
• Number of adult admissions per 
month (an “adult” in Uganda 
being defined as a person 15 
years old or older) 
• The cumulative number of 
patients on ART per month  
• The total number of deaths per 
month  
 What is the overall effect of free ART 
access on hospital mortality trends? 
• Accomplished by analysing the 
mortality rates and trends (the number 
of deaths per 100 admissions) and by 
comparing them with the estimated 
ART coverage 
Data collection tool B:  
• The number of adult 
admissions per month  
• The total number of deaths per 
month 
Independent 
variables  
To what extent can adult hospital mortality 
trends be correlated with factors such as 
age, gender, cause of death, length of 
stay in hospital (i.e. the number of days 
the patient is admitted in hospital before 
death), the out-of-pocket payments (or 
health user fees that are usually paid by 
relatives) in the pre-free ART era and the 
post-free ART era? 
Data collection tool A 
• The cause/s of death 
• The age of the patient 
• The gender of the patient 
• The average length of stay in 
hospital (abbreviated as 
“ALOS”) or the number of days 
the patient remains admitted to 
hospital before death  
• The out-of-pocket payments 
(user fees) that are paid by 
relatives  
 
Table 3.1 (above) summarises the variables under review in this study (see section 
3.1.1 for a detailed description of the content of table 3.1) according to the research 
questions under investigation. This table also indicates the specific tool that the 
researcher utilised to collect this information. This table lists the variables, the study 
questions and the study instruments. On the basis of these study variables, the 
researcher analysed the data that he collected and thus provided considered answers 
to the research questions. 
 
3.2 RESEARCH DESIGN 
 
Research design is “the strategy of research” (Bowling 2007:436) because it indicates 
how the sampling is conducted, how the variables are operationalised and measured, 
and what kind of analysis will be conducted. 
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“Research design provides the glue that holds the research project 
together. A design is used to structure the research, to show how all of 
the major parts of the research project – the samples or groups, 
measures, treatments or programs, and methods of assignment – work 
together to try to address the central research questions” 
 
(Trochim 
2006b: [1]). 
Research design may also be defined as the “plan to be followed to realize the research 
objectives or hypothesis. It [the research design] represents the master plan that 
specifies the methods and procedures for collecting and analyzing the required 
information” (Van Wyk 2005:82). A specific research design guided the researcher in 
the overall planning and implementation of the study in order to accomplish the 
research goals.  
 
The researcher chose a quantitative, retrospective, descriptive and cross-sectional 
research design for this study to enable him to provide a detailed description of the adult 
mortality trends both before and after the introduction of free antiretroviral therapy (ART) 
into the particular rural hospital in Uganda.  
 
3.2.1 Quantitative study design 
 
A quantitative research design provides a “quantitative or numeric description of trends, 
attitudes, or opinions by studying a sample of that population” (Creswell 2003:153). A 
quantitative study design provides a sound basis for generalising the results obtained 
from a particular study population to general population that it represents (Creswell 
2003:153). The assumptions of a quantitative methodology are justifiable in terms of a 
positivist epistemology that assumes that the nature of the reality that human beings 
experience is objective and external to the human mind, and that it can be expressed 
numerically. It therefore emphasizes the dependability of measurement and 
quantifiability, and seeks to determine invariable relationships between similar 
phenomena (Glatthorn & Joyner 2005:40). In quantitative studies, the “theory becomes 
the framework for the entire study, an organising model for the research questions or 
hypothesis and for the data collection procedure”(Creswell 2003:125). In addition to this, 
“the researcher advances theory, collects data to test it, and reflects on the confirmation 
or disconfirmation of the theory by the results” (Creswell 2003:125). 
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The quantitative information in this study was gathered by the researcher and his 
assistants from a structured audit and review of all the hospital’s patient records in the 
period covered by the study. He then analysed the data thus obtained by making use of 
the Epi info program and determined frequencies for the responses to all the items 
listed in the audit, collated these in the results section of the report, and used the 
information collected in this way as a basis for further discussion, analysis and 
conclusions.  
 
3.2.2 Descriptive design 
 
Descriptive design “is constructed to answer who, what, when, where and how 
questions.” (Van Wyk 2005:86). Descriptive researchers therefore observe, then explore 
and describe key aspects related to a situation as it occurs (Polit & Beck 2006:192). In 
descriptive research, a researcher acquires a basic understanding of the underlying 
relationships that prevail in the problem under study, and uses structured and 
quantitative methods such as the audit tools that were used in this study (Van Wyk 
2005:86). 
 
This study was therefore also descriptive in nature because it described a particular set 
of phenomena and their reported frequencies, and because it determined the averages 
and percentages pertaining to the characteristics of the population by examining a 
specific sample of that population (Glatthorn & Joyner 2005:103).  
 
This study investigated and described adult mortality trends both before and after the 
introduction of free antiretroviral therapy in a rural hospital in Uganda in order to 
enhance scientific knowledge about the numerous unexplained factors and unanswered 
questions that pertain to this area of public health. 
 
3.2.3 Cross-sectional studies 
 
Cross-sectional studies require “the collection of quantitative data on at least two 
variables at one point in time and from a number of cases”. [The] data are used to look 
for patterns of association or relationships either in the group as a whole (all cases) or in 
subgroups sharing characteristics or attributes” (Somekh & Lewin 2005:216). In this 
study, the cross-sectional study design was used to collect the necessary data from the 
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medical records department of the hospital about the death of all adult members of the 
population (an “adult” is defined in Uganda has been 15 years and older) over a six-year 
period from between June 2002 and June 2008. 
 
3.3 POPULATION AND SAMPLE 
 
The population is the entire set of individuals that have the same characteristic or set of 
characteristics in common. 
 
3.3.1 Population 
 
Population therefore refers to that conglomeration of individuals towards which the 
questions that motivate the research are directed (Bland 1995:27; Polit & Beck 
2006:259). A study population may be defined as “the entire aggregate of cases that meet 
specified criteria” (Polit & Beck 2006:259) or the complete set of units that is being studied 
(Somekh & Lewin 2005:217). In addition to this, a population is also “an aggregate of 
people or objects” (Bowling 2002:176). The study population is the whole population 
group to which the results of a study will and should be generalized. In quantitative 
studies, the specific characteristics that delimit the study population are put into effect 
by means of eligibility or inclusion criteria (Polit & Beck 2006:259). In this study, the 
study population was the total number of adult deaths (including those that occurred in 
the facility and at home) that occurred in the district under study throughout the length of 
the study period.  
 
3.3.2 Sampling frame 
 
Sampling is defined as the process and techniques that are used to select a portion or a 
subset of the population called a sample, which will serve to represent the entire 
population (Bowling 2002:436; Polit & Beck 2006:260). Once the study population has 
been identified, the population from which the sample will be drawn is identified. The 
sample size is defined as the number of elements or subjects that are included in the 
population that will be studied (Polit & Beck 2006:267). The use of a representative 
sample in a study enhances the generalisability of the research results (Rudestam & 
Newton 2007:106; Polit & Beck 2006:268).  
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In general, a sample size increases in proportion to the population size and the 
sampling error decreases in proportion to the sampling size. The larger the sample, 
therefore, the smaller will be the sampling error because the sample becomes more and 
more representative of the population as its size increases (Polit & Beck 2006:268). 
 
The sample selected for this study included all adult deaths among those who were 
admitted to the medical and surgical wards of the rural hospital as a subset of all the 
deaths that occurred in the district. Although the sample that the researcher used in this 
study is therefore representative of what happened in Mpigi district during the period 
investigated by the study, its results cannot be generalised to mortality trends across 
the rest of Uganda during the same period. These trends nevertheless remained 
pertinent to and indicative of what was happening in hospitals in similar settings in 
Uganda.  
 
3.3.3 Sampling and sample 
 
A sample “is a subset of a population selected to participate in a study” (Polit & Beck 
2006:260). A sample may also be defined as “a finite part of a statistical population 
whose properties are studied to gain information about the whole” (Merriam-Webster's 
Medical Dictionary 2009f:[1]). In other words, a sample is a basic level or unit of 
investigation, or the representative unit of a population that one studies in order to 
appreciate and understand the population from which it is drawn (Somekh & Lewin 
2005:218; Van Wyk 2005:340). In cases of finite resources, it is far preferable to study 
the whole population, but because finite resources do not occur, researchers tend to 
use a sample rather than the whole population “because it more economical and 
practical” (Polit & Beck 2006:260). 
 
The two main concerns in quantitative studies are “how the sample is selected and how 
many elements [it possesses]” (Polit & Beck 2006:261). There are two broad sampling 
techniques that are used in quantitative studies, and they are “probability sampling and 
non-probability sampling” (Polit & Beck 2006:261).  
 
In probability sampling, a researcher uses the technique of random selection to 
assemble a sample because this process or procedure ensures that the different units 
in the population will all have an equal probability of being chosen (Polit & Beck 
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2006:264; Trochim 2006c:[1]). But random selection and probability sampling are not 
used in to determine a sample in non-probability sampling. This does not necessarily 
mean that such a sample will not be representative of the general population, but it does 
imply that the sample will not be dependent upon the rationale of the probability theory 
(Trochim 2006d:[1]). In non-probability sampling, there is an insufficient amount of 
evidence to prove that the sample that is being investigated in the study is 
representative of the general population and that the results obtained can be 
generalised to it (Polit & Beck 2006: 261; Trochim 2006d:[1]). In non-probability 
sampling, a segment of the population is also very likely to be systematically 
intentionally or non-intentionally underrepresented. In this study, the researcher used 
the method of non-probability sampling because of convenience of access to the 
sample and because of the necessity to economise with the resources available for the 
study (Polit & Beck 2006: 264).  
 
The researchers selected the Mpigi district by using the convenience or opportunity 
sampling method, which is a non-probability approach and which was suitable for this 
study (Creswell 2003:156; Somekh & Lewin 2005:219). He also used convenience 
sampling because the Mpigi district and the hospital in which the study took place were 
accessible, were ready and eager to participate in the study (Bowling 2002:187). 
Convenience sampling enabled the researcher to explore a number of complex issues, 
including health facility utilisation trends and certain features of out-of-pocket payments 
made by patients because both of these factors are of extreme importance for those 
who devise health policies at the level of central government (Bowling 2002:187).  
 
Another reason why the researcher selected this particular hospital for review was, 
firstly, because approximately 40% of all the deaths that occurred in Mpigi district during 
the study period occurred in the health facilities of this hospital (this calculation was 
based on the patient workload that had to be serviced by the hospital staff). Secondly, 
because of the systems that had already been in place in the hospital from the period 
before the study commenced, the researcher expected that the mortality records would 
be more complete and accessible (in comparison to the records maintained by other 
public health facility settings). The assumption was therefore that the mortality trends in 
the hospital under study were indicative of the mortality trends in the district as a whole, 
and that the results of the study would be useful for helping health care administrators 
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and policymakers to plan effective interventions to reduce the rates of morbidity and 
mortality.  
 
Because the number of deaths that occur in rural hospitals are relatively small, the 
researcher included all adult deaths of patients who had been admitted to the hospital 
during the study period in the sample.  
 
The eligibility criteria for inclusion in the sample were therefore as follows:  
 
1. They had to be adult deaths in the hospital (i.e. the deaths of individuals who 
were 15 years and older at the time of their demise).  
2. The deaths had to have occurred in either the medical or the surgical wards.  
3. The deaths had to have occurred during the period between June 2002 and June 
2008. 
 
The lack of information that was sufficiently reliable and comprehensive to capture the 
various aspects of life-threatening complications among pregnant women hindered the 
researcher's assessment of the impact of HIV infection on rates of maternal mortality 
and morbidity (Graham & Newell 1999:837). The researcher therefore decided to 
exclude maternal deaths from the sample because of the limited and often fragmentary 
nature of the information about the impact of HIV infection on maternal mortality (Khana, 
Pillay, Moodleyc & Connollya 2001:1861-62). An additional reason for this exclusion 
was provided by another study that investigated the effects of HIV/AIDS on maternal 
mortality in Malawi and Zimbabwe. It concluded that “further study is required to assess 
how HIV/AIDS affects pregnancy-related mortality rates”(Bicego, Boerma & Ronsmans 
2002:1080). The researcher also excluded the deaths of any patients that occurred 
before admission to the hospital, and dead bodies that were admitted to the hospital for 
post-mortem or autopsy reports.  
 
The study population was identified from a comprehensive examination of the hospital’s 
patient records for the period under study. These records included death certificates, 
hospital inpatient case notes and registers.  
 
Because the researcher utilised a non-probability convenience sampling approach in 
this study, the results were focused on the morbidity and mortality trends in the hospital 
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under study and are therefore only indicative of what was happening in similar hospital 
settings in rural areas in Uganda during the same period.  
 
3.3.4 Estimation of sample size 
 
The size of the sample is of major importance in conducting quantitative research and in 
evaluating the findings of quantitative research (Polit & Beck 2006:267). A sample is the 
group of elements or subjects that are selected to take part in or participate in a 
research activity as study subjects (Trochim 2006e:[2]). The researcher used the 
convenience sampling approach in this study because it provided an easy and cost-
effective method of access to the study sample (Somekh & Lewin 2005:219).  
 
Adult mortality in this Uganda setting refers to the mortality of individuals who were 15 
years and older during the period of study (Uganda Bureau of Statistics, Government of 
Uganda 2006b:42), and they were the focus of this study. In Uganda, 50.6% of the 
population is either 15 years or older (Earthtrends 2003:[1]; The International Institute 
for Strategic Studies 2000:[1]; Uganda Bureau of Statistics, Government of Uganda 
2006b:17). By September 2002, the adult (“15 years and older”) population in Mpigi 
district was estimated at 206 342, with an annual district population growth rate of 1.3% 
(Uganda Bureau of Statistics, Government of Uganda 2006b:47). By June of 2008, the 
estimated district adult population was 222 348. There is a distinct lack of information 
about the mortality trends in Mpigi district.  
 
The crude adult mortality rate in Uganda is 8.8 deaths per 1000 population per annum 
(Uganda Bureau of Statistics – Government of Uganda 2006c:278). Thus an estimated 
1 816 deaths occurred in 2002 while an estimated 1 957 deaths occurred in 2008 of 
individuals aged 15 years and older, in Mpigi district during the length of the study 
period. To estimate the number of deaths that occurred in the district during the study 
period, the researcher used an average of the estimated number of deaths at the 
beginning of the study period and at the end of the study period. During the period 
between 2002 and 2008, the researcher estimated that an annual average of 1 887 
deaths occurred (this represents an assumption of an adult mortality rate of 8.8 deaths 
per 1 000 population per annum) of adults who were 15 years or older at the time of 
their death in the district. By extrapolating these assumptions to the total number of 
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adult deaths had occurred over the six-year study period, the researcher estimated that 
11 316 deaths occurred during this time.  
 
In a rural setting in Malawi, 47% of the adult deaths of individuals who were 14 years 
and older occurred in a health facility (Jahn et al. 2008:1606). Although the overall 
mortality data for the district was not available, the researcher assumed that the Malawi 
experience was similar to what was happening in Uganda at the time, and therefore 
estimated that 47% of the deaths (or fewer) had occurred in health facilities.  
 
In 2007/08, the estimated population of Mawokota South health sub-district was 99 607 
(Lumala 2008:9,10). An estimated 50.6% (50 401) of these inhabitants were adults 
(Uganda Bureau of Statistics, Government of Uganda 2006b:17). With an adult crude 
mortality rate of 8.8 deaths per 1 000 of the population, an estimated 444 adult deaths 
occurred in the health sub-district per annum. Therefore, over the six-year period of the 
study, an estimated 2 664 deaths occurred in health facilities in the health sub-district.  
 
To determine the size of the sample size, the researcher assumed that the Mawokota 
South health sub-district adult population of 50 401 represented the population size (N). 
Because of the inadequacy of accurate information about the prevalence of the adult 
death rate in Mawokota South, the researcher hypothesized a percentage (%) 
frequency of adult deaths in the population (p) at 50%+/-5. Since the confidence limit 
that he used to determine the sample size as a percentage (%) of 100 (absolute +/- 
%)(d) was 3%, the confidence limit was 97%. By using this technique, the sample size 
(n) at a 97% confidence level was 467 deaths. During the study period, 561 deaths 
occurred in the hospital and therefore, all deaths in the hospital were included in the 
study (no sampling was carried out). The design effect (DEFF) of 1 was used for the 
calculation of the sample size (OpenEpi 2009:[1].) 
  
The equation that the researcher used to determine the sample size was:  
 
Sample size n = [DEFF*Np(1-p)]/ [(d2/Z21-α/2*(N-1)+p*(1-p)] (OpenEpi 2009:[1]). 
 
In order adequately to determine the overall mortality trends in the hospital, all adult 
deaths (i.e. those of individuals who were 15 years and older), and the death of all 
individuals who were admitted alive but who later died either in the surgical or medical 
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wards during the study period (July 2002 to June 2008), were included in the study 
sample.  
 
On review of the medical records, 17 of the 561 records were considered too 
incomplete to be included in the analysis. Seventeen of the patient records were too 
incomplete or fragmentary to be included for the purposes of this study, and were 
therefore excluded from the analysis. The sample therefore ultimately comprised 544 
deaths, which represented 3.9% of all the deaths that were estimated to have occurred 
in the district during the study period and 20.4% of all the deaths that were estimated to 
have occurred in the Mawokota county health facilities during the study period.  
 
The deaths that were analysed in this study therefore met the requirements of the 
sample size of the study at a 97% confidence limit and the results are thus 
representative of mortality patterns in Mawokota South health sub-district. 
 
3.4 DATA COLLECTION INSTRUMENTS 
 
Measurement is the process of “observing and recording the observations that are 
collected as part of a research effort” (Trochim 2006f:[1]). Two structured data 
abstraction/audit tools enabled the researcher to collect and analyse the data in a 
quantitative manner. The data collection instruments comprised two data collection tools 
(see Annexure 1 and Annexure 2). The data was identified, examined and collated from 
the hospital’s patient records by means of a data sifting and “mining” process. Data 
sifting is the process of selecting the most important information that is embedded in 
records for purposes of analysis (Van Wyk 2005:486). In quantitative studies, research 
data is collected by using structured instruments that yield numerical and/or statistical 
data (Creswell 2003:18). The data was collected in terms of a structured plan that 
indicated who, when and how of the data collection process. Structured methods yield 
data that is relatively easy to quantify and analyse. Structured methods also impart 
objectivity to data that is collected by eliminating bias that is caused by a researcher’s 
personal feelings, assumptions or beliefs (Polit & Hungler 1995:311).  
 
An audit tool was designed by the researcher for the study in order to compile a case-
by-case summary. Data collection tool A collected information about the following facts: 
the date of admission, the date of death, the cause of death, the primary cause of 
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death, the associated cause or causes of death, the gender of the patient, the hospital 
ward in which the patient died, the patient’s age at the time of death, the patient’s HIV 
status (if this had been indicated in the records), and history of the ART treatment at the 
patient had received from the hospital (as indicated by the records). On the basis of the 
diagnosis and established cause of death in each case, all deaths were classified either 
as HIV-related or non-HIV-related or under the category of “HIV status undetermined”. 
 
Data collection tool B (Audit tool B) consisted of six templates that the investigators 
used to compile a summary of cumulative monthly figures of adult patients on ART, the 
ARV supply records, and all hospital admissions and deaths from between June 2002 
and July 2008.  
 
All the information collected by means of the data collection tools were mined by the 
researcher’s research assistants, and were then compiled, coded and prepared for data 
entry. The data preparation process involved checking each entry for completeness 
before the data was logged. The data checking process therefore comprised a prior 
checking of the data for accuracy before it was entered into the Epi Info and the SPSS 
software. 
 
3.4.1 The development of the audit tool 
 
The researcher developed the data collection tool on the basis of a literature search and 
made recommendations about the measurement and monitoring of mortality trends. 
Information required for this purpose included the number of deaths in terms of age, 
gender, cause (whether direct, indirect, and the associated causes of death), date, and 
extent of residence aboard (see section 2.10). Because of the requirement of monitoring 
mortality trends in relation to the patient’s free access to ART, other features that were 
included in the data collection tools were the patient’s HIV status and the patient’s 
history of ART participation. The researcher therefore developed audit data collection 
tools that will enable him to obtain the required information that is necessary for data 
analysis and subsequent discussion of results in relation to the study variables. This 
would enable him to comply with the requirements for quantitative data analysis and for 
the research in general. The data collection tools that were developed in this way 
ensured uniformity and consistency in the process of data collection. All of the data 
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connected with each individual death was compiled into the data collection tool by the 
trained research assistants.  
 
Since the research instrument was designed to be completely unambiguous and 
unvarying in terms of the kind of data that it required, the data that was collected from 
the patient's records was simple and straightforward in terms of its parameters. Bowling 
(2007:258) refers to the ability of a structured tool to collect unambiguous and easy-to-
count responses that would enable a clearly defined quantitative data analysis, as the 
advantage of such a tool. 
 
The variables included in the data collection tool were selected in order to ensure that 
data could be extracted from the patient’s case notes or records and that such data 
would be what was required for the research objectives. The relevant cases were 
identified from the hospital admission and mortality registers and records before 
individual case files were collected from the records department and were compiled into 
the data collection instrument. The data collection tool A was a simple data collection 
tool that consisted of a two page straightforward and unambiguous structured items. 
These two data collection tools were evaluated for internal, content and face validity by 
colleagues of the researcher and by the research supervisor.  
 
The researcher therefore developed the data collection tool on the basis of the research 
questions and objectives of the study and on the kind of data that could be retrieved 
from the hospital's records. This tool guided the data collection process. 
 
3.4.2 The structure of the data collection tool 
 
The researcher used audit tools A and B to collect data from the hospital's records of 
the admissions and deaths that occurred in the hospital during the study period. The 
data collection tools focused on the specific variables that were necessary for 
accomplishing the study research questions and objectives. All the data collection 
elements were selected on the basis of their relevance to the study and were compiled 
in simple and easily comprehensible English. The data collection tool was deliberately 
structured in order to enhance the comparability of the information that would be 
collected from the records and in order minimize ambiguity. The audit tools consisted of 
sections that recorded the following information (see section 1.8.2.2), Audit tool A: 
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Section 1: The patient’s demographic profile  
Section 2: The last recorded visit that the patient paid to the hospital, and the 
Out-of-pocket payments that the patient made to the hospital  
Section 3:  Whatever information was available from the patient’s record about 
the patient’s HIV status and access to ART 
Section 4: An endorsement by the research assistant 
 
Data collection tool B was also specifically designed by the researcher for this study. 
The audit tool 2 (referred to as tool B) consisted of two sections that recorded the 
following information (see section 1.8.2.2):  
 
Section 1: The name of the hospital, the district and the date of data collection 
Section 2: A month-by-month summary of the number of adult admissions, the 
number of patients who are being treated by means of ART, and 
the total number of deaths 
Section 3: Information from the records about the supply of medicines and 
drugs  
 
3.4.3 Rationale for using a structured audit tool 
 
According to Hamer and Collinson (2005:129), a mortality audit is one of the numerous 
medical audits that serve the vital function of evaluating and confirming clinically 
effective care provided in health settings. It can also be immensely useful for guiding 
reviews to a variety of approaches to the delivery of health care. An audit tool 
retrospectively measures how well the clinical guidelines and standards that have been 
set for clinical care have complied with. The audit in this study was designed to 
determine whether a key objective of providing a specific service (which was, in this 
case, free access to ART in order to reduce the incidence of morbidity and mortality 
among patients) had been met or why it had not been met, and the suggestions for 
possible solutions to solve the problems that were identified.  
 
Patient’s records such as patient ward and outpatient registers, clinical notes and death 
certificates, all constitute a valuable source of information that can be used to answer 
specific research questions and provide possible explanations as to why a specific 
observation has occurred (LoBiondo – Wood & Haber 2006:328). Hospital records are a 
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cost-effective source of information (Brink et al. 2006:154). These records permit 
researchers to examine trends over time and to minimize or eliminate the need for a 
researcher to actively solicit the cooperation of participants. 
 
The researcher used an audit tool to examine trends in adult mortality in the hospital 
and to identify the factors that contributed to the rates of adult mortality in the rural 
hospital setting by assessing the clinical care records of all the deaths that occurred in 
the hospital.  
 
This method of data collection was a cost-effective for the researcher because the 
records were accessible and no consent or cooperation was required from the 
respondents. With a structured audit tool, the data that is collected is objective and 
consistent with the minimal bias that might arise between the two research assistants 
who had compiled the data from the available medical and hospital records.  
 
3.4.4 Pre-testing the audit tool 
 
De Vos et al. (2005:171-172) assert that newly constructed research tools should be 
thoroughly pre-tested before being utilised in an investigation. After the development of 
the audit tools, the researcher and his assistants pre-tested the research tools in the 
same hospital by sampling ten randomly selected mortality records from outside the 
study period and compiled the data using data collection tool A. Because the pre-test 
records were not identified from the study period, they were not included in the data that 
was compiled for the final analysis of this study. Tool B was pre-tested by reviewing the 
available hospital registers in order to determine whether the specified items could be 
compiled from the records. The data collected during the pre-test was then analysed to 
ensure that the data that had been collected from the medical records had adequately 
met the research objectives.  
 
After the necessary (minor) changes had been made to the data collection tools, these 
tools were deemed suitable for data collection, and they were subsequently used for the 
purpose of data collection. This pre-test data analysis also ensured that the data 
collected would accurately measure the true attributes that would be able to provide 
answers to the study questions. Pre-testing or piloting ensures that errors are 
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immediately rectified in a cost-effective way before the implementation of the study is 
launched.  
 
3.5 DATA COLLECTION  
 
Burns and Grove (2001:49) define data collection as “the precise systematic gathering 
of information relevant to specific research objectives or questions.” “A
 
ccording to Burns 
and Grove (2001:50), data [can be] collected in several ways (depending on the study), 
and [can] include a variety of methods”. They point out, however, that the research 
objectives must be accomplished by means of the instrument that is used.  
Data collection can be defined as the process of identifying or selecting subjects and 
gathering data from these selected individuals or subjects. The actual steps involved in 
the collection of data are specific to each study, and are derived from the research 
design and the methods of measurement that are used. Data may be collected by 
observing, testing, measuring, questioning, data mining (as in this study) or recording – 
or by any combination of any of these methods. The researcher should always be 
actively involved in this process, either by the collection of data, or in his or her capacity 
as the supervisor of the data collectors (Burns & Grove 2005:430).  
 
The data for this study was gathered retrospectively by means of an audit tool that the 
researcher developed to accomplish his research aims and objectives. The data was 
collected from the records department of the hospital, where all patient files were kept 
under lock and key. To ensure and maintain the confidentiality associated with 
information contained in the records, it was not possible to remove any of the records 
from the records department. All the records associated with patients past and present 
therefore had to be examined in situ by research assistants. Even though the hospital 
authorities gave the researcher and his assistants their express permission to access 
and examine all records for the purpose of this research, the entire process of data 
abstraction was overseen and monitored by the hospital records clerk. 
 
A structured audit tool used was constructed in such a way that all data would be 
presented in the same way. They were thus no variations in the wordings of each of the 
questions and categories, and some of these were associated with pre-coded response 
choices. After the researcher had trained and briefed all the research assistants, and 
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engaged them in the pilot phase, he was satisfied that each item in the data collection 
tools meant exactly the same thing to each of the data collectors (Bowling & Ebrahim 
2005:394). Structured data collection tools of this kind have the capacity to collect and 
assemble unambiguous and easy-to-count answers, and such data is ideal for the 
purposes of quantitative data analysis.  
 
The structured data collection tool that the researcher used for this study was in form of 
an audit tool that he developed on the basis of information and prototypes that he had 
examined in the literature review of the study. The data collection tool was therefore 
completely suited to accomplish the objectives of the study. 
 
One may therefore assert that the data collection tool that was used complied with the 
following three requirements: 
  
• It was objective. The data were not influenced by perspectives of the research 
assistant who collected the information  
• It was systematic. The data was collected in exactly the same manner by 
everyone who was involved in the collection of the data.  
• It was consistent. The data that was collected from each file in the study was 
collected in exactly the same way (or as close as possible to the same way). This 
served to minimise the bias that can be introduced into data collection methods 
when more than one person is embarking the collection of data (LoBiondo-Wood 
& Haber 2006:317-320).  
 
Because the audit tools were objective and systematic, the data was collected in exactly 
the same way by the research assistants, all of whom had been trained by the 
researcher in the correct methods of data collection before they began to collect data 
from the hospital's records (Lobiondo-Wood & Haber 2006: 317-320). In this study, the 
data was collected by the research assistants who used the audit tool that had been 
custom-designed by the researcher to elicit the precise and exact responses that were 
necessary to answer the predetermined research questions. The development of this 
audit tool required decisions about the type of questions that needed to be asked, how 
the answers would be compiled, and, finally, a refinement of the audit tool so that there 
would be no redundant or unnecessary items. The following section explains how the 
researcher ensured that the research instrument would be objective and systematic. 
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3.5.1 The data collection process 
 
The researcher requested an authorisation to collect data from the Research and Ethics 
Committee at University of South Africa (UNISA) (Department of Health Studies), The 
District Health Office and the management of the hospital in Mpigi district (see 
Annexure 3, Annexure 4 and Annexure 5). 
 
The researcher was able to find two experienced research assistants to help with the 
collection of the data. He then trained these research assistants in how to collect the 
necessary information from all the available mortality records (which included the 
hospital’s registers, the patients’ death certificates and the patient case notes). The 
research assistants were also trained in how to compile the data they collected into the 
format of the data collection tools and to comply with the instructions that governed the 
process. The researcher himself validated the quality of all the data that was collected 
and supervised the research assistants throughout the data collection process. The 
researcher also checked the data that had been collected at the end of each week and 
identified any omissions or inconsistencies that would require the research assistants to 
check the records again and complete the data collection tools according to the 
requirements of the process. The data was collected over a period of six weeks 
between December 2008 and January 2009.  
 
All data was collected from the hospital records section, where all the files of past 
patients were securely stored under lock and key. In order to ensure confidentiality, 
permission was never granted for these records to be removed from their places in the 
records section. Permission was, however, granted to the researcher and his assistants 
to access the records for the purposes of this research, and this process was 
supervised by the hospital clerk responsible for the records section.  
 
After the cleaning and verification of the case summaries compiled into the audit tools 
format, the researcher entered the data into a pre-designed Epi Info database (version 
3.5.1) designed by the researcher  assisted by a colleague with advanced statistical 
analysis skills. During this last stage of data entry, further clarification was sought from 
the hospital records department for any missing or incomplete information, and when 
found it was added to the data base. In a number of instances, specific items were not 
available in the various records that were being used to compile the information, and 
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these patient histories were therefore relegated to the missing records pile on each 
analysis table.  
 
3.6 DATA ANALYSIS 
 
Data analysis consists of the systematic organisation and synthesis of research data 
and, in quantitative studies, the testing of the original hypotheses by means of such 
data (Polit & Beck 2008:751). The data analysis involved three major steps, namely, 
cleaning and organising, describing the data, and investigating the data for possible 
associations (Trochim 2006g:[1]).  
 
In descriptive statistics a researcher organizes data in ways that will give meaning and 
explanation to various phenomena that seem to be unrelated and to explore a variety of 
phenomena from a number of different angles. Descriptive statistics include frequency 
distributions, measures of central tendency or dispersion and standardised scores 
(Burns & Grove 2005:461). In addition to this, Olds, London, Ladewig and Davidson 
(2004:17) state that descriptive statistics report the facts in a concise and easily retrieval 
way. 
 
The researcher used descriptive statistics to describe and summarise data. Data was 
converted, condensed and categorised, into visual representations so that it would be 
more easily comprehensible to the average reader. The researcher used descriptive 
statistics mainly for the purpose of obtaining answers to his research questions. 
 
Because this is a descriptive study, the researcher used descriptive statistics to 
describe the basic features of the data in the study. Simple summaries of information 
about the sample and various measures, together with simple graphic analyses, 
provided the basis of the quantitative analysis of the data in this study. In this study, the 
findings were presented and described in a manageable and easily understood format 
so that the key patterns or findings that emerged from the data would be readily 
observable (Rudestam & Newton 2007:27;Trochim 2006h:[1]). Descriptive statistics 
helped the researcher to reduce a large body of data to a series of plausible and 
comprehensible statements. Each descriptive statistic reduced the data into a simple 
summary that described a number of discrete events that initially might have seemed 
unrelated to one another. Wherever a number of observations are reduced to a single 
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indicator, there is always a risk of distorting the original data and losing important and 
telling details. However, despite these limitations, the use of descriptive statistics 
enabled the researcher to assemble a convincing summary that enabled him to make 
vital comparisons across variables (Trochim 2006h:[1]). 
 
The research also performed bivariate analysis, and converted categorical variables 
with three or more levels or categories into two by two dummy variables. He then 
presented the results in terms of prevalence proportion ratios (PPR). All factors with 
significant odds ratio (p < 0.05) in the bivariate analysis were included in discussion. 
Chi-square statistics were also performed on those variables that revealed a high 
statistically significant association with hospital mortality. 
 
The rest of the trend data was compiled and presented in terms of trends that occurred 
over time or in the form of time series in line graphs. Trend studies are recommended 
for the assessment of changes over time and for situations that are associated with 
prediction questions – mainly because, with such a technique, variables are measured 
at more than one time (Social Research Methods ca 2006:[2]; Van Aardt 2005:486). 
This study was designed to determine change in mortality trends in a rural hospital 
setting so that they would be useful to those responsible for macro policy and for 
decision makers who needed to make evidence-based decisions. In a trend analysis, 
data is collected at more than one point in time. This gives the researcher the 
opportunity of observing changes over time (Social Research Methods ca 2006a:[2]; 
Van Aardt 2005:486). In analyzing the data, the researcher drew conclusions and 
attempted to find correlations between variables. Both the advantages and 
disadvantages of trend studies are described below. 
 
Disadvantages of trend studies:   One of the limitations of trend analyses arises out of 
the fact that they are subject to threats of validity. Thus, for example, when data is 
unreliable, a researcher may end up with false or invalid trends. Trend studies may also 
reveal pseudo-trends. These are caused by changes in methods of measurement – and 
can deceive both researchers and readers alike (Social Research Methods ca 
2006a:[2].) In this study, the approach and formats of recording deaths in the hospital 
did to undergo specific changes that could lead to changes in methods of measurement 
of a recorded event. Therefore, in the study period, the recording of a death was similar 
in terms of the key variables included in this analysis and was thus comparable across 
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the years. The risk of changes in methods of measuerement was thus not a factor and a 
not a risk to this study.  
 
Advantages of trend studies:   The main advantage of trend studies is in their ability to 
describe long-term changes in a population. They can also establish a pattern over time 
that will enable a researcher to identify changes in a series of event (Social Research 
Methods ca 2006a:[2]). 
 
The study was undertaken to evaluate the trends and patterns of mortality through the 
compilation of mortality data in terms of the causes of patient mortality, as well as the 
gender and age (and other information about the patient) with regard to all adult deaths 
that occurred in the hospital setting. This data analysis was performed for both the pre-
free and post-free ART eras. The researcher then compared the trends from the two 
periods and drew various conclusions from the analyses thus compiled. These 
comparisons enabled the researcher to present and develop a discussion and make 
possible recommendations for government policy makers and programme designers.  
 
3.7  VALIDITY AND RELIABILITY 
 
The following section explains the concepts of validity and reliability as applied to this 
research. 
 
3.7.1 Validity 
 
Validity is defined by Polit and Beck (2008:457) “as the degree to which an instrument 
measures what it is supposed to measure”. Rudestam and Newton (2007:113) define 
internal validity as “the degree to which the results of an observation are correct for the 
particular people” (or sample) which is being studied. Validation is the degree to which 
the trustworthiness of the reported study observations, interpretations and conclusions 
can be assured (Rudestam & Newton 2007:113). Validity is therefore the extent to 
which a measure “in fact measures what is purports to measure” (Rudestam & Newton 
2007:96).  
 
In simple terms, “validity refers to whether or not the measurement collects the data 
required to answer the research question” (Somekh & Lewin 2006:216). 
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Validity is categorised into the following three forms. Content validity is extent to which 
the items in the study tools measure the content or variables that they were intended to 
measure. Predictive or concurrent validity is the extent to which it is possible that the 
scores in the survey tool effectively do, in fact, predict a criterion measure and whether 
the results thus obtained correlate with other measures. Construct validity is the degree 
to which the scores that are obtained serve a useful purpose and will result in good 
outcomes and positive consequences when they are used (Creswell 2003:157-8.)  
 
The focus of this study was to determine changes in mortality patterns and also to 
determine the association between changes in mortality patterns and free access to 
ART as an intervention. Basically, what the researcher wanted to know was whether 
there was any significant relationship between the introduction of free access to ART in 
the rural hospital and the prevailing mortality trends post-free ART eras. He also wanted 
know whether there was any corroborating evidence for the truth of possible 
associations that had been reported in other studies (Trochim 2006i:[1]).  
 
Rudestam and Newton (2007:113) define external validity as the “generalisability of the 
findings of the study”. Generalisability refers to the extent to which the results of a study 
can be validly applied to the wider population that the group represents or a highly 
similar group in other contexts (Somekh & Lewin 2006:216). Generalisability in this 
study is limited to the mortality trends in all similar rural hospitals across Uganda at the 
same time as the period during which the study was being conducted. But such 
similarities are nevertheless indicative of what may have happened (or be happening) in 
the similar settings. 
  
In this study, the researcher emphasised specific aspects of validity and their 
applications, and these are all described below.  
 
3.7.1.1 External validity 
 
“External validity refers to the generalisability of the research findings to the wider 
population of interest”(Beaglehole et al. 2000:50; Bowling & Ebrahim 2005:398). The 
researcher achieved external validity by using a statistically significant sample of the 
population available for his particular study in order to increase the generalisability of his 
research findings. 
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3.7.1.2 Internal validity 
 
Internal validity is defined as the degree to which the findings or results of an 
observation reflect an accurate description of what is happening in the sample 
population that is being studied (Beaglehole et al. 2000:50). A tool or instrument is said 
to possess internal validity if it has produced satisfactory results after having been 
repeatedly tested in the population for which it was designed (Bowling & Ebrahim 
2005:398).  
 
The researcher pre-tested the audit tool in this study to ensure that it measured what it 
was supposed to measure, that is, the trends and other elements of interest that 
contributed to adult mortality in a rural setting in Uganda.  
 
3.7.1.3 Content validity 
 
The content validity of a data collection tool refers to the degree to which the items in 
the data collection tool adequately represent the phenomenon that has been selected 
for study (Parahoo 2006:304). 
 
The researcher used content validity to measure the degree to which the audit tool 
measured the range of meanings that are inherent in the concept by conducting a 
logical analysis of the kind described by described by Babbie and Mouton (2007:123). 
Burns and Grove (2005:377) describe the content-related validity of a data collection 
tool “as the extent to which the method of measurement includes all [the] major 
elements” that are descriptors of the concepts that a researcher wishes to measure and 
describe.  
 
The audit tool was validated by means of a technical review conducted by health 
experts in the field of public health research and health care professionals who were 
responsible for providing health care in health facilities that were located in similar rural 
settings as the hospital in the study. Among these experts were the District Health 
Officer, the medical officers who worked in the hospital, and other health professionals 
who were experienced in the field of public health research. All of their suggestions 
were considered by the researcher and included in the final version of the audit tool 
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before he used it for the collection of data. He also viewed his literature review in order 
to ensure that all the relevant items were included in the audit tool. 
 
3.7.1.4 Face validity  
 
“Face validity refers to [an] investigator’s subjective assessment of the presentation and 
relevance of the” (Bowling & Ebrahim 2005:398) questionnaires. Such an assessment 
requires him to certify that all the data collection items in the audit tools appear to him 
be relevant, reasonable, unambiguous and clear – in accordance with the procedure 
suggested by Bowling and Ebrahim (2005:398). 
 
The researcher therefore requested various experts in public health research and health 
service delivery in similar settings, who possessed the necessary research experience, 
to assess the audit tool for practicability, ease of use, and its ability to collect the 
necessary data that he required in order to answer the research questions that formed 
the basis of this study. After considering their suggestions, he incorporated them into 
the final versions of the audit tools that he used for the data collection process.  
 
In this study, internal validity was enhanced by making use of structured audit tools, by 
a careful prior training of data collection assistants, and by the meticulous attention to 
detail. Internal validity was also be enhanced by random verifications of the completed 
data collection tools by the principal researcher. The sample size was adequate 
because it consisted of an estimated 4.7% of all the deaths that had occurred in the 
district and 20 % of all the deaths that occurred in the health facilities in Mpigi (see 
section 3.3.4). The researcher’s data collection tools were also approved by the study 
supervisors and the researcher was able to give the assurance that all of the data 
collection items that were required for answering the questions were included in the 
collection tools. The researcher then proceeded to pre-test the data collection tools. 
 
3.7.2 Reliability 
 
De Vos et al. (2005:162 -163) define reliability as the stability or consistency of the 
measurement process over time. Reliability can also be defined as the repeatability of 
measures or the ability of a research instrument to measure and produce consistent 
results in similar circumstances and environments (Beaglehole et al. 2000:49; 
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Rudestam & Newton 2007:96). If the same variable is measured under similar 
conditions, a measure or procedure that is considered to be reliable would produce 
similar results. Reliability is therefore the ability of a tool to produce consistent numerical 
results each time that it is applied (Rudestam & Newton 2007:113; Somekh & Lewin 
2005:216). “Reliability is [also] concerned with the consistency of the measurement 
[techniques]” (Burns & Grove 2005:374). Reliability is therefore a measurement of the 
extent of the precision and accuracy of the data collection instrument.  
 
The reliability of the audit tools was evaluated by pre-testing and the revision of the data 
collection tools before they were used for the study. Pre-testing ensured that the tools 
would be capable of producing consistent results under similar conditions. 
 
In this study, the data collection items were carefully phrased in order to avoid 
ambiguity. The reliability of a research instrument is also related to the characteristics of 
the population that the instrument is designed to measure (Rudestam & Newton 
2007:96). A measure may be unreliable because it may be a difficult for the subject to 
understand the question (as in the case, for example, of ambiguous questions) or 
because the setting or methods of administration affect the stability of the measuring 
instruments (Ovretveit 1998:214).  
 
In this study, the ambiguity of the data collection tool was maximised by the use of 
structured audit data collection tools that enhanced the extent of reliability. Reliability 
was also enhanced by a data collection tool that was developed on the basis of the 
researcher’s research objectives and by a process of pre-testing that would ensure that 
the tool was able to measure the key variables of the study. Reliability was also 
enhanced by a data collection approach that systematically standardized the retrieval of 
all the information from all the (usable) records of all reported deaths. This data 
collection approach was highly reliable, and it will be able to obtain the same outcomes 
if the study is repeated. The results of this study can therefore be replicated by a 
researcher who uses the same approach, research design, research instruments and a 
setting that is almost identical to the original research setting in the rural hospital.  
 
The training of the research assistants so that they clearly understood the purpose the 
study, the methods that would be used in data collection, and the ethical principles that 
governed the research process, also contributed to the overall reliability of the data 
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collection process. Clearly defined parameters in the data collection instrument and the 
use of two research assistants minimized the risk of inter-observer differences and thus 
enhanced the accuracy of data that was collected. The researcher also enhanced the 
reliability of the data that was collected by soliciting peer review of the input and the 
results in order to test the data collection tool for relevance and coherence of structure.   
 
Since both validity and reliability are vital considerations for undertaking a study, it is 
important to note that a measure might be reliable (i.e. it will always generate the same 
results) even though it might not be valid (i.e. it does not measure the concept that it 
was intended to measure) (Somekh & Lewin 2005:216). 
 
3.8 ETHICAL CONSIDERATIONS 
 
Ethics may be defined as “moral principles that control or influence a person’s 
behaviour, or a system of moral principles or rules of behaviour” (Hornby 2005:498). All 
rresearchers are responsible for conducting their research according to the ethical 
principles recommended by the institution to which they are presenting their study and 
ethical principles that are universally accepted in the worldwide research community as 
essential for the achievement of morally acceptable research results.  Any failure or 
breach of such ethical principles would bring the scientific process into disrepute and 
negate the acceptability of the research results (Brink et al. 2006:30). The three 
fundamental ethical principles that guide all research work include: respect for all the 
people involved in the research, beneficence and justice (Brink et al. 2006:31).  
 
These principles are based on the declaration of human rights that was explicitly 
promulgated in the Universal Declaration of Human Rights that was accepted by the 
General Assembly of the United Nations on 10 December 1948, and which has been 
accepted and observed by all civilised nations who are signatories to the declaration. 
These universal principles of human rights are the basis for the human rights that are 
protected in the processes of scientific research. They include the right to privacy, the 
maintanance of anonymity and confidentiality, the right to fair treatment and protection 
from from any kind of discomfort and harm (Brink et al. 2006:31). The ethical conduct of 
public health search not only focuses on the participants of the study, but also on other 
people or communities whose health needs to be protected or improved by the 
application of the research findings (Beaglehole et al. 2000:50) 
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In order to accomplish this study in an ethical manner, the researcher obtained permission 
from the Ethics Committee of the University of South Africa, authorization from Mpigi 
District Administration, and similar authorisation from the hospital management (see 
Annexure 3, Annexure 4 and Annexure 5). All the information that was obtained as a result 
of the study was used solely for the purposes of this study alone, and any publication in 
scientific journals needs to be subject to the prior approval of Mpigi District Health Office. 
The study focused on the medical records of dead patients and the principle of respect 
for the deceased patients and their personal information was closely adhered to. With 
regard to the principle of beneficence, the researcher ensured that this study would 
benefit the institutions that were involved in the study in the planning and development 
of their interventions to minimize mortality. The researcher also took measures to 
ensure that during the implementation of the study, no participant would suffer any kind 
of extraneous discomfort or harm – whether physical, emotional, spiritual, economic, 
social or legal (Brink et al. 2006:32). Justice was ensured by the application of a fair and 
a transparent approach to the selection of the subjects who participated in the study, 
and each case record was treated with the utmost privacy and confidentiality.  
 
The principle of voluntary participation (Beaglehole et al. 2000:50) and the protection of 
the participants from harm were achieved by means of obtaining the approval of the 
district and hospital management boards. This ensured that the study was in 
compliance with research guidelines and was sound enough to ensure the protection of 
participants. The District Health Officer and the hospital management were provided 
with comprehensive summaries of the information that was relevant to their participation 
in the study in both written and verbal forms. This procedure helped them to become 
aware of the benefits that might result from the study. All the information that was 
collected was treated with confidentiality and was not made available to any 
unauthorised individuals who were not directly involved in the study. The researcher 
adhered to the principles of voluntary participation, confidentiality, informed consent and 
the minimisation of harm in this study.  
 
The medical research establishment has promulgated various ethical measures to 
protect the rights of volunteers who participate in research projects. These ethical 
standards also require that researchers not to place any participants in situations in 
which they might be at risk of harm as a result of their agreement to participate (Trochim 
2006j:[1]). The risk of harm in this study were indeed minimal because none of the 
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procedures in this study involved any kind of invasive procedures, but consisted almost 
wholly of a review of the personal hospital medical records of deceased patients who 
had already died in the hospital prior to the commencement of the study. The 
researcher explained the scope and benefits of the study to the district and hospital 
management and he obtained the informed consent of the guardians of the patient 
records of the hospital before he commenced the study.  
 
The hospital records were carefully respected and handled, and were all returned to 
their exact locations once the research assistants had obtained the data that they 
required from each of them. No patient file was ever removed from the hospital records 
department. Anonymity means that no one – not even the researcher himself – knows 
the identity of the participants whose personal details and information were used in the 
study (Rudestam & Newton 2007:280). After transcribing the information from the 
records, the researcher made use of a hospital reference number for validating the 
information that had been collected in each case, and in order to undertake any further 
clarification or validation of the information that might have been needed.  
 
After the data had been transcribed by the data collection assistant, the case files were 
triangulated with other records such as the death certificates and ward registers. This 
process was accomplished by making use of the hospital reference numbers mentioned 
above. The researcher trained the data collection assistants to maintain the 
confidentiality of patient records, and only the required information that was necessary 
for completing the data collection tool was extracted from the hospital patient records. 
All data collection forms were subsequently endorsed by the research assistant, and the 
researcher himself performed random validations of the information that the research 
assistants were transcribing from the records. Two other aspects of the ethical 
principles that govern research are described below. 
 
Ethical considerations during data analysis:  In the analysis and interpretation of 
findings, issues emerge that necessitate sound ethical decisions (Creswell 2003:66). 
The anonymity of individuals was maintained in the data collection process. The data 
collection instruments will be kept for three years after the study has been presented 
before they will be finally disposed of. 
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Ethical considerations in the dissemination of the findings:  In the writing the 
report, the researcher exercised caution in order to ensure that no use of language and 
words that could create bias or prejudice against particular people because of gender, 
race or ethnicity, disability or age (Creswell 2003:67; Rudestam & Newton 2007:282). In 
spite of this, the researcher did not intentionally suppress, falsify or invent any findings 
to bias the terms of the research towards his own implicit expectations or those of the 
audience or possible readership (Creswell 2003:67; Glatthorn & Joyner 2005:12). In 
other words, the researcher explicitly declares that he did not engage in any fraudulent 
practices in any part or process of this study. The researcher was also commited to 
ensuring that the results of this study would not be interpreted in any manner that would 
provide support for the prejudices and biases of any particular interest group or lobby.  
  
3.9 THE LIMITATIONS OF THE STUDY  
 
Firstly, the limitations of the study were mainly connected to the incomplete state of the 
hospital’s patient records. The inadequate focus on mortality data over a period of time 
resulted in inconsistencies in the records to an extent that made the process of data 
collection vulnerable to data collection researcher biases – especially in those cases in 
which the diagnoses were not well written out or were incomplete or incoherent in the 
records. Although the researcher made attempts to ensure that the audit tools were as 
complete as possible and in although he utilised the technique of triangulating the 
hospital’s records to ensure that the information collected by the data collection tool 
would be as accurate as possible, this deficiency remains an inherent limitation.  
 
Secondly, this study did not focus only on the mortality trends among patients on ART 
but on the overall mortality trends in the hospital. While the effects of ART are most 
appreciated by patients who are actually receiving ART, a more detailed focus on ART 
patients, the length of time during which they had been on ART, the key outcomes of 
the ART access programmes, and the specific qualitative interviews of patients on ART 
and health workers were beyond the scope of this study.  
 
Thirdly, the diagnoses that were used in this analysis were based on clinical diagnoses, 
on limited laboratory investigations and on post-mortem diagnoses of the cause of 
death. These diagnoses were therefore not confirmed, but were classified in terms of 
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good clinical practice, and, to a significant extent, they portrayed the patterns of 
illnesses that occurred in this rural setting during the period of this study.  
 
The efforts of the researcher to minimise errors and misinformation by the careful 
training of research assistants and the utilisation of an audit tool, went a long way in 
guiding the data collection processes and in minimising bias. Despite these limitations, 
the findings of this study are vitally important because they can function as a benchmark 
for mortality audits in other hospitals in Uganda, and will therefore be able to serve as a 
basis for sound evidence-based decision making. 
 
3.10 CONCLUSION 
 
Chapter 3 covered the research design and methodology, and described the study 
population, the sampling approach, the sample itself, the research instruments, the 
process of data collection, the way in which the data was analysed, the ethical 
principles that governed the conduct of the study, and the limitations of the study.  
 
Chapter 4 sets out the data analysis and the interpretations of the findings of the study.  
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CHAPTER 4 
 
Presentation and interpretation of findings 
 
 
4.1 INTRODUCTION 
 
The previous chapters of this study dealt with the background, literature review, the 
research design and methodology of this study. This chapter focuses on the data 
analysis, the findings and the interpretation of the results of the study. The data analysis 
involved data cleaning, the organisation of the data for analysis, the data analysis itself, 
a description of the data and an interpretation of the findings (Trochim 2006j:[1]). From 
the introduction and the background that was he presented in chapter 1, the researcher 
formulated the following research question: What have the overall adult mortality trends 
been in the rural hospital setting chosen for this research since the introduction of free 
ART in Uganda? This study has therefore focused on the determination of mortality 
trends, an identification of the factors associated with death and the causes of adult 
mortality in the rural hospital setting that was chosen for the study. The study also 
compared the overall hospital mortality trends in the post-free ART period with the 
overall hospital mortality trends that prevailed in the pre-ART era.  
 
The overall purpose of this study was therefore to identify and analyse the mortality 
trends and demographic characteristics of those patients who died in a rural hospital in 
the Mpigi district of Uganda over a period of six years. The study reviewed the trend of 
mortality in terms of causes and the percentage of deaths that were caused by 
HIV/AIDS-related illnesses before and after the roll out of free ART to HIV-infected 
patients. The focus of this study was on Mawokota South County, which is also referred 
to as the Mawokota South health sub-district. This county is one of the four counties 
that form the Mpigi District of Uganda. The other three counties of the district are 
Maddu, Butambala and Mawokota North. Since the government of Uganda through the 
National Health Policy has empowered each health sub-district with the responsibility of 
ensuring the health of the whole population in any particular county, the county is 
therefore the catchment population of each health sub-district (Ministry of Health – 
Government of Uganda 2005:20).  
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Mawokota South health sub-district is responsible for a catchment population of 99 607 
(Lumala 2008:10) in three sub-counties, namely Buwama, Nkozi and Kituntu. The 
hospital located in Mawokota South health sub-district is the headquarters of the health 
sub-district and was chosen by the researcher as the focus of this study. The hospital 
that forms the basis for this study is a district level general hospital and a private-not-for-
profit hospital that is responsible for the provision of preventive, curative and 
rehabilitative care and referral services. It also functions as the base and headquarters 
for the health sub-district management team. In Uganda, 29 (13.6%, n=214) of the 
health sub-district headquarters are private-not-for-profit hospitals (Ministry of Health – 
Government of Uganda 2005:20). The hospital that the researcher chose for the study 
therefore offers a wealth of experience in the long history of health care provisions that 
are similar in most ways to other settings throughout the country. It therefore provided 
the researcher with an ideal opportunity for reviewing and developing interventions that 
would serve to reduce the rates of hospital mortality throughout Uganda as a whole. 
 
The objectives of this research study were: 
 
• To investigate the trends exhibited by adult hospital mortality rates and to 
compare the trends of the pre-free ART period to the trends of the post-free ART 
periods in the rural hospital in the Mpigi district of Uganda. 
• To determine the overall effect of free ART access on hospital mortality rates in 
the rural hospital in the Mpigi district of Uganda.  
• To make recommendations about ways in which the provision of free ARVs could 
be administered so that the exceptionally high mortality rates in the Mpigi district 
and in similar settings in Uganda could be radically reduced. 
 
The Uganda National Strategic Plan for HIV/AIDS was developed as a direct response 
to the AIDS epidemic, and covers the period from between July 2007 and June 2012. 
This plan provides hospitals, physicians and health care administrators with the 
direction they need to plan and implement interventions that will reduce the incidence of 
HIV-related morbidity and mortality. The plan is designed “achieve universal access 
targets for HIV & AIDS prevention, care, treatment and social support by 2012” (Ministry 
of Health – Government of Uganda 2009:21). Among the objectives of this plan are the 
following: 
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• to improve the quality of life for PLWHA 
• to mitigate the social, cultural and economic effects of HIV & AIDS at the levels of 
individuals, households and communities 
• to design, construct and sustain effective support systems that will ensure the 
quality of access as well as equitable and timely patterns of service delivery 
 
This plan is based on the “need to generate evidence about the effectiveness, efficiency 
and relevance of the national HIV & AIDS response interventions so that they can be 
continuously improved” (Ministry of Health – Government of Uganda 2009:21.)  
 
Although the results of this study cannot be generalised to morbidity and mortality 
patterns in all other rural hospital settings in Uganda, it has identified key mortality 
factors and trends in Mpigi District in both the pre-ART and post-ART eras. The findings 
of this study therefore provide powerful benchmarks for assessing the effectiveness of 
free access to ART in typical rural communities in countries such as Uganda.  
 
Chapter 4 presents the methods of data collection that the researcher used, the data 
analysis itself, the findings of the study, and a concluding discussion on the significance 
of the data and what one can deduce from the way in which the data was analysed.  
 
4.2 DATA COLLECTION  
 
The researcher collected the data by using structured audit tools A and B. He compiled 
the data from available hospital admission and death records which included patients’ 
case notes, ward registers and death certificates. Audit tool A consisted of the following 
sections (these are also described in section 1.8.2.2): 
 
Section 1: The demographic profiles of patients  
 
Section 2: Information about the last visit that a patient made to the hospital. This 
included information about the date of admission, the date of death, the reason 
for admission, the cause of death, and the out-of-pocket payments that the 
patient made to the hospital for the health services that he or she received. 
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Section 3: This section assembled information from the patient’s records that 
related to HIV infection – information that included the patient’s HIV status (if 
recorded), the patient’s history of being on an ART regimen, and the date when 
the patient began to receive ART for the first time. 
 
Section 4: The last section consisted of an endorsement by the research 
assistant. 
 
Audit tool B consisted of the following three sections (also referred to in section 1.8.2.2):  
 
Section 1: The name of the hospital, the district in which it was situated, the date 
on which the data was collected. 
 
Section 2: A month-by-month summary of the number of adult admissions, the 
number of adult patients that were receiving ART, and the total number of all 
deaths. 
Section 3: This section described the ART medicines/drugs that were (in terms of 
the records available in the hospital) available to HIV/AIDS patients.  
 
4.3 DATA ANALYSIS  
 
This study reviewed 561 death records of which 17 death records were so incomplete 
and were thus excluded in this analysis. Therefore, 544 deaths that occurred over a 
period of six years in a rural hospital in Mawokota South health sub-district in the Mpigi 
district of Uganda were analysed. All this data was entered into the Epi Info (version 
3.5.1) and the SPSS (version 12.0) databases and analysed by the researcher with 
assistance from a colleague proficient in statistical analysis. Graphical presentations of 
the results were subsequently constructed by utilising the Microsoft Office Excel 
Worksheet (xlsx) program and the SPSS program.  
 
The parameters that were analysed related to the overall mortality trends included the 
age, gender, hospital length of stay and the out-of-pocket payments that patients made. 
Descriptive statistics were used to describe the basic features that were discernible in 
the data and to transform them into summaries that formed the basis for the subsequent 
discussions. Graphic presentations were then developed from a quantitative analysis of 
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the data so that the various findings could be more easily visualised (Trochim 
2006k:[1]). The use of descriptive statistics enabled the researcher to simplify the data 
into a simple, straightforward and easy flow of ideas. Each descriptive statistic reduced 
the data into a form of a simple summary that illuminated a number of otherwise 
discrete and apparently unrelated events.  
 
Bivariate analysis refers to the analysis of the relationship between two variables (Tustin 
2005:646). The researcher therefore carried out bivariate analyses and – by making use 
of a specific rationale – he grouped together variables with three or more categories into 
two broader categories and then proceeded to analyse them. The results are presented 
in terms of prevalence proportion ratios (PPR). The researcher also conducted chi-
square statistical procedures by using two by two contingency tables to determine the 
statistical significance of the association between specific factors and rates of hospital 
mortality. All factors with significant odds ratios and a p value < 0.05 in the bivariate 
analysis were included in discussion. 
 
The remainder of the data trends were compiled and presented as trends that occurred 
over a period of time or by means of a time series that made use of line graphs. Trend 
studies are recommended for assessing changes over time and for situations that 
require or relate to prediction questions, mainly because variables are measured at 
more than one time (Social Research Methods ca 2006:[2]). The researcher 
accomplished the trend analyses by using data that had been collected on a monthly 
basis over a period of 72 months (six years) by the hospital authorities. This gave the 
researcher an opportunity to observe changes over a period of time, and enabled him to 
forecast three years of trends in the period that ended in June 2011 (Social Research 
Methods ca 2006a:[2]; Van Aardt 2005:484).  
 
Because of the seasonal variations in hospital morbidity and mortality data, the 
researcher compiled and smoothed the time series by using the Exponential Smoothing 
(ES) technique. Exponential Smoothing is a forecasting method that is used for 
modifying a time series that exhibits seasonal variations (Arsham 1994:[21]). The 
concept of a time series considers each observation to consist of a constant in 
conjunction with an error component in each segment of the series, and although the 
constant is relatively stable, it can change over time.  
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The formula for exponential smoothing is: 
 
Ft+1 = α Dt + (1 - α) F
 
t 
Where: Dt= the actual value; Ft-= 
 
the forecasted value; a or α= the weighting factor, 
which ranges from 0 to 1; and t = the current time period.  
The smoothed values are the forecast for period t + 1. In this study, t +1 is the current 
month plus one, which is the forecast for the subsequent month (Arsham 1994:[21]). 
Each smoothed value was calculated as the weighted average (based on the dumping 
factor) of the current observation and the previous smoothed observation. Therefore, 
each smoothed value was based on the weighted average of the previous observations, 
which decrease exponentially, depending on the value of parameter α (alpha) (StatSoft 
Electronic Statistics Textbook: Time Series Analysis n.d.:[10].)  
 
In the analysis of hospital mortality trends and three-year trend forecasts, due to the 
importance of increased ART coverage in determining morbidity and mortality trends, a 
dumping factor of 0.95 was applied. By application of the 0.95 dumping factor to 
mortality and morbidity data, the most recent observations were given more weight in 
determining future trends compared to previous observations. Individual observations 
declined exponentially, indicating the importance of key aspects of the most recent post-
free ART era in terms of ART coverage on mortality trends in determining future trends 
when compared to earlier pre-free ART observations.  
 
The researcher used the Exponential Smoothing (ES) technique in this analysis to 
adjust for past errors, to produce a wide variation of monthly statistics, and to prepare 
three-year forecasts. He then included both graphs (representing the actual data 
collected and the smoothed data) together on one chart, and summarized discussion 
about the observations below the graphs. By means of this analysis, the researcher 
developed predictable trends and forecasts that will serve as a guide for decision 
making in Mawokota health sub-district and in the Mpigi district in general.  
 
The gender distribution (female:male) in Uganda is 51% females and 49% males 
(Uganda Bureau of Statistics, Governement of Uganda 2006:viii). That the different 
effects of health conditions and the different responses of individuals to their disease 
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conditions depend on their gender, is a fact that cannot be sufficiently overemphasised. 
The gender composition of a population therefore has significant implications for 
developing targeted and effective interventions (Uganda Bureau of Statistics, 
Governement of Uganda 2006:viii). Because of the crucial importance of this effect, 
mortality rates and all factors related to mortality were analysed in this report both in 
general (i.e. with male and female data combined), and according to gender. The 
reason for making gender-focused analyses was to determine the varying effects and 
trends of mortality in terms of the different effects produced by gender so that 
programme planners could design more accurate and specifically targeted interven-
tions.  
 
In the course of analyzing the data, the researcher also investigated the association 
between variables and drew possible conclusions, identified un-answered questions, 
and recognised where information gaps would appear for future research. This study 
was designed to determine the course of adult mortality rates over a six-year period in a 
rural hospital setting.  
 
The results of this study were designed to guide decision makers in the making of 
evidence-based decisions and in the development of approaches for evaluating 
mortality trends in the pre-ART and post-ART eras so that they could implement 
targeted interventions to reduce rates of mortality and morbidity.   
 
4.4 FINDINGS OF THE STUDY  
 
The first item in the presentation of findings of the study begins with the demographic 
profile of the study population. After that, the researcher reviews morbidity and mortality 
trends and analyses the factors associated with mortality. The presentation then 
continues with an analysis of factors that are associated with mortality in the pre-free 
and post-free ART eras before concluding the chapter.  
 
The researcher made assumptions at the beginning of the study. The accuracy of these 
assumptions was confirmed during data collection. Since the collection of data involved 
an audit that was conducted by means of sifting or mining data from existing hospital 
records, a pre-testing of the audit tool enabled the researcher to narrow down the 
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variables on the basis of on the information that he could compile from the hospital 
mortality records.  
 
The first assumption that the researcher made was that all hospital-based deaths had 
been duly recorded and certified. Although it emerged that all deaths had indeed been 
recorded, not all duplicate death certificate records were available for analysis. In those 
cases where the copy of the death certificate was not available, the cause of the 
patient’s death was compiled from the patient’s ward registers or treatment records. The 
second assumption was that all hospital deaths had all been written up by qualified 
health workers who had recorded and investigated the primary and associated causes 
of death. But because of limitations on resources and the professional technical 
expertise required to carry out post-mortem analyses, the causes of death had not been 
confirmed by post-mortems. The direct or primary cause of death and the associated 
causes of death were in each case based on the clinical presentation of the patient at 
the time of death and the limited laboratory tests that had been available in the hospital 
for purposes of diagnosis. The third assumption that the research made was that the 
free uptake of ART in the hospital had not been interrupted ever since the patient had 
commenced with his or her ART regimen and that ART was freely accessible to the 
whole catchment population of the hospital. An analysis of the supplier of ART 
medications was not, however, included in the researcher’s analysis. 
 
The HIV status of individual patients, the history of their observance of the ART dosage 
regimen, and the dates on which individual patients began to participate in ART, were 
incomplete, and were therefore not taken into account for this analysis. The HIV status 
of patients was in fact inferred from the reported direct and associated cause/s of death. 
 
The discussions about the conclusions that the researcher reached are based on the 
findings that were compiled and analysed in terms of references to the deaths 
(mortalities) that had occurred in the hospital from between July 2002 and June 2008. 
This analysis in this study was based on the findings of the Ugandan Government’s 
financial and reporting year that run in cycles between 1st July and 30th
 
 June of the 
following year. The pre-free ART years that are referred to in this analysis include the 
years 2002/2003, 2003/2004, 2004/2005, and the post-free ART years include the years 
2005/2006, 2006/2007, 2007/2008.  
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4.4.1 The demographic profile of the study population  
 
This section describes the study population in terms of age, gender, sub-county of 
residence, year of death, and by the treatment era in which they were living when they 
died (either the pre-free and post-free ART era).  
 
4.4.1.1 Age distribution of the study population 
 
The ages of the patients at the time of their death were compiled from the hospital 
records. Every patient (or a relative of the patient) is routinely asked for age when he or 
she is admitted. The reported age was then recorded as the patient's age at the time of 
admission in the patient’s admission notes and ward registers. Since most of the 
patients died shortly (within 0 [zero] and 67 days) after admission, the recorded age on 
admission was considered as the age at time of death.  
 
Vital information registration systems in Uganda are generally of a poor quality. Despite 
the errors associated in hospital records with regard to the reported age of patients 
(misinformation that includes ignorance about the exact date of birth, the age of the 
patient upon admission, or even deliberate misreporting), the reported age in these 
records was the only recorded age-related information that was available to the 
researcher for this analysis (Uganda Bureau of Statistics, Government of Uganda 
2007:15).  
 
The errors that were previously associated with the recording of reported ages in 
Uganda have nevertheless shown a downward (reducing) trend over the years. One 
finds, for example, a more accurate reporting of ages in the 2002 census than one finds 
in the 1969 census (Uganda Bureau of Statistics, Government of Uganda – 2006:15). 
Since one may assume that the reported age in health facilities was within limits of the 
actual age of the patient, the reported age as recorded in the hospital records was used 
by the researcher for analysis in this study. In order to guide the analysis, the 
researcher grouped the ages into the following categories: 15-24, 25-34, 35-44, 45-54, 
55-64, 65-74, 75-84 and 85. He also recorded the gender of each patient for the 
purposes of statistical analysis, tests and comparison.  
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The researcher standardised and analysed the hospital mortality rate by comparing the 
Crude Death Rates (CDR). The Crude Death Rate is defined as the “number of deaths 
over a given period divided by the person-years lived by the population over that period. 
It is expressed as number of deaths per 1,000 population” (United Nations – Population 
Division of the Department of Economic and Social Affairs 2009a:[1]). By making use of 
the CDR, the researcher compared the annual hospital-based mortality rates by age 
group to the general population figures reported by the United Nations and the Uganda 
Demographic Health Survey of 2006. This analysis provided an overall summary of 
hospital mortality rates in this rural setting. 
 
Table 4.1: Hospital mortality rates categorised by age and gender 
 
Age group 
(years) 
Female 
deaths  
n (%) 
Male 
deaths  
n (%) 
TOTAL 
number of 
deaths in 
6 years 
n (%) 
The Uganda 
National  
age-group 
distribution  
of the 
population*  
(%) 
Estimated 
population  
of  
Mawokota 
South health 
sub-district  
by  
age-group 
Age adjusted 
crude death 
rates  
by age 
 group per    
1 000 
population 
15-24 25(47.2) (13.2) 
28(52.8) 
(9.0) 
53 
(10.6) 20.2 20164 0.4 
25-34 
 
57(45.2) 
(30.0) 
69(54.8) 
(22.2) 
126 
(25.1) 13.2 13108 1.6 
35-44 
 
38(34.5) 
(20.0) 
72(65.5) 
(23.2) 
110 
(22.0) 7.1 7094 2.6 
45-54 
 
17(29.8) 
(8.9) 
40(70.2) 
(12.9) 
57 
(11.4) 4.4 4394 2.2 
55-64 
 
15(34.9) 
(7.9) 
28(65.1) 
(9.0) 
43 
(8.6) 3.1 3110 2.3 
65-74 
 
15(26.8) 
(7.9) 
41(73.2) 
(13.2) 
56 
(11.2) 1.8 1791 5.2 
75-84 
 
19(42.2) 
(10.0) 
26(57.8) 
(8.4) 
45 
(9.0) 0.7 718 10.4 
≥85 
 
4(36.4) 
(2.1) 
7(63.6) 
(2.3) 
11 
(2.2) 0.1 97 18.9 
TOTAL 190(37.9) 311(62.1) 501 50.7 50475 9.9 
(n=501, missing = 43),  
(*Source: United Nations - Population Division of the Department of Economic and Social Affairs of the 2009b:[1-2]) 
 
The age distribution of 501 deaths was 15-24 (10.6%), 25-34 (25.1%), 35-44 (22.0%), 
45-54 (11.4%), 55-64 (8.6%), 65-74 (11.2%), 75-84 (9.0%) and above 85 years (2.2%).  
 
In the 15-64 age bracket (the economically active population), the highest CDR was in 
the 35-44 age group of 2.6 per 1 000. The CDR was lowest in the 15-24 age group (0.4 
per 1 000 population), which also is reported to have the lowest prevalence of HIV 
(3.1%) in the 15 years and above age-group population in Uganda (Uganda AIDS 
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Commission – Government of Uganda 2006:21). The CDR in the 35-44 age group (2.6 
per 1 000 population) was six times the CDR in the 15-24 age group and 1.6 times the 
CDR in the 25-34 (1.6 per 1 000 population) age group.  
 
Comparatively, the Uganda demographic health survey showed that mortality in the 35-
44 age group (with a CDR of 15.7 per 1 000 population) was four times the mortality in 
the 15-24 age group (at 3.8 per 1 000 population) and 1.6 times the CDR in the 25-34 
age group (at 9.6 per 1 000 population) (Uganda Bureau of Statistics – Government of 
Uganda 2006a:280). The hopital-based CDR was therefore comparable to the adult 
mortality patterns in the general population.  
 
The findings also showed that, in the 15-64 age bracket, the CDR peaked (was at its 
highest) in the 35-44 age group, and that CDR progressively decreased in the 45-54 
age group (2.2 per 1 000 population) and the 55-64 age group (2.3 per 1 000 
population). These findings coincided with the high HIV prevalence in the population 
which peaks in the 35-44 age group at 9.2% (9.6% for the 35-39 age group and 8.8% 
for the 40-44 age group) (Uganda AIDS Commission – Government of Uganda 
2006:21). 
 
After the age of 65, the CDR subsequently doubled for every ten year age group. In the 
65-74 age group, the CDR was 5.2 per 1 000 of the population compared to 2.3 per 1 
000 of the population in the 55-64 age group. In the 75-84 age group, the CDR was 
10.4 per 1 000 of the population. When this CDR is compared to that of the 65-74 age 
group and that of the population above 85 years, the CDR stood at 18.9 per 1 000 
population, which represented twice the CDR in the 75-84 age group. In all age groups, 
the hospital-based CDR was highest in the above 85 year age group.  
 
The overall CDR was 9.9 per 1 000 population, which was comparable to the CDR of 
Uganda at 12.9 per 1 000 of the population in the general population and the CDR of 
8.8 per 1 000 of the population in the 15-49 age group (Uganda Bureau of Statistics – 
Government of Uganda 2006a:280; United Nations – Population Division of the 
Department of Economic and Social Affairs. 2009c:[1]).  
 
To summarise, the distribution of mortality in terms of age group showed that, 
proportionally, the highest number of deaths occurred in the 25-34 age group, which 
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accounted for 25.1% (n=501) of all adult hospital deaths. It is important to note was that 
the CDR in the 15-64 age bracket was highest in the 35-44 age group (2.6 per 1 000 
population), which coincided with the highest HIV-prevalence rate in the adult 
population. The findings also show that after the age of 65 years, hospital-based CDRs 
doubled for every successive ten-year age group. Overall, the age-standardised CDR 
was lowest in the 15-24 age group (0.4 per 1 000 population) and highest in the 85 year 
age group (18.9 per 1 000 population). The overall CDR was 9.9 per 1 000 population.  
 
4.4.1.2 Mortality distribution in terms of age and gender  
 
HIV/AIDS affects specific genders and age groups differently. In Uganda, females 
experience a higher prevalence of HIV-infection compared to males, especially in the 
15-24 age group (Ministry of Health – Government of Uganda 2009:17). It was therefore 
important for the researcher to analyse mortality in terms of gender and age group, and 
this analysis determined the gender and age group in which the most deaths occurred 
in the hospital. 
 
 
 
Figure 4.1: Distribution of hospital deaths in terms of age group and gender 
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More male deaths than female deaths occurred in the hospital in all the age groups that 
were examined. In the 45-54 and the 65-74 age groups, 70.2% (n=57) and 73.2% 
(n=56) of all the recorded deaths were those of males. The least difference between 
male and female mortality rates occurred in the 15-24 age group, in which 47.2% (n=53) 
of the deaths were female and 52.8% (n=53) were male respectively, while in the 25-34 
age group, 45.2% (n=126) of the deaths were female and 54.8% (n=126) of the deaths 
were male.  
 
Table 4.1 and figure 4.1 reveal that the high mortality in the 25-34 and 35-44 age 
groups was similar to those that are being revealed in findings from other studies and 
reports. In Uganda, the highest HIV prevalence was found among the 25-39 age group, 
with a peak prevalence of 10.3% in the 30-34 age group (Ministry of Health – 
Government of Uganda 2009:21,29; Uganda AIDS Commission – Government of 
Uganda 2008:12).  
 
Figure 4.1 reveals that 30.0% (n=190) of the female deaths occurred in the 25-34 age 
group, 20.0% (n=190) in the 35-44 age group, and 13.2% (n=190) in the 15-24 age 
group. Among the males, 23.2% (n=311) of the deaths occurred in the 35-44 age group, 
22.2% (n=311) in the 25-34 age group, and 9% (n=311) of the deaths occurred in the 
15-24 age group. 
 
The highest mortality rate occurred among females in the 25-34 age group and in the 
35-44 age group among males. Therefore, proportionally more females died at a 
younger age compared to males. These findings further emphasize the findings as 
outlined in table 4.1, which shows that 43.2% of the female deaths and 31.2% of the 
male deaths occurred in the first twenty years of adulthood (in the 15-34 age group).  
 
The high HIV prevalence in the age bracket 25-39 was therefore associated with high 
hospital mortality rate. While the highest number of deaths among females occurred in 
the 25-34 age group (30%), the highest number of male deaths occurred in the 35-44 
age group (23.2%). This study showed that 43.2% of the female deaths and 31.2% of 
the male deaths occurred in the first twenty years of adulthood (in the 15-34 age group). 
Proportionally therefore more females died at a younger age when they mortality rates 
are compared to those of males. In all age groups, more males than females died in the 
hospital. The least proportional difference between the female and male mortality rates 
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occurred in the 15-24 age group, in which 47.2% of the deaths were those of females 
and 52.8% were those of males. The highest proportional diference between female to 
male mortality rates occurred in the 65-74 age group, in which 26.8% of the deaths 
were those of females while 73.2% were those of males.  
 
4.4.2 Distribution of hospital mortality rates in terms of gender  
 
The researcher analysed the mortality rates in terms of gender in order to determine the 
distribution of deaths in terms of gender and in order to find out which gender was most 
affected by mortality.  
 
4.4.2.1 The distribution of hospital mortality rates in terms of gender 
 
On a national level, the HIV prevalence among females in rural areas was 6.5% 
compared to an HIV prevalence of 4.8% among males living in the same areas (Uganda 
AIDS Commission – Government of Uganda 2006:6). In this study, the HIV prevalance 
of reference for the Mpigi district that was used for this analysis was the HIV prevalence 
of Central Uganda, which was 8.6% (10.4% for females and 6.4% for males) (Ministry of 
Health – Government of Uganda 2009:22).  
 
 
 
 
Figure 4.2: The distribution of hospital mortality in terms of gender 
Female
37.9%
Male
62.1%
The Distribution of hospital mortality in terms of gender. 
(n=501)
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The researcher’s analysis of 501 deaths that occurred over a period of six years is 
graphically depicted in figure 4.2 (above). It reveals that 37.9% and 62.1% of all the 
deaths that occurred were those of females and males respectively. Despite a higher 
prevalence of HIV in females than in males, more adult males than females died in the 
hospital. The United Nations estimates the proportion of mortality in terms of gender for 
Uganda at 1:1 (2005-2010) for males and females respectively (United Nations – 
Population Division of the Department of Economic and Social Affairs. 2009d:[1]). 
Although the expected male-to-female mortality ratio was therefore 1:1, the results of 
this study showed that the hospital mortality in terms of gender was 1.6 male deaths to 
every single (1) female death. The results of this study are similar to those of other 
studies that have also revealed a higher mortality in men that that of women in low-
resource settings (Braga 2007:326; Nicastri 
 
2005:582).  
More adult males therefore died in comparison to adult females – with a ratio of two 
(1.6) male deaths to every single (1) female death. Since this study focused on hospital 
deaths, this gender distribution of deaths raised the following questions:  
 
• Firstly, what was the gender distribution of adult mortality for the deaths that 
occurred in the community (these deaths that were not reported in the formal 
health system and were not included in this study)? In other words, did more 
females compared to males die in the community?  
• Secondly, why did more male deaths occur in the hospital? Was this factor 
influenced by access? Were more males with terminal illnesses accessing health 
services compared to females with terminal illness? These are issues that 
require further research.  
 
4.4.2.2 Annual mortality trends in terms of gender 
 
The variations in mortality were analysed by the researcher in order to determine any 
changes in annual mortality patterns in terms of gender that had occurred over the 
previous six-year period. The results of this analysis are presented in table 4.2 (below): 
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Table 4.2: Distribution of hospital deaths in terms of year of death and gender  
 
  Gender    
Year of 
Death 
Female 
deaths  
n (%) 
Percentage 
annual 
increase 
(%) 
Male 
deaths  
n (%) 
Percentage 
annual 
increase 
(%) 
TOTAL 
number of 
deaths  
n (%) 
Percentage 
annual 
increase 
(%) 
2002/03 31(40.3) (14.7) - 
46(59.7) 
(14.0) - 
77 
(14.3) - 
2003/04 31(37.8) (14.7) 0.0 
51(62.2) 
(15.5) 10.9 
82 
(15.2) 6.5 
2004/05 36(46.2) (17.1) 16.1 
42(53.8) 
(12.8) -17.6 
78 
(14.4) -4.9 
2005/06 34(40.0) (16.1) -5.6 
51(60.0) 
(15.5) 21.4 
85 
(15.7) 9.0 
2006/07 38(37.6) (18.0) 11.8 
63(62.4) 
(19.1) 23.5 
101 
(18.7) 18.8 
2007/08 41(35.0) (19.4) 7.9 
76(65.0) 
(23.1) 20.6 
117 
(21.7) 15.8 
Total 211(39.1) (Av*) 6.0 329(60.9) (Av) 11.8 540 (Av) 9.1 
(n=540, Missing = 4) Av*- Average  
 
Proportionally, the highest number of deaths that occurred during the six-year period 
that was covered by this study occurred in 2007/2008 (21.7%, n=540), which also 
happened to be the last year of the post-free ART era with the highest levels of ART 
coverage. This contrasted with the expectation that increased ART coverage would 
reduce hospital mortality rates. The least number of deaths occurred in 2002/2003 
(14.3%, n=540) which is a year in the pre-free ART era.  
 
In the six-year period covered by the study, the male mortality increased at twice the 
annual rate of increase in female deaths. An analysis of the two years of pre-free ART 
period showed that, on average, the male mortality decreased by 3.4% while female 
mortality increased by 8.1% annually. In the post-free ART era (2005/2006 to 
2007/2008), male deaths (on average) increased by 21.7% annually while females 
deaths which increased by 4.6% annually.  
 
The annual mortality changes by gender therefore reversed in the post-free ART era 
compared to the pre-free ART with male mortality increasing at 4.7 times the annual 
increase in female mortality. This rate of male mortality was therefore identified as an 
issue of concern that required further research. 
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4.4.3 The distribution of deaths in terms of sub-county of residence 
 
The hospital that was the locus of this study serves a rural community with a population 
catchment area from the three sub-counties of Nkozi, Kituntu and Buwama sub-
counties, which together form the Mawokota South health sub-district which is located in 
the Mpigi District. The health sub-district is neighboured by the Bulo, Kamengo, Maddu, 
Kabulasoke sub-counties in the Mpigi District and the Lukaya sub-county in the Masaka 
District (see section 1.2.2 for further details). Because of its location and the services 
that it offers, the hospital is accessible to all patients within and from outside the 
population catchment area. Apart from the physical accessibility of hospital services, the 
access to services is also determined by choice or preference (among other factors). It 
was therefore a matter of great significance for the hospital authorities and the district 
mangers to determine the composition and nature of the population that was being 
served by the facility, and, in this case, to analyse mortality rates in terms of the 
different geographical areas from which patients were admitted.  
 
The distribution of the deaths in terms of the location of the patient’s residence (i.e. the 
patient’s home) will enable managers to design appropriate and targeted financial and 
programmatic interventions that will ensure that the hospital will be able to meet the 
expectations that populations have with regard to services. Population distribution in 
terms of places of residence also enables managers to establish and maintain regular 
communication with local community leaders. Communications with communities 
served by the hospital ensures that the health challenges that the communities face can 
be adequately explained at a local level and so that suggestions can be made about 
how such health challenges can be met and ameliorated.  
 
4.4.3.1 Mortality in terms of sub-county of residence  
 
It has been reported by the WHO that “only 49% of the households [in Uganda] have 
access to health care facilities” (WHO 2001:[1]). Because the locations of the sub-
county of residence of all patients is a key determinant of access to health care 
(because the sub-county of residence indicates the distance that a patient has to travel 
to get to the hospital), the researcher was also determined to analyse mortality rates in 
terms of the sub-county of residence. Hospital deaths from Mawokota South health sub-
district (which comprise the Nkozi, Buwama and Kituntu sub-counties) and the four 
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neighbouring sub-counties were duly analysed. Since the number of recorded deaths 
from other sub-counties such as Budde, Ngando, Kyegonza were few in number, the 
researcher categorised them under the blanket heading of “other sub-counties”. 
 
Table 4.3: Distribution of mortality in terms of sub-county of residence and 
gender  
 
Sub-County 
Female 
deaths  
n (%) 
Male 
deaths 
n (%) 
TOTAL 
number of 
deaths n (%) 
Bulo 
 
5(31.3) 
(2.5) 
11(68.7) 
(3.5) 
16 
(3.1) 
Buwama 
 
31(36.9) 
(15.5) 
53(63.1) 
(17.1) 
84 
(16.5) 
Maddu 
 
6(46.2) 
(3) 
7(53.8) 
(2.3) 
13 
(2.5) 
Kabulasoke 
 
2(50) 
(1) 
2(50) 
(0.6) 
4 
(0.8) 
Kamengo 
 
11(33.3) 
(5.5) 
22(66.7) 
(7.1) 
33 
(6.5) 
Kituntu 
 
49(38.3) 
(24.5) 
79(61.7) 
(25.5) 
128 
(25.1) 
Nkozi 
 
79(43.6) 
(39.5) 
102(56.4) 
(32.9) 
181 
(35.5) 
Other sub-
counties 
17(33.3) 
(8.5) 
34(66.7) 
(11.0) 
51 
(10) 
TOTAL 200(39.2) 310(60.8) 510 
   (n=510, missing - 34) 
 
Table 4.3 indicates that 35.5% (n=510) of all deaths occurred in the Nkozi sub-county, 
25.1% (n=510) occurred in the Kituntu sub-county, and that 16.5% (n=510) occurred in 
the Buwama sub-county. These findings reveal that 77.1% (n=510) of all hospital 
deaths were those of patients who lived within the hospital catchment population. The 
results also show that, only 22.9% (n=510) of the number of deaths that occurred were 
of patients who came from sub-counties outside the hospital catchment area.  
 
Among the sub-counties that were classified as being outside hospital catchment area, 
Kamengo recorded the highest number of deaths, with 6.4% (n=510) of these deaths 
occurring in the hospital. The deaths from Bulo (3.1%), Maddu (2.5%), Kabulasoke 
(0.8%) and the other sub-counties (10%) were too few in number for significant 
analysis. They were however useful for providing a breakdown of the sub-counties of 
residence of the patients who accessed the services of the hospital and the number of 
deaths that occurred in terms of the sub-county of residence of the patients concerned.  
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As one might expect, the people who lived within the sub-county of the hospital enjoyed 
the best degree of physical access to the hospital in comparison to all those people 
from other sub-counties (who, according to the findings of the study) constituted the 
majority of this sample. In all the sub-counties, the number of male deaths was 
proportionally higher than the number of female deaths. The female-to-male proportions 
from the different sub-counties was more or less similar, with 61.7% (n=128), 56.4% 
(n=181) and 63.1 (n=84) of the recorded deaths being those of male patients from the 
Kituntu, Nkozi and Buwama sub-counties respectively.  
 
In summary, the highest number of deaths from the Mpigi District that occurred in the 
hospital were of Nkozi sub-county (35.5%, n=510) residents, followed by those from 
Kituntu sub-county (25.1%, n=510), and those from Buwama (16.5%, n=510) sub-
county. The least number of deaths among patients were recorded among those from 
Kabulasoke sub-county (0.8%, n=510). These findings show that the 77.1% (n=510) of 
all the hospital deaths that occurred during the study period were from the hospital's 
population catchment area while 22.9% (n=510) of the patients who died in hospital 
came from outside the hospital's defined catchment area. It is also noteworthy that more 
males than females from all sub-counties died in the hospital.  
 
4.4.3.2 Mortality in terms of sub-county of residence and treatment era  
 
In this study, the researcher analysed mortality rates, not only in terms of residence but 
also in terms of the treatment era in which the patients died (whether in the pre-free or 
post-free ART eras). The researcher therefore compiled a comparison of the proportion 
of deaths in terms of sub-county of residence as well as in terms of the pre-free and 
post-free eras in which the deaths occurred. This analysis was carried out in order to 
determine the changes (if any) in the mortality (number and proportion of deaths) in the 
pre-free ART era in comparison to those of the post-free ART era. Table 4.4 (below) 
presents the findings for these variables. 
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Table 4.4: Hospital deaths in terms of sub-county of residence and treatment 
era  
 
Sub-County 
Pre- free 
ART 
deaths  
n (%) 
Post- free 
ART 
deaths  
n (%) 
TOTAL 
Number of 
deaths  
n (%) 
Variance 
(% Change in  
number of  
deaths from 
 the sub-county)   
Bulo 
 
8(50) 
(3.6) 
8(50) 
(2.7) 
16 
(3.1) -0.9 
Buwama 
 
42(49.4) 
(18.9) 
43(50.6) 
(14.7) 
85 
(16.6) -4.2 
Maddu 
 
7(53.8) 
(3.2) 
6(46.2) 
(2.1) 
13 
(2.5) -1.1 
Kabulasoke 
 
1(25) 
(0.4) 
3(75) 
(1) 
4 
(0.8) 0.6 
Kamengo 
 
11(33.3) 
(5) 
22(66.7) 
(7.5) 
33 
(6.4) 2.5 
Kituntu 
 
49(38.0) 
(22.1) 
80(62.0) 
27.4 
129 
(25.1) 5.3 
Nkozi 
 
90(49.2) 
(40.5) 
93(50.8) 
(31.9) 
183 
(35.6) -8.6 
Other Sub-
Counties 
14(27.5) 
(6.3) 
37(72.5) 
(12.7) 
51 
(9.9) 5.4 
TOTAL 222(43.2) 292(56.8) 514 13.6 
(n=514, missing - 30)  
 
These findings reveal that 56.8% (n=514) of the deaths occurred in the post-free ART 
era in comparison to the 43.2% (n=514) of deaths that occurred in the pre-free ART era 
– representing a 13.6% higher proportion of deaths in the post free-ART era. (These 
findings are further analysed in figure 4.3 below.) 
 
Absolute numbers and percentages of mortalities indicated the difference in the 
proportion of deaths in the pre-free and post-free ART eras in terms of sub-county. In 
spite of this, the most appropriate measure of hospital mortality trends was 
accomplished by an analysis of the mortality rates (number of deaths per 100 hospital 
admissions) that is described in section 4.5.3.4.  
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Figure 4.3: Hospital deaths by sub-county of residence and treatment era  
(2002-2008) 
 
The findings set out in table 4.4 and figure 4.3 (above) indicate that when one compares 
the post-free ART era to the pre-free ART era, the number of deaths from Nkozi and 
Buwama sub-counties declined by 8.6% (n=183) and 4.2% (n=85) respectively. This 
was a noteworthy reduction in the proportion of deaths from these sub-counties in the 
population catchment area. The additional finding that partially explained this reduction 
in mortality in the two sub-counties of Mawokota South (when compared to the other 
sub-counties that the researcher analysed in this study) was that Nkozi and Buwama 
sub-counties, possessed one authorised ART-provision site each (Ministry of Health – 
Government of Uganda 2009:45). These two ART sites had been established in the 
Nkozi Hospital and the Buwama Health Centre in Nkozi and Buwama sub-counties, and 
had been providing free ART since July 2005 and January 2007 respectively. By June 
2008, the Nkozi Hospital and the Buwama Health Centre reported that they had 
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cumulatively provided ART to 495 and 287 patients (respectively). It was these two ART 
sites that facilitated patient access to ART in the Mawokota South county, and this, in 
turn, contributed to the recorded reduction in the mortality rates of the post-free ART era 
in these two sub-counties.  
 
Proportionally, the number of deaths from Kituntu, other sub-counties and Kamengo 
increased in the post-free ART era by 5.3% (n=129), 6.4% (n=51) and 2.5% (n=33) 
respectively. Since these sub-counties had no established free ART access clinics, 
patients from these sub-counties obviously encountered many more obstacles in their 
attempts to access free ART, and it is this factor (the absence of ART-distribution sites 
in their sub-counties) that may have contributed to the increase in mortality rates in 
these sub counties that became evident in the post-free ART era. 
 
It is therefore clear that  increased access to free ART in Nkozi and Buwama sub-
counties contributed to the 8.6% (n=183) and 4.2% (n=85) decline in the mortality rates 
in Nkozi and Buwama sub-counties respectively. Mortality in sub-counties which did not 
have a designated free ART site (such as those in Kituntu and Kamengo sub-counties) 
increased by 5.3% (n=129) and 2.5% (n=33) respectively.  
 
4.4.4 Statistical correlations between mortality and place of residence  
 
Access to ART services and other general health services are influenced by the 
distances between the patients’ homes and the health facility, the cost of transport, and 
by gender. The population that resides in the hospital catchment area obviously lives 
much closer to the hospital and is therefore much more likely to be better informed 
about available services such as free ART programmes and the other services offered 
by the hospital. The population that lives in closer proximity to the hospital will also need 
to spend far less on transport in order to get to the hospital and to access its 
programmes (such as ART) and other services.  
 
As one may therefore expect, the majority of deaths that occurred in the hospital were 
those of patients from the hospital’s catchment area. In the post-free ART era, 
observers expected that an increased access to ART in the health care would cascade 
into more adults accessing ART and that this, in turn, would contribute to a significant 
reduction in the rates of hospital adult mortality. Figure 4.3 shows how the number of 
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deaths from the Nkozi and Buwama sub counties did, in fact, decline. The challenge for 
the researcher inherent in this observation was to determine whether or not the 
proportional reduction in number of deaths was statistically significant.  
 
4.4.4.1 Mortality in terms of sub-county of residence and treatment era  
 
In order to determine the association between sub-county of residence and mortality, 
the researcher divided (categorised) all the deaths into two groups the following:  (a) the 
number of deaths that had occurred among residents in the Mawokota South health 
sub-district (the Nkozi, Buwama and Kituntu sub-counties within the catchment area), 
and (b) the number of deaths that occurred among residents of other sub-counties 
(outside the catchment area). The researcher accomplished the analysis of the 
association between the risk of mortality in terms of residence and in terms of gender by 
using a two by two contingency table, and the results that he obtained are discussed 
below.  
 
Table 4.5:  Association between mortality in terms of residence and treatment 
era 
 
  
Treatment Era 
 
Sub-county of 
Residence 
Post- free ART 
deaths 
n (%) 
Pre- free ART 
deaths 
n (%) 
TOTAL 
number of 
deaths 
n (%) 
Mawokota County  216(54.4) (74.0) 
181(45.6) 
(81.5) 
397 
(77.2) 
Other counties  
 
76(65.0) 
(26.0) 
41(35.0) 
(18.5) 
117 
(22.8) 
TOTAL 292(56.8) 222(43.2) 514 
(n=514, missing - 30) 
 
The distribution of the hospital mortality in terms of residence and treatment era set out 
in table 4.5 (above) show that, in the post-free ART era, there was a proportionally 
lower number of deaths that occurred in Mawokota County. The number of deaths that 
occurred from Mawokota South declined by 7.5% from 81.5% (n=222) in the pre-free 
ART era to 74.0% (n=292), in comparison to the number of deaths that occurred from 
other counties, which increased by 7.5% from 18.5% (n=222) to 26.0% (n=292).  
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The findings that are set out in table 4.5 (above) also indicate that, in the post-free ART 
era, there was a diminished likelihood that a patient from a Mawokota South health sub-
district would die in the hospital when one compares with the pre-free ART era. The 
likelihood that a patient from Mawokota would die in hospital was therefore reduced by 
10.6% (a risk difference of 10.6%, 95% CI[-20.5%-0.6%]; OR=0.64, 95% CI[0.42-0.98]; 
RR=0.84, CI[0.71-0.98]). An association was therefore evident between a patient’s 
place of residence and the treatment era in which the death occurred since patients 
from the Mawokota South health sub-district residents had lower odds of death in the 
hospital in the post-free ART era compared to those they had in the pre-free ART era 
(χ²=4.10; p=0.043). As was pointed out earlier in this chapter, the Nkozi and Buwama 
sub-counties had designated free ART sites and health clinics in these sub-counties 
had already been providing free ART from July 2005 and January 2007 respectively.  
 
One may therefore note that, in the post-free ART era, the residence of a patient in the 
hospital catchment area which had increased access to free ART was associated with a 
reduced likeliness of death in the hospital. In the post-ART era, an increased access to 
ART in the catchment area therefore contributed to a 10.6% reduction in the likelihood 
(risk) that a patient who lived in the population catchment area would die in the hospital.  
 
4.4.4.2 Female mortality in terms of county of residence  
 
After the researcher had determined the significance of the association between 
treatment era and county/sub-county of residence, he engaged in a further analysis to 
determine the significance of gender differences in hospital mortality in terms of place of 
residence.  
 
In order to determine variations in mortality rates in terms of gender and place of 
residence, the researcher analysed female and male deaths from within the hospital’s 
catchment area of the hospital and from outside the catchment. A two by two 
contingency table took account of the treatment era (whether the pre-free or the post-
free ART era) and the analysis for statistical association was accomplished and 
presented below. 
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Table 4.6: The association between female mortality and county of residence 
 
  Treatment Era  
County of 
Residence 
Post-free ART 
deaths  
n (%) 
Pre-free ART 
deaths 
n (%) 
TOTAL 
number of 
deaths 
n (%) 
Mawokota South 
County 
85(53.5) 
(78.7) 
74(46.5) 
(80.4) 
159 
(79.5) 
Other Counties 
 
23(56.1) 
(21.3) 
18(43.9) 
(19.6) 
41 
(20.5) 
TOTAL 108(54.0) 92(46.0) 200 
(n=200, missing - 11)  
 
The findings set out in table 4.6 revealed that, among females who had resided in 
Mawokota South county, there was a 1.7% reduction in the proportional mortality from 
80.4% (n=92) in the pre-free ART era to 78.7% (n=108) in the post-free ART era. But 
this reduction was not statistically significant (χ²=0.09; p=0.76).  
 
This means that whether the deceased females had been admitted in the pre-free ART 
era or in the post-free ART era, they were faced with an equal likelihood of hospital 
death if they were residents of the Mawokota South health sub-district residents. One 
may therefore conclude that free access to ART exerted no significant effects on female 
hospital mortality in terms of their place of residence. 
 
4.4.4.3 Male mortality in terms of county of residence  
 
After the researcher had analysed the female pre-free and post-free ART era mortality 
in terms of county of residence, he proceeded to apply the same techniques in order to 
determine whether there was any significant difference in the male pre-free and post-
free ART-era mortality in terms of county of residence.  
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Table 4.7: The association between male mortality and county of residence 
 
  
Treatment Era 
 
Sub-county of 
Residence 
Post- free ART 
deaths  
n (%) 
Pre- free ART 
deaths  
n (%) 
TOTAL 
number of 
deaths  
n (%) 
Mawokota County 129(55.1) (70.9) 
105(44.9) 
(82.0) 
234 
(75.5) 
Other  
Counties  
53(69.7) 
(29.1) 
23(30.3) 
(18.0) 
76 
(24.5) 
TOTAL 182(58.7) 128(41.3) 310 
(n=310, missing-29) 
 
In contrast to what was discovered about the female deaths, the researcher found that 
the number of male deaths from Mawokota South county residents declined by 11.1% 
from 82.0% (n=128) in the pre-free ART era to 70.9% (n=182) in the post-free ART era. 
This reduction was statistically significant (χ²=5.05; p=0.024). As far as males were 
concerned, in the post-free ART era, the possibility (risk) of a male hospital death of a 
resident of the Mawokota South health sub-district, declined by 14.6% (95% CI[-26.8%--
2.5%]; OR=0.53, 95% CI[0.31-0.93];).  
 
Therefore, the provision of free access to ART in Mawokota South health sub-district 
was associated with a reduced likelihood of male hospital death among males from the 
hospital’s catchment area. 
 
4.4.5 Average length of stay and out-of-pocket payments  
 
In a study that was undertaken in Botswana, the most important barrier to adherence to 
ART was the cost of ARVs. In a modelling that eliminated cost as a factor in the process 
of accessing ART, the researchers projected that adherence to ART would increase 
from 54% to 71% (Wilson & Fairall 2008:485). But in spite of the fact that there is free 
access to ART, the various costs associated with health services remain a key barrier to 
ART access, especially for the poorer sector of the population and for those who live 
some distance away from ART access sites.  
 
The length of a patient’s hospital stay is a critical factor in calculating the cost of 
services to the patients concerned and to the hospital. The objective of free access to 
ART is to reduce morbidity and mortality rates in high-prevalence settings. In such high-
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prevalence settings, free access to ART is expected to reduce the number of 
admissions and the number of days spent in the hospital, especially in the case of 
HIV/AIDS-related diseases. This downward trend in morbidity is expected to be directly 
related to reduction in cost of service delivery for both the hospital and to the patients.  
 
As part of this research, the researcher analysed the average length of stay (ALOS) in 
the hospital and the out-of-pocket payments that were made by patients who died in 
hospital during the research period. He also analysed the factors that were associated 
with out-of-pocket payments in both the pre-free and post-free ART eras. A further 
analysis to assess the correlation between factors associated with out-of-pocket was 
also undertaken and discussed.  
 
4.4.5.1 The average length of hospital stay before death occurred 
 
This study has reviewed the number of admission days before death, the ALOS in 
hospital, and median number of admission days. The analysis of the number of 
admission days before death intervened was obtained by subtracting the date of 
admission from the date of death in order to determine the total number of days that 
were spent in hospital. The actual time of admission and the time of death were not 
used in this analysis to determine the exact number of hours that the patient spent in 
hospital before his or her death. The result was a discrete number of days of admission 
– days that ranged from a minimum number of zero (0) days (implying that death had 
occurred within one day (24 hours) of admission), to the highest number of admission 
days.  
 
In this analysis, the researcher categorised the number of admission days into the 
following four categories:  
 
1. less than or equal to one day of admission  
2. two to three days (2-3) of admission 
3. four to five days (4-5) of admission  
4. more than five days of admission 
 
The analysis of the number of days of admission before the patient’s death was 
important for determining the severity of the illnesses with which patients presented on 
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admission to the hospital. The average number of days of admission was also important 
for determining the time that was available to health workers to investigate, diagnose 
and manage the patient before he or she died. By analysing the number of days before 
patient death, the researcher was also able to suggest how targeted health promotion 
efforts could be implemented in the community in order to encourage patients to obtain 
access to hospital services before their conditions became so acute that the risk of 
imminent death intervening very soon after admission became very high indeed.  
 
The researcher analysed the number of hospital admission days in hospital before 
patient death, and presented his findings as follows:  
 
Table 4.8: Number of admission days spent in hospital before death occurred 
 
Number of 
admission days 
before death 
occurred  
Frequency 
Percentage 
% (95% 
Confidence Limits) 
Cumulative 
percentage of 
frequencies 
% 
≤1 days 135 27.6 (23.7-31.8) 27.6 
2-3 days 155 31.6 (27.6-36.0) 59.2 
4-5 days 130 26.5 (22.7-30.7) 85.7 
>5 days 70 14.3 (11.4-17.8) 100.0 
Total 490 100.0  
(n=490, missing-54) 
 
The results show that 27.6% (n=490; 95% CI [23.7% - 31.8%]) of the deaths occurred 
within one day (or 24 hours) of admission while 31.6% (n=490; 27.6-36.0) of the deaths 
occurred within two to three days of admission to hospital.  
 
These findings are set out on the graph below, and demonstrate the frequency of 
deaths in terms of the number of days of admission that elapsed before death 
intervened.  
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Figure 4.4: Number of admission days before death in Mawokota South  
(2002-2008) 
 
It is evident from these figures that the shortest period of hospital stay before death was 
less than a day while the longest period of hospital stay in this study was 67 days. In 
total, 59.2% (n=490) of the patients died within three days of admission to hospital while 
85.7% (n=490) of the patients died within five days of admission.  
 
There was notably high mortality on the first day (the first 24 hours) and within three 
days of admission (see table 4.8 and figure 4.4). There was limited time for hospital staff 
to examine, manage and observe the patient before death intervened. This finding 
indicates that patients presented with severe and critical illnesses and conditions upon 
admission, which may have been largely due to late presentation to the hospital. This 
factor (late presentation to hospital) contributed to the high mortality rate on the first day 
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of admission. In many cases, the hospital staff did not even have opportunities to 
properly investigate the patient’s causes of morbidity and subsequent mortality, and this 
frequently resulted in inadequate and incomplete investigations and threfore mortality 
records were incomplete in terms of a fully investigated and appropriately managed 
death event.  
 
This high mortality on the first day of admission is similar to findings observed in the 
research conducted by Garko, Ekweani and Anyiam (2003:69) in Nigeria, where they 
found that 30% of all deaths occurred on the first day of admission. In this same 
Nigerian study, 65% of the deaths occurred within five days of admission in comparison 
to the 85.7% (n=490) of deaths that the present researcher identified in his Ugandan 
study (Garko et al  2003:69). In this study, mortality on the fifth day of admission is 
20.7% higher than the mortality on the fifth day of admission in the study undertaken by 
Garko et al in Nigeria. It is, however, important to note that the study in Nigeria was 
conducted in a tertiary hospital whereas the Uganda study was conducted in a district 
hospital.  
 
The shortest period of hospital stay before death was therefore less than one day while 
the longest period of hospital stay identified in this study was 67 days. The highest 
mortality among patients occurred on the first day of admission, with 27.6% (n=490; 
95% CI [23.7% - 31.8%]) of the deaths occurring within one day (24 hours) of admission 
while 31.6% (n=490; 27.6-36.0) occurred within two to three days of admission. Overall, 
59.2% (n=490) of the patients died within three days of admission and 85.7% (n=490) of 
the deaths occurred within five days of admission.  
 
4.4.5.2 Average length of stay in the pre-free and post-free ART eras  
 
The ALOS for patients in this study was calculated by the using the total number of 
inpatient days for all deaths, which were determined by subtracting from the date of 
admission from the date of death, and then by dividing the total number of days spent in 
hospital by the total number of deaths that occurred per annum (Pennsylvania 
Department of Health 2001:[1]; European Union Public Health Information System – 
EUPHIX 2009:[1]). 
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Table 4.9: The average length of hospital stay in Mawokota South (2002-2008)  
 
 Average length of 
stay before death 
(n±SD) 
Mortalities 
reviewed 
2002/03 6.0±9.5 74 
2003/04 4.2±4.4 81 
2004/05 4.1±4.4 69 
2005/06 3.9±4.4 72 
2006/07 5.1±5.3 89 
2007/08 6.0±9.7 105 
Average 4.9±6.9  
(n=490, missing 54) SD-Standard Deviation  
  
The findings set out in table 4.9 (above) show that the ALOS in this study was 4.96 
days. These findings were similar to the ALOS that was identified in another study 
undertaken in Nigeria that reported an ALOS in hospital of 4.95 days before death 
occurred (Yisa et al. 2004:69). It is therefore evident that the overall ALOS in hospitals 
in this rural setting falls within earlier reported limits that have been reported by other 
similar studies.  
 
In terms of a simple average, the ALOS before death in the pre-free ART era was 4.8 
days while, in the post-free ART era, it was five days.  
 
The overall ALOS before death in the hospital was five days, with 4.8 days before death 
in the pre-free ART era and 5 days before death in the post-free ART era. It is therefore 
evident that free access to ART had not reduced the ALOS before death in a hospital.  
 
4.4.5.3 The trend of the average number of admission days before death 
 
In order to determine the ALOS before death trends over the six-year period of the 
study, and to  provide a basis for projecting future ALOS trends, the researcher 
exponentially smoothed the annual ALOS with a dumping factor of 0.8 in the line graph 
below.  
 
Hospital efficiency factors are dependent upon factors such as the number of health 
workers (nurses, medical doctors and other health workers) and their skills and 
approaches to the management of health systems. Other factors that are critical in 
enhancing the efficiency of the way in which the hospital manages its patients and 
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which have an impact on the ALOS before death include the availability and 
functionality of diagnostic equipment, and the speed with which patients were able to 
gain access to emergency care and referral services.  
 
Apart from hospital factors, patient factors play a significant role in determining the 
ALOS before death. As discussed earlier in 4.4.5.1, late presentation of patients for 
hospital care is a key determinant of ALOS in hospital.   
 
Since ALOS is a measure of efficiency with which a hospital system is able to manage 
and refer patients to minimise the risk of death, the dumping factor of 0.8 ensured that a 
greater weight was given to the most recent practices and conditions that had been 
implemented in the hospital to improve the efficiency with which patients are managed. 
The researcher therefore gave less weight to earlier practices and conditions, therefore, 
these findings and projections closely resemble the features that will be evident in future 
trends.  
 
 
 
Figure 4.5: Average number of admission days before death (2002-2011) 
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A review of 490 deaths and an analysis of ALOS before death shows that in 2002/2003, 
the average number of admission days before death was six days, and that this average 
figure progressively reduced to five days in 2007/2008. The researcher projected that 
the ALOS would reach four days of admission before death intervened by June 2011.  
 
The ALOS before death therefore demonstrated a decreasing trend. This finding in a 
way compliments findings in section 4.4.5.1 that are indicative of the increasing number 
(percentage) of patients who were being admitted to hospital with critical or severe 
illnesses that caused their death in progressively fewer days of hospital stay. The 
reduction in ALOS is also an indication of the capacity of the hospital to use its human 
resources, equipment, medicines and management systems to manage critical illnesses 
as well as its capacity for referring refer critically ill patients to other levels of care to 
reduce the risk of mortality. In this study therefore, reductions in the ALOS before death 
is an indicator of the challenges that the hospital is facing as it tries to contain or reduce 
mortality rates. 
 
The determination of the degree of efficiency with which the hospital was able to 
manage inpatients was beyond the scope of this study, but it would offer a fruitful area 
of study for future researchers.  
 
4.4.5.4 The median number of admission days before death  
 
Because of the risks associated with the measurement of the ALOS before death in the 
hospital, that are caused by outlier values on both extremes of the spectrum (values 
that could affect the accuracy of the mean as a measure of central tendency), the 
researcher decided to use the median number of admissions days as a better measure 
of central tendency. He therefore used the median number of days of admission to 
determine the trend in median admission days per annum and this enabled him to make 
a comparison between the pre-free and post-free ART eras.  
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Figure 4.6: The median number of admission days before death (2002-2008) 
 
Figure 4.6 shows that, the median number of admission days before death, remained 
constant at three days of admission during the pre-free ART era but increased to four 
days in 2006/2007 before it fell back to three days in 2007/2008(a period that 
represented the pre-free ART era).  
 
There was therefore no change in the median number of admission days in the three 
pre-free ART era years compared to the three years of the post-free ART era. There 
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was, however, there was an increase in variation (between the minimum and maximun 
number of days of admission) of the number of admission days in the 2007/2008 period. 
This was indicative of the increasing number of chronic conditions among those who 
were being admitted to the hospital and who were remaining in the hospital for 
prolonged periods before their death. Specific conditions that fell into this category were 
frequently observed in HIV-related conditions such as TB. Among the top 15 patients 
who spent the longest time in hospital before death, three of them were TB patients, 
and these three spent 67, 45 and 26 days in hospital respectively before their deaths.  
 
These findings showed that increased access to ART did not affect (i.e. did not either 
reduce or prolong) the median length of hospital stay for patients who died in the 
hospital.  
 
4.4.6 Out-of-pocket payments for hospital services  
 
In the rural setting of the Mpigi district, patients endured a variety of costs during the 
process of accessing health care. Out-of-pocket payments allow a researcher to make 
an estimate of the direct cost of health service delivery to service providers and to 
patients. Although out-of-pocket payments are the main form of payments for most 
health services in developing countries, they also constitute a key barrier to health care 
for poor families (Forgarty International Centre of the United States [U.S] National 
Institutes of Health,The World Bank, WHO, Population Reference Bureau, Bill and 
Melinda Gates Foundation 2007:4). In this study, the researcher made a record of all 
the out-of-pocket payments that were made by patients before their death from medical 
records before analysing them. As has already been pointed out earlier in this text, out-
of-pocket payments in Uganda are also referred to as “user fees” or “user charges”. The 
researcher therefore analysed the trends and patterns of out-of-pocket payments and 
sought to find a meaningful association between out-of-pocket payments and the 
number of hospital deaths that occurred in the pre-free and post-free ART eras. 
 
Although out-of-pocket-payments included the cost of medicines, medical sundries, 
laboratory fees and consultation fees, they excluded other costs that were incurred by 
the patient during the process of accessing health care – costs such as transport to and 
from the hospital, the cost of food and revenue that was lost because of absence from 
work or family business. 
189 
 
4.4.6.1 Average of out-of-pocket payments per death 
 
For each adult death, the researcher entered the total amount of hospital fees or 
charges that each patient paid in Uganda Shillings into the data analysis database and 
then proceeded with the analysis. For comparability across years, Uganda Shillings 
were converted into United States of America dollars (US$). Since the exchange rates 
between Uganda Shillings and US$ varied significantly over the six years of the study, 
the historical annual average exchange rate of one (1) US$ to Uganda Shillings (by 
year) was determined and was thereafter used for converting Uganda Shillings into an 
equivalent amount of US dollars. The researcher rounded off the Uganda Shilling values 
and their US$ equivalents to the nearest single decimal point. The historical rates 
showed that one US$ equivalent to Uganda Shillings was 1 807.5 in 2002/2003, 1 995 
in 2003/2004, 1 800.9 in 2004/2005, 1 899.1 in 2005/2006, 1 883.2 in 2006/2007, and 1 
776 in 2007/2008 (OANDA Corporation 1997:[1]).  
 
By using this approach to establish a rational exchange rate that would serve for the 
period under study, the researcher was able to give values to out-of-pocket rates and 
then perform a trend analysis that would guide the discussion.  
 
Table 4.10: The trend of out-of-pocket payments per death (2002–2008)  
 
Year 
Average  
out-of-pocket 
payment 
per death 
(±-SD*) 
(in US$) 
Median  
out-of-pocket 
payment 
per death 
(in US$) 
Range 
(Minimum- 
Maximum) 
Number of 
deaths 
reviewed 
2002/2003 10.1±7.1 9.4 1.7-44.8 72 
2003/2004 9.3±9.9 8.5 1.5-80.2 74 
2004/2005 9.6±6.2 9.4 1.7-29.4 76 
2005/2006 9.5±5.3 10.5 2.1-26.3 76 
2006/2007 12.7±8.6 10.6 1.6-65.3 96 
2007/2008 16.3±12.5 14.1 1.9-84.5 108 
Average  11.3±8.3 10.4 1.7-55.1 502 
*SD-Standard Deviation, (n=502, missing-42)  
 
The average out-of-pocket payment in the pre-free ART era was US$ 9.7 (the average 
of 10-12002/2003, 9.3-2003/2004 and 9.6-2004/2005) compared to US$ 12.8 (average 
of 9.5-2005/2006, 12.7-2006/2007 and 16.3-2007/2008) per death in the post-free ART 
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era. Over the six years of the study, the overall average out-of-pocket payment per 
death was US$ 11.3 (ranging from the lowest out-of-pocket payment of US$ 9.3 in 
2003/2004 to the highest payment of US$ 16.3 in 2007/2008). Out-of-pocket payments 
increased by 61.4% from US$ 10.1 in 2002/2003 to US$ 16.3 per death in 2007/2008. 
In the post-free ART era, the average out-of-pocket payment increased steadily from 
US$ 9.5 to US$ 16.3 per death. 
 
In research undertaken in Thailand, the average inpatient cost per episode for diarrhoea 
was US$ 76.8, of which US$ 58.8 (77%) was consumed by hotel costs (Riewpaiboon, 
Intraprakan & Phoungkatesunthorn 2008:446). The other costs that were identified in 
the study included those that were made for meals, medical and nursing care, 
laboratory services, drugs and medical supplies. Apart from the hotel costs, the cost of 
the other services in the Thailand study (that is, the cost of the medical items, the 
laboratory services and health care) were US$ 18 per episode of diarrhoea. In 
Zimbabwe, the cost of inpatient care for malaria and tuberculosis were US$ 28 and US$ 
33 respectively (Hongoro & McPake 2003:248).  
 
These references to the research undertaken in Thailand and Zimbabwe provided the 
researcher with a basis of comparison for average out-of-pocket payments in other 
settings, and enabled him to evaluate how the findings of his study compared with the 
parameters reported by estimates from other studies.  
 
The findings in this study show that the out-of-pocket of US$ 11.3 for the ALOS before 
death of 4.9 days (see table 4.9) was comparatively less than the out-of-pocket 
payments that patients needed to make in Thailand and Zimbabwe. Needless to say, a 
comparison of such average costs should be approached with a degree of caution and 
are difficult to compare because of the variations in cost focus for each of the studies 
involved. The most important questions to ask with regard to all these out-of-pocket 
payments is, “How much did the patient pay?” and “Is such an average out-of-pocket 
payment in this rural setting affordable to the average patient?” In a population with a 
per capita expenditure on health of US$ 18 and a Gross Domestic Product (GDP) of 
US$ 243 (WHO 2005b:[1]), an average out-of-pocket payment per death of US$ 11.3 
represents a very high proportion of the per capita annual expenditure on health, and 
probably creates an obstacle that prevents patients who are suffering from severe and 
critical health conditions to access the emergency care that they require in good time. 
191 
When one links the conclusions at the researcher made in section 4.4.5.1 with regard to 
the high mortality rate that prevailed on the first day (24 hours) after admission, one 
may regard the cost of services per death as a confirmatory indicator that most patients 
only accessed hospital services very late in the course of their disease when no further 
options of health care were available to them. At this stage of illness, nearly all patients 
are critically ill and succumb to death in less than 24 hours after admission.  
 
Because of the high prevalence of HIV in the region, patients should be encouraged to 
find out their HIV status as early as possible (certainly long before the symptoms of 
advanced disease have begun to appear), and should also be encouraged to 
commence treatment as early as possible so as to minimise the risk of severe illness 
that is associated with high costs and a high risk of mortality. 
 
Total out-of-pocket payments were a good indicator of cost trends in the delivery of 
health services in the hospital. They are, however, estimates of costs that are based on 
the prevailing market prices of medical goods and supplies at the time, and they are 
unable to provide exact estimates of the actual daily cost of hospital services.  
 
4.4.6.2 Average out-of-pocket payments in terms of gender 
 
In order to understand the differences between out-of-pocket payments in terms of 
gender, the researcher carried out a further analysis on males and females separately. 
The purpose of a separate analysis of out-of-pocket payments made by females and 
males respectively was to determine whether there were any significant differences in 
out-of-pocket payments per death in terms of gender. 
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Table 4.11: The average out-of-pocket payments per death in terms of gender  
 
 Female deaths (n=190, missing-21) 
Male deaths 
(n=305, missing-24) 
Year 
Average out-
of-pocket 
payment per 
death(in 
US$)(±SD*) 
Median 
out-of-
pocket 
payment 
per death 
(in US$) 
Number 
of deaths 
reviewed 
n 
Average out-
of-pocket 
payment per 
death (in 
US$)(± SD) 
Median 
out-of-
pocket 
payment 
per death 
(in US$) 
Number 
of 
deaths 
reviewed 
n 
2002/2003 10.2±6.0 9.4 28 10.2±6.0 9.4 42 
2003/2004 7.4±3.8 7.0 26 10.4±3.8 8.5 48 
2004/2005 7.8±4.5 7.8 33 11.0±4.5 9.4 41 
2005/2006 10.5±5.7 10.5 31 8.8±5.7 10.5 45 
2006/2007 14.6±11.6 10.6 36 11.4±11.6 10.6 58 
2007/2008 12.9±7.6 11.3 36 17.9±7.6 16.9 71 
Average 10.6±6.6 9.4  11.6±6.6 10.9  
 
 
*SD-Standard Deviation 
In the pre-free ART era, the average out-of-pocket payment per death for females was 
US$ 8.5 (the average of US$ 10.2, 7.4 and 7.8) compared to US$ 12.7(the average of 
US$ 10.5, 14.6 and 12.9) in the post-free ART era. For males, the average out-of-
pocket payment during the pre-free ART era was US$ 10.5 (the average of US$ 10.2, 
10.4 and 11.0) compared to the US$ 12.7(the average of US$ 8.8, 11.4 and 17.9) in the 
post-free ART era. This represented a 49.4% (US$ 4.2) and 21% (US$ 2.2) increase in 
out-of-pocket payments in the post-free ART era compared to the payments made by 
both the females and males respectively in the pre-free ART era Table 4.11 shows that 
the average out-of-pocket payments for males and females in the three-year, post-free 
ART era out-of-pocket payments were equal at US$ 12.7 per death event.  
 
There was therefore no difference in the post-free ART era in the out-of-pocket 
payments in terms of gender. On average, the cost of death for each patient (male or 
female) was US$ 12.7 in the post-free ART era. 
 
4.4.6.3 Average out-of-pocket payments for HIV-related and non HIV-related 
deaths  
 
HIV/AIDS and malaria were the most prevalent causes of death in the hospital (this is 
also described in section 4.5.3.1). Since this study focused on the effect of how access 
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to ART influenced mortality trends, the researcher undertook a further analysis of the 
out-of-pocket payments for HIV- and non-HIV-related deaths. He therefore analysed all 
out-of-pocket payments that were connected with all deaths after he had categorized 
them into HIV-related and non-HIV-related deaths.  
 
Table 4.12: Out-of-pocket payments for HIV-related and Non HIV-related deaths 
  
 HIV-related deaths (n=185, missing 14) 
Non HIV-related 
(n=277, missing 23) 
 
Average out-
of-pocket 
payment for 
HIV-related 
deaths 
(±SD) 
Exponentially 
Smoothed 
average out-of-
pocket payment 
for HIV-related 
deaths 
Number 
of  
deaths 
reviewed 
Average Out-
of-pocket 
payment 
for non HIV-
related 
deaths (±SD) 
Exponentially 
Smoothed 
average out-of-
pocket payment 
for non HIV-
related deaths 
Number 
of  
deaths 
reviewed 
2002/2003 9.5(3.9) - 22 12(8.8) - 32 
2003/2004 9.1(4.5) 9.5 24 9.7(11.8) 12.0 48 
2004/2005 10.7(5.9) 9.4 26 9.3(6.9) 11.5 41 
2005/2006 10.7(5.1) 9.7 24 9.1(5.5) 11.1 46 
2006/2007 11.4(5.4) 9.9 44 14(10.8) 10.7 49 
2007/2008 15.5(11.5) 10.2 45 17.1(13.4) 11.4 61 
Average 11.1(6)   11.9(9.5)   
 
In the six year period, the average out-of-pocket payment for HIV-related deaths was 
US$ 11.1 in comparison to the US$ 11.9 average out-of-pocket payments that patients 
had to make for non-HIV-related deaths.  
 
4.4.6.4 Average out-of-pocket payment trends  
 
By making use of the exponential smoothing technique with a dumping factor of 0.8 to 
minimize the effect of seasonality on average out-of-pocket payments, the researcher 
analysed trends and projections until June 2011. These are set out in figure 4.7 (below). 
The dumping factor of 0.8 ensured that the most recent trends that influence current 
post-free ART era trends were more heavily weighted in the determination of future 
trends. 
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Figure 4.7: Average out-of-pocket payments for hospital deaths (2002-2011) 
 
Figure 4.7 shows the average out-of-pocket payments and the projected costs as they 
will be in June 2011. These findings showed that, throughout the six-year study period 
(2002-2008), the average out-of-pocket payments for non-HIV-related deaths were 
higher than the average out-of-pocket payments for HIV-related deaths. But since the 
differences in average out-of-pocket payments were narrowing, the researcher 
projected that by the end of 2009/2010, the average cost for both HIV-related and non-
HIV-related deaths would intercept (or equalise) at an estimated US$ 10.5 per death. 
The research also projected that, by June 2011, the average cost for HIV-related deaths 
would exceed the cost of non-HIV-related deaths.  
 
Non HIV-related out-of-pocket payments were declining at an estimated rate of US$ 0.2 
per annum (y = -0.2x + 12.2) from the US$ 12 that they cost per death in 2002/2003, 
and they are projected to decline to US$ 10.4 by June 2011. On the contrary, out-of-
pocket payments for HIV-related deaths have increased at a rate of US$ 0.2 per annum 
(y = 0.2x + 9.0) from US$ 9.2, and are projected by the researcher to increase to US$ 
10.8 by June 2011.  
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The trends show that HIV-related costs are revealing a rising trend while non-HIV-
related out-of-pocket payments are exhibiting a declining trend. The researcher projects 
that the average out-of-pocket payment for HIV-related illnesses will reach US$ 10.8 per 
death in June 2011 in Uganda. 
 
4.4.6.5 The daily out-of-pocket payments for hospital services 
 
After he had analysed the average out-of-pocket payments made by patients, he also 
proceeded to analyse the daily out-of-pocket payments that patients made. Flessa 
(1998:404) reported an average daily fee per inpatient in a Tanzanian hospital at US$ 
1.5, with an average cost of health service delivery being kept within the sustainable 
limits of US$ 6.4 per inpatient day. It is the cost of health services that determine 
whether or not patients can obtain timely access to available health services, and it is 
late access to such services that is associated with the extremely high morbidity and 
mortality rates that characterise the first 24 hours after admission to hospital (Yisa et al. 
2004:53). It is because of the high cost of health services, that patients only consider 
the hospital as a completely last resort for care and treatment, and will exhaust all other 
options for health care (including traditional medicine and the services of herbalists and 
private clinics) before they can present themselves at the hospital.  
 
Table 4.13: Daily out-of-pocket payment per death (2002-2008) 
 
 Average daily 
out-of-pocket 
payment in US$ 
(±SD) 
Median daily out-
of-pocket 
payment in US$  
Range (Minimum-
Maximum) daily out-of-
pocket payment in US$  
Number of 
deaths 
reviewed 
2002/2003 3.1±2.6 2.5 0.1-14.9 60 
2003/2004 3.0±2.5 2.3 0.3-16.0 65 
2004/2005 4.1±4.9 2.9 0.2-27.8 56 
2005/2006 3.5±2.5 2.8 0.2-10.5 58 
2006/2007 4.0±4.1 2.7 0.4-29.7 79 
2007/2008 6.0±7.7 3.5 0.1-54.1 85 
Average  3.9±4.0 2.8 0.2-25.5 403 
(n=403, missing 141) 
 
The average daily out-of-pocket payments that patients made increased from US$ 3 in 
2003/2004 to their most recent high point of US$ 6 in 2007/2008. Although the median 
daily out-of-pocket payments made by patients as a measure of central tendency was 
less sensitive to outlier values, these payments increased by 40% (US$ 1) from US$ 2.5 
to US$ 3.5 over a six-year period. In order to analyse these trends, the researcher 
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exponentially smoothed the average daily out-of-pocket payments with a dumping factor 
of 0.8, and the findings are presented in figure 4.8 below.  
 
 
 
Figure 4.8: The trend of average daily out-of-pocket payments (2002-2011) 
 
The data presented in figure 4.8 show a slow increase in the daily out-of-pocket 
payments that patients made. With 2002/2003 as the index year, these daily out-of-
pocket payments increased by US$ 0.1 annually (y = 0.1x + 2.9). The researcher 
therefore projected that, by June 2011, the daily out-of-pocket payments would be US$ 
3.7 per death.  
 
The median daily out-of-pocket payment of US$ 3.5 (in 2007/2008) was therefore twice 
the earlier reported out-of-pocket payments for inpatients in a similar setting in Tanzania 
even though it was below the average cost of a sustainable service delivery. 
 
  
y = 0.0971x + 2.8623
R² = 0.9117
0
2
4
6
8
2002/2003 2003/2004 2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011
D
ai
ly
 o
ut
-o
f-p
oc
ke
t p
ay
m
en
t i
n 
U
S 
do
lla
rs
Year 
The trend of average daily out-of-pocket payments, 2002-2011. (n=403)
Average daily out-of-pocket payment in US$ 
Exponentially smoothed Average daily out-of-pocket payment in US$ (dumping factor=0.8)
Linear (Exponentially smoothed Average daily out-of-pocket payment in US$ (dumping factor=0.8))
197 
Table 4.14: The daily out-of-pocket payments per death in terms of gender 
 
 Female deaths 
(n=161, missing-50) 
Male deaths  
(n=239, missing-90) 
 Average daily 
out-of-pocket 
payment in 
US$ (±SD) 
Median 
daily out-
of-pocket 
payment in 
US$ 
Number  
of  
deaths 
reviewed 
Average daily 
out-of-pocket 
payment in 
US$ (±SD) 
Median 
daily out-
of-pocket 
payment 
in US$ 
Number  
of  
deaths 
reviewed 
2002/2003 2.8±2.0 2.4 27 3.3±3.0 2.5 32 
2003/2004 2.9±2.2 2.4 22 3.0±2.6 2.3 43 
2004/2005 3.6±3.8 1.9 25 4.5±5.6 3.1 31 
2005/2006 3.6±2.2 3.3 25 3.4±2.7 2.6 33 
2006/2007 4.0±3.4 3.2 33 4.0±4.6 2.7 45 
2007/2008 4.4±3.7 3.2 29 6.8±9.2 3.8 55 
Average  3.5±2.9 2.7 
 
4.2±4.6 2.8 
  
 
Because the median is a more reliable measure of variables with wide dispersion, the 
researcher used the median daily out-of-pocket payment in order to carry out an 
analysis of changes in out-of-pocket payments. For females, the out-of-pocket 
payments increased by 33.3% from US$ 2.4 (2002/2003) to US$ 3.2 (2007/2008). 
Among males, comparable out-of-pocket payments increased by 52.0% from US$ 2.5 
(2002/2003) to US$ 3.8 (2007/2008). Although table 4.14 indicates that the daily out-of-
pocket payments for both males and females increased during these periods, the 
increase in daily out-of-pocket payments for males was higher than that for females. 
These findings indicated that male admissions and deaths were significant cost drivers 
in overall out-of-pocket payments.  
 
Despite free access to ART in this high HIV prevalence setting, the average direct out-
of-pocket payment on the part of patients for health care increased by 33.3% to 52.0% 
over a six-year period. Such a dramatic increase in out-of-pocket payments in a private-
not-for-profit hospital makes it evident that the cost of service delivery per mortality to 
the hospital and to the patients during the period under consideration increased sharply 
and revealed a rising trend.  
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4.4.7 The associations between length of stay, out-of-pocket payments and HIV  
 
Apart from the out-of-pocket payments the researcher evaluated in this study, the cost 
of services and problems connected with the fixing of out-of-pocket payments were 
beyond the scope of this study. Other aspects including the maintenance of a reliable 
and constant supply of sufficient ARV medicines to the hospital and various other 
barriers that prevented effective access to ART, were also beyond the scope of this 
study. But in this section, the researcher summarises the findings of the relationship 
between HIV-related mortality and patient length of stay in hospital before death, and 
correlates these factors with an increase in ART coverage in Mawokota South Health 
sub-District.  
 
4.4.7.1 Average length of stay and post-free ART era out-of-pocket payments  
 
Any illness that results in death is considered serious. However, in order to facilitate the 
discussion on the association between the degree of severity of illness before death and 
the out-of-pocket payments, the researcher categorised deaths objectively by using the 
average number of days the patient spent in the hospital after admission before death, 
and categorised deaths by degree of severity at the time of admission. The number of 
days before death was thus an indicator of the diagnosed or undiagnosed degree of 
severity of the illness on admission.  
 
Deaths that occurred in less than one day of admission were considered to be ‘very 
serious (critical) illnesses’ by the time of admission. Deaths that occurred in two to three 
days of admission were considered to be ‘moderately serious illnesses’ on admission, 
while deaths that occurred after three days of admission were considered to be ‘mild but 
serious illnesses” on admission that lead to death. Deaths were therefore categorised 
into: (a) deaths that occurred within three days of admission or less, and (b) deaths that 
occurred after three days of admission. In this study, analysis of 404 deaths showed 
that the average daily out-of-pocket payment was US$ 4 per patient. By using the 
average daily out-of-pocket payment of US$ 4 per death, the researcher categorised 
out-of-pocket payments into the following two categories: (a) death events for which a 
patient paid US$ 4 or less, and (b) death events for which the patient paid more than 
US$ 4 (above average) as an out-of-pocket payment per day. The cut-off point of US$ 4 
per day of admission or less as the amount of money that is expended on direct health 
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care in the hospital was considered to be average, while an amount of more than US$ 4 
per day of admission was considered to be above average.  
 
Table 4.15: Average length of stay in hospital and out-of-pocket payments  
 
 Daily out-of-pocket payment in 
US$ 
 
Number of 
admission  
days 
Equal to or 
 less than  
US$ 4 n (%) 
More than 
US$ 4 
n (%) 
TOTAL 
number of 
deaths n (%) 
≤3 days of 
admission 
102(49.3) 
(36.7) 
105(50.7) 
(91.3) 
207 
(52.7) 
>3 days of 
admission 
176(94.6) 
(63.3) 
10(5.4) 
(8.7) 
186 
(47.3) 
TOTAL 278(70.7) 115(29.3) 393 
(n=393, missing-151)  
 
The researcher detected a statistically significant association between the number of 
admission days that patients spent in the hospital and the out-of-pocket payments that 
the patient made (χ²=97.2, p=<0.0001), in a context in which 91.3% (n=115) of all 
patients who paid out-of-pocket payments of more than US$ 4 died within three days of 
admission.  
 
There was therefore a higher probability that patients who died within three days of 
admission to the hospital would pay more than US$ 4 in out-of-pocket payments 
compared to those who remained in hospital for more than three days after they had 
been admitted (OR=0.06, 95% CI[0.03-0.11]). This finding once again confirmed the 
severity of the illnesses and conditions with which patients presented that resulted in 
death within three days of admission to the hospital. This may have been caused by the 
fact that the management and care of patients who were admitted with serious illnesses 
and conditions that resulted in death in fewer than three days after admission, required 
more expensive investigations as well as more medications and treatments.  
 
4.4.7.2 Association between HIV mortality and out-of-pocket payments  
 
The research analysed the relationship between HIV-related mortality and the out-of-
pocket payments that patients made for the care that they received in the hospital. 
Since HIV/AIDS-related deaths are a major cost driver in the hospital, this analysis 
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offered some insight into what was the cost of HIV-related mortality is in relationship to 
the cost of non-HIV-related mortality.  
 
Table 4.16:  The association between deaths and daily out-of-pocket payments  
 
 Average daily out-of-pocket 
payment (US $) 
 
HIV-related 
deaths 
Less than 
US$ 4 
n (%) 
More than 
US$ 4 
n (%) 
Total 
n (%) 
Yes 115(72.8) (44.2) 
43(27.2) 
(38.1) 
158 
(42.4) 
No 
(Other deaths) 
145(67.4) 
(55.8) 
70(32.6) 
(61.9) 
215 
(57.6) 
Total 260(69.7) 113(30.3) 373 
(n=373, missing-171) 
 
In table 4.16, 72.8% (n=158) of the patients who died from HIV-related causes paid less 
than US$ 4 per day compared to the 67.4% (n=215) of patients who died from non-HIV-
related causes. But this difference was not statistically significant (χ²=0.99; p=0.32; 
OR=1.29 [0.82-2.03]).  
 
The odds of a patient having to pay US$ 4 or less as an out-of-pocket payment were 
similar for those who died from both HIV-related and non-HIV-related causes. Thus the 
HIV status of the patient did not in fact increase or reduce the risk of having to pay more 
or less than US$ 4 as an out-of-pocket payment per admission day in hospital before 
death intervened.  
 
4.5  THE EFFECT OF ANTIRETROVIRAL TREATMENT ON MORTALITY  
 
Since HIV/AIDS exerts a significant and fundamental socio-economic impact on all 
communities in which it is highly prevalent. The health systems and the overall 
development patterns in countries experience an enormous effect due to HIV/AIDS. The 
fundamentally destructive impact of HIV on morbidity and mortality trends cannot be 
sufficiently overemphasized. In East and Central Africa, rates of adult mortality 
substantially increased because of the high prevalence of HIV. This in itself indicates 
that mortality trends in the region have been fundamentally driven by patterns of HIV 
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prevalence (McMichael et al. 2004:1156). Since one third of all adult deaths in Uganda 
were HIV-related by 2005, HIV/AIDS was already the leading cause death at that time 
(Hladika et al. 2008:509).  
 
In this section, the researcher examines hospital morbidity and mortality trends, and 
presents and discusses the results that he obtained below.  
 
4.5.1 Antiretroviral therapy and the risk of disease progression  
 
Since the way in which HIV infection progresses to an advanced stage of morbidity 
(AIDS) as a determinant of mortality was beyond the scope of this study, references to 
this factor were included in the literature review but have not been included in this 
section of the overall analysis.  
 
4.5.2 Hospital morbidity and mortality trends  
 
Since antiretroviral medicines forestall the multiplication of the HIV and reduce the risk 
of disease progression, they serve to reduce HIV-related morbidity and mortality. 
Studies have reported that the reasons for admission to the hospital have changed over 
the years, with opportunistic infections now cited as the reason for proportionately fewer 
admissions. In this study, the researcher evaluated morbidity patterns by means of an 
analysis of adult admission trends.  
 
Hospital morbidity and mortality trends exert a significant impact on the workload that a 
hospital has to sustain and the cost of service delivery. Since the overall goal of free 
access to ART was to reduce the incidence of morbidity and mortality trends among 
HIV-affected patients, the researcher compiled data about admission and mortality 
trends and analysed these in an attempt to answer various questions. Because of the 
seasonal variations in admissions and mortality, the researcher was able to project 
overall trends and make future projections by using the technique of exponential 
smoothing with a dumping factor of 0.95. This approach ensured that the most recent 
admission and mortality data that was influenced by the effects of ART coverage and 
other more recent socio-economic factors were more heavily weighted than older data 
and this provided a basis for more realistic and accurate future projections.  
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This study did not concern itself primarily with the mortality rates of HIV patients or 
patients who were participating in ART programmes. It was rather concerned with an 
overall examination of the morbidity and mortality trends in the pre-free and post-free 
ART eras in terms of the number of admissions, the causes of death, the number of 
deaths that occurred, and the hospital’s overall mortality rate. There for mortality 
patterns among patients accessing free ART were not the focus of this discussion. 
 
4.5.2.1 Adult admission trends in Mawokota South health sub-district  
 
 
 
Figure 4.9: Adult hospital admissions per month in Mawokota South (2002-2011) 
 
The researcher’s review of the monthly admission trends of 5 575 adult patients over a 
72-month (six year) period showed that adult admissions in the hospital decreased by 
16.7% from an average of 90 admissions per month in July 2002 to 75 admissions per 
month in June 2008. He also projected that hospital admissions would drop to 65 
admissions per month by June 2011. By June 2011, mortality trends will have been 
reduced by 27.8% of the 2002/2003 monthly adult admission average. 
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Similar findings by other researchers (Beck et al. 1999:2160; Carter 2005:[1]; Kumar et 
al. 2000:[1]; Smart 2008:[1]) have indicated that free ART access has contributed the 
16.7% reduction in adult monthly hospital admissions. The researcher also projected 
that, in the near future (subject to similar conditions in hospitals and in the population) 
the number of adult admissions was on a declining trend. The projections about hospital 
admission rates should however, be taken with a pinch of salt because this trend may 
be masked by other factors that influence access to hospital services for example out-
of-pocket payments that were analysed in the earlier part of this study or by factors that 
are beyond the scope of this study.  
 
4.5.2.2 Adult mortality trends in Mawokota South health sub-district  
 
After the analysis of adult admission trends that were available from the hospital's 
records, the researcher also analysed the trends observed in the number of adult 
deaths per month. He applied an exponentially smoothed trend with a dumping factor of 
0.95 signifying the importance of the recent increased access ART as a key determinant 
of current and future mortality patterns and presented the results below in figure 4.10 
(below).  
 
 
 
Figure 4.10: Adult hospital deaths per month in Mawokota South (2002-2011) 
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Four hundred and ninety seven (497) deaths were reviewed by the researcher. Figure 
4.10 shows that adult deaths increased by 133.3% from an average of three deaths per 
month in July 2002 to seven deaths per month in June 2008. This rate of mortality was 
projected to continue to increase, and by June 2011, the researcher expected the 
hospital mortality rate to increase to ten deaths per month. This increase in mortality 
rates from three deaths per month in 2002/2003 to a projected ten deaths per month in 
June 2011 will represent a 233.3% increase in the monthly average of hospital deaths.  
 
This increasing number of hospital deaths that are occurring in a rural hospital setting in 
Uganda run contrary to the findings in other studies that have reported a reduction in 
HIV/AIDS mortality and overall mortality rates as ever greater numbers of the population 
gain access to ART (Carter 2005:[2]; Gomez et al2004:[1], Jahn et al. 2008:1607; 
Thaczuk & Differding 2008:[2]; United Nations 2008:28).  
 
In the post-free ART era, the number of adult hospital deaths per month increased and 
was projected by the researcher to reach on average of ten deaths per month in June 
2011. What is evident from the data is that free access to ART in Mawokota South 
health sub-district over a three-year period did not reduce hospital mortality rates (i.e. 
the number of patient deaths that occur each month).  
 
This rising mortality trend together with reductions in the morbidity trends could be 
ascribed to the initial positive impact that ART makes on morbidity trends and minimal 
impact that it makes on mortality trends. This increase in mortality trends could also be 
ascribed to the limited targeting of interventions and the limited access to ART to 
PLWHA with the highest risk of mortality due to HIV related illness (high risk groups). 
 
4.5.2.3 Mortality trends in Nkozi sub-county in Mawokota South Country  
 
Despite the increase in the rates of hospital mortality during the period under study, 
figure 4.3 indicates that Nkozi sub-county showed an 8.7% (n=183) reduction in hospital 
deaths. This is a finding that requires a further analysis of the mortality trends in this 
sub-county.  
 
205 
 
 
Figure 4.11: Number of adult hospital deaths from Nkozi sub-county (2002-2011) 
 
Figure 4.11 shows that the number of hospital deaths in the sub-county in which the 
hospital under study was located (a sub-county which ART was introduced in June 
2005) showed a downward trend. Despite the overall increase in hospital mortality from 
three deaths per month to seven deaths per month (see figure 4.10), the number of 
deaths that occurred in the Nkozi sub-county showed a decline from 2.4 deaths per 
month (in July 2002) to 2.2 deaths per month in (in June 2008), and the researcher 
projects that this rate will be reduced to 2.1 deaths per month in June 2011. Although 
this is a marginal decline in the monthly mortality in from Nkozi sub-county, this 
marginal decline is significant and worth monitoring in the context of the increasing 
overall mortality rate. 
 
It seems that this decline in number of hospital deaths from Nkozi sub-county indicates 
one of the initial effects of increased access to free ART in the sub-county and its effect 
on the overall hospital mortality trends. All the other factors that might have determined 
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this reduction in the rate of hospital deaths for Nkozi residents were beyond the scope 
of this study.  
 
4.5.2.4 Association between length of stay and HIV-related mortality  
 
The researcher investigated the association between the average length of hospital stay 
in the pre-free and post-free ART eras and making use of the median length of hospital 
stay. The patient deaths were categorized according to the average length of stay that 
the patient had spent in hospital – whether a period of three admission days and less or 
a period of more than three admission days.  
 
As highlighted earlier, the number of admission days before death was indicative of the 
severity of illness presented with on admission. Deaths that occurred within three days 
of admission were considered to be the most serious and critical illness. This analysis 
enabled the researcher to determine whether there had been a difference in the severity 
of illness patients presented with on admission, indicated by proportion of deaths that 
occurred within less than three days of admission days in both the pre-free and post-
free ART eras.  
 
Table 4.17: The association between length of hospital stay and treatment era 
 
 Length of hospital stay 
before death 
 
Treatment 
Era 
≤3 days of 
admission 
n(%) 
>3 days of 
admission 
n(%) 
TOTAL 
number of 
deaths  
n(%) 
Post-free 
ART 
154(57.9) 
(53.1) 
112(42.1) 
(56.0) 
266 
(54.3) 
Pre-free 
ART 
136(60.7) 
(46.9) 
88(39.3) 
(44.0) 
224 
(45.7) 
TOTAL 290(59.2) 200(40.8) 490 
(n=490, missing 54) 
 
The results of the analysis of 490 pre-free and post-free ART deaths showed that, in the 
post-free ART era, 57.9% (n=266) of the patients died within three days of admission 
compared to the 60.7% (n=224) of patients who died within the same period in the pre-
free ART era. This difference was not statistically significant (OR=0.89, 95% CI [0.62-
1.28]; χ²=0.3; p=0.59) since the risk of death intervening within three days of admission 
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was similar for patients who admitted in both the pre-free and post-free ART eras, 
therefore one can conclude that free ART access among other factors had not 
significantly affected the severity of illness which patients presented on admission. 
Therefore, using number of days of admissions before death as an indicator of the 
severity of illness patients presented with, patients continue to present with serious 
illness with no significant difference in this before between the pre-free and post-free 
ART eras.   
 
If one therefore compares the mortality rate of patients who were admitted in the post-
free ART with that of patients who admitted in the pre-free ART era, no change was 
detectable in the proportion of patients who were admitted with serious or critical 
illnesses and conditions that resulted in their death within three days of admission. 
Since most of the patients were accessing health care with advanced symptoms of 
disease, a significant proportion (59.2%, n=490) of all deaths among such patients 
occurred within three days of admission to the hospital.  
 
With a significant proportion of patients presenting with serious and critical illness, it is 
evident that there is minimal possibility of reducing mortality patterns. With this scenario, 
hospital mortality rates can only stagnate or increase. This confirms the findings of 
increasing hospital mortality rates, despite increased access to free ART.   
 
Table 4.18: Association between HIV related mortality and hospital stay for 
females  
 
  
Length of Hospital stay before death 
 
HIV related death 
Equal to or less 
than 3 days of 
admission 
n (%) 
More than 3 days 
of admission after  
n (%) 
TOTAL 
number of 
deaths  
n (%) 
Yes 37(47.4) (37.4) 
41(52.6) 
(49.4) 
78 
(42.9) 
No 
 
62(59.6) 
(62.6) 
42(40.4) 
(50.6) 
104 
(57.1) 
TOTAL 99(54.4) 83(45.6) 182 
  (n=182, missing-29) 
 
Table 4.18 above shows that 37.4% (n=99) of all the female deaths that occurred within 
three days of admission were due to HIV-related causes in comparison to the 49.4% 
(n=83) of deaths that occurred within more than three days of admission. The difference 
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in the likelihood (risk) of HIV-related deaths for females within less than three days of 
admission and in more than three days of admission was not statistically significant 
(χ²=2.20; p=0.14; OR=0.61, 95% CI[0.33-1.13]). However, the relative risk of HIV-
related death within less than three days after admission was less by 20.4% (95% CI[-
4.6%-40.1%]) when compared to the number of deaths that occurred within more than 
three days after admission.  
 
Female HIV-related and non-HIV-related deaths were therefore equally likely to be 
admitted with severe or critical illnesses and conditions that resulted in their death within 
less than three days after admission to the hospital.  
 
Table 4.19: Association between HIV-related mortality and hospital stay for 
males 
 
  
Length of hospital stay before death 
 
HIV-related death 
≤3 days of 
admission 
n (%) 
>3 days of 
admission 
n (%) 
TOTAL 
n (%) 
Yes 50(50.0) (31.6) 
50(50.0) 
(46.7) 
100 
(37.7) 
No 
 
108(65.5) 
(68.4) 
57(34.5) 
(53.3) 
165 
(62.3) 
TOTAL 158(59.6) 107(40.4) 265 
 (n=265, missing-64) 
 
Table 4.19 shows that 50% (n=100) of male HIV-related deaths occurred within three 
days of admission compared to 65.5% (n=165) of non-HIV-related deaths. This 
difference was statistically significant (χ²=5.55; p=0.02). Therefore, the odds that a male 
patient would die from IV-related death occurred within three days of admission were 
0.53 (95% CI [0.32-0.88]). Male HIV-related deaths were less likely to occur within three 
days of admission to the hospital. 
 
Therefore, compared to females, male HIV-related deaths occurred in more than three 
days of admission. Female HIV-related and non HIV-related had equal likelihood of 
occurring in less than three days and after three days of admission.  
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4.5.3 The effect of antiretroviral therapy on mortality tends  
 
Since ART became increasingly available to the Ugandan population, the reasons why 
people are hospitalised and the causes of death among HIV-positive patients are 
changing and therefore need to be carefully monitored. In Uganda, HIV/AIDS has 
significantly affected morbidity and mortality trends and remains the major single most 
urgent challenge to the delivery of health services. In 2003 to 2004, it was estimated 
that HIV/AIDS caused 25% of all deaths among people of all ages in Uganda (WHO 
2004a:2).  
 
This section summarised the causes of mortality in the pre-free ART era and compared 
those causes with the causes of mortality in the post-free ART era. In this section, the 
researcher also analysed and discussed the impact of ART on the overall (“all causes") 
reasons for death since the introduction of free ARVs. 
 
4.5.3.1 The effect of antiretroviral therapy on the causes of mortality  
 
The determination of the causes of death was a key focus of this study. By making use 
of the diagnoses in the patients’ hospital records, the researcher was able to compile a 
list of all the causes of death listed in the pre-free ART era and in the post-free ART era 
for the time period covered by this study. This section focuses on the frequency 
distribution of the causes of death (since each patient could have died from more than 
one cause of death). As a result of this investigation, the researcher discovered that the 
average number of causes of death for each patient who died was 1.7 in the pre-free 
ART era and 1.6 in the post-free ART era.  
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Table 4.20: Causes of death in the pre-free and post-free ART eras (2002-2008) 
 
 
Pre-free ART 
causes of 
death 
n (%) 
Post-free ART  
causes of 
death 
n (%) 
Percentage 
of causes  
of death 
n (%) 
Percentage 
change in the 
post-free ART 
era (%) 
Tuberculosis  37(12.8) 29(6.6) 66(9) -6.2 
Cardiovascular causes 26(9) ‡ 22(5) 48(6.6) -4.0 
Meningitis  16(5.5) 13(2.9) 29(4) -2.6 
Respiratory causes (RTI† 34(11.7) ) 39(8.8) 73(10) -2.9 
Malignancies  6(2.1) 3(0.7) 9(1.2) -1.4 
Anaemia  11(3.8) 20(4.5) 31(4.2) 0.7 
Other Causes 15(5.2) 28(6.3) 43(5.9) 1.1 
Other GIT* 6(2.1)  conditions 13(2.9) 19(2.6) 0.8 
Diabetes mellitus  2(0.7) 6(1.4) 8(1.1) 0.7 
Renal conditions  1(0.3) 8(1.8) 9(1.2) 1.5 
Gastro enteritis  8(2.7) 25(5.6) 33(4.5) 2.9 
HIV/AIDS  80(27.6) 119(26.9) 199(27.1) -0.7 
Malaria  48(16.5) 118(26.6) 166(22.6) 10.1 
Total  290 443 733  
(n=733) 
 
‡ While cardiovascular causes included cerebral vascular accident, hypertension 
and heart failure, but excluded anaemia. 
†  RTI – Respiratory tract infections. 
* 
 
GIT – Gastro intestinal tract. Other GIT conditions included peptic ulcer disease 
and intestinal obstruction. 
Table 4.20 indicates that HIV/AIDS was the most prevalent cause or associated cause 
of death and that it was responsible for 27.1% (n=733) of all the deaths in the hospital. 
The second most common cause of death was malaria, which was responsible for 
22.6% (n=733) of all deaths. The third most common cause of death was respiratory 
tract infections (RTI) 10% (n=733), while tuberculosis (TB) was responsible for 9% 
(n=733) of all hospital deaths in the period covered by this study.  
 
The number of deaths that were caused by TB in the hospital was very similar to the 
number of deaths that were caused by TB in a study in Zambia, which reported that TB 
caused 7% of all the deaths that were investigated in that study (Kelly et al. 1998:883). 
With regard to HIV/AIDS as a cause of mortality, the findings in this study reported 
similar findings to the WHO report of HIV contributing to 25% of all deaths in Uganda 
(WHO 2004a:2).  But in two previous studies that were conducted in Northern Uganda, 
the researchers had showed that HIV/AIDS-related factors had been determined as the 
cause of death among 11.5% and 20.2% of the deaths (Accorsi, Fabiani, Lukwiya, 
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Onek, Di Mattei & Declich for the Italian-Ugandan AIDS cooperation program 2001:157; 
Fabiani, Accorsi, Aleni, Rizzardini, Nattabi, Gabrielli, Opira & Declich for the Italian-
Ugandan AIDS cooperation program 2003:65). 
 
In the Lacor study, TB had been the cause of death for 17.2% of the sample (compared 
to 9% in this study), respiratory tract infections had been the cause of death for 11.8% 
of the sample (as opposed to 10% in this study), and gastro-enteritis had been the 
cause of death for 4.4% of the sample (as opposed to the cause of death for 2.9% in 
this study) (Fabiani et al. 2003:65). There were differences in the findings about the 
extent to which malaria was a cause of death. The Lacor study reported malaria as a 
cause of death in only 2.2% of the sample (as opposed to the 22.6% who identified as 
having died from malaria in this study). Malaria and lower respiratory tract infections 
contribute 11% each to the overall mortality rate (WHO 2004a:2).  
 
The key limitation of this study was incomplete and sometimes fragmentary state of the 
mortality records that were available to the researcher for analysis. Eight percent (8.3%, 
n=544) of the study population had been assigned no recorded direct or associated 
cause of death. Secondly, while 27.6% (n=544) of the deaths of patients who were at 
risk of HIV because of their age profile, these records had no record on their HIV status.  
 
An analysis of the records show that HIV/AIDS, malaria and RTIs were the most 
widespread causes of death, and that they accounted for 59.7% (n=733) of the deaths 
that occurred in the hospital. A study conducted by the WHO, on the other hand, 
reported a mortality rate due to these three conditions (namely, HIV/AIDS, malaria and 
RTIs) of only 47% of all recorded deaths (WHO 2004a:2; WHO 2006b:2). In this study, 
HIV/AIDS and malaria were reported as being a direct or associated cause of death in 
49.8% (n=733) of the deaths. 
 
Therefore, in this rural hospital setting, the frequency of HIV/AIDS, malaria, respiratory 
tract infections and TB as causes of mortality were comparable in frequencies with the 
causes of death in Uganda reported in other studies. HIV/AIDS was the leading cause 
of death follwed by  malaria. 
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The findings that were set out in table 4.20 are presented in figure 4.12 (below) so that 
changes in the frequency of causes of death are more easily visible. These findings will 
be discussed and analysed below. 
 
 
 
Figure 4.12:  Changes in causes of death in Mawokota South (2002-2008) 
 
The burden of HIV/AIDS in a 1999 hospital sero-survey reported that more than 52.6% 
of the patients in the medical wards in northern Uganda were HIV-positive, and that HIV 
disease was contributing to enormous overcrowding in out-patients departments 
(Fabiani et al. 2003:63-4). Figure 4.12 shows that the frequency of HIV/AIDS as a cause 
of death was reduced by 0.7% (n=199) in the post-free ART era compared to the pre-
free ART era, that malaria as a cause of death increased by 10.1% (n=166), and that 
gastro-enteritis increased by 2.9% (n=33) as a cause of death in the same period. By 
contrast, tuberculosis as a cause of death reduced by 6.2% (n=66) and cardiovascular 
causes and meningitis reduced by 4% (n=48) and 2.6% (n=29) respectively as causes 
of death in the same period.  
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This slight reduction of 0.7% in the prevalence of HIV/AIDS as a cause of death 
requires further study (research) especially in view of the fact that 27.6% (n=544) of the 
deaths in the hospital did not have a confirmed or documented HIV status. The absence 
of any post mortem diagnosis in so many cases is a factor that limits research into 
accurate diagnoses of the cause(s) of death. The initial findings with regard to the 
reduction in HIV/AIDS-related deaths show that this reduction was low and not 
statistically significant (χ²=0.39; p=0.53: see table 4.20), but they are indicative of a 
trend that needs to be carefully monitored and analysed. Since free access to ART had 
only been available in the previous three years, this represented a period that was too 
short for making meaningful measurements about the impact of ART. But more long-
term studies (such as, for example, a 14-year period study), would show that the AIDS-
related causes of death (when compared to non-HIV-related causes of death) had 
decreased by 80% between the post-ART and the pre-ART eras (Crum et al. 2006:195).  
 
The opprotunistic infections that the researcher included in this analyis were TB, gastro-
enteritis and meningitis. During the post-free ART era, there was a 6.2% reduction in 
the incidence of deaths caused by pulmonary tuberculosis, a 2.9% reduction in the 
incidence of deaths caused by meningitis, and an increase of 2.9% in the incidence of 
deaths caused by gastro-enteritis. Another researcher has reported an increase of the 
rate of TB infections in the Mpigi district that he attributed to the influence of HIV/AIDS-
related factors (Miti 2008:[1]). The present study showed that TB as a cause of death 
declined by 6.2% during the period in which the study was undertaken. But this finding 
is at variance with the number of reports that indicate an increase in the number of TB 
cases. This discrepancy may imply challenges that the professional staffs of the hospital 
are having in diagnosing TB as a cause of death. The low and decreasing percentage of 
TB deaths reported by the present study may be associated with various challenges in 
the timely diagnosis of TB, and may also be attributable to a number of TB cases that 
have been missed and reported as RTIs. It is also interesting to note that Thaczuk and 
Differdin
 
g (2008:[2]) reported that deaths attributable to HIV/AIDS and tuberculosis fell 
from 22 and 23 per 1 000 person-years in women and men respectively in 2003/2004 
(pre-ART), to a level of 16 among women and 18 among men in 2005/2006 respectively 
after the introduction of ART. 
The hospital in which the research was conducted did not have a an X-ray machine for 
five out of six years of the study period. Any diagnosis of TB would therefore have to 
214 
depend upon a clinical and laboratory (sputum) evaluation. Because 59.2% (see section 
4.4.5.1) of the patients died within three days of admission to the hospital, it is more 
than probable that, by the time of their death, diagnostic investigations would have been 
incomplete to either confirm or eliminate the presence of TB as a cause of death. It is 
therefore very likely that TB as a cause of death was widely under-diagnosed and 
under-reported.  
 
The results of the present study show that the prevalence of malaria as a cause of 
death increased by 10.1% (n=166) in the post-free ART era. The increase in reported 
deaths caused by malaria my be indicative of of the following two situations that are 
described below: 
 
1. There might well have been an increase in the incidence of malaria as a cause of 
death in the community in the post-free ART era. A synergy between HIV and 
malaria has been reported in various studies. In a study undertaken in the Lacor 
Hospital in Northern Uganda, the prevalence of HIV among malaria in-patients 
was 52.2% in 1999 (Fabiani et al. 2003:65). This implies that there is a very high 
possibility that the increase in mortality due to malaria can be asssociated with 
the high incidence of HIV-related conditions among admitted patients. 
 
2. Because of the limited diagnostic capacity of a hospital during the period of 
study, the reported increase in malaria could be attributed to an absence of any 
confirmable cause of death for the purposes of post-mortem reports. It is 
therefore likely that a number of fever-related causes of death were simply 
diagnosed as deaths caused by malaria, without any further investigation. If this 
were the case, the data in the hospital records would indicate a false increase in 
malaria-related mortality. 
 
Similar findings were reported in the study conducted by Crum et al. (2006:195). They 
found that opportunistic infections such as tuberculosis and meningitis as a causes of 
death were less frequently reported in the post ART era compared to the pre ART era. 
On the other hand, malaria and gastroenteritis were more frequently reported as a 
cause of death in the in the post-free ART era. The implications of these findings 
suggest that the impact of ART on the incidence of opportunistic infections need 
carefully monitoring. None of these figures should be taken at face value and all the 
215 
proximate and peripheral causes of death in these settings need careful and continuous 
evaluation. 
 
This study found that the causes of death in this period of research were frequently 
based on inadequate confirmation of causes of death. Therefore, the mortality trends 
due to conditions such as lymphomas, malignancies and other non-HIV-related causes 
of death are undoubtedly also inadequately reported.  
 
But the key findings of this analysis were that there has been an increase in malaria and 
gastro-enteritis as causes of death and a reduction in tuberculosis and meningitis as 
causes of death in the post-free ART era as compared to the pre-free ART era.  
 
4.5.3.2 Antiretroviral treatment coverage in Mawokota South (2002-2008) 
 
In Mawokota South health sub-district, which was the focus of this study, ART coverage 
was estimated at 60% coverage of 29.2% of PLWHA (see figure 4.14). This extent of 
coverage in Mawokota South health sub-district was higher than the national average 
coverage of ART, which was reported as being 50.2% at the end of 2008 (Ministry of 
Health – Government of Uganda 2009:42). 
 
4.5.3.3 Hospital mortality rates in Mawokota South health sub-district 
 
On the basis of the monthly number of hospital deaths and the number of admissions in 
the hospital, the researcher estimated the monthly mortality rate as the number of 
deaths per 100 admissions. Information was presented by means of a line graph in 
figure 4.13 (below). This section analyses the mortality trends in the Mawokota South 
health sub-district. 
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Figure 4.13: Hospital mortality rates in Mawokota South (2002-2008) 
 
While the researcher’s analysis of 497 hospital deaths showed that the mortality rate by 
month varied significantly from no deaths in October 2002 to 34 deaths per month in 
July 2007, the overall mortality rate showed a rising trend. The researcher calculated 
the monthly mortality rate by using the number of hospital deaths (as the numerator) 
and the number of hospital admissions (as the denominator).  
The resultant trend showed an increase in the hospital’s monthly mortality rate over the 
period of the study.  
 
4.5.3.4 Hospital mortality trends and antiretroviral treatment coverage rates  
 
The researcher estimated the number of PLWHA in need of ART in the health sub-
district from the national estimates of 322 819 people who were in need of ART out of 
an estimated 2005 population in Uganda of 28.7 million (Ministry of Health of the 
government of Uganda 2009:42; United Nations Population Division 2009:[1]). This 
figure represented an estimated 1.1% of the total population of Uganda in need of ART, 
which was extrapolated retrospectively using the annual district population growth rate 
to determine the number of people in need of ART from June 2002 to June 2008. Using 
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the data on the monthly number of patients on ART accessed from ART sites in Nkozi 
Hospital and Buwama Health Centre, the researcher determined the monthly (total) 
number of patients on ART in Mawokota South health sub-district over the 72 months of 
the study period.  
 
Using the total monthly number of people accessing ART per month as a numerator and 
the estimated monthly number of PLWHA in need of ART in Mawokota South as the 
denominator, the researcher determined the monthly trend of ART coverage. The key 
limitation of this analysis of coverage was lack of information on residents in Mawokota 
South accessing ART in other facilities either outside the health sub-district or from 
private facilities within the sub-district. Despite this limitation, the researcher was sure 
that more than 90% (estimated anecdotally) of the PLWHA in the sub-district were 
accessing ART at the public free ART sites. Therefore, the number of patients 
accessing free ART at the two public ART sites was representative of the number of 
people accessing ART in the Mawokota South sub-district.  
 
The researcher therefore calculated the need for ART coverage among the residents of 
the Mawokota South health sub-district population. The ART coverage revealed a steep 
increase from the zero coverage of June 2005 to an estimated 60% (n=1270) coverage 
in June 2008.  
 
 
Figure 4.14: Hospital mortality and ART coverage in Mawokota South (2002-2011) 
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This analysis required the researcher to review the hospital records of 497 adult deaths 
and 5 575 adult admissions over a six-year period. The findings showed that there was 
a steep and rapid increase in ART coverage from 0% in June 2005 to 60% coverage in 
June 2008 in the Mawokota South health sub-district.  
 
These calculations showed that the adult mortality rate increased from three (3) deaths 
per 100 admissions (3%) per month (in June 2002) to 11 deaths per 100 admissions 
(11%) in June 2008, and that the projection is that the adult will increase to 15 deaths 
per 100 admissions (15%) by June 2011.  
 
Dore et al. (2002:391) reported a noteworthy reduction in mortality rates – even with a 
low ART coverage of 11%. In other settings, other researchers have observed that an 
increased access to ART in low-resource settings (with a high prevalence of HIV 
prevalence that is similar to the rate of prevalence that prevails in the health sub-district 
under study), resulted in a 10% decline in the overall mortality rate (Jahn et al. 
2008:1607) and a 22% decline in the overall mortality rate in another study (that took 
place in South Africa) (Thaczuk & Differding 2008:[2]).  
 
In contrast to these findings, the researcher observed that increasing levels of access to 
ART in Mawokota South did not lead to the kind of reductions in hospital mortality that 
were reported in a number of other studies (Carter 2005:[2]; Gomez et al2004:[1]; Jahn 
et al. 2008:1607; Thaczuk & Differding 2008:[2]; United Nations 2008:28). The findings 
of the present study in fact demonstrated an increasing trend in mortality rates in the 
Mawokota South health sub-district.  
 
Thus, despite the ART coverage of 60%, the hospital mortality rates revealed by this 
study showed an increasing trend. During the three years of free access to ART in this 
rural hospital setting, the researcher was unable to confirm any significant reduction in 
overall hospital mortality rates. Similar findings that reflected no change at all in the all-
cause death rates among HIV-infected women and the number of deaths attributed to 
HIV/AIDS-related causes despite a significant expansion in free access to ART in the 
post-free ART era were reported by Smith et al. (2003:679). These findings more 
closely resemble the projected increase in the annual HIV/AIDS global death rate from 
2.8 million (in 2002) to a pessimistic estimation of 6.5 million deaths per annum in 2030 
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(which represents the worst-case scenario) – even with a world-wide ART coverage of 
80% by 2012 (Mathers & Loncar 2006:8). 
 
Possible explanations for this increasing trend in mortality rates in spite of ART 
coverage include the late commencement of antiretroviral therapy by patients in the 
community who present in the terminal stages of AIDS, poor adherence to the required 
ART regimen on the part of PLWHA or due to facility factors. Other factors that may 
contribute to inadequate or no change to the trend in hospital mortality are inadequate 
or ineffectual targeting of HIV-infected people who urgently need ART, an inadequate 
awareness of the ultimate consequences of what it means to be HIV-positive, and a 
general ignorance among the population of how to minimize the risks of death in the 
community – even for people who are already infected with HIV.  
 
The critical delays in commencing with ART could be attributed to the effects of policies 
and guidelines, to a shortage of the necessary medicines, a general lack of awareness 
in the community of the benefits of commencing ART treatment as soon as possible 
after infection, and a reluctance on the part of the general population to have their HIV 
status confirmed by means of diagnostic tests – even on the part of those who may 
have good reasons to believe that they are infected. A combination of all these factors 
lead patients to request for ART when they are really suffering from the advanced and 
acute symptoms that characterise the last stages of AIDS before death intervenes 
(Lawn et al. 2008:1905).  
 
Because of the declining number of hospital admissions that were being recorded in the 
health districts in the study, and increasing mortality rates among the population at large 
in the post-ART era, the researcher held that there was a need for ongoing review and 
analysis of morbidity and mortality indicators. Although the analysis of outpatient 
morbidity patterns was beyond the scope of this study, it is an area that is in urgent 
need of further research and investigation.  
 
In the best-case scenario, the reduction in the number of admissions in the post-free era 
showed that fewer and fewer adults were requiring admission to the hospital, and were 
able instead to be managed as out-patients. This was indicated by the fact that over 
time (i.e. during the six-year period and three years after that), fewer adults patients 
were seriously ill enough to warrant admission to the hospital. In the absence of major 
220 
policy changes in the guidelines that set out the conditions upon which an adult might 
be admitted to the hospital, this pattern was mainly attributed to a reduction in the 
severity of the various forms of morbidity that warranted admission. In high HIV-
prevalence settings, the main causes of admission were malaria and HIV. Although the 
introduction of free access to ART and the consequent reduction in hospital admissions 
was thus partly attributed to an increased access to ART in the hospital, further 
research is needed in order to determine the actual impact of free access to ART on 
morbidity patterns in the district.  
 
In the worst-case scenario, patients with mild or moderate (in terms of the severity of 
the disease) illnesses avoided the hospital, and they only come to the hospital as a very 
last resort after exhausting every other possible resource including the services of 
indigenous traditional healers. By the time these people present themselves at the 
hospital, they are nearly always critically ill and the majority of them die within 24 hours 
of admission or by the third day of admission.  
 
These two scenarios, best and worst-case scenario provide possible explanations for 
the high and increasing hospital mortality rate amidst the declining morbidity patterns 
that are evident from hospital admission rates.   
 
4.5.4 Life expectancy and the age of patients at the time of death  
 
Although this study did not focus on life expectancy trends and HIV-specific mortality 
trends, one of the key findings of the study was the trend in the median age at time of 
patient death.  
 
Studies have reported a five- to twenty-year reduction in life expectancy due to the 
effect of the HIV epidemic (Mathers, Sadana, Salomon, Murray & Lopez 2000:1687; 
McMichael et al. 2004:1156). In South Africa, the life expectancy of black South 
Africans is expected to drop by nine years by 2011 because of the effects of AIDS 
(Benatar et al. 2004:279).HIV/AIDS has therefore exerted a significant impact on the life 
expectancy of populations and has significantly reduced the life expectancy of the 
general population and especially the life expectancy of young adults because 
HIV/AIDS has significantly shifted the median age of people at the time of death and the 
average person’s life expectancy. In high HIV-prevalence settings such as the one 
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reviewed on this study, HIV-related mortality has significantly contributed to premature 
mortality.  
 
Changes in the median age at time of death can be caused by a variety of factors but 
are mainly influenced by mortality patterns in the population as a whole. Notably, the 
age structure of adults (who are defined in Uganda as people who are 15 years and 
above) in the population of Uganda and in the district and sub-districts under study, did 
not change significantly during the period of the study (United Nations – Population 
Division of the Department of Economic and Social Affairs of the United Nations 
2009b:[1-2]). In essence, the major factor on life expectacy in the health sub-district is 
HIV/AIDS. Since the introduction of ART into settings where HIV/AIDS was among the 
top two main causes of death, the expectation has been that this intervention (free ART 
access) would exert an impact on the median age at time of death. The researcher 
therefore used the median age at time of death as an indicator of life expectancy 
patterns in the population after the introduction of free access to ART.  
 
4.5.4.1 The median age at the time of death in Mawokota South (2002-2008)  
 
The trend of the median age of the deceased at the time of death was a critical indicator 
in determining shifting mortality patterns. Analysis of these trends provides a basis for a 
more considered evaluation of the factors inherently associated with mortality. The 
researcher therefore analysed these factors, and they are presented in figure 4.15 
(below).  
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Figure 4.15: Median age at time of death in Mawokota South (2002-2008) 
 
In this analysis, the researcher examined trends of the age of people at time of death by 
making use of the median age at time of death. The median was used as a better basis 
for trend analysis than the mean because the median as a measure of central tendency 
is less sensitive to extreme values or outliers (Tustin 2005a:543). In a period of one 
year, the median age at time of death declined by 3.5 years (8.8%) from 40 years in 
2002/2003 to 36.5 years in 2003/2004. This represented a dramatic reduction in the 
median age at the time of death. Thereafter, the median age at the time of death 
remained constant for two years at 37 years until 2004/2005. Once free access to ART 
had been introduced in 2005/2006, it was observed that the median age at death 
increased progressively by seven years over a three-year period. This represented an 
18.9% increase from 37 years to 44 years by 2007/2008.  
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In the post-free ART era, the median age of death has increased when one compares it 
to the median age of death in the pre-free ART era. This means that adults died at 40 
years of age and above while, in the pre-free ART era, they died at 40 years and below.  
 
On average, patients died prematurely before the national life expectancy of 46.2 years 
(for adults of 15 years of age and older). These findings are similar to the findings 
reported by Crum et al. (2006:195), who reported that the age of patients at time of 
death among HIV-infected people increased from 37 to 40 years after introduction of 
free access to ART. Amidst minimal changes in the age structure of the population 
(United Nations – Population Division of the Department of Economic and Social Affairs 
of the United Nations 2009b:[1-2]), changes in the median age of death in the 
Mawokota South health sub-district were therefore largely due to changes in mortality 
trends which are significantly influenced by HIV/AIDS.  
 
The determination of the median age at death therefore resulted in an indication of 
premature mortality trends in the health sub-district. The researcher also correlated the 
median age at death with the efficacy of treatment interventions, including the 
promptness and correctness of diagnosis and the management of illnesses (Jannerfeldt 
& Hörte 1988:680). An increasing median age at time of death is therefore an indirect 
indication of improved health and longevity of the population in the Mawokota South 
health sub-district – an assertion that needs to be substantiated by means of further 
research. Although the association between the ages of various groups of patients on 
ART at time of their death was beyond the scope of this study, it is a topic that will 
benefit from future research.  
 
The key finding of this analysis was that free access to ART has contributed to the 
overall increase in median age of hospital deaths. Hospital deaths have been occurring 
at an older age in the post-free ART era in comparison to the ages at which they 
occurred in the pre-free ART era. It may therefore be asserted that the introduction of 
ART has contributed to people dying at an older age or as enabled them to live longer in 
the community that was the locus for this study.  
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4.5.5 Scenarios of expected mortality trends in the post-free ART era 
 
From the possible scenarios that the researcher suggested in section 2.13, three 
mortality and morbidity scenarios have been selected to serve as benchmarks for 
assessing hospital mortality trends. The three scenarios concerned are: 
 
1. a reduction in mortality trends 
2. static or unvarying mortality trends 
3. increasing mortality trends 
 
4.5.5.1 Mortality trends based on the three scenarios of expected mortality  
 
The introduction of ART has resulted in a profound overall decline in HIV-associated 
morbidity and mortality (Kessler 2003:S101). The impact of the increase in free access 
to ART in high HIV-prevalence settings (even when there is low coverage) was 
conclusively shown by the increases in the patient survival rate and reductions in the 
overall mortality rates. It is therefore imperative that increased access to ART in high 
HIV prevalence settings be directly related to a reduction in overall mortality if ART 
provision is to be considered a success. That was why this study focused on what the 
overall effect of increased access to ART might be on mortality rates in a rural setting in 
Uganda. 
 
4.5.5.2 Morbidity and mortality trends in the pre-free and post-free ART eras 
 
The findings of this study showed that this rural setting experienced a decreasing trend 
of adult admissions and an increasing trend in the number of hospital deaths. While the 
hospital experienced an increasing mortality trend, which implied that the three years of 
free access to ART in the Mawokota South health sub-district contributed to a reduction 
in morbidity patterns, free access in the area did not significantly affect mortality trends 
in this rural setting.  
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4.5.6 The effect of access to antiretroviral treatment on demography 
 
Mortality as a patient outcome is influenced by a number of factors that can significantly 
(either positively or negatively) influence the overall trends. In this section of the report, 
the researcher further analysed the relationship between mortality and other factors in 
order to determine the level of significance among these factors in relation to mortality 
trends.  
 
HIV/AIDS affects different genders and age groups differently (Ministry of Health – 
Government of Uganda 2009:21). In Uganda, females, for example, experience a higher 
prevalence of HIV in the 15-39 age group compared to males while males experience a 
higher prevalence of HIV compared to females in the older age brackets of 40 years old 
and above (Ministry of Health – Government of Uganda 2009:17, 21). It was therefore 
important for the researcher to analyse mortality by gender and age group in order to 
determine which particular gender and age group was being most affected by death and 
in order to investigate the PMR in the pre-free and post-free ART eras. In order to 
investigate the demographic trends in number of reported mortalities, the researcher 
compared mortality by age group and determined the association between mortality, 
age and gender in this rural population. According to Stanecki and Walker (2002:289), 
all demographic indicators are affected by a high HIV-prevalence rate. It has also been 
reported that 58% of those living with HIV/AIDS were women and that an estimated 
33.3% of all PLWHA are between 15 and 24 years of age (Benatar et al. 2004:276, 
283).  
 
This analysis therefore investigated the differences in mortality in terms of different age 
groups and the two eras of ART access.  
 
4.5.6.1 Hospital mortality in terms of treatment era and age at time of death  
 
The researcher categorised the results of an analysis of 505 adult hospital deaths in 
terms of age groups and in terms of the relevant treatment era. 
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Table 4.21: Hospital mortality in terms of age group and treatment era 
 
Age 
group 
(years) 
Pre-free ART 
n (%) 
Post-free ART 
n (%) 
TOTAL 
n (%) 
Variance  
(% change in 
mortality in  
the post-free  
ART era) 
15-24 
 
27(50.9) 
(11.8) 
26(49.1) 
(9.4) 
53 
(10.5) -2.4 
25-34 
 
69(54.3) 
(30.3) 
58(45.7) 
(20.9) 
127 
(25.1) -9.4 
35-44 
 
44(39.6) 
(19.3) 
67(60.4) 
(24.2) 
111 
(22.0) 4.9 
45-54 
 
19(32.8) 
(8.3) 
39(67.2) 
(14.1) 
58 
(11.5) 5.8 
55-64 
 
22(50.0) 
(9.7) 
22(50.0) 
(7.9) 
44 
(8.7) -1.8 
65-74 
 
29(51.8) 
(12.7) 
27(48.2) 
(9.7) 
56 
(11.1) -3.0 
75-84 
 
13(28.9) 
(5.7) 
32(71.1) 
(11.6) 
45 
(8.9) 5.9 
≥85 
 
5(45.5) 
(2.2) 
6(54.5) 
(2.2) 
11 
(2.2) 0.0 
TOTAL 228(45.1) 277(54.9) 505  
(n=505, missing 39)  
 
This analysis showed that, as a proportion of all deaths that occurred in the hospital, the 
deaths in the post-free ART era declined by 9.4% (n=127) in the 25-34 age group, by 
3.0% (n=56) in the 65-74 age group, and by 2.4% (n=53) in the 15-24 age group. In 
contrast to this, the proportion of deaths in the post-free ART era increased by 4.9% 
(n=111) in the 35-44 age group, by 5.8% (n=58) in the 45-54 age group, and by 5.9% 
(n=45) in the 75-84 age group when one compares these figures to the mortality rates in 
the pre-free ART era. 
 
Sixty-seven percent (67.2%, n=58) of the deaths in the 45-54 age group, 60.4% (n=111) 
in the 35-44 age group, and 71.1% (n=45) in the 75-84 age group, occurred in the post-
free ART era.  
 
The key finding that emerged from this analysis was that there was a proportional 
decrease in deaths in the 15-24 and 25-34 age groups, and an increase in deaths in the 
35-44 and 45-54 age groups during the six-year period covered by this study.  The 25-
34 age group therefore experienced the highest reduction in proportional mortality while 
the 35-44, 45-54 and 75-84 age groups experienced a proportional increase in mortality 
rates.  
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These findings gave rise to the following question: “What was happening in these four 
age groups that caused such trends to emerge?” These results require an evaluation of 
ART access in terms of age group in order to determine the factors that have 
contributed to differences in mortality rates in two adjacent age groups (the 25-34 age 
group experienced a reduction in mortality rates while the 35-44 age group experienced 
an increase in mortality rates). 
 
While an analysis of access to ART in terms of age groups is beyond the scope of this 
study, the data assembled above has provided an insight into the relationship between 
access to ART and mortality trends in terms of age groups.  
 
4.5.6.2 The association between mortality, age and gender 
 
In Uganda, life expectancy at the age of 15 and above was 46.2 years (47.6 years for 
females and 44.8 years for males) (Uganda Bureau of Statistics, Government of 
Uganda 2006c:43). In this analysis, the researcher examined mortality in terms of age 
and categorised all deaths into the categories of early adult deaths and late adult 
deaths. On the basis of an average life expectancy of 46.2 years, a death in the 15-34 
age groups (which consisted of the 15-24 and the 25-34 age groups) was considered to 
be an early adult death, while death at the age of 35 or above was considered to be a 
comparatively late adult death. In order therefore to determine whether women were 
dying at a younger age in comparison to men, the researcher categorised the whole 
study population into the two categories of (1) 15-34, and (2) 35 and above. He then 
compared these two categories in order to determine which gender was dying at a 
significantly earlier adult age (all such deaths would, by any standards, be regarded as 
premature).  
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Table 4.22:  The association between early adult deaths and gender 
 
   
Gender 
 
Age group 
(years) 
Female 
deaths  
n (%) 
Male  
deaths  
n (%) 
Total number 
of deaths  
n (%) 
15-34 82(45.8) 
(43.2) 
97(54.2) 
(31.2) 
179 
(35.7) 
35 and above 108 (33.5) 
(56.8) 
214(66.5) 
(68.8) 
322 
(64.3) 
Total 190 (37.9) 311(62.1) 501 
(n=501, missing - 43) 
 
The researcher’s analysis of 501 deaths that is set out in table 4.22 (above) showed 
that 43.2% (n=190) of the female deaths occurred in the 15-34 age group compared to 
31.2% (n=311) of the number of male deaths that occurred in the 15-34 age group. The 
differences between the rate of female and male deaths in the 15-34 age group and in 
the 35 (and above) age groups, was found to be statistically significant (χ²=6.85, 
p=<0.009). It may be concluded from these figures that when the population is 
categorized into the two age categories of 15-34 years and 35 years (and above), 
females in the 15-34 age group were at a significantly greater risk of dying more 
frequently in hospital when compared to males from the same age group (OR: 1.68, 
95% CI[1.15-2.43]).  
 
The researcher therefore concluded that proportionally more females were dying at a 
younger age compared to males in the 15-34 age group, and that females were 37% 
more likely to die in hospital (Risk Ratio (RR)=1.37, 95% CI[1.08-1.71]) when compared 
to males of the same age group.  
 
This finding confirmed reports by the Ministry of Health of Uganda of a high HIV 
prevalence among females in the 15-24 age group when it reported a prevalence of 4% 
compared to 1% among males in the same age group (Ministry of Health – Government 
of Uganda 2009:21). These findings were also similar to findings in other studies that 
have provided evidence that HIV/AIDS affects more women at an early age than men 
(Benatar et al. 2004:276, 283).  
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4.5.6.3 HIV-related mortality in terms of gender  
 
HIV/AIDS was responsible for between one-third and two-thirds (Lopez et al. 
2006:1752) of mortality (deaths) in low-resource settings such as the one that formed 
the basis of this study in Uganda. This study also reviewed and compared the rates of 
mortality that were caused by HIV/AIDS-related causes with other causes of death in 
terms of gender.  
 
Table 4.23:  The association between HIV-related deaths and gender  
  
  
HIV related deaths 
 
Gender HIV-related 
deaths 
n (%) 
Non HIV-related 
deaths  
n (%) 
TOTAL 
number of 
deaths  
n (%) 
Female 84(43.5) 
(42.6) 
109(56.5) 
(36.6) 
193 
(39.0) 
Male 113(37.4) 
(57.4) 
189(62.6) 
(63.4) 
302 
(61.0) 
Total 197(39.8) 298(60.2) 495 
(n=495, missing-49)  
 
The researcher analyzed 495 female and male deaths and then categorised them into 
HIV-related and non-HIV-related deaths in table 4.23. This analysis revealed that 43.5% 
(n=193) and 39.8% (n=302) of female and male deaths respectively were attributable to 
HIV-related causes. But this difference was not statistically significant (χ²=1.59; p=0.21, 
OR=1.29 [0.89-1.86]). The results also showed that females were 16.3% less likely (CI[-
44.0% - 6.6%]) to have died as a result of an HIV-related illness in comparison to males. 
Other studies have also reported higher HIV related deaths among men than among 
women (Braga 2007:326; Nicastri, 2005:582). Studies have also reported that women 
exhibited better records of ART regimen adherence than men (Nachega et al. 2006:78). 
Women were therefore more likely to enjoy a greater degree of health and thus suffer 
from lower mortality rates while on an ART regimen than were men. 
 
However, the inadequacies and deficiencies in the evaluation of all admitted patients 
and all mortalities of people who were at risk because of HIV/AIDS as an underlying 
cause of admission and death, continued to be a key limitation in the determination of 
the actual effect of HIV/AIDS on mortality. Thesethese limitations may have resulted in 
an underestimation of this effect.  
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Despite such limitations, the key finding of this research was that both women and men 
were at equal risk of dying from HIV/AIDS-related causes in this rural setting during the 
period under review.  
 
4.5.7 Association between antiretroviral treatment and mortality  
 
This section investigates the effect of ART on overall morbidity and mortality trends. 
Since an ARV medication stops or inhibits the replication of the HIV (WHO 2002:1), it 
also reduces the risk of morbidity and mortality that is associated with HIV disease. A 
reduction in morbidity and mortality rates is therefore the key goal of all ART 
programmes (Amoroso et al. 2002:323). It has been reported that, with a 39% increase 
in ART utilization by PLWHA, the mortality rate fell from 7.0 (in 1996) to 1.3 deaths per 
100 person years (in 2004) while the incidence of AIDS-related deaths significantly 
declined from 3.8 (in 1996) to 0.3 deaths per 100 person years (in 2004) (Palella et al. 
2006:29). This discussion therefore focussed on the effect of ART on mortality and not 
on the impact of ART on mortality because the post-free ART period of three years was 
too short a period for any significant impact of ART to emerge and be identified.  
 
HIV/AIDS still remains the leading cause of death in sub-Saharan Africa and continues 
to sigificantly affect morbidity and mortality trends (Lopez et al. 2006:1753). In order to 
compare HIV mortality in the pre-free and post-free ART eras, the researcher 
categorised patient deaths into HIV-related and non-HIV-related (other diagnoses) 
deaths and analysed the effect of ART on hospital mortality trends in the pre-free ART 
era in comparison to the effects in the post-free ART era in terms of gender.  
 
This section investigates the effect of free access to ART on hospital mortality trends, 
and the researcher discusses the findings below.  
 
4.5.7.1 HIV-related mortality in the pre-free and post-free ART eras  
 
The hospital that was the locus for the study serves a rural community in Uganda where 
significant changes in HIV prevalence have been observed and reported. The most 
important factor that affects mortality trends in population catchment area of this study 
was a reduction in the prevalence of HIV (Ministry of Health – Government of Uganda 
2009:17) and an increase in access to free ART from an estimated coverage of 0% to 
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60% in the three years of the post-free ART era (see figure 4.14). It is noteworthy that, 
even with an ART coverage rates of only 11%, a significant reduction in overall adult 
mortality rates have been reported (Thaczuk & Differding 
 
2008:[2]). It is therefore 
apparent that even with a limited ART coverage in other settings; ART made a 
significant impact on mortality trends. But another study has reported a higher death 
rate in the early ART era in low-resource settings when this death rate is compared to 
that in the later ART era – a trend that demonstrated an overall decrease of 80% in a 
number of deaths from between 1990 and 2003 (Crum et al. 2006:195).  
The present study focused on the first three years of ART access, which is considered 
an “early ART” access phase. This phase exhibits most of the overall effects of ART on 
the overall hospital mortality rate during the initial phases of free ART availability. 
However, in view of other factors such as the rapid increase in ART coverage and a 
decrease in the prevalence of HIV in rural communities in Uganda, rates of HIV-related 
mortality and overall mortality were expected to show a declining trend or an indication 
of reductions in the mortality rate (Ellman & Simms 2008:1071).  
 
This analysis suggests even more profound indications of the possible effects of ART 
on mortality rates in similar settings. 
 
Table 4.24: Association between HIV-related deaths in terms of treatment era 
 
  
Treatment Era 
 
HIV-related 
death 
Post-free ART 
deaths 
n (%) 
Pre-free ART 
deaths 
n (%) 
TOTAL number 
of deaths  
n (%) 
Yes 
 
119(59.8) 
(41) 
80(40.2) 
(38.3) 
199 
(39.9) 
No (other 
causes of death) 
171(57) 
(59) 
129(43) 
(61.7) 
300 
(60.1) 
TOTAL 290(58.1) 209(41.9) 499 
(n=499, missing 45) 
 
After the researcher had analysed 499 hospital deaths, he was able to categorise 
39.9% (n=499) of the deaths as HIV/AIDS-related deaths, and therefore indicate 
HIV/AIDS as the leading cause of death. This finding was consistent with findings in the 
research of Lopez et al. (2006:1752), who provided evidence that HIV/AIDS was the 
cause of one-third to two-thirds of the mortality rate in sub-Saharan Africa. In this study, 
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the PMR of HIV-related illnesses in the post-free ART era was 41.0% (n=290) in 
comparison to 38.3% (n=209) in the pre-free ART era.  
 
The difference in the prevalence of HIV as a cause of hospital death in the post-free and 
pre-free ART eras was not statistically significant (χ²=0.39; p=0.53). The possibility (risk) 
of an HIV/AIDS-related hospital death in the post-free ART era remained similar to the 
possibility (risk) of an HIV/AIDS-related death in the pre-ART era (OR=0.89, 95% CI 
[0.62 – 1.28]).  
 
There was therefore no statistically significant difference in the PMR due to HIV/AIDS 
between the pre-free ART era and the post-free ART era.  
 
4.5.7.2 HIV-related mortality by treatment era and gender  
 
Significant gender differences in access to ART and in the necessity for a meticulous 
adherence to the ART regimen in order to obtain any benefit whatsoever, have 
influenced the expected rates of reduced morbidity and mortality. More females than 
males were accessing treatment in South African townships and 70% of the patients 
who were on ART were women (Boulle 2004:15). It has also been reported that women 
are much more likely to seek treatment than men and they therefore experience better 
health outcomes compared to males who live with HIV/AIDS (Wilson & Fairall 
2008:489).  
 
In another study in Ethiopia among men, the rate of AIDS deaths declined by 21.9% in 
comparison to a 9.3% decline experienced by women (Reniers et al. 2009:511). The 
researcher therefore analysed HIV-related mortality rates in this study in terms of 
gender in order to determine the specific differences in mortality rates among affected 
females and males.  
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Table 4.25: Association between female HIV-related deaths and treatment era 
 
  Treatment Era  
HIV-related  
deaths 
Post-free ART 
death 
n (%) 
Pre-free ART 
death 
n (%) 
TOTAL number 
of deaths 
n (%) 
Yes 
 
44(52.4) 
(40.7) 
40(47.6) 
(47.1) 
84 
(43.5) 
No 
(other causes of 
death) 
64(58.7) 
(59.3) 
45(41.3) 
(52.9) 
109 
(56.5) 
TOTAL 108(56) 85(44) 193 
  (n=193, missing-17) 
 
Among females, HIV as a cause of death declined by 6.4% in the post-era from 47.1% 
(n=85) in the pre-free ART era to 40.7% (n=108) in the post-free ART. This difference in 
the proportion of female deaths due to HIV-related causes in the pre-free ART and post-
free ART era was, however, not statistically significant (χ²=0.54; p=0.4).  
 
This analysis demonstrated that there was no significant change in the possibility of 
hospital HIV-related deaths for females in the post-free ART when compared to the 
same possibility in the pre-free ART era (OR=0.77, 95% CI [0.42-1.43]). These finding 
are similar to the findings in the research carried out by Smith et al. (2003:679), in which 
they reported that the all-cause death rates among HIV-infected women remained 
unchanged between the pre-ART and post-free ART eras. 
 
In other words, free ART access in the post-free ART era did not reduce the possibility 
that of a female HIV-related hospital death.  
 
Table 4.26:  Association between male HIV-related deaths and treatment era 
 
  
Treatment Era 
 
HIV-related  
deaths 
Post-free ART 
deaths  
n (%) 
Pre-free ART 
deaths 
n (%) 
TOTAL number 
of deaths  
n (%) 
Yes 
 
74(65.5) 
(41.1) 
39(34.5) 
(32.0) 
113 
(37.4) 
No  
(other causes of 
death) 
106(56.1) 
(58.9) 
83(43.9) 
(68.0) 
189 
(62.6) 
TOTAL 180(59.6) 122(40.4) 302 
(n=302, missing 27) 
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Table 4.26 shows that, among males in the post-free ART era, the proportional mortality 
that was attributable to HIV-related causes increased by 8.1% from 32% (n=122) in the 
pre-ART era to 41.1% in the post-free ART era (n=180). This difference was not 
statistically significant (χ²=2.50; p=0.11). The relative risk of an HIV-related death for 
males in the post-free ART era was 16.8% (RR=1.17, CI [0.97-1.39; OR=1.49 [95% CI 
[0.918-2.40]) higher in comparison to the pre-free ART era. Males were therefore more 
likely to have died from an HIV-related illness in the post-free ART era compared to the 
possibility of this happening in the pre-free ART era. These findings indicated that a 
minimal or zero effect could be attributed to free ART access in relation to overall male 
hospital mortality trends.  
 
Therefore, there were no statistically significant changes in HIV-related mortality for 
both males and females. These findings are similar to findings by Crum et al (2006:195) 
who reported that despite increased access to ART, the gender of patients who died in 
the pre and post ART eras did not substantially change among HIV-infected persons.  
Despite the lack of statistically significant differences between the pre-free ART and the 
post-free ART era in relation to proportional mortality due to HIV for both females and 
males, these findings demonstrated a reduction in female mortality and an increase in 
male mortality. In tables 4.25 and 4.26, HIV/AIDS as a cause of death was reduced by 
6.4% for females while, for males, HIV/AIDS as a cause of death, increased by a margin 
of 8.1%.  
 
These findings were nevertheless important and useful for placing the understanding of 
the factors that are associated with female and male hospital mortality trends into a 
better-informed and more nuanced context of evidence-based research and 
speculation. 
 
In support of the fact that HIV-related mortality rates differ in terms of gender, Sani et al. 
(2006:864) have reported that AIDS-related mortality among females was 43% in 
comparison to 37% among males. This present study also reported HIV/AIDS as the 
cause of death for 43.5% and 37.4% of affected females and males respectively.  
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In the post-free ART era, PMR due to HIV/AIDS declined among females but increased 
among males. These differeces between proportional mortality due to HIV-related 
mortality in the pre-free and post-free ART access eras was not statistically significant.  
 
4.6 CONCLUSION  
 
This study (and this chapter in particular) investigated and discussed morbidity and 
mortality trends in a specific rural setting in Uganda, and identified the factors that were 
associated with hospital mortality. The study also provided evidence from other 
research and indicated where significant gaps in our overall understanding of these 
phenomena would benefit from more focused research so that more adequate and 
precise information could become available for further evidence-based decision-making.  
 
Chapter 5 summarises the conclusions, limitations and recommendations of this study.  
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CHAPTER 5 
 
Conclusions, limitations and recommendations 
 
 
5.1 INTRODUCTION 
 
Chapter 4 presented and discussed the findings of this study. This chapter focuses on 
the conclusions, limitations and recommendations of the study.  
 
The researcher’s purpose in conducting this study was to investigate, describe and 
draw conclusions about adult mortality trends since the introduction of free antiretroviral 
therapy in a rural hospital in Uganda. In order to achieve this objective, the researcher 
compiled and analysed data about adult mortality trends and the demographic 
characteristics of patients who had died in a rural hospital in the Mpigi district of Uganda 
over a period of six years (three years before and three years after the introduction of 
free ART). The study focused on a rural hospital in Mawokota South County, which is 
also referred to as Mawokota South health sub-district, and is one of the four counties of 
Mpigi District. The health sub-district has its headquarters in the Nkozi Hospital which 
provides health and medical services for a catchment population of 99 607 in the three 
sub-counties of Buwama, Nkozi and Kituntu (Lumala 2008:10). The researcher focused 
his investigative efforts on the headquarters of the health sub-district, which is a private 
not-for-profit hospital. This hospital (like others in Uganda) has operationalised the 
national health policy that was designed to provide operational responsibility and 
leadership for the delivery of the minimum package of health services to the catchment 
population (Ministry of Health – Government of Uganda 2005:20).  
 
The researcher reviewed 544 hospital deaths that occurred in the hospital in terms of 
the direct and associated causes of death and any other concomitant causes that could 
be discerned from the hospital death records, patient files and death certificates. He 
then ascertained the percentages of deaths that had been caused by HIV/AIDS-related 
illnesses before and after free access to ART and analysed the hospital morbidity and 
mortality trends over the six year period and during the pre-free and post-free ART eras.  
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The objectives of the study were to:  
 
1. To investigate the trends in adult hospital mortality in terms of cause in a 
selected rural hospital of the Mpigi district in Uganda, and also to compare the 
differences in adult hospital mortality trends in the same hospital in the pre-free 
and post-free ART eras  
2. To determine the overall effect of free ART access on hospital mortality trends in 
a selected rural hospital of the Mpigi district in Uganda  
3. To make recommendations about methods and approaches to the provision of 
free ARVs that would further help to reduce and minimize the prevailing high 
mortality rates in the hospital and in the catchment area population that is served 
by the hospital 
 
This study met the objectives of the 2007/08 to 2011/12 Uganda National Strategic Plan 
for HIV/AIDS. The key objectives of the National Strategic plan were to mitigate the 
social, cultural and economic effects of HIV-infection and AIDS among individuals, 
households and communities, and to build effective support systems. This strategic plan 
highlighted the “need to generate evidence about the effectiveness, efficiency and 
relevance of the national HIV & AIDS response interventions so that they [could] be 
continuously improved” (Ministry of Health – Government of Uganda 2009:21.)  
 
This study identified various key factors that were associated with hospital morbidity and 
mortality trends and the researcher made three year projections to June 2011 on the 
basis of the data available to him. These findings to hospital administrators and macro 
health care policy designers are benchmarks for calculating and evaluating future 
trends. An understanding of such trends and probabilities will enable those who are 
responsible for HIV/AIDS programmes to refine whatever elements of the current 
programmes need revision and adjustment, and they will also enable hospital managers 
to assess and review the impact that free ART is having on the mortality and morbidity 
trends in institutions at any given time in a future. 
 
This chapter summarised the findings and limitations of the study, and provides 
recommendations for strengthening and refining the present systems that have been 
designed to reduce hospital mortality in low-resource rural settings. The chapter will 
conclude with recommendations for further research.   
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5.2 CONCLUSIONS OF THE STUDY  
 
The researcher presented the conclusions in a specific order. Firstly, the researcher 
reviews the demographic profile of the study population. Secondly, the researcher 
summarises the conclusions about morbidity and mortality trends and about the factors 
that were associated with HIV/AIDS in the pre-free and post-free ART eras within the 
specific time frame delimited by this study.  
 
The researcher based these conclusions on an analysis of findings about the number of 
deaths that had occurred in the rural hospital in the period between July 2002 and June 
2008. He then presented the results in terms of the Uganda Government’s annual 
financial and reporting cycle that extends from between 1 July and 30 June in each non-
calendar year.  
 
The pre-free ART years that were referred to in this analysis were those of 2002/2003, 
2003/2004, 2004/2005, and the post-free ART years were those of 2005/2006, 
2006/2007, 2007/2008.  
 
5.2.1 The demographic profile of the study population  
 
This section summarises the demographic profile of the study population in terms of 
age, gender, sub-county of residence, year of death and the treatment era in which the 
patient died.  
 
5.2.1.1 Age distribution of the study population 
 
The age distribution of the 501 deceased patients who comprised the research sample 
fell to the following categories: 15-24 (10.6%), 25-34 (25.1%), 35-44 (22.0%), 45-54 
(11.4%), 55-64 (8.6%), 65-74 (11.2%), 75-84 (9.0%), and all those who were above 85 
years at the time of their death (2.2%). Proportionally, the highest number of deaths 
therefore occurred in the 25-34 age group. These deaths accounted for 25.1% (n=501) 
of all the adult deaths that occurred in the hospital.  
 
The age standardised Crude Death Rate (CDR) in the 15-64 age bracket, was highest 
in the 35-44 age group with 2.6 deaths per 1 000 population. This was the age group 
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that also experienced the highest HIV prevalence rate in the Ugandan population (9.2%) 
(Uganda AIDS Commision – Government of Uganda 2006:21). The CDR was lowest in 
the 15-24 age group (0.4 per 1 000 population), and highest in the 85 year age group 
(18.9 per 1 000 population). The researcher observed that after the age of 65 years, the 
hospital-based CDR doubled for every ten-year increase in the age group concerned. 
The overall hospital-based CDR was 9.9 per 1 000 population. 
 
5.2.1.2 Mortality distribution in terms of age and gender  
 
The high prevalence of HIV in the 25-39 age group was associated with a 
correspondingly high hospital mortality rate. While the highest number of deaths 
occurred among females in the 25-34 age group (30%), the highest number of male 
deaths occurred in the 35-44 age group (23.2%). This study revealed that 43.2% of the 
female deaths and 31.2% of the male deaths occurred in the first twenty years of 
adulthood (i.e. in the 15-34 age group). While proportionally more females died at a 
younger age compared to a comparable number of males in all age groups, more males 
that females died in the hospital itself. The least difference between the proportion of 
female and male mortality rates in terms of age group occurred in the 15-24 age group, 
where 47.2% of the deaths were those of females and 52.8% were those of males. The 
highest difference in the proportions of female to male mortality occurred in the 65-74 
age group, in which 26.8% of the deaths were those of females while 73.2% were those 
of male.  
 
5.2.2 The distribution of hospital mortality in terms of gender  
 
With regard to the distribution of hospital mortality in terms of gender, 37.9% (n=501) 
and 62.1% (n=501) of the adult deaths were female and male respectively over a period 
of six years. More adult males therefore died in comparison to adult females – the ratio 
being two (1.6) male deaths for every one (1) female death.  
 
5.2.2.1 Annual mortality trends in terms of gender 
 
The research analysed these variations in mortality patterns in terms of gender over the 
six-year period of the study in order to determine any significant changes in annual 
mortality patterns. He therefore analysed the mortality rates in terms of year of death 
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and gender in order to be in a position to capture any significance in the mortality trends 
among adults in the hospital in terms of gender. 
 
The annual increase in mortality rates during the two years of the pre-free ART era, 
revealed that while, on average, the rates of male mortality decreased by 3.4%, the 
rates of female mortality increased by 8.1% annually. In the post-free ART era 
(2005/2006 to 2007/2008), the average number of male deaths increased by 21.7% 
annually when compared to the average number of females deaths that increased by 
4.6% annually. The researcher was therefore able to conclude that, in the post-free ART 
era, the number of male deaths increased by 4.7 times the number of female deaths 
annually during the same period. He therefore identified these figures (findings) as an 
issue of concern that required further investigation and analysis. 
 
5.2.3 Distribution of deaths in terms of sub-county of residence 
 
The hospital catchment area of three sub-counties of Nkozi, Kituntu and Buwama sub-
counties in Mpigi district are bordered (in close proximity) by the sub-counties of Bulo, 
Butambala, Kamengo, Maddu, Kabulasoke and Lukaya sub-county in Masaka District. 
Because of its location and the services that it offered, the hospital was accessible to 
patients both within and from outside the catchment area.  
 
5.2.3.1 Mortality in terms of sub-county of residence  
 
The notice that the highest number of hospital deaths were of patients who had come 
from Nkozi (35.5%, n=510). The other hospital deaths were mainly of patients who 
came from Kituntu (25.1%, n=510) and Buwama (16.5%, n=510) sub-counties. The 
least number of deaths occurred among patients from Kabulasoke (0.8%, n=510). 
These findings indicated that 77.1% (n=510) of all hospital deaths during the study 
period were patients who resided from within the catchment area, while 22.9% (n=510) 
of the deaths had occurred among patients who were coming from outside the 
catchment area.  
 
These statistics indicated that, in terms of access across the sub-counties, 
proportionally more males died in the hospital. The findings also revealed that a larger 
number of deaths were of people living within the Nkozi sub-county (35.5%, n=510) and 
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the Mawokota South county (77.1%, n=510) when one compares their figures to those 
of other counties. 
 
5.2.3.2 Mortality in terms of by sub-county of residence and treatment era  
 
The researcher also analysed differences in access to hospital services and compared 
these proportions to the distribution of deaths in pre-free and post-free ART eras in 
terms of sub-counties of residence. The findings revealed that 56.8% (n=514) of the 
deaths occurred in the post-free ART era in comparison to the 43.2% (n=514) that 
occurred in the pre-free ART era. This revealed an increase of 13.6% in the post-free 
ART era.  
 
Increased access to free ART in Nkozi and Buwama sub-counties contributed to the 
8.6% (n=183) and 4.2% (n=85) reduction in the mortality rate in Nkozi and Buwama 
sub-counties respectively. The research also noticed that mortality rates in sub-counties 
that did not have a designated ART site (such as Kituntu and Kamengo sub-counties) 
increased by 5.3% (n=129) and 2.5% (n=33) respectively in the post-free ART era.  
 
In Mawokota South health sub-district, the major point of difference that differentiated 
the mortality patterns in the Nkozi and Buwama sub-counties (when compared to 
Kituntu sub-county) during the study period was the accessibility of free ART to patients 
in Nkozi and Buwama sub-counties.  
 
The conclusion is that, in the post-free ART era, an increased access to ART in Nkozi 
and Buwama sub-counties contributed to the reduction in hospital deaths that was 
evident in these two sub-counties. Kituntu sub-county and other sub-counties which had 
limited access to ART, experienced a far lower reduction in mortality rates (less than 
1.0% reduction) – or even an increase in the rate of the incidence of hospital deaths. 
 
5.2.4 The association between mortality rates and patients’ place of residence  
 
Access to ART services and other general health services are influenced by a number 
of factors that include the distance to the health facility, the cost of transport in order to 
get to the health facility whenever necessary, and gender. Since the people who lived in 
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the hospital’s catchment area were closer to the hospital itself, they were more likely to 
know about and, consequently, to utilize hospital services such as free access to ART.  
 
5.2.4.1 Hospital mortality in terms of sub-county of residence and treatment era  
 
The researcher noticed that in the post-free ART era, the factor of residence in the 
catchment area was significantly associated with a reduced likelihood that the patient 
would die in the hospital. In the post-free ART era, there was thus a 7.5% reduction in 
the number of deaths of patients from Mawokota South County – in comparison to a 
7.5% increase in the number of deaths of patients whose place of residence was in sub-
counties outside Mawokota South County (i.e. other sub-counties). The researcher 
found that the association between a patient’s place of residence (their home county) 
and the treatment era in which they were treated (whether in the pre-free or post-free 
ART eras) was statistically significant (χ²=4.10; p=0.043). The post-free ART era was 
therefore associated with a reduced likelihood that a HIV-infected patient from 
Mawokota South County would die in the hospital. In the post-ART era, the increased 
access to ART in the population catchment area contributed to a 10.6% reduction in the 
likelihood (risk) that a patient from the hospital's immediate population catchment area 
would die in the hospital. 
 
In the post-ART era, an increased access to ART in the hospital contributed to a 7.5% 
reduction in the rate of hospital deaths from the hospital’s population catchment area, 
and it also reduced the likelihood (risk) by 10.6% that a patient from the hospital’s 
population catchment area would die in the hospital.  
 
5.2.4.2 Female and male mortality in terms of county of residence  
 
The researcher also observed that, when one compares the pre-ART and post-ART 
eras, there was equal likelihood that female patients would die at the same rate as male 
patients in the hospital if they were resident in the Mawokota South health sub-district. 
But in contrast to the female patient death rate, the number of male deaths of patients 
from Mawokota South county declined by 11.1% in the post-free ART era. This 
reduction was observed to be statistically significant (χ²=5.05; p=0.024). Among males, 
in the post-free ART era, the possibility (risk) that a male patient from Mawokota South 
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health sub-district would die in the hospital, reduced by 14.6% (95% CI[-26.8%--2.5%]; 
OR=0.53, 95% CI[0.31-0.93]).  
 
It therefore seems logical to conclude that the free access to ART in Mawokota South 
health sub-district was associated with an 11.1% reduction in male hospital deaths and 
a reduced likelihood that a male from this population catchment area would die in 
hospital. In contrast to this, free ART access exerted no significant effect on female 
hospital mortality rates in terms of the place of residence of the patient.  
 
5.2.5 Average length of stay (ALOS) are and out-of-pocket payments  
 
While the shortest period of hospital stay before death occurred was observed to be 
less than a day (24 hours), the longest period of hospital stay that was observed in this 
study was 67 days. High rates of mortality were in fact associated with the first day of 
the admission of HIV-infected patients. It is notable that 27.6% (n=490; 95% CI [23.7% - 
31.8%]) of all these patient deaths occurred within in one day (24 hours) of admission 
while 31.6% (n=490; 27.6-36.0) of patient death occurred between two and three days 
of admission. Overall, 59.2% (n=490) of patients died within three days of admission, 
and 85.7% (n=490) of all deaths occurred within five days of admission to the hospital.  
 
While the ALOS before death in the hospital was 4.8 days before death in the pre-free 
ART era, the ALOS increased to 5 days before death in the post-free ART era. Free 
access to ART did not therefore reduce the ALOS of patients in hospital before they 
died.  
 
5.2.5.1 Observable trends in the average number of admission days before 
death 
 
The researcher’s analysis of average lengths of stay before death revealed that, in 
2002/2003, the average number of admission days before death was six days, and that 
this had progressively declined to five days in 2007/2008. The researcher therefore 
projected that the ALOS would reach four days of admission before death by June 
2011. Since the ALOS before death had revealed a decreasing trend, this may have 
been indicative of the increasing percentage of patients who were being admitted with 
critical or severe illnesses that results in their deaths in less and less days. Because of 
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this result and because of the risk that outlier values could influence the researcher’s 
ALOS analysis, he preferred the median number of admission days as a measure for 
monitoring mortality (and therefore used it in this analysis). 
 
5.2.5.2 The median number of admission days before death 
 
When he used the median number of admissions days to determine the trend of length 
of hospital stay before death, the researcher observed no significant change in the 
median number of admission days in the three pre-free ART era when he compared 
them to the three years of the post-free ART access. These findings therefore indicated 
that an increased access to ART did not affect (i.e. either reduce or prolong) the median 
length of hospital stay before death occurred.  
 
5.2.6 Out-of-pocket payments for hospital services  
 
The out-of-pocket payment per patient death was calculated at US$ 11.3 per death. In a 
population where the per capita expenditure on health is US$ 18 and the Gross 
Domestic Product (GDP) in US$ 243 (WHO 2005b:[1]), the average out-of-pocket 
payment of US$ 11.3 that was required for each patient death was proportionately high. 
The cost of these services might therefore have functioned as a substantial obstacle 
that limited the willingness and ability of patients to gain timely access to health care 
before severe HIV-related illnesses and conditions were well established – illnesses and 
conditions that required emergency care and substantially increased the risk of hospital 
death and the cost to each patient of the necessary health care service delivery that 
they required. 
 
5.2.6.1 Average out-of-pocket payment in terms of gender and in terms of 
treatment era 
 
In the pre-free ART era, the average out-of-pocket payment that each female patient 
was required to make was US$ 8.5, compared to an amount of US$ 12.7 in the post-
free ART era. For males, the average out-of-pocket payment during the pre-free ART 
era was US$ 10.5, compared to the US$ 12.7 in the post-free ART era.  
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The researcher detected no significant differences in the out-of-pocket payments in 
terms of gender in the post-free ART era, and the average out-of-pocket payment per 
patient death was US$ 12. 
 
5.2.6.2 Average out-of-pocket payments for HIV and non-HIV-related deaths  
 
In the six year period of the study, the average out-of-pocket payment for HIV-related 
deaths was US$ 11.1 in comparison to the US$ 11.9 average payment for non-HIV-
related deaths. 
 
5.2.6.3 Average out-of-pocket payment trends (2002-2008) 
 
Out-of-pocket payments for non-HIV-related deaths declined at an estimated US$ 0.2 
per annum (y = -0.2x + 12.2) from US$ 12 per death in 2002/2003, and the researcher 
projected that they would further decline to US$ 10.4 by June 2011. By contrast, out-of-
pocket payments for HIV-related deaths increased at a rate of US$ 0.2 per annum (y = 
0.2x + 9.0) from US$ 9.2, and the researcher projected that these would increase to 
US$ 10.8 by June 2011.  
 
These trends revealed that while HIV-related costs demonstrated an upward trend, non-
HIV-related out-of-pocket payments demonstrated a declining trend during the same 
period.  
 
5.2.6.4 Daily out-of-pocket payments for hospital services 
 
The research also observed that daily out-of-pocket payments increased by 40% (from 
US$ 1 to US$ 2.5 to US$ 3.5 over the six-year period of the study). He also projected 
that the daily out-of-pocket payment made by patients for each death would reach US$ 
3.7 by June 2011.  
 
Despite free access to ART, the average amount of direct out-of-pocket payments 
increased by 33.3% for females from US$ 2.4 (2002/2003) to US$ 3.2 (2007/2008). 
Among males, comparable out-of-pocket payments increased by 52.0% from US$ 2.5 
(2002/2003) to US$ 3.8 (2007/2008). From these increases in average out-of-pocket 
payments in a private-not-for-profit hospital, it became evident that the cost of service 
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delivery per mortality to the hospital and to the patients themselves was increasing and 
demonstrating an upward trend.  
 
5.2.7 Associations between length of stay, out-of-pocket payments and HIV 
 
The researcher identified a statistically significant association between length of stay 
(number of admission days) and out-of-pocket payments. Of the patients who had paid 
out-of-pocket payments, more than the average out-of-pocket payment per death of 
US$ 4, were 91.3% (n=115, χ²=97.2, p=<0.0001) of patients that died within three days 
of admission. Therefore, patients that died within three days of admission were more 
likely to have paid more than US$ 4 as an out-of-pocket payment – compared to 
patients who died in any period subsequent to three days after their admission to the 
hospital (OR=0.06, 95% CI[0.03-0.11]).  
 
The researcher also observed that the odds of a patient having to pay US$ 4 or less as 
an out-of-pocket were similar for both HIV-related and non-HIV-related deaths. The HIV 
status of the patient therefore did not increase or reduce the likelihood that a patient 
would have to pay more or less than the average US$ 4 out-of-pocket payment per 
individual mortality.  
 
5.3  FACTORS ASSOCIATED WITH HOSPITAL MORTALITY  
  
HIV/AIDS has exerted a significant socio-economic impact on the communities, health 
systems and overall development of all countries in which the prevalence of HIV 
infections is high. The impact of HIV on morbidity and mortality trends cannot be 
overemphasized.  
 
The researcher’s review of the monthly admission trends of 5 575 adult patients over a 
72-month (six-year) period showed that adult admissions in the hospital decreased by 
16.7% from an average of 90 admissions per month in July 2002 to 75 admissions per 
month in June 2008. The researcher projects that hospital admissions will drop to 65 
admissions per month by June 2011. It is therefore clear that access to free ART has 
contributed to a 16.7% reduction in the rate of hospital admissions in a rural hospital in 
Mpigi District, Uganda. 
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5.3.1 Adult hospital mortality trends in Mawokota South  
 
The researcher reviewed 497 deaths that had occurred over a 72 month (six-year) 
period for the purposes of this study. He observed that the adult death rate increased 
during this period by 133.3% – from an average of three deaths per month in July 2002 
to an average of seven deaths per month in June 2008. He also projected that the 
number of deaths would increase to ten deaths per month by June 2011.  
It is therefore clear that free access to ART in Mawokota South health sub-district over 
this three-year period did not reduce hospital mortality (the average number of deaths in 
the hospital per month).  
 
5.3.2 The trend of deaths from Nkozi sub-county (2002-2011) 
 
Free ART was first made accessible to patients in the hospital in the study from the 
beginning of June 2005. Despite the overall increase in the number of hospital deaths 
(from an average of three deaths per month to seven deaths per month), the average 
number of deaths that occurred in the hospital of residents of Nkozi sub-county showed 
a slow and steady decline from 2.4 deaths per month (in July 2002) to 2.2 deaths per 
month (in June 2008), and the researcher projects that they will decline even further to 
an average of 2.1 deaths per month in June 2011. This 8.7% (n=183) reduction in 
mortality rates in Nkozi sub-county in the post-free ART provided the researcher with an 
opportunity for further analysing the trends in hospital deaths in the sub-county. This 
reduction in the average number of hospital deaths in Nkozi sub-county indicated that 
an increase in access to free ART in the sub-county had at least made an initial impact 
on hospital mortality trends in patients from the sub-county.  
 
5.3.2.1 Association between length of stay and HIV-related mortality  
 
The results of the study indicated that, in the post-free ART era, 57.9% (n=266) of the 
patients died within three days of admission – compared to the 60.7% (n=224) who had 
died within three days of admission in the pre-free ART era. But this difference in 
mortality rates was not statistically significant (OR=0.89, 95% CI[0.62-1.28]; χ²=0.3; 
p=0.59). The data indicated that the risk of death within three days of admission was 
similar in both the pre-free and post-free ART eras.  
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Among females, 37.4% (n=99) of deaths that occurred within three days of admission 
were HIV-related deaths, compared to 49.4% (n=83) of the deaths that occurred within 
more than three days after admission. But the difference in the likelihood (risk) of HIV-
related deaths for females within less than three days of admission and within more 
than three days after admission, was not statistically significant (χ²=2.20; p=0.14; 
OR=0.61, 95% CI[0.33-1.13]). Female HIV-related and non-HIV-related deaths were 
equally likely to be admitted with a variety of severe morbidities or critical illnesses that 
resulted in death in fewer than three days after admission.  
 
Among males, 50% (n=100) of male HIV-related deaths occurred within three days of 
admission in comparison to the 65.5% (n=165) of male deaths that were attributed to 
non-HIV causes during the same period. This difference was statistically significant 
(χ²=5.55; p=0.02). The odds male patient who succumbed to an HIV-related death 
within three days after admission were 0.53 (95% CI [0.32-0.88]). HIV-related male 
deaths were therefore more likely to occur within the three days after admission than 
within three days or less of admission.  
 
5.3.3 Average length of stay and out-of-pocket payments  
 
The researcher analysed the average length of hospital stay (ALOS) and out-of-pocket 
payments in this study in order to determine the trends and factors that were associated 
with out-of-pocket payments.  
 
5.3.3.1 Length of hospital stay in the pre-free and post-free ART eras  
 
The average length of hospital stay was a key determinant for the cost of services to 
patients who were admitted and the cost for the service providers and the hospital. The 
objective of free access to ART is to reduce rates of morbidity and mortality. Free 
access to ART is also therefore expected to reduce the number of admissions and the 
number of hospital admission days. Such reductions in morbidity are expected to 
contribute to reductions in the cost of service delivery on the part of the hospital and on 
the part of the patients who make use of the hospital’s services.  
 
The results of the study showed that, while 27.6% (n=490; 95% CI [23.7% - 31.8%]) of 
the deaths occurred within 24 hours of admission, 31.6% (n=490; 27.6-36.0) occurred 
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within two to three days after admission. In total, therefore, 59.2% (n=490) of all patients 
who were admitted died within three days of admission, and 85.7% (n=490) of all these 
deaths occurred within five days of admission.  
 
The high mortality rate on the first day of admission and within three days after 
admission is attributable to the fact that patients present with severe and critical illness 
and conditions on admission. It is for this reason that such a high percentage of patients 
die within the first day (24 hours) of admission. It is often usually the case that patients 
in such circumstances die even before they can be properly examined and investigated 
for the causes of their morbidity. This state of affairs, as has already been mentioned 
above, frequently resulted in the compilation of incomplete and inadequate records and 
death certificates because the attending physician and health care personnel had no 
time in which to manage the patient.   
 
5.3.3.2 Average and median length of hospital stay  
 
The ALOS before death was 4.9 days. The analysis of ALOS before death showed that 
the ALOS before death in 2002/2003 was six days, and had declined to five days in 
2007/2008. The ALOS was projected by the researcher to decline even more to four 
days per patient before death by June 2011.  
 
5.3.3.3 The median number of admission days  
 
The research also evaluated the trend revealed by the median number of days of 
admission and used to the results of this calculation to compare trends in the pre-free 
and post-free ART eras. While the median number of admission days remained 
constant at three days of admission during the pre-free ART era, they increased to four 
days in 2006/2007, but declined again to three days before death (the number or level 
at which it stood into the pre-free ART era).  
 
Although this analysis shows that there was no change in the number of admission days 
in the six-year period of the study, there was an increased variation in the number of 
admission days in 2007/2008. This implies that there is an increase in the number of 
terminal illness that warrant long admission days before death. This is a pattern that 
requires further research.  
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5.3.4 Out-of-pocket payments for hospital services  
 
The research also calculated the average length of hospital stay in the pre-free and 
post-free ART eras, and used these figures to determine trends in user charges per 
patient before death (the so-called “out-of-pocket payments”). 
 
5.3.4.1 Average of out-of-pocket payments per death 
 
The researcher used out-of-pocket payments as an estimate of the direct cost of health 
services to patients. The average out-of-pocket payment remained almost constant for 
three years (from 2003/2004 to 2005/2006). In the post-free ART era, the average out-
of-pocket payment per patient mortality increased steadily from US$ 9.5 to US$ 16.3. 
Therefore, while the average out-of-pocket payment in the pre-free ART era was US$ 
9.7, it rose to US$ 12.8 per death in the post-free ART era. Out-of-pocket payments 
therefore increased by 61.4% from US$ 10.1 in 2002/2003 to US$ 16.3 per hospital 
death in 2007/2008.  
 
5.3.4.2 The average out-of-pocket payment in terms of gender 
 
In order to obtain a better understanding of the differences in out-of-pocket payments in 
terms of gender, the researcher carried out a separate analysis on the data relating to 
males and females respectively. In this analysis, the researcher compared the out-of-
pocket payments made by females and males in order to determine whether there were 
any differences in the out-of-pocket payments made by patients in terms of gender per 
patient mortality. What he found out was that the average out-of-pocket payments that 
were being made by both males and females in the three-year, post-free ART era were 
in fact equal – at US$ 12.7 per patient death event.  
 
5.3.4.3 Average out-of-pocket payments for HIV and non-HIV-related deaths  
 
Since HIV/AIDS was the most prevalent cause of death in the hospital, the researcher 
carried out a further analysis of the rates of HIV-related mortality and extent of out-of-
pocket payments. What he found was that the average pre-free ART out-of-pocket 
payment for an HIV-related death was US$ 11.1 compared to US$ 11.9 for each non-
HIV-related death.  
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5.3.4.4 Average out-of-pocket payment trends (2002-2011) 
 
An analysis of the out-of-pocket payment trends over the six-year period of the study 
(2002-2008), showed that, on average, out-of-pocket payments for non-HIV-related 
deaths were higher than the out-of-pocket payments for HIV-related deaths. Non-HIV-
related out-of-pocket payments for death declined at an estimated US$ 0.2 per annum 
while out-of-pocket payments for HIV-related deaths increased at a rate of US$ 0.2 per 
annum.  
 
Out-of-pocket payments for HIV-related deaths were therefore lower than those 
required for the non-HIV-related deaths. HIV-related costs also increased while non-
HIV-related out-of-pocket payments continued to decline.  
 
Despite free access to ART in the hospital, the other costs of hospital care for HIV-
related conditions were slowly but steadily increasing and this should be an issue of 
concern if the full benefits of free access to ART are to be fully understood and 
appreciated. 
 
5.3.4.5 Daily out-of-pocket payments for hospital services 
 
For females, out-of-pocket payments increased by 33.3% from US$ 2.4 (2002/2003) to 
US$ 3.2 (2007/2008). Among males, corresponding out-of-pocket payments increased 
by 52.0% from US$ 2.5 (2002/2003) to US$ 3.8 (2007/2008). The daily out-of-pocket 
payments for both males and females steadily increased and the increases for males 
were higher than increases for females. The researcher therefore projected that by June 
2011, the daily out-of-pocket payments for terminally ill patients or patients with critical 
illness (that die in hospital) will be US$ 3.7. 
 
These findings reveal that the costs associated with male admissions and deaths in the 
hospital are significant drivers of the overall rises in the amounts that patients had to 
pay in out-of-pocket payments. In spite of the benefits of free access to ART, in this 
high-HIV-prevalence setting, the average direct out-of-pocket payment by patients for 
health care steadily increased by 33.3% to 52.0% over the six-year period of the study. 
The out-of-pocket payments per death are projected to continue increasing.  
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5.3.5 Association between length of stay and out-of-pocket payments  
 
In this section, the researcher investigates the associations between length of stay and 
out-of-pocket payments.  
 
5.3.5.1 Length of stay and out-of-pocket payments in the post-free ART era  
 
The researcher identified a statistically significant association between admission days 
and out-of-pocket payments.  Of the patients who paid an out-of-pocket payments of 
more than US$ 4, 91.3% (n=115) died within three days of admission to the hospital 
(χ²=97.2, p=<0.0001).  
 
It was therefore probable that patients who died within three days of admission to the 
hospital are more likely to have to pay more than US$ 4 as an out-of-pocket payment – 
in comparison to those patients who died in the period after three days from the time 
when they were admitted to the hospital (OR=0.06, 95% CI[0.03-0.11]). 
 
5.3.5.2 Associations between HIV mortality and out-of-pocket payments  
 
Since HIV/AIDS-related mortality was one of the top two most prevalent causes of death 
in the hospital, it was also a major driver of hospital care costs. The researcher 
therefore compared the average cost (out-of-pocket payment) of an HIV-related 
mortality with the average cost of anon-HIV-related mortality.  
 
For 72.8% (n=158) of the HIV-related deaths, the out-of-pocket payments were less 
than US$ 4 per hospital death – in comparison to 67.4% (n=215) for non-HIV-related 
deaths. The difference was not statistically significant (χ²=0.99; p=0.32; OR=1.29 [0.82-
2.03]).  
 
The odds therefore of having to pay US$ 4 or less as an out-of-pocket for a hospital 
death (the privilege of dying in the hospital) were similar for both patients who died from 
HIV-related causes and those who died from non-HIV-related causes. Therefore, the 
HIV status of a patient did increase or reduce the probability that he or she (or the 
relatives) would have to pay more or less than US$ 4 as an out-of-pocket payment to 
the hospital after a death occured.  
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5.4 THE EFFECT OF ANTIRETROVIRAL TREATMENT ON MORTALITY   
 
This discussion focussed on the effect of ART on mortality and not the impact of ART 
on mortality. This was because the post-free ART period of three years was too short a 
period for a significant impact of ART to be examined. The hypothesis tested in this 
study was; the introduction of free antiretroviral treatment in a rural hospital lead to 
reduction in overall morbidity and mortality. The overall goal of free access to ART is to 
reduce morbidity and mortality. The researcher therefore compiled and analysed 
monthly admission and mortality trends.  
 
This study was not designed to focus on mortality trends among HIV patients or patients 
on ART. It was designed to identify and analyse the overall hospital adult morbidity and 
mortality trends in both the pre-free and post-free ART eras in terms of causes of death, 
number of admissions, number of deaths, and the overall hospital mortality rates. 
 
5.4.1 Hospital morbidity and mortality trends (2002-2008) and 2011 projections  
 
The researcher evaluated morbidity patterns in this rural setting by analysing adult 
admission trends. Hospital morbidity and mortality trends exert a significant impact on 
workload and the costs associated with service delivery in any hospital.  
 
This section determined the effect of free access to ART on hospital morbidity and 
mortality trends and the findings discussed below.  
 
5.4.1.1 Adult admission trends in Mawokota South Health sub-district  
 
The review of monthly admission trends revealed that adult admissions in the hospital 
decreased by 16.7% from an average of 90 admissions per month in July 2002 to 75 
admissions per month in June 2008. The researcher further projected that hospital 
admissions would drop to 65 admissions per month by June 2011. By June 2011, 
therefore, mortality trends in the hospital will have reduced by 27.8% of the 2002/2003 
monthly adult admission average.  
 
These findings indicated that free ART access contributed to the 16.7% reduction in 
monthly hospital adult admissions.   
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5.4.2 The effect of antiretroviral treatment on mortality trends   
 
As free access to ART becomes more and more widely available, the reasons why 
patients seek hospitalisation and the causes from which HIV-positive patients die, have 
been changing and therefore need to be carefully monitored and analysed. This section 
summarises the causes of mortality in the pre-free ART era and compares them with 
the causes of mortality in the post-free ART era. The researcher also analyses and 
discusses the impact of ART on overall (“all cause”) mortality trends since the 
introduction of ARVs in this section. 
 
5.4.2.1 The effect of antiretroviral treatment on causes of mortality  
 
The determination of the causes of death was a key focus of this study. Over the six-
year period of the study, HIV/AIDS-related illnesses were the most frequent diagnosis 
as a cause of death. During this period, HIV/AIDS contributed (caused) 27.1% (n=733) 
of all deaths in the hospital, followed by malaria with 22.6% (n=733). Respiratory tract 
infections (RTIs) were responsible for 10% (n=733) of the causes of death, and 
tuberculosis was designated as the cause of death in 9% (n=733) of all mortalities. The 
two conditions of HIV/AIDS and malaria were therefore reported as a direct or an 
associated cause of death in 49.8% (n=733) of all the hospital deaths during this period. 
During the same period, HIV/AIDS, malaria and RTIs were diagnosed as the most 
frequent cause of death in 59.7% (n=733) of all the hospital deaths. 
 
In the post-free ART era, the frequency of HIV/AIDS as a cause of death declined by 
0.7%, and tuberculosis, cardiovascular disease and meningitis declined as diagnosed 
causes of death reduced by 6.2%, 4% and 2.6% respectively. On the other hand, 
malaria as a cause of death increased by 10.1% while gastro-enteritis as a cause of 
death increased by 2.9%.  
 
The slight reduction of 0.7% in the prevalence of HIV/AIDS-related illnesses as a cause 
of death during this period requires a more careful investigation – especially in view of 
the fact that, in the case 27.6% of the deaths in the hospital, the HIV status and thus the 
underlying component of HIV as an associated cause of death had not been evaluated 
or reported by laboratory diagnosis. Although this initial finding of a reduction in 
HIV/AIDS-related causes of death was low and was not statistically significant (χ²=0.39; 
255 
p=0.53), it is indicative of a trend that needs to be carefully monitored. But, as has been 
mentioned before, the absence of opportunities for post-mortem diagnoses of causes of 
death leads one to question on the accuracy of the reasons that were adduced at the 
time for the causes of the death of patients who died during the study period.  
 
In addition to this, the period of three years of access to ART was too short to serve as 
an experimental period in which to determine the impact of ART on all of these factors. 
The course of the limited resources and limited diagnostic capacity available in the 
hospital during the study period, much of the information about causes of death might 
well have been inadequate and even inaccurate. It is quite possible that, in the 
circumstances of acute and chronic resource deprivation that prevail in the hospital, 
causes of death that should have been attributed to conditions such as lymphomas, 
malignancies and other non-HIV-related conditions were inadequately or sketchily 
reported.  
 
The key findings of this analysis were an increase in malaria and gastro-enteritis as 
causes of death and a reduction in HIV/AIDS, tuberculosis and meningitis as causes of 
death in the post-free ART era when the same causes are compared to corresponding 
figures as causes of death in the pre-free ART era.  
 
5.4.2.2 The effect of antiretroviral treatment on hospital mortality rates and 
trends  
 
Free access to ART was first initiated in various programmes in Uganda in 2003. The 
extent of ART coverage in Mawokota South health sub-district (which was the locus of 
this study) ART coverage was estimated at 60% of the 29.3% of PLWHA.  
 
The researcher based the hospital mortality rates on the monthly number of hospital 
deaths and the monthly number of admissions, and presented the resultant equation as 
the number of deaths per 100 admissions in any given period of the study. The 
researcher’s analysis of 497 adult deaths and 5 575 adult admissions revealed that 
hospital adult mortality per month varied significantly from zero (0) deaths per month in 
October 2003 to the highest number, which was 34 patient deaths that occurred in the 
month of July 2007.  
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The results showed that mortality rates increased from three (3) deaths per 100 
admissions (3%) per month (in June 2002) to 11 deaths per 100 admissions (11%) in 
June 2008. The researcher then projected that the hospital’s mortality rate would 
increase to 15 deaths per 100 admissions (or 15%) by June 2011.  
 
In this study, despite an ART coverage rate of 60%, the hospital mortality rates have 
shown a rising trend. This implies that over the three years during which patients have 
had free access to ART in this rural hospital setting, no notable changes in the overall 
hospital mortality rates have yet been observed. The researcher therefore concluded 
that free access to ART in Mawokota South health sub-district during this period had not 
significantly affected hospital mortality trends. 
 
This study has, in fact, demonstrated that this hospital has experienced both a declining 
trend in adult admissions and an increasing trend in the number of hospital deaths.  
 
5.4.3 The age at time of death 
 
Although this study was not designed to focus on life-expectancy rates and HIV-specific 
mortality trends, one of the key findings of the study was the trend in median age at time 
of death. The trend of age at the time of patient death is a critical indicator of shifts in 
mortality trends, and provides a basis for deeper evaluations of the inherent factors that 
are associated with mortality trends. The researcher therefore analysed the trend of age 
at time of patient death by using the median age of the patients at the time of their 
deaths. 
 
In a period of one year, the median age at time of death declined by 3.5 years (8.8%, 
n=40 years) to 36.5 years (2003/2004), and remained steady at 37 years in 2004/2005. 
With the introduction of free access to ART, deaths were occurring later (at an older 
age) every year. The median age at death increased by 7 years (18.9% increase) in a 
three year period from 37 years (2004/2005) to 44 years (2007/2008). On average, 
therefore, patients died prematurely before the national life expectancy age of 46.2 
years for all Ugandan adults (i.e. for everyone who was 15 years and older). 
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The key finding of this analysis was that free access to ART contributed to an overall 
increase in life expectancy analysed by use of the median age at time of death in the 
hospital.  
 
5.4.4 Demographic effects of antiretroviral treatment  
 
The researcher also analysed mortality in terms of gender and age group in order to 
determine the particular gender and age groups that were dying in hospital and the 
change in the PMR in the pre-free and post-free ART eras.  
 
5.4.4.1 Hospital mortality in terms of treatment era and age   
 
When the researcher categorised adult hospital deaths in terms of the age groups of the 
patients concerned and in terms of the treatment era, he found that, in the post-free 
ART era, hospital deaths declined by 9.3% (n=127), 3.0% (n=56) and 2.5% (n=53) in 
the 25-34, 65-74 and in the 15-24 age groups respectively.  
 
By contrast, the number of deaths increased by 4.9% (n=111), 5.8% (n=58) and 5.9% 
(n=45) in the in 35-44, 45-54 and the 75-84 year age groups respectively in the post-
free ART era, when one compares these figures to the corresponding figures for the 
pre-free ART era.  
 
The key finding of this analysis was a proportional decrease in the number of deaths in 
the 15-24 and 25-34 age groups, and a proportional increase in the 35-44 and 45-54 
age groups in the post-free ART era, when one compares these figures to the 
corresponding figures in the pre-free ART era. This is an indication that hospital death 
are reducing in the younger adults (15-34) and increasing in the middle age adults (35-
54). These trends also need careful monitoring to determine the factors associated with 
these patterns. 
 
5.4.4.2 The associations of between mortality, age and gender 
 
The researcher observed that 43.2% (n=190) of female deaths occurred in the 15-34 
years old age group as opposed to 31.2% (n=311)of males deaths that occurred in the 
same age group. The difference between female and male deaths in the 15-34 age 
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group, and in the 35 year old and above age group, was statistically significant (χ²=6.85, 
p=<0.009). It was more probable or likely that females in the 15-34 age group would die 
in the hospital compared to males in the same age group (OR: 1.68, 95% CI[1.15-
2.43]). What the researcher found was that proportionally more females were dying at a 
younger age in comparison to males, and that they had a 37% (Risk Ratio (RR)=1.37, 
95% CI[1.08-1.71]) higher chance of dying if they were in the 15-34 age group 
Compared to their male counterparts. The researcher therefore concluded that more 
females in Mawokota South health sub-district were dying at an early adult age in the 
15-34 age group than males in the same age group. 
 
5.4.4.3 HIV-related mortality in terms of gender  
 
When the researcher categorised all deaths into HIV-related and non-HIV-related 
deaths, he noticed that 43.5% (n=193) and 39.8% (n=302) of female and male deaths 
respectively were HIV-related. This difference was not statistically significant (χ²=1.59; 
p=0.21, OR=1.29 [0.89-1.86]). The results however indicated that females were 16.3% 
(CI [-44.0% - 6.6%]) less likely (lower risk) to die of an HIV-related illness than males in 
the same age group. 
 
In spite of these indications, it should always be borne in mind that the inadequate 
evaluation of the involvement of all the HIV-related factors in the admission of patients 
to hospital and all subsequent mortalities, remains a key limitation of this study as one 
attempts to determine the actual effect of HIV/AIDS on mortality rates. Because of the 
acute lack of resources in the hospital that was used for the study and the enormous 
number of critically ill patients who were being admitted at the time, they may well have 
been an underestimation of HIV-related factors as physicians and health care personnel 
attempted to determine the precise causes of death among so many fatalities. It is 
reasonable to admit that, at the time of death, the HIV status of at least 27.6% (n=544) 
patients waseither undiagnosed/(undetermined) or not recorded in hospital records.  
 
Despite these limitations, the key finding from this analysis was that women and men 
had an equal chance of dying from an HIV/AIDS-related condition or illness in this rural 
setting during the period under review.  
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5.4.5 Antiretroviral treatment coverage and mortality trends (2002-2008) 
 
HIV/AIDS is the leading cause of death in sub-Saharan Africa and continues 
overwhelmingly to affect morbidity and mortality trends in this region of the world (Lopez 
et al. 2006:1753). In order to compare trends in HIV mortality in the pre-free and post-
free ART eras, the researcher categorised all deaths in the sample into those caused by 
HIV-related conditions and those caused by non-HIV-related conditions. He then 
analysed the effects of ART on hospital mortality trends in the pre-free ART era and 
compared them to the hospital mortality trends in the post-free ART era in terms of the 
gender of the deceased patients.  
 
5.4.5.1 HIV-related mortality in the pre-free and post-free ART eras  
 
In this study, the researcher focused on the first three years during which access to free 
ART in Uganda was made available to all patients who asked for it. This period is 
considered to be the ”early” ART access phase because most of the effects that the free 
availability of ART would later exert on overall hospital mortality trends were still in their 
incipient initial phases. In other words, how the free availability of ART would later affect 
morbidity and mortality trends among affected and new patients, had not yet had 
sufficient time in which to manifest themselves to the extent that they would later in the 
implementation of free access to ART. 
 
In the six-year study period, the PMR caused by HIV/AIDS was 39.9% (n=499). This 
made HIV/AIDS the most prominent direct and associated cause of death among 
patients who were dying. But in the post-free ART era, the PMR caused by HIV-related 
illness was 41.0% (n=290) in comparison to the 38.3% (n=209) in the pre-free ART era.  
 
In the post-free ART era, the PMR caused by HIV/AIDS related illness compared to 
non-HIV-related illnesses increased by 2.7%. The differences in HIV-related conditions 
as a cause of hospital death in the post-free and pre-free ART eras, was not statistically 
significant (χ²=0.39; p=0.53).  
 
If one therefore compares the pre-free and post-free ART eras, there was no 
observable difference in the PMR caused by HIV/AIDS. The possibility (risk) of an 
HIV/AIDS-related hospital death in the post-free ART era was therefore similar to the 
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degree of risk that patients had of dying from an HIV/AIDS-related cause in the pre-ART 
era (OR=0.89, 95% CI[0.62 – 1.28]).  
 
One therefore has to conclude that free access to ART did not reduce the probability 
that an HIV-infected patient would die from a HIV/AIDS-related cause in the post-free 
ART era. 
 
5.4.5.2 HIV-related mortality in the pre-free and post-free ART eras in terms of 
gender  
 
Among females, HIV as a cause of death declined by 6.4% in the post-free ART era 
from 47.1% (n=85) in the pre-free ART era to 40.7% (n=108) in post-free ART era. But 
this difference was not statistically significant (χ²=0.54; p=0.4). This analysis shows that, 
if one compares the post-free ART era with the pre-free ART era, there was no 
significant change in the probability that an HIV-infected female would die in hospital 
from a HIV-related cause (OR=0.77, 95% CI [0.42-1.43]). In other words, ART access in 
the post-free ART access era did not reduce the probability that a female would die of 
an HIV-related cause.  
 
Among males, however, in the post-free ART era, the proportional mortality due to HIV-
related illnesses increased by 8.1% from 32% (n=122) in the pre-ART era to 41.1% 
(n=180). Although this difference was also not statistically significant (χ²=2.50; p=0.11), 
the relative risk that males would die from an HIV-related cause in the post-free ART 
era increased by 16.8% (RR=1.17, CI [0.97-1.39; OR=1.49 [95% CI [0.918-2.40]) in 
comparison to the probability that they would die from the same causes in the pre-free 
ART era. Males were nevertheless more likely to have died from an HIV-related illness 
or condition in the post-free ART era than in the pre-free ART era.  
 
These findings show that the PMR caused by HIV-related conditions and illnesses in the 
post-free ART era was not significantly different from the PMR in the pre-free ART era.  
Despite this lack of a statistically significant differences in the mortality rates attributable 
to HIV/AIDS-related causes for both females and males in both the pre-free ART era 
and post-free ART eras, these findings nevertheless indicate that there was a reduction 
in the female mortality rate and an increase in the male mortality due to HIV-related 
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conditions in the post-free ART era. While HIV/AIDS as a cause of death declined by 
6.4% for females, it increased as a cause of death for males by 8.1%.  
 
While the advent of free ART access did not therefore reduce the proportion of mortality 
rates among males and females because of HIV-related illnesses and conditions, there 
was some indication in the data that males stood a higher chance of dying from HIV-
related causes in the post-free ART era in the sample that was analysed by the 
researcher.  
 
5.4.6 Scenarios for expected mortality trends in the post-free ART era 
 
The researcher defined three mortality and morbidity scenarios as benchmarks for the 
assessment of future hospital mortality trends. These three scenarios are:   
 
• a reduction or decline in mortality trends 
• stagnant or static mortality trends 
• increasing mortality trends 
 
5.4.6.1 Morbidity and mortality trends in the pre-free and post-free ART eras 
 
The findings of this study revealed that this particular rural setting experienced a 
declining trend in adult admissions and an increasing trend in the number of hospital 
deaths during the years covered by this study. Therefore, on the overall, the hospital 
experienced an increasing mortality rate trend. This implied that while the three years of 
free access to ART in Mawokota South health sub-district contributed to a reduction in 
morbidity rates, it did not significantly affect mortality trends.  
 
5.5 SUMMARY OF FINDINGS   
 
• The age distribution of 501 deaths was 15-24(10.6%), 25-34(25.1%), 35-
44(22.0%), 45-54(11.4%), 55-64(8.6%), 65-74(11.2%), 75-84(9.0%), and the 
group of those above 85 years old (2.2%).  
• The research sample from a hospital mortality records was divided in the 
following way in terms of gender: 37.9% (n=501) of the deceased adults were 
female and 62.1% (n=501) of the deceased adults were male (an adult in 
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Uganda is defined as someone of 15 years or older). More adult males than 
females died. The ratio of deaths in the study sample was two (1.6) male deaths 
to one (1) female death.  
• The age-standardised Crude Death Rate (CDR) in the 15-64 age bracket was 
highest in the 35-44 age group at 2.6 deaths per 1 000 of the population. 
Proportionally, the highest number of deaths occurred in the 25-34 age group, 
and the deaths in this age group accounted for 25.1% (n=501) of all the adult 
deaths in the hospital.  
• The findings from the study revealed that the 77.1% (n=510) of all the hospital 
deaths were of patients who resided in the hospital’s population catchment area 
while 22.9% (n=510) of the patients who had died in hospital had come from 
outside the hospital’s population catchment area.  
• The findings revealed that 56.8% (n=514) of all the deaths in the sample 
occurred in the post-free ART era in comparison to 43.2% (n=514) of the deaths 
that had occurred in the pre-free ART era. This revealed an increase of 13.6% in 
the mortality rate in the post-free ART era.  
• The highest number of deaths among females occurred in the 25-34 age group 
(30%), while the highest number of deaths among males occurred in the 35-44 
age group (23.2%). This study showed that 43.2% of the female deaths and 
31.2% of the male deaths occurred in the first twenty years of what can be 
defined in Uganda as ‘early’ adulthood (i.e. in the 15-34 age group). 
Proportionally, therefore, a larger number of females died at a younger age in 
comparison to males. 
 
5.5.1 Summary of findings in terms of the objectives of the study  
 
In this study, the provision of free ART coverage increased from zero (0) until an 
estimated 60% of 29.3% of PLWHA in the hospital’s catchment area in which free ART 
was available to the population.  This study therefore took place against a background 
of a rapid increase in ART coverage in this particular rural setting, and the researcher 
analysed as thoroughly as possible the morbidity and mortality trends that he observed 
from the data that was collected.  
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5.5.5.1 Objective 1 
 
To investigate the trend of adult hospital mortality in terms of cause and to compare 
these causes and trends in the pre-free ART to causes and trends in the post-free 
ART/HAART era in a selected rural hospital of the Mpigi district in Uganda. 
 
• In the post-free ART era, the frequency of HIV/AIDS as a cause of death 
declined by 0.7%, and tuberculosis, cardiovascular disease and meningitis also 
declined as a cause of death by 6.2%, 4% and 2.6% respectively. On the other 
hand, malaria increased as a cause of death by 10.1% and gastro-enteritis 
increased as a cause of death by 2.9%.  
• When the researcher compared the pre-free and post-free ART eras, he 
observed no significant difference in the proportional rates of mortality due to 
HIV/AIDS. He calculated that the probability (risk) of dying from an HIV/AIDS-
related cause in hospital in the post-free ART era was similar to the probability 
(risk) that the patient would die from an HIV/AIDS-related cause in the pre-free 
ART era (OR=0.89, 95% CI[0.62 – 1.28]). He therefore concluded that free 
access to ART in the circumstances that prevailed in the study had not reduced 
the probability that a patient would die from a HIV/AIDS-related cause in the 
hospital. 
• HIV as a cause of death among females declined by 6.4% in the post-ART era 
from 47.1% (n=85) in the pre-free ART era to 40.7% (n=108) in post-free ART 
era. This difference was, however, not statistically significant (χ²=0.54; p=0.4). In 
other words, access to free ART did not reduce the probability that a female 
would die from an HIV-related cause in the hospital in the post-free ART access.  
• In the post-free ART era, among males, the proportional mortality attributable to 
HIV-related illnesses and conditions increased by 8.1% from 32% (n=122) in the 
pre-free ART era to 41.1% in the post-free ART era (n=180). Although this 
difference was not statistically significant (χ²=2.50; p=0.11), the relative risk of an 
HIV-related death in the post-free ART era for males increased by 16.8% 
(RR=1.17, CI [0.97-1.39; OR=1.49 [95% CI [0.918-2.40]) in comparison to the 
rate that prevailed in the the pre-free ART era. Males were therefore more likely 
to have died of an HIV-related illness in the post-free ART era than in the pre-
free ART era.  
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5.5.5.2 Objective 2 
 
To determine the overall effect of free ART access on hospital mortality in a selected 
rural hospital of the Mpigi district in Uganda. 
  
• The researcher’s analysis of the two years of the pre-free ART period revealed 
that, on average, the male mortality decreased by 3.4% while the female 
mortality increased by 8.1% annually during the period of the study. In the post-
free ART era (2005/2006 to 2007/2008), the number of male deaths increased by 
21.7% annually in comparison to the number of females deaths which increased 
by 4.6% per annum. In the post-free ART era, the annual increase in number of 
male deaths was 4.7 times greater than the number of comparable female 
deaths. This high incidence of male mortality was therefore identified by the 
researcher as an issue of concern. 
• An increased access to free ART in Nkozi and Buwama sub-counties contributed 
to a 8.6% (n=183) and 4.2% (n=85) reduction in mortality in Nkozi and Buwama 
sub-counties respectively. Mortality in sub-counties that did not have a 
designated ART site (counties such as like Kituntu and Kamengo) experienced a 
5.3% (n=129) and 2.5% (n=33) respective increase in their mortality rates.  
• In the post-ART era, the increased access to ART in the hospital contributed to a 
7.5% reduction in the overall number of hospital deaths from the hospital’s 
population catchment area. Free ART access also contributed to the reduction in 
the likelihood (risk) of a hospital death for patients from the hospital’s population 
catchment area by 10.6%.  
• The researcher’s review of monthly admission trends revealed that the adult 
admission rate decreased by 16.7% from an average of 90 admissions per 
month in July 2002 to 75 admissions per month in June 2008. The researcher 
projected that hospital admissions would drop to 65 admissions per month by 
June 2011. Free ART access therefore contributed to a 16.7% reduction in 
hospital admissions in a rural hospital in Mpigi District, Uganda, during the period 
of study. 
• During a period of one year in the pre-free Art era, the median age at time of 
death declined by 3.5 years (8.8%, n=40 years) to 36.5 years (2003/2004), and 
remained at 37 years in 2004/2005. But after free access to ART had been 
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introduced over a three-year period, the median age at death increased by 7 
years (18.9%) from 37 years to 44 years (2007/2008).  
• Adult deaths increased by 133.3% from an average of three deaths per month in 
July 2002 to seven deaths per month in June 2008. The researcher projected 
that the number of deaths per month would increase to ten deaths per month by 
June 2011. Free access to ART in Mawokota South health sub-district over a 
three-year period therefore did not reduce the hospital mortality rate (i.e. the 
number of deaths in the hospital per month).  
• The results of the study showed that mortality rates increased from three (3) 
deaths per 100 admissions (3%) per month (in June 2002) to 11 deaths per 100 
admissions (11%) in June 2008. The researcher projected that the hospital 
mortality rate would increase to 15 deaths per 100 admissions (15%) by June 
2011.  
• In the post-free ART era, hospital deaths declined by 9.3% (n=127), 3.0% (n=56) 
and 2.5% (n=53) in the 25-34, 65-74 and the 15-24 age groups respectively. By 
contrast, proportionally, the number of deaths increased by 4.9% (n=111), 5.8% 
(n=58) and 5.9% (n=45) in the 35-44, 45-54 and 75-84 year age groups 
respectively in the post-free ART era compared to the number of deaths that 
occurred in the pre-free ART era.  
• Although the number of admission days spent in the hospital before death 
remained constant at three days of admission during the pre-free ART, they 
increased to four days in 2006/2007 and fell back again to the pre-free ART era 
rate of three days in 2007/2008. The trend in the number of admission days 
before death showed no significant change in the number of admission days in 
pre-free ART era in comparison the number of admission days in the post-free 
ART access. One may therefore conclude that an increased access to ART did 
not affect (reduce or prolong) the length of hospital stays on the part of patients 
before death intervened.  
 
These findings indicate that over the three years during which patients had free access 
to ART in this rural hospital setting, the researcher was able to observe noteworthy 
changes in morbidity and mortality rates –in spite of the fact that the overall hospital 
mortality rates did not decline or show any downward trend. One may therefore 
conclude that free access to ART in Mawokota South health sub-district in the context of 
this research did not significantly decrease overall hospital mortality trends.  
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5.5.5.3 Summary of factors associated with hospital mortality  
 
• While the shortest period of hospital stay before death was less than a day, the 
longest period of hospital stay observed in this study was 67 days.  
• The highest mortality rates occurred during the first day (24 hours) after 
admission, with 27.6% (n=490; 95% CI [23.7% - 31.8%]) of deaths occurring 
within in one day (24 hours) of admission while 31.6% (n=490; 27.6-36.0) 
occurred between two to three days after the patient had been admitted. What 
the researcher observed was therefore that 59.2% (n=490) of all patients died 
within three days after admission and 85.7% (n=490) of all deaths occurred 
within five days of admission.  
• In the post-free ART era, 57.9% (n=266) of patients died within three days after 
admission compared to 60.7% (n=224) of patients who died in the same period in 
the pre-free ART era. Since this difference was not statistically significant 
(OR=0.89, 95% CI[0.62-1.28]; χ²=0.3; p=0.59), the risk of death within three days 
of admission was similar during the pre-free and the post free ART eras.  
• Female HIV-related and non-HIV-related patients were equally likely to be 
admitted with severe or critical illnesses and conditions that resulted in their 
death within less than three days of admission to the hospital. 
• Among males, 50% (n=100) of HIV-related deaths occurred within three days of 
admission to the hospital – compared with 65.5% (n=165) of patients who died 
from non-HIV-related causes. This difference was statistically significant 
(χ²=5.55; p=0.02). The odds that a male would die from an HIV-related cause 
within three days of being admitted to hospital were therefore 0.53 (95% CI [0.32-
0.88]). Males were also more likely to die from HIV-related causes than females 
within more than three days after they had been admitted to hospital. 
• The ALOS before death in the hospital was 4.8 days before death in the pre-free 
ART era and 5 days before death in the post-free ART era. Free access to ART 
therefore contributed to no reduction in the ALOS in hospital before death.  
• The average out-of-pocket payment that each patient was required to pay was 
US$ 11.3 per patient death.  
• In the post-free ART era, the researcher could detect no differences in out-of-
pocket payments in terms of gender, and the average out-of-pocket payment for 
each patient death was US$ 12. 
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• In the six-year period of the study, the average out-of-pocket payment for HIV-
related deaths was US$ 11.1 in comparison to the US$ 11.9 that patients who 
died from non-HIV-related causes were required to pay. 
• Out-of-pocket payments for non-HIV-related deaths declined from US$ 12 per 
patient death in 2002/2003, and the researcher projected that they would further 
decline to US$ 10.4 by June 2011. By contrast, out-of-pocket payments for HIV-
related deaths increased from US$ 9.2 per patient, and the researcher projected 
that these payments would increase to US$ 10.8 by June 2011. The trends 
revealed that HIV-related costs demonstrated an increasing trend while non-HIV-
related out-of-pocket payments demonstrated a reducing trend.  
• Out-of-pocket payments increased by 61.4% from US$ 10.1 in 2002/2003 to US$ 
16.3 per patient death. The average out-of-pocket payments that males and 
females had to pay in the three-year, post-free ART era were equal at US$ 12.7 
per patient death event. Despite free access to ART, the other costs involved in 
the care of HIV-related conditions increased, the researcher identified this as an 
issue of concern if the successful outcomes of free access to ART were to be 
fully realised in the context of the community and the country as a whole. 
• The odds of having to pay US$ 4 or less (US$ 4 was the average out-of-pocket 
payment per death) as an out-of-pocket were similar for both HIV-related and 
non-HIV-related deaths. The HIV status of the patient did increase or reduce the 
risk of the patient having to pay more or less than US$ 4 as an out-of-pocket 
payment prior to death.  
• When the researcher categorised the deaths in terms of HIV-related and non-
HIV-related causes, he found that 43.5% (n=193) and 39.8% (n=302) of female 
and male deaths respectively were HIV-related. This difference was not 
statistically significant (χ²=1.59; p=0.21, OR=1.29 [0.89-1.86]). The results, 
however, showed that females were 16.3% less likely than males (CI [-44.0% - 
6.6%]) to have died from an HIV-related illness. 
 
The analysis of the data in this study revealed the following findings: 
 
• Hospital admissions were declining and continuing to decline.  
• Hospital mortality rates were increasing and continuing to increase.  
• The number of deaths in the two sub-counties that had been designated as ART 
sites were reduced and each revealed a downward trend.  
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• The more free access to ART is made available at the sub-county level, the more 
it will contribute to a reduction in overall mortality rates. 
 
The hypothesis that the researcher tested in this study was formulated as follows: The 
introduction of free antiretroviral treatments in a rural hospital lead to a reduction in the 
overall morbidity and mortality (in the hospital). 
 
The results revealed that the mortality rates increased from three (3) deaths per 100 
admissions (3%) per month (in June 2002) to 11 deaths per 100 admissions (11%) in 
June 2008. The researcher projected that hospital mortality rates would increase to 15 
deaths per 100 admissions (15%) by June 2011.  
 
In this study, despite the ART coverage of 60%, hospital mortality rates showed a rising 
trend. This therefore implies that the provision of free access to ART in this rural 
hospital setting over a period of three years made no observable changes to the overall 
hospital mortality rates that prevailed in the hospital at the beginning of this study. Free 
access to ART in Mawokota South health sub-district therefore exerted no significant 
effect on mortality trends in the hospital during the period of this study. 
 
5.5.5.4 Objective 3 
 
To make recommendations that would enhance the provision of free ARVs so that the 
current high mortality rates (see section 5.7) could be reduced and minimised.  
 
5.6 LIMITATIONS  
 
The fact that the review of the effects of ART on hospital mortality trends was not able 
to be extended beyond the three-year period of the study, was one of the key limitations 
of the study. After a period of only three years of free access to ART, the possibility of 
observing a definite effect on the mortality rate in a particular hospital is fairly low. It was 
necessary, however, and important to undertake this analysis at this particular juncture 
in the implementation process so that hospital managers and ART programme 
administrators are enabled to review the effects of free access to ART on their patients 
on the basis of the data presented in this study and thus to develop targeted 
interventions that will minimise rates of morbidity and mortality.  
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A determination of the degree of efficiency with which free ART services to inpatients 
are managed by hospital administrators and other health care workers is also a key 
determinant of mortality trends. Although this factor was beyond the scope of this study, 
it is an area that urgently requires further research.  
 
The inadequate and incomplete mortality records in the hospital's archives also 
constituted a major limitation on the degree to which these findings could be asserted 
with a high degree of confidence. Eight percent (8.3%, n=544) of the deaths were 
unaccompanied by any record of a direct or an associated cause of death while 27.6% 
of the deaths that have occurred in the hospital had not been assessed or described in 
terms of the possibility of HIV involvement. This indicated that the health system was 
losing immensely valuable opportunities for screening patients for HIV. All patients 
admitted to hospital need to be screened for HIV infections so that targeted 
interventions can be designed to reduce the extremely high rates of mortality in this era 
of free access to ART.  
 
The diagnoses that physicians and other health care workers used to reach their 
conclusions were based on clinical symptoms and signs and on whatever laboratory 
tests were available in the hospital at the time. The invariable absence of post mortem 
diagnoses limited the accuracy of the description of the recorded causes of patient 
deaths, and this was a key limitation that hampered the degree of accuracy with which 
the researcher could present his conclusions on the basis of these results.  
 
Whatever hospital-based mortality records were available to the researcher constituted 
the only documentary evidence that describe the causes of patient deaths throughout 
the six-year period of the study. It was these records that provided the data that enabled 
this analysis, and, in spite of all limitations, they will provide important evidence for 
informing whatever future interventions will be designed to reduce the high rate of adult 
mortality in rural health facilities.  
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5.7 RECOMMENDATIONS  
 
The evidence that the HIV/AIDS male mortality rates were disastrously high and that 
they were increasing at an alarming rate in Uganda and throughout all of sub-Saharan 
Africa motivated the researcher to undertake this research. The researcher focussed on 
the factors that were contributing to the high rate of hospital deaths throughout the 
region by gender and more specifically among males.   It was therefore the researcher's 
purpose to investigate and design specifically targeted interventions to develop and 
facilitate increased access to health services that will ensure that freely available ART 
minimises the catastrophic rate of mortality throughout the region.  
 
It was also one of the aims of the researcher that the findings from this study would 
provide benchmarks for HIV programme managers and hospital managers so that they 
would be able to monitor the impact of the effect of free ART on hospital and community 
mortality trends from the basis of solid research. The parameters on which the 
researcher focused included ALOS in hospital, the attributed causes of death, the a 
median age at death and the amount of out-of-pocket payments that patients while 
accessing hospital services in Uganda. Other parameters studied included the age and 
gender distributions of hospital deaths, the rates of ART coverage in proportion to the 
number of people in the community, and the specific HIV/AIDS mortality rates in the 
context of the overall hospital mortality rates. It is vitally important for health care 
managers and administrators to be constantly aware of past, future and projected 
mortality rates and to compare the mortality rates in their own institutions with these 
benchmarks. The researcher therefore recommends that all health care and hospital 
administrators and physicians monitor the impact of ART on mortality trends in the 
various categories that he has examined throughout the course of this study.   
 
The alarmingly high and increasingly unacceptable hospital mortality rates indicate the 
urgent need for extensive reviews of the capacity of hospitals to manage medical 
emergencies and the capacity and efficiency of the management of referral systems. 
The findings adduced in the study also indicate that there is an urgent need for 
extensive reviews of the guidelines, policies and community mobilization strategies that 
are currently in place in sub-Saharan Africa, for early diagnosis and treatment of people 
who are infected with HIV is the most important single factor in the long-term 
management of this lethal virus. Although what the average person in Uganda knows 
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and understands about HIV and its possible consequences for human health and 
survival are much better than in many other places in Africa, it is nevertheless important 
to determine just how well the public understands the benefits of ART so that they can 
be motivated to access treatment as early as possible. The patient’s understanding of 
ART benefits is a motivation to adhere strictly to ART treatment requirements and 
comply meticulously with the ART dosage regimen so that they are able to maintain a 
desirable standard of life and health.  
 
The extremely high mortality of patients who die within their first day (24 hours) of 
admission to hospital also needs to be urgently investigated. Other factors that require 
urgent investigation, review and monitoring are the following: the capacity of the hospital 
to manage severe and/or critical illnesses and conditions; the investigative capacity of 
individual hospitals and health care centres and clinics; the capacity of emergency 
support services to respond efficiently in critical situations; continuity in the supply and 
quality of medicines and other necessary hospital equipment; the ability of hospitals to 
maintain and service all their equipment and other facilities in such a state of readiness 
that the lives of patients will not be endangered by malfunctioning or dysfunctional 
equipment; the ongoing training and education of existing nursing and medical 
personnel in the latest techniques of HIV/AIDS and other kinds of patient care so that 
both they and their patients will be able to benefit from the latest evidence-based 
findings from research conducted throughout the world; the establishment of health 
promotion activities that will encourage patients to seek medical attention before the 
most severe complications of HIV/AIDS illness have reduced their health status to an 
unmanageable degree; the targeting of ART access to that sector of the population that 
is most in need of ART (such people would include, for example, patients who are 
presenting with stage four HIV disease), and assisting such patients to participate in 
HAART and other forms of necessary treatment before their immunity becomes too at a 
severely compromised.  
 
Possible explanations for the increasing mortality rates that afflict sub-Saharan Africa 
more than any other region in the world include late access to health services and the 
arrival of patients who present with such severe forms of critical illness that they die 
soon after being admitted to hospital. There is an enormous need in the community and 
in all out-patients departments to test people for their HIV status and the screening of all 
adults will go a long way in ensuring that people at the highest risk of HIV related 
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mortality are identified and managed.  In settings where HIV infection is widely 
prevalent, a significant proportion of the patients who are already receiving treatment in 
a hospital are already highly likely to be HIV-positive. If, in such instances, they are 
treated in a hospital without being screened for HIV, they will miss the vitally important 
opportunity to access the treatment that they need and will give them an opportunity to 
receive free ARV and enjoy a reasonable standard of life and health in the future. When 
health care providers miss the opportunity of the early identification of HIV-positive 
patients, they increase the probability that such patients will eventually only access ART 
so late that they will probably die within days or hours of being admitted to hospital. 
 
The researcher came to the conclusion that the mortality rate was highest in the 24-44 
age group and among males. If health care administrators wish significantly to minimise 
mortality trends, they need specifically to focus (without forgetting all of the patients who 
are at risk of death because of HIV/AIDS-related illnesses) on efforts to reach high-risk 
males and could target the 24-44 age group in both genders. As a result of the findings 
in this study, the evaluation of ART access in terms of age groups so that researchers 
will be able to determine the factors that contribute to reducing or increasing mortality 
with reference to gender and age group are identified. 
 
In order to deliver a successful ART programme to those who need it, the costs involved 
in health services will be a critical factor that needs to be considered. Because of the 
poverty and financial constraints with which innumerable individuals have to live, the 
affordability of free HAART and other forms of health care need to be taken into careful 
account within the context of the whole health care equation because these factors can 
undermine the success of any free HAART programme, however well designed it may 
be. Individual poverty in Africa (as well as in other regions of the world) is a factor that 
needs to be taken into consideration when policymakers and health care experts design 
free ART and other patient treatment programmes. 
 
Finally, well-informed advocacy for universal access to ART is important if the current 
mortality rates are to be contained and reduced to levels far below those that are 
currently observable in sub-Saharan Africa.  
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5.8 FURTHER RESEARCH  
 
The researcher identified the following key themes, topics and problems for further 
research.  
 
What is the gender distribution of adult mortality for the deaths that occur in the 
community (i.e. for those deaths that are not reported in formal health system records)? 
In other words, are more females than males dying deaths occurring in the community?  
 
Why do more males than females die in hospital? Is this phenomenon related to 
obstacles that prevent males from accessing health care services more readily? Or is it 
the case that more males with terminal illness are accessing health services in 
comparison to the number of females with terminal illness who access hospital 
services?  
 
The medical records in the hospital's archives revealed that not only did males die in 
greater numbers than females, but that the annual increase in male deaths in the post-
free ART era was 4.7 times greater than the annual increase in the number of female 
deaths. This is obviously a set of problems that urgently requires further research and 
investigation. 
 
Apart from the cost of health services in terms of out-of-pocket payments that the 
researcher investigated in this study, the continuous and timely supply of the necessary 
ARV medicines and other possible barriers that prevented ready access to ART were 
beyond the scope of this study. Nevertheless, these barriers represent important factors 
in the chain of HAART delivery, and can result in major challenges to effective service 
delivery to those who most need it in an.  
 
This study revealed a proportional decrease in the number of deaths in the 15-24 and 
25-34 year age groups and an increase in the 35-44 and 45-54 year age groups in the 
post-free ART era when statistics from that era are compared to statistics from the pre-
free ART era. The question that arises is: What is happening in these specific four age 
groups that results in these particular trends?  
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The relationship between mortality trends and ART access at the level of districts and 
sub-districts are areas that need further detailed research. 
 
Although the associations between the age at time of death of various groups of 
patients who have been on an ART regimen of varying lengths of time was beyond the 
scope of this study, it is also an area that requires future research.  
 
5.9 CONCLUSION  
 
The researcher concluded from the literature review that HIV/AIDS has made a 
devastating impact on mortality trends throughout the world but especially in sub-
Saharan Africa. While the introduction of ART into developing countries has reduced the 
mortality that is attributable to HIV-related causes, some studies that were undertaken 
in developing countries had indicated that mortality rates have diminished in proportion 
to the greater availability of access to free ART.  
 
Since Uganda has been providing free ART to the public for over four years in all of the 
district hospitals and health centres in the country, it has been able to point to some 
remarkable achievements in the fight against HIV/AIDS. The theoretical expectation in 
Uganda (where free antiretroviral therapy has been available to HIV-infected patients for 
the past four years) was that clear positive or negative mortality trends would reveal 
themselves to investigators. It was on the basis of this assumption that this study was 
undertaken to determine the effects of free access to antiretroviral therapy on mortality 
rates in a rural hospital. The researcher therefore undertook this study in Mpigi district –
a rural district in Uganda that has borne a significant burden of HIV morbidity and 
mortality rates during the past decade. Mpigi district is one of the rural districts in 
Uganda that has satisfactorily met the targeted objectives of this study. On the basis of 
the literature review that he conducted, the researcher explored mortality trends by 
means of this study in a rural hospital setting with a view to making recommendations 
about facilitating and expanding access to ART for those patients who needed it.  
 
But the findings of this study revealed that the hypothesis that states that the 
introduction of free antiretroviral treatment in a rural hospital lead to a reduction in the 
overall morbidity and mortality was not entirely true of Mpigi District. In Mpigi District 
hospital, the number of admissions diminished and did indeed reveal a downward trend, 
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but the hospital mortality rate increased and demonstrated a clear upward trend. The 
researcher therefore concluded that after three years of free access to ART in 
Mawokota South health sub-district, the hospital mortality had increased and had 
revealed an increasing trend. The number of deaths from two of the sub-counties (Nkozi 
and Buwama), each of which had a designated ART site reduced with increasing 
availability of free ART.  
 
While an increased access to ART at the sub-county level did indeed contribute to a 
reduction in mortality from the sub-counties who enjoyed ready access to ART, this but 
did not lead to an overall reduction in the mortality rates in the district hospital. 
 
This study has emphatically emphasised the urgent need for a careful, meticulous and 
regular monitoring of the mortality and morbidity rates of highly prevalent diseases such 
as HIV/AIDS in public health interventions – a recommendation that has also been 
emphasised by officials and researchers from the WHO on many different occasions. 
Mortality trends are important because they guide the design and implementation of 
ART programmes at the district and national levels, and it is vitally important to 
determine whether the goals of free access to ART are being adequately accomplished.  
 
This study investigated and identified the morbidity and mortality trends in a rural 
hospital setting and identified a variety of factors that were associated with hospital 
mortality. The study also identified the research and information gaps that need to be 
investigated so that an adequate amount of information can be made available for 
evidence-based decision-making. Such findings as these will be able to serve as 
benchmarks for evaluating mortality trends and will provide a solid basis of research-
based investigations that will be able to guide future studies into the problem of hospital 
mortality research rates as all who are concerned with public health and well-being 
attempt to design and implement interventions that will reduce the current rates of 
patient mortality.  
 
The findings in this study will therefore serve as a benchmark for future research 
activities as researchers and those concerned with macro health policy develop 
interventions to reduce current rates of mortality and meet the targets of the Uganda 
National Strategic Plan for HIV/AIDS. Targeted interventions will enable Uganda to 
attain goal number six of the Millennium Development Goals that targets combating 
276 
HIV/AIDS, malaria and other diseases and focuses on ensuring that by 2015, 
throughout the world, the spread of HIV/AIDS should have been halted or reversing (UN 
2008:28). 
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